<SEC-DOCUMENT>0001213900-21-014575.txt : 20210310
<SEC-HEADER>0001213900-21-014575.hdr.sgml : 20210310
<ACCEPTANCE-DATETIME>20210310160648
ACCESSION NUMBER:		0001213900-21-014575
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20201231
FILED AS OF DATE:		20210310
DATE AS OF CHANGE:		20210310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TFF Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001733413
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				824344737
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39102
		FILM NUMBER:		21729731

	BUSINESS ADDRESS:	
		STREET 1:		2600 VIA FORTUNA, SUITE 360
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78746
		BUSINESS PHONE:		737-802-1973

	MAIL ADDRESS:	
		STREET 1:		2600 VIA FORTUNA, SUITE 360
		CITY:			AUSTIN
		STATE:			TX
		ZIP:			78746
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>f10k2020_tffpharma.htm
<DESCRIPTION>ANNUAL REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND
EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Washington, D.C.
20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

 <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;
 <B>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the fiscal year ended December 31,
2020</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>or</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;
<B>TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For the
transition period from&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Commission file number: 001-39102</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img_001.jpg" ALT="" STYLE="height: 132px; width: 200px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 14pt"><B>TFF
Pharmaceuticals, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact name of registrant
as specified in its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 49%; text-align: center"><FONT STYLE="font-size: 10pt"><B>82-4344737</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">(State or Other Jurisdiction of<BR>
Incorporation or Organization)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer<BR>
Identification&nbsp;Number)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>2600 Via Fortuna, Suite 360</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Austin, Texas
78746</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Address of principal
executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(737) 802-1973</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(Registrant&rsquo;s
telephone number, including area code)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Securities registered pursuant to Section
12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 32%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">Common stock: Par value $0.001</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">TFFP</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center">&nbsp;</TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">The Nasdaq Global Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Securities registered pursuant to Section
12(g) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">None</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by
check mark if the registrant is a well-known seasoned issuer, as defined in Rule&nbsp;405 of the Securities Act. Yes <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
No <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark if the registrant
is not required to file reports pursuant to Section&nbsp;13 or 15(d)&nbsp;of the Exchange Act.  Yes <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
No <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by
check mark whether the registrant (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d)&nbsp;of the
Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to
file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
No <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark whether the registrant
has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&nbsp;405 of Regulation S-T (&sect;&nbsp;232.405
of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post
such files).  Yes <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT>
No <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 25%; text-align: left; white-space: nowrap"><FONT STYLE="font-size: 10pt">Large accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 25%; text-align: left"> <FONT STYLE="font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 25%; text-align: left; white-space: nowrap"><FONT STYLE="font-size: 10pt">Accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 25%; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; white-space: nowrap"><FONT STYLE="font-size: 10pt">Non-accelerated filer</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"> <FONT STYLE="font-size: 10pt">&#9746;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; white-space: nowrap"><FONT STYLE="font-size: 10pt">Smaller reporting company </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left; white-space: nowrap"><FONT STYLE="font-size: 10pt">Emerging growth company </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9746;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section&nbsp;13(a) of the Exchange Act. <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check
mark whether the registrant has filed a report on and attestation to its management&rsquo;s assessment of the effectiveness of
its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered
public accounting firm that prepared or issued its audit report. Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Act). Yes &#9744; No &#9746;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Indicate by check mark whether the registrant
is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>
No <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">State the aggregate market value of voting
and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold,
or the average bid and asked price of such common equity, as of the last business day of the registrant&rsquo;s most recently completed
second fiscal quarter:&nbsp;$83,662,145.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The number of shares of the registrant&rsquo;s
common stock outstanding as of March&nbsp;5, 2021 was 23,139,900.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">DOCUMENTS INCORPORATED BY REFERENCE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Portions of the registrant&rsquo;s definitive
proxy statement for the registrant&rsquo;s 2021 Annual Meeting of Stockholders to be filed pursuant to Regulation 14A within 120
days of the registrant&rsquo;s year ended December 31, 2020 are incorporated herein by reference into Part III of this Annual Report
on Form 10-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: justify"><B>&nbsp;</B></TD>
    <TD STYLE="width: 1%"><B>&nbsp;</B></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; padding-left: 9pt; text-indent: -9pt; text-align: justify"><B>&nbsp;</B></TD>
    <TD STYLE="width: 1%"><B>&nbsp;</B></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="5" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B><A HREF="#a_001">PART I</A></B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_002">Item 1.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_002">Business</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_003">Item 1A.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_003">Risk Factors</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">18</FONT></TD></TR>

<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="width: 9%"><A HREF="#a_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 1.B.</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 80%"><A HREF="#a_025"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unresolved Staff Comments</FONT></A></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: center; width: 9%">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 2.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_026"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Properties</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD><A HREF="#a_027"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 3.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_027"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Legal Proceedings</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">35</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_028"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Item 4.</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="#a_028"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mine Safety Disclosures</FONT></A></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">35</TD></TR>

<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify; width: 9%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify; width: 80%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center; width: 9%">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD COLSPAN="5" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B><A HREF="#a_004">PART II</A></B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_005">Item 5.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_005">Market for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_006">Item 6.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_006">Selected Financial Data</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">37</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_007">Item 7.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_007">Management&rsquo;s Discussion and Analysis of Financial Condition and Results of Operations</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">37</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_008">Item 7A.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_008">Quantitative and Qualitative Disclosures About Market Risk</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">40</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_009">Item 8.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_009">Financial Statements and Supplementary Data</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">F-1</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_010">Item 9.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_010">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">41</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_011">Item 9A.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_011">Controls and Procedures</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">41</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_012">Item 9B.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_012">Other Information</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">41</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="5" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B><A HREF="#a_013">PART III</A></B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_014">Item 10.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_014">Directors, Executive Officers and Corporate Governance</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_015">Item 11.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_015">Executive Compensation</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_016">Item 12.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_016">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_017">Item 13.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_017">Certain Relationships and Related Transactions and Director Independence</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_018">Item 14.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_018">Principal Accountant Fees and Services</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">42</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="5" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><FONT STYLE="font-size: 10pt"><B><A HREF="#a_019">PART IV</A></B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_020">Item 15.</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_020">Exhibits and Financial Statement Schedules</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">43</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; padding-left: 9pt; text-indent: -9pt; text-align: justify">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="#a_021">Signatures</A></FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">45</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CAUTIONARY NOTICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This annual report
on Form&nbsp;10-K contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as
amended, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended. Those forward-looking statements include our
expectations, beliefs, intentions and strategies regarding the future. Such forward-looking statements relate to, among other things,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">our future financial and operating results;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">our intentions, expectations and beliefs regarding anticipated growth, market penetration and trends in our business;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the timing and success of our plan of commercialization;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to successfully develop and clinically test our product candidates;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to file for FDA approval of our product candidates through the 505(b)(2) regulatory pathway;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to obtain FDA approval for any of our product candidates;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to comply with all U.S. and foreign regulations concerning the development, manufacture and sale of our product candidates;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the adequacy of the current working capital;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the effects of market conditions on our stock price and operating results;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to maintain, protect and enhance our intellectual property;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the effects of increased competition in our market and our ability to compete effectively;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">costs associated with initiating and defending intellectual property infringement and other claims;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">the attraction and retention of qualified employees and key personnel;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">future acquisitions of or investments in complementary companies or technologies; and</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-size: 10pt">our ability to comply with evolving legal standards and regulations, particularly concerning requirements for being a public company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">These and other factors
that may affect our financial results are discussed more fully in &ldquo;Risk Factors&rdquo; and &ldquo;Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations&rdquo; included in this report. Moreover, we operate in a very competitive
and rapidly changing environment, and new risks emerge from time to time. It is not possible for us to predict all risks, nor can
we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual
results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties
and assumptions, the forward-looking events and circumstances discussed in this report may not occur and actual results could differ
materially and adversely from those anticipated or implied in our forward-looking statements. Although we believe that the expectations
reflected in our forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance
or events and circumstances described in the forward-looking statements will be achieved or occur. Moreover, neither we nor any
other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We caution readers not
to place undue reliance on any forward-looking statements. We do not undertake, and specifically disclaim any obligation, to update
or revise such statements to reflect new circumstances or unanticipated events as they occur, and we urge readers to review and
consider disclosures we make in this and other reports that discuss factors germane to our business. See in particular our reports
on Forms 10-K, 10-Q, and 8-K subsequently filed from time to time with the Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin-top: 0pt; text-align: center; margin-bottom: 0pt; font: normal 10pt Times New Roman, Times, Serif"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_001"></A>PART&nbsp;I</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_002"></A>Item
1. Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Background</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">TFF Pharmaceuticals,
Inc. was formed as a Delaware corporation on January 24, 2018 for the purpose of developing and commercializing innovative drug
products based on our patented Thin Film Freezing, or TFF, technology platform. We were formed by Lung Therapeutics, Inc., or LTI,
an early stage biotechnology company focused on the development of certain technologies in the pulmonary field. In March 2018,
we completed a Series&nbsp;A preferred stock financing with third-party investors, at which time we acquired certain of LTI&rsquo;s
non-core intellectual property rights and other assets, all of which relate to our TFF technology, for 4,000,000 shares of our
common stock. As of March 5, 2021, LTI owns 2,950,000 shares of our common stock, or approximately 12.7% of our capital stock.
We are no longer a subsidiary of LTI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our formation, we have focused on the development of our initial drug candidates, the establishment of strategic relationships
with established pharmaceutical companies for the licensing of our TFF technology platform and the pursuit of additional working
capital. We have not commenced revenue-producing operations. Unless otherwise indicated, the terms &ldquo;TFF Pharmaceuticals,&rdquo;
&ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; and &ldquo;our&rdquo; refer to TFF Pharmaceuticals, Inc. and its wholly-owned
subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our organization in 2018, we have engaged in several capital raising transactions, which are summarized below in &ldquo;Management&rsquo;s
Discussion and Analysis of Financial Condition and Results of Operations &ndash; General.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an early-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on our patented
Thin Film Freezing, or TFF technology platform. We believe, and early testing confirms, that our TFF platform can significantly
improve the solubility of poorly water-soluble drugs, a class of drugs that makes up approximately 33% of the major pharmaceuticals
worldwide, thereby improving the pharmacokinetic effect of those drugs. We believe that in the case of some new drugs that cannot
be developed due to poor water-solubility, our TFF platform has the potential to increase the pharmacokinetic effect of the drug
to a level allowing for its development and commercialization. In November 2019, we initiated Phase I human clinical trials of
our lead product, TFF Voriconazole Inhalation Powder, or VIP, completed the clinical portion of the Phase 1 trial in July 2020
and progressed to a Phase 1b clinical trial in asthma patients in November 2020. In June 2020, we commenced Phase I human clinical
trials of our TFF Tacrolimus Inhalation Powder, or TIP, product in Melbourne, Victoria, Australia, but in July 2020, the Phase
I trials of our TFF TIP product were delayed due to a resurgence of COVID-19 in the Melbourne area. A second clinical trial site
in Brisbane, Queensland, Australia was opened and we resumed dosing in the Phase 1 clinical trials in Australia during the third
quarter 2020. As of the date of this report, we have not progressed the development of any other of our drug candidates to human
clinical trials and our efforts have focused on the formulation, early stage animal testing and formal toxicology studies of our
initial drug candidates in preparation for our first clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.
While the TFF platform was designed to improve solubility of poorly water-soluble drugs generally, the researchers at University
of Texas at Austin, or UT, found that the technology was particularly useful in generating dry powder particles with properties
which allow for superior inhalation delivery, especially to the deep lung, which is an area of extreme interest in respiratory
medicine. We believe that our TFF platform can significantly increase the number of pulmonary drug products that can be delivered
by way of breath-actuated inhalers, which are generally considered to be the most effective and patient-friendly means of delivering
medication directly to the lungs. Our dry powder drug products will be designed for use with dry powder inhalers, which are generally
considered to be the most effective of all breath-actuated inhalers. We plan to focus on developing inhaled dry powder formulations
of existing off-patent drugs intended for lung diseases and conditions, which we believe includes dozens of potential drug candidates,
many of which have a potential market ranging from $100 million to over $500 million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">We also focused on the joint development of dry powder formulations
of proprietary drugs owned or licensed by other pharmaceutical companies. As of the date of this report, we are at various stages
of feasibility studies of new chemical entities with multiple international pharmaceutical companies. In addition, we are actively
engaged in the analysis and testing of dry powder formulations of certain drugs and vaccines through topical, ocular and nasal
applications in connection with our participation in submissions made to certain government agencies for government contracts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 4; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business model is to develop proprietary innovative drug product candidates that offer commercial or functional advantages, or
both, to currently available alternatives. Because our initial dry powder drug candidates, TFF VIP and TFF TIP, will be established
drugs that are off-patent, we believe that our initial drug product candidates will qualify for approval by the U.S. Food and
Drug Administration, or FDA, through the FDA&rsquo;s 505(b)(2) regulatory pathway and in corresponding regulatory paths in other
foreign jurisdictions. The 505(b)(2) pathway sometimes does not require clinical trials other than a bioequivalence trial. However,
to the extent we claim that our product candidates target a new indication or offer improved safety compared to the existing approved
products, and it is our present expectation that we will in many cases, it is likely that we will be required to conduct additional
clinical trials in order to obtain marketing approval. For example, and as more fully described below, based on a February 2019
pre-Investigational New Drug Application, or IND, meeting with the FDA concerning TFF VIP, we believe we will need to conduct
Phase I and Phase II studies prior to filing for marketing approval for TFF VIP. In addition, based on a September 2019 pre-IND
meeting with the FDA concerning TFF TIP, we also believe we will require Phase I and Phase&nbsp;IIb/IIIa studies prior to filing
for marketing approval for TFF TIP. However, there can be no assurance that the FDA will not ask for additional clinical data
for either TFF VIP or TFF TIP.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
we intend to target the development of off-patent drugs for which we would directly pursue the development of a dry powder formulation
through the FDA&rsquo;s 505(b)(2) regulatory pathway, not all of our product candidates will target off-patent drugs and, at least
in the case of a dry powder formulation of cannabidiol, or CBD, our product candidate may not be a drug. We do not expect our
proposed dry powder formulation of CBD drug product to be off-patent and our proposed dry powder formulation of aluminum salt
vaccines may not be off-patent. We also expect that our dry powder formulation of a CBD drug product will likely require a full
New Drug Application, or NDA, through the FDA&rsquo;s 505(b)(1) regulatory pathway; however, a non-pharmaceutical CBD dry powder
formulation, such as a dietary supplement, may not require FDA pre-market approval. We expect that our dry powder formulation
of aluminum salt vaccines will require a biological license application, or BLA, which is very similar to a full NDA through the
FDA&rsquo;s 505(b)(1) regulatory pathway.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also believe that in some cases our dry powder drug products may qualify for the FDA&rsquo;s orphan drug status. Upon and subject
to receipt of the requisite approvals, we intend to commercialize our drug product candidates through a combination of our internal
direct sales and third-party marketing and distribution partnerships. In some cases, such as the development of combination drugs
or the development of dry powder formulations of patented drugs, we intend to pursue the licensing of our TFF platform or a joint
development arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Intended Regulatory Pathway</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
505(b)(2) pathway is intended for molecules that have been previously approved by the FDA or have already been proven to be safe
and effective. A 505(b)(2) product reformulates the known molecule in a new strength or dosage form. 505(b)(2) products have the
advantage of potentially significantly lower development costs and shorter development timelines versus traditional new molecular
entities. We expect to utilize the 505(b)(2) pathway for all of our current product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
505(b)(2) NDA is an application that contains full reports of investigations of safety and effectiveness, but where at least some
of the information required for approval comes from studies not conducted by or for the applicant. This alternate regulatory pathway
enables the applicant to rely, in part, on the FDA&rsquo;s findings of safety and efficacy for an existing product, or published
literature, in support of its application. A 505(b)(2) product candidate might rely on the clinical studies or literature of a
previously FDA-approved drug, or rely on the literature and physician usage of an FDA-unapproved, or DESI, drug. The clinical
requirements for a 505(b)(2) drug candidate can vary widely from product to product and may include new clinical trials, bioequivalence
trials, limited safety and efficacy trials, or full Phase I through III trials. Unless the FDA has released a guidance document,
the clinical requirement for a new product candidate is typically not known until the drug sponsor has a Pre-IND meeting with
the FDA. We believe there is a significant opportunity to pursue dry powder formulations of off-patent drugs using the 505(b)(2)
regulatory pathway.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also believe that in some cases the indication for some of our dry powder drug product candidates may qualify for the FDA&rsquo;s
orphan drug status. Under the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease
or condition generally affecting fewer than 200,000 individuals in the United States, or in other limited cases. Orphan drug designation
provides for seven years of exclusivity, independent of patent protection, to the company that brings a particular orphan drug
to market. In addition, companies developing orphan drugs are eligible for certain incentives, including tax credits for qualified
clinical testing. In addition, an NDA for a product that has received orphan drug designation is not subject to a prescription
drug user fee unless the application includes an indication other than the rare disease or condition for which the drug was designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
Problem We Address</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Solubility
is an issue that all drugs must address. No matter how active or potentially active a new drug is against a particular molecular
target, if the drug is not available in solution at the site of action, it is most likely not a viable development candidate.
Based on independent third-party studies, 40% of newly discovered drugs have little or no water solubility, and in some therapeutic
areas this number can reach 90%, which in most cases will prohibit development since most pharmaceutical companies cannot or will
not conduct rigorous preclinical and clinical studies on a molecule that does not have a sufficient pharmacokinetic profile due
to poor water solubility. Water solubility can also be an issue for some marketed drugs. Based on independent third-party studies,
only two-thirds of the drugs on the World Health Organization, or WHO, Essential Drug List were classified as high solubility.
A marketed drug with poor water solubility can show performance limitations, such as incomplete or erratic absorption, poor bioavailability,
and slow onset of action. Effectiveness can vary from patient to patient, and there can be a strong effect of food on drug absorption.
Finally, it may be necessary to increase the dose of a poorly soluble drug to obtain the efficacy required, which can lead to
adverse side effects, toxicity issues and increased costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to water solubility issues generally, certain drugs that target lung conditions and diseases have poor solubility that
prevent them from being delivered by way of a breath-actuated inhaler and can only be given orally or intravenously. Breath actuated
inhalers include dry powder inhalers, metered dose inhalers and nebulizers. A dry powder inhaler (such as the Advair Diskus) delivers
drugs in a dry powder form directly to the lungs by way of a deep, fast breath on the mouth of the inhaler. A metered dose inhaler
(such as the Symbicort asthma inhaler) uses propellant to push medication to the lungs. A nebulizer (such as the Aeroneb Pro)
creates a mist that is breathed into the lungs through a mouthpiece. The dry powder inhaler is generally considered to be the
most effective and convenient form of breath-actuated inhaler for all users, other than for those whose severe condition does
not allow them to take a sufficiently deep breath.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe the primary benefit of a breath-actuated inhaler is its ability to administer a greater portion of the drug dosage directly
to the target site. Dosing directly to the lungs has been shown to allow for better effect with fewer adverse events. In addition,
it has been shown that dosing directly to the lungs requires a much lower dose of drug, sometimes as little as 10%, compared to
delivery by oral or parenteral routes. While breath-actuated inhalers allow for a greater portion of the administered drug to
reach the treatment site, which should allow for much smaller dosages compared to oral or intravenous delivery, not all drugs
targeting lung conditions and diseases can be formulated for use with a breath-actuated inhaler. We believe there are dozens of
off-patent drugs targeting lung conditions and diseases that are currently not eligible for delivery by way of breath-actuated
inhalers, many of which have a potential market of $100 million to over $500 million. This is the market we intend to initially
address through our development of dry powder drugs utilizing our TFF platform.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Thin Film Freezing Platform</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
development of dry powder drugs is enabled by technology licensed to us by the University of Texas at Austin, or UT. Researchers
at UT have developed a technology employing a process called Thin Film Freezing, or TFF. While the TFF platform was designed to
improve solubility of poorly water-soluble drugs generally, the researchers at UT found that the technology was particularly useful
in generating dry powder particles with properties suitable for inhalation delivery, especially to the deep lung, an area of extreme
interest in respiratory medicine. It was found that the TFF platform yields particles that are particularly well suited to dry
powder inhaler delivery. The process results in a &ldquo;Brittle Matrix Particle,&rdquo; which possess low bulk density, high
surface area, and typically an amorphous morphology, allowing them to supersaturate when contacting the target site, such as lung
tissue. The aerodynamic properties of the particles are such that the portion of drug deposited to the deep lung may reach as
high as 75% or greater of the administered dose, compared to 10% or less when given orally or intravenously.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
TFF process, outlined in the figures below, involves dissolving a drug or drugs in a solvent system, and it will often include
agents designed to promote dispersion and avoid clumping and excipients to promote adhesion to the target site. The drug solution
is then applied to a cryogenic substrate, such as a liquid nitrogen cooled stainless steel drum. When the drug solution contacts
the cryogenic surface it vitrifies, or flash freezes, resulting in a &ldquo;drug ice&rdquo; typically with amorphous drug morphology.
The solvent system is removed by lyophilization, resulting in Brittle Matrix Particles, shown in the photographs below, that are
highly porous, large surface area, low-density particles. The process uses industry standard solvents, lung-approved excipients,
a custom-made TFF drum and conventional process equipment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><IMG SRC="img_002.jpg" ALT="" STYLE="height: 291px; width: 700px">&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our TFF platform is a breakthrough platform technology for making dry powders from drugs which previously were not candidates
for the dry powder inhaler or any breath-actuated inhaler. We believe our TFF technology opens the way for direct-to-lung delivery
of dozens of pharmaceuticals, including the reformulation of existing drugs into a more safe and convenient inhaled dry powder
product. We believe the technology can be used with molecules of all types and works with existing and off-the-shelf dry powder
inhalers without the need for any additional equipment or devices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe our TFF platform presents the following high value opportunities:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reformulation
    of drugs for lung conditions.</B> Today, many drugs intended for lung conditions are only given orally or intravenously due
    to properties that make them ill-suited for direct delivery by inhalers. Given by these routes, typically only 10% of the
    drug reaches the lungs, and these drugs may cause unwanted and even deadly side effects. We believe that our TFF platform
    for the first time will allow many of these medications to be formulated into the convenient, direct-to-lung dry powder inhaler
    format, thereby enhancing efficacy, reducing or eliminating side effects and providing for delivery of drug direct to the
    target site.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Biologics.
    </B>Biopharmaceuticals (or biologics) are by far the fastest growing sector in the pharmaceutical industry today. According
    to Visiongain, the market for biologics is expected to top $270 billion by 2019. Biologics are most commonly delivered intravenously,
    and they can be an especially challenging class of drugs for formulation into a dry powder. We believe our TFF platform is
    uniquely suited to meet many of the challenges of biologic formulations, and our UT collaborators have demonstrated, via animal
    model testing and in vitro testing, the effectiveness of the TFF technology to produce dry powder biologics with up to 100%
    activity retained. We intend to explore dry powder forms of numerous biological drugs, including drugs intended to treat indications
    other than lung conditions and diseases. We are also pursuing TFF formulations of salt containing vaccines, which we believe
    may provide significant advantages over the traditional method of handling vaccines through liquid suspension and cold chain.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Combination
    Drugs.</B> Combination drugs are products with two or more active pharmaceutical ingredients. In addition to providing for
    increased patient compliance with multiple medications, some drugs act synergistically and provide for superior benefit when
    given as a combination. However, combining pharmaceutical agents can be challenging, especially for inhalation delivery. Our
    TFF platform has shown the ability to produce fixed dose combinations of many agents in a manner that delivers the drugs simultaneously
    to the site of action in a precise amount.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">UT
initially licensed the TFF technology to The Dow Chemical Company, or Dow, and Dow researchers pursued the development of the
TFF platform until Dow&rsquo;s decision to divest its pharmaceutical assets in 2007. While at Dow, the technology was scaled from
laboratory (milligrams) to pilot/commercial quantities (kilos). In addition, the Dow team showed that the scaling process did
not alter the morphology or other properties of particles made using TFF. More than a dozen drugs, including both small molecules
and biologics, were processed by Dow researchers and UT collaborators using the technology, and the benefits were quantified using
both in vivo and analytical techniques. In a report published by Dow researchers in 2008, they reported that in several drugs
tested by them, there was evidence of enhanced dissolution rates using the TFF platform compared to bulk drugs. In one instance,
the researchers measured that a TFF prepared drug was able to reach 96% dissolution in two minutes compared to 60% dissolution
in 30 minutes by the same drug in bulk form.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
its decision to divest its pharmaceutical assets in 2007, Dow&rsquo;s license rights to the TFF platform were terminated. In July
2015, UT granted to our former parent, LTI, an exclusive worldwide, royalty bearing license to the patent rights for the TFF platform
in all fields of use, other than vaccines, for which LTI was granted a non-exclusive worldwide, royalty bearing license to the
patent rights for the TFF platform. In January 2018, we entered into a Contribution and Subscription Agreement with LTI, pursuant
to which we agreed to acquire from LTI certain intellectual property rights and other assets, including the UT patent license
agreement, all of which relate to our TFF platform. We closed on the acquisition of the LTI assets in March 2018. In November
2018, we and UT amended the UT patent license agreement pursuant to which, among other things, our exclusive patent rights to
the TFF platform were expanded to all fields of use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
continue to work with the inventors of the TFF platform through a series of Sponsored Research Agreements, or SRAs, with UT. Our
SRAs with UT are industry standard sponsored research agreements pursuant to which UT provides to us certain product formulation,
characterization and evaluation services with regard to our product candidates incorporating our TFF technology in exchange for
our payment of UT&rsquo;s expenses and reasonable overhead. The services conducted by UT are to be carried out under the
direction of a principal investigator at UT who is the principal inventor of the TFF technology. The current SRA expires in April
2022 and is subject to renewal upon mutual agreement of the parties. The SRAs includes customary provisions concerning
confidentiality, indemnification and intellectual property rights, including each party&rsquo;s exclusive ownership of all intellectual
property developed solely by them and the parties&rsquo; joint ownership of all intellectual property developed jointly. All patented intellectual property rights relating to the TFF technology developed solely or jointly by UT are subject to our
patent license agreement with UT and are included among our licensed patent rights. Pursuant to those SRAs, the research
scientists, together with their labs and collaborators, provide expertise and initial development work, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    preliminary development and in vitro evaluation of our drug candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    determination of the key characteristics influencing performance of our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    determination of the formulation and manufacturing parameters that influence the key characteristics of our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">supply
    of bulk dry powders for initial good laboratory practice, or GLP, and non-GLP toxicity studies;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">supportive
    stability for future GLP and GMP studies; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    evaluation of the in vivo performance of our product candidates in various animal models.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have entered into short-term contract manufacturing agreements with IriSys, Inc. and CoreRx, Inc. for their provision of certain
product testing, development and preclinical and clinical manufacturing services for our TFF VIP and TFF TIP product candidates,
respectively. Our agreements with IriSys and CoreRx include customary provisions concerning confidentiality, indemnification and
intellectual property rights, including our exclusive ownership of all intellectual property developed severally or jointly relating
to our TFF technology. We have not entered into agreements with any contract manufacturers for the commercial supply, however,
we believe that both IriSys and CoreRx, among several other manufacturers, have the experience and the capacity to serve as a
commercial contract manufacturer. We believe we will be able to engage a commercial contract manufacturer for our product candidates
in a timely manner at competitive pricing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of CoreRx&rsquo;s and IriSys&rsquo; facilities and services are conducted in accordance with the FDA&rsquo;s current good manufacturing
practices, or cGMPs, regulations, and IriSys and CoreRx are in the process of onboarding the TFF technology to support preclinical
and clinical supply of our TFF VIP and TFF TIP drug product candidates, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the agreements with CoreRx and IriSys, they will generate clinical supplies and provide release and stability testing of the
respective TFF drug product candidate. Specific tasks will include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Engineering
    review and TFF technology installation;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Familiarization
    with TFF technology, including powder processing and handling;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analytical
    method transfer, development, and validation;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
    process development trials and short-term supportive stability analysis;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Scale-up
    and demonstration batches of the product candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacture
    and analytical characterization of materials to support toxicology studies, both, placebo and active;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Process
    train qualification for cGMP manufacturing;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing
    and release of cGMP batches for clinical trials; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conducting
    formal stability study under the guidelines of International Council for Harmonisation of Technical Requirements for Pharmaceuticals
    for Human Use, or ICH.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Because
our dry powder drug candidates will represent a new formulation of an existing drug, we will need to obtain FDA approval of the
TFF prepared drug candidate before we can begin commercialization. However, because we begin our formulation with a drug that
has previously received FDA approval in another form, we believe that in most cases we should qualify for the FDA&rsquo;s 505(b)(2)
regulatory pathway, which potentially will take less time and investment than the standard FDA approval process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Our
Initial Drug Targets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.
Our dry powder drug product candidates will be designed for use with dry powder inhalers, which are generally considered to be
the most effective of all breath-actuated inhalers. We intend to develop dry powder drugs that can be used with existing dry powder
inhalers that are commercially available without licensing. We plan to focus on developing dry powder drugs intended for lung
diseases and conditions that are off-patent, which we believe includes dozens of potential drug candidates, many of which have
a potential market ranging from $100 million to over $1&nbsp;billion. As of the date of this report, we have identified and are
focusing on three initial drug candidates and with each we are in the early stages of formulation and testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TFF
Voriconazole Inhalation Powder, VIP &ndash; For the Treatment of Invasive Pulmonary Aspergillosis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing an inhaled dry powder drug intended to treat invasive pulmonary aspergillosis, or IPA, a severe fungal pulmonary
disease with a mortality rate that can reach 90% in some patient populations. IPA occurs primarily in patients with severe immunodeficiency,
such as bone marrow transplant recipients, other transplant patients, patients with chemotherapy-induced immunodeficiency, and
HIV patients. To date, the antifungals used to treat IPA have been delivered orally or intravenously. However, these delivery
methods have resulted in low drug concentrations in the lung due to poor bioavailability. We believe these antifungals have serious
side effects and drug interaction issues, which places a premium on any solution that can provide effective treatment in more
limited dosages. Due to the nature of these drugs, it has not been possible to make formulations for breath-actuated inhalers
that might maximize lung concentration while limiting side effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe, and our preclinical studies and clinical trials to date confirm, that our TFF platform can be used to formulate a dry
powder version of Voriconazole, generally considered to be one of the best antifungal drugs used in the treatment of IPA. Voriconazole
is an off-patent drug and our TFF prepared version of Voriconazole would represent the first inhaled antifungal medication for
the treatment of IPA, which has the potential to put the drug exactly where it is needed while minimizing off target effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Voriconazole
is currently marketed in Australia, Europe and the U.S. as Vfend, and is available in several strengths and presentations for
oral delivery or IV infusion. As of the date of this report, the Clinical Practice Guidelines released by the Infectious Diseases
Society of America recommend Voriconazole as first-line monotherapy for IPA. However, since the registration of Vfend in Europe
and the U.S. in 2002, several studies have examined the exposure-response relationship with Voriconazole, identifying a relationship
between low Voriconazole exposure and higher rates of treatment failure, as well as a higher propensity for neurotoxicity at higher
exposures. Studies have shown that when delivered orally or intravenously Voriconazole can have differing bioavailability, and
therefore differing concentration of the drug available to the lungs, based on whether the patient recently had food. In addition,
Voriconazole when delivered orally or intravenously has been shown to have various side effects including nausea and headaches,
and adverse events including optic neuritis and papilledema, hepatic toxicity, galactose intolerance, arrhythmias and QT prolongation.
These studies confirm that when administered orally or intravenously, Voriconazole provides a narrow therapeutic window between
treatment failure and unacceptable treatment toxicity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe a TFF prepared dry powder formulation of Voriconazole can maximize both the prophylactic value to the lungs for immunocompromised
patients susceptible to IPA and the treatment value of patients suffering from chronic IPA. We also believe our dry powder drug
would benefit patients by providing the drug at the &ldquo;port of entry&rdquo; of invasive fungal infections, while also reducing
or eliminating the unpleasant and potentially fatal side effects associated with Voriconazole and other last line antifungals.
We also believe that the administration of our TFF prepared dry powder formulation directly to the lungs will significantly reduce
any potential differences in bioavailability due to the effects of eating or fasting. In addition, animal and in vitro studies
have shown that our TFF prepared dry powder formulation will improve the solubility of Voriconazole compared to oral or intravenous
delivery. We believe that the combination of improved solubility and direct-to-lung administration of our TFF prepared dry powder
formulation will allow for a lower dose directly to the lungs and thereby reduce the high systemic exposure of oral administration
and associated side effects, including optic neuritis and papilledema, hepatic toxicity, galactose intolerance, arrhythmias and
QT prolongation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
our work with UT, we successfully conducted preclinical testing of a TFF formulation of Voriconazole in 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2019, we participated in a pre-IND meeting with the FDA for purposes of discussing our proposed regulatory pathway for
TFF VIP and obtaining guidance from the FDA on the pre-clinical plan leading to the filing and acceptance of an IND application
for TFF VIP. We were successful in gaining agreement that a 505(b)(2) approach would be appropriate for TFF VIP. In October 2019,
we submitted to the FDA an IND for our TFF VIP and initiated our Phase I human clinical trials in November 2019. We completed
the clinical portion of our Phase 1 trial in July 2020 and progressed to a Phase 1b clinical trial in asthma patients in November
2020. We believe that subject to a successful completion of a well-controlled and adequately powered Phase II study, we will be
able to file FDA marketing approval. However, there can be no assurance that the FDA will not ask for additional clinical data.
We also believe that our dry powder formulation may qualify as an orphan drug, as there are an estimated 50,000 transplants in
the U.S. each year that are at risk of developing IPA as well as approximately 50,000 patients suffering with IPA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TFF
Tacrolimus Inhalation Powder, TIP &mdash; For Immunosuppression to Prevent Organ Transplant Rejection</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing TFF TIP, a dry powder version of Tacrolimus, an immunosuppressive drug used in transplant medicine. Prograf Tacrolimus
is currently the second most commonly administered immunosuppressive agent in solid organ transplantation despite what we believe
to be the many challenges for patients and physicians when used for extended periods. Prograf Tacrolimus can cause nephrotoxicity,
particularly when used in high doses. According to product labeling and prescribing information for Prograf Tacrolimus, nephrotoxicity
was reported in approximately 52% of kidney transplantation patients and in 40% and 36% of liver transplantation patients receiving
Prograf in the U.S. and European randomized trials, respectively, and in 59% of heart transplantation patients in a European randomized
trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
Tacrolimus has been shown via animal models to be beneficial for a number of immunological diseases that affect the lung, systemic
toxicity (including renal failure, hypertension, hirsutism, diabetes) has limited its use. In addition, Tacrolimus when delivered
orally or intravenously has been shown to have side effects including nausea, indigestion, stomach pain and headaches. Adverse
events associated with Tacrolimus when delivered orally or intravenously include increase in cancer, increase in infections, anemia,
kidney problems, nervous system problems (including seizures, coma, tremors, confusion, headaches), high blood pressure, QT prolongation,
high level of potassium in the blood, myocardial hypertrophy, diabetes, damage to the brain, high level of fats or lipids or phosphates
in the blood, constipation, diarrhea, bronchitis, inability to sleep, low magnesium levels, reduction in white blood cells, lack
of energy, damage to the peripheral nerves, and fluid around the heart.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tacrolimus
is an off-patent drug and we intend to develop a dry powder version suitable for use with a dry powder inhaler. Because our dry
powder version would provide for a high local lung concentration without the typical systemic toxicity frequently experienced
with oral dosage form immunosuppressants, we believe our drug candidate should have a high likelihood of success in competing
in the immunosuppressant market for lung and heart/lung transplants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through
our partners at UT, we successfully conducted preclinical testing of our dry powder formulation of Tacrolimus in 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2019, we participated in a pre-IND meeting with the FDA for purposes of discussing our proposed regulatory pathway for
TFF TIP and obtaining guidance from the FDA on the pre-clinical plan leading to the filing and acceptance of an IND application
for TFF TIP. We were successful in gaining agreement that a 505(b)(2) approach would be appropriate for TFF TIP. We are conducting
Phase I clinical trials for our TFF formulation of Tacrolimus in Australia, which we consider to be a highly desirable site to
conduct human clinical trials. On March 13, 2020, we received the approval of the Alfred Hospital Human Research Ethics
Committee to commence Phase I trials in Melbourne, Victoria, Australia. However, later in March 2020, our contract research
organization partner in Australia informed us that due to the spread of the COVID-19 virus in Australia, there would be a delay
in initiating the trial. One contributing factor is that Tacrolimus is an immunosuppressant drug and, given the threat of
the COVID-19 virus, we were concerned that even though we would be dosing healthy volunteers the inhalation of an immunosuppressant
could increase the risk of severe complications if a volunteer was to contract COVID-19. In June 2020, we were able to begin
dosing in the Phase I trial our TFF TIP in Melbourne, however, in July 2020, due to the resurgence of COVID-19 in the Melbourne
area, the Phase I trials were delayed. With the flaring of COVID-19 in the Melbourne area and in order to remain dynamic, a second
clinical trial site in Brisbane, Queensland, Australia was opened and we resumed dosing in the Phase I clinical trials during
the third quarter of 2020. As of the date of this report, we intend to submit to the FDA an IND for TFF TIP when we initiate Phase
2 clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Triple
Combination For COPD/Asthma</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are developing a dry powder drug combination intended to treat chronic obstructive pulmonary disease, or COPD, and asthma. There
is a trend towards a three-drug combination in the treatment of uncontrolled COPD and asthma. Data suggests that therapy with
a long-acting antimuscarinic agent, or LAMA, a long-acting &beta;2-agonist, or LABA, and an inhaled corticosteroid, or ICS, is
effective in patients with severe COPD. GSK has received FDA approval for a triple combination drug, Trelegy Ellipta, for the
treatment of pulmonary disease. In addition, a variety of triple combinations are currently under development by large pharmaceutical
companies, including AstraZeneca and Chiesi Farmaceutici.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently pursuing the development of a combination dry powder drug intended for use with a dry powder inhaler for the maintenance
treatment of bronchospasm associated with moderate to severe COPD. Unlike most other triple combinations, which are chosen in
part from the pharmaceutical company&rsquo;s list of existing products, our triple combination drug contains what we consider
will be the best-in-class drug in each category of LAMA, LABA and ICS.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Each
of the drugs in our proposed dry powder triple combination is currently off-patent and each is available for delivery individually
by way of breath-actuated inhalers. However, the three drugs in combination are not available for delivery through any breath-actuated
inhalers due to the inability to deliver the drugs through the airway in the exact ratio designed for treatment. We believe, however,
that our TFF platform allows for all three drugs to end up in each particle delivered to the airway in the exact ratio designed
for treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
competition exists, and typically large clinical trials are needed to approve this type of triple combination drug, our strategy
would be to develop the triple combination dry powder drug in partnership with a large pharmaceutical company looking to compete
in the COPD and asthma markets. We intend to engage large pharmaceutical companies in discussions concerning a potential joint
development of our triple combination dry powder drug. However, as of the date of this report we have no agreements, understandings
or arrangements concerning a joint development program and there can be no assurance we will be able to enter into a joint development
agreement on terms acceptable to us. We do not intend to pursue the development of our triple combination dry powder drug beyond
performance characterization and efficacy data through early animal testing until such time, if ever, as we obtain a development
partner.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Potential Dry Powder Products</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
business model is to develop proprietary innovative drug product candidates that offer commercial or functional advantages, or
both, to currently available alternatives. In our initial evaluation of the market, we have identified a number of potential drug
candidates that show promise upon initial assessment, for two of which we have conducted meaningful development activities, including
dry powder formulations of:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inhaled
SARS-CoV2 Monoclonal Antibody (Joint development with Augmenta BioWorks)</B>, is an inhaled powder form of a novel neutralizing
monoclonal antibody (mAb) produced using the proprietary TFF process. The proprietary mAb in this formulation was identified by
Augmenta BioWorks and has demonstrated potent binding and neutralization activity against the SARS-CoV2 virus that causes the
COVID-19 disease. Recent Emergency Use Authorizations of anti-SARS-CoV2-mAbs delivered by intravenous infusion have been achieved
by Regeneron and Eli Lilly. Early testing confirmed that our TFF platform can be used to formulate a dry powder mAb for inhalation
delivery. We believe a TFF prepared anti-SARS-CoV2-mAb administered directly to the lungs can maximize the early outpatient treatment
of patients with COVID-19 infections who are at risk for serious disease complications while minimizing the amount of antibody
required to achieve efficacious doses.</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"></P>
                                    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="margin-top: 0; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Niclosamide
Inhalation Powder</B>&nbsp;is an inhaled dry powder formulation of Niclosamide produced using the proprietary TFF process. Niclosamide
has been used to treat tapeworm infections in humans since the 1960s and was recently reported to be one of the most potent approved
drugs in screens for antiviral activity against the SARS-CoV2 virus that causes the COVID-19 disease. Early testing confirmed
that our TFF platform can be used to formulate a dry powder version of Niclosamide, which is no longer subject to patent protection.
We believe a TFF prepared dry powder formulation of Niclosamide administered directly to the lungs can maximize both the early
outpatient treatment of patients with COVID-19 infections who are at risk for serious disease complications and for prophylactic
use for persons exposed to COVID-19. TFF has also obtained the rights to a novel formulation that may enhance the bioavailability
of Niclosamide through oral delivery under our license from the University of Texas. Systemically delivered Niclosamide has shown
promise for the treatment of COVID -19 and various forms of cancer.</FONT></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cannabidiol</B>,
                                    or CBD, a controlled substance as defined in the federal Controlled Substances Act of 1970,
                                    or CSA, that is reported to be used by some for the treatment of various epilepsy syndromes
                                    as well as anxiety, insomnia, and different types of pain. We are in the early stages of developing
                                    an inhaled dry powder drug that could be used to support or to treat a variety of health issues
                                    that may benefit from CBD administration. Researchers have explored using the broader class
                                    of cannabinoids for inflammation, symptoms of multiple sclerosis, anorexia, schizophrenia,
                                    and other conditions. The FDA has approved Epidiolex for the treatment of seizures associated
                                    with Lennox-Gastaut syndrome or Dravet syndrome in patients two years of age or older. The
                                    Epidiolex product is an oral solution containing 100 mg/mL of CBD.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe, and early in-vitro research confirms, that our TFF platform can be used to formulate a dry powder version of CBD. Through
our work with UT, early animal model testing of TFF formulations of CBD administered via inhalation have been completed. The inhaled
CBD showed more sustained pharmacokinetic blood levels compared to the IV delivery method in the animal studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to engage pharmaceutical and non-pharmaceutical companies in the CBD space in discussions concerning a potential joint
development of our dry powder formulation of CBD, which may target a CBD drug product subject to FDA regulation or a non-drug
CBD product that may not be subject to FDA approval. We do not intend to pursue the development of our dry powder formulation
of a CBD drug product beyond performance characterization and efficacy data through early animal testing until such time, if ever,
as we obtain a drug development partner. There can be no assurance that our early testing and development will lead to a commercial
dry powder formulation of a CBD drug product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2018 Farm Bill, which was signed into law on December 20, 2018, liberalized to some degree the regulation of hemp and hemp-derived
products, such as CBDs, under the CSA. However, the 2018 Farm Bill did not alter the FDA&rsquo;s authority to regulate products
containing cannabis or cannabis-derived compounds, including CBD, under the Federal Food, Drug, and Cosmetic Act, or the FDCA.
Following passage of the 2018 Farm Bill, the FDA reaffirmed its enforcement authority and reiterated the requirement that a CBD
product (hemp-derived or otherwise) that is marketed with a claim of therapeutic benefit, or with any other disease claim, be
approved by the FDA for its intended use before it may be introduced into interstate commerce. However, we believe that CBD products
that are not marketed with a claim of therapeutic benefit, or with any other disease claim, and meet the requirements of a dietary
supplement, may not require FDA pre-marketing approval. Hemp products, including CBDs, that qualify as drugs, food, dietary supplements,
veterinary products, and cosmetics will continue to be regulated by the FDA under the applicable regulatory frameworks. As of
the date of this report, we believe that Epidiolex is the only CBD-based product that has received market approval from the FDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Vaccines
    </B>containing aluminum salts, which make up approximately 35% of all vaccines. Aluminum salts are incorporated into many
    vaccine formulations as an adjuvant, which is a substance added to vaccines to enhance the immune response of vaccinated individuals.
    A major limitation with these vaccines is that they are very fragile and to maintain their efficacy they must be formulated
    as liquid suspensions and kept in a cold chain (2&ndash;8&deg;C) during transport and storage, which is burdensome and expensive.
    Also, exposure of the liquid vaccines to either ambient or freezing temperatures will cause a loss of efficacy, including
    particle aggregation in the case of freezing. Alternatives to cold chain have been examined, including the introduction of
    stabilizing agents in vaccines to prevent aggregation during freezing and the application of novel freezing and drying techniques;
    however, we believe that to date none of these techniques have led to an acceptable alternative to cold chain.</FONT></TD></TR>
</TABLE>
<P STYLE="margin-left: 0.75in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have conducted drug and performance characterization activities of certain TFF formulated salt containing vaccines. Our activities
suggest that the salt containing vaccines can be successfully converted from liquid suspension into dry powder using our TFF platform
using a relatively low concentration of trehalose as an excipient, and that the dry powder can later be reconstituted at the time
of use without causing particle aggregation or decrease in efficacy. In addition, the dry vaccine powder did not aggregate after
repeated dry-freezing-and-thawing. We believe that the TFF platform may be used to formulate new vaccines, or to reformulate existing
vaccines, that are adjuvanted with aluminum salts into dry vaccine powder without significant loss of efficacy.</FONT></P>

<P STYLE="margin-left: 0.75in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin-left: 0.75in; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to engage pharmaceutical companies in the vaccine space in discussions concerning a potential joint development of TFF
formulated salt containing vaccines and, in the meantime, we do not intend to pursue the development of our dry powder formulation
of salt containing vaccines beyond performance characterization and efficacy data through early animal testing until such time,
if ever, as we obtain a development partner. There can be no assurance, however, that our early testing and development will lead
to a commercial dry powder formulation of salt containing vaccines.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have identified a number of additional drug candidates that show promise upon initial evaluation. In each case, these are drugs
for which we would directly pursue the development of a dry powder formulation for use through a dry powder inhaler. We have not
commenced meaningful development activities for any of these product candidates at this time and there can be no assurance that
we will pursue any of the product candidates below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 25%; font-weight: bold; text-align: left">Candidate</TD><TD STYLE="text-align: center; width: 1%; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 25%; font-weight: bold; text-align: center">Intervention</TD><TD STYLE="text-align: center; width: 1%; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; width: 48%; font-weight: bold; text-align: center">Indication</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Rapamycin</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Acute Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Lymphangioleiomyomatosis</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Alpha-1-antitrypsin</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Chronic Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Vitamin A deficiency</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">GM-CSF (filgrastim)</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Autoimmune pulmonary alveolar proteinosis</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Treprostinil</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Pulmonary Arterial Hypertension</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Pembrolizumab (Keytruda)</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Acute Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Cancer: Non&ndash;Small Cell Lung Cancer, Liver, brain, melanoma, metastatic</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Cisplatin</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Acute Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Lung or esophageal cancer</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Gemcitabine</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Acute Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Lung or esophageal cancer</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Isoniazid/Rifampicin</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Acute Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Tuberculosis</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Amphotericin B</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Acute Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Antifungal</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Palivizumab</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Prophylaxis</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Tuberculosis</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Ciprofloxacin</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Acute Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Infection</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Tobramycin</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Acute Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Infection</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Azithromycin</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Acute Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Infection</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Calcium channel blockers</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Acute Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Raynaud&rsquo;s disease</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: left">Sumatriptin</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Acute Treatment</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Migraine</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: top; text-align: left">Stem cells</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Lung remodeling</TD><TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">Pneumococcal pneumonia; cardiomyopathy</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that our TFF technology provides a very diverse and effective way to develop solutions for lung specific disorders. Many
potentially beneficial drugs for lung diseases and disorders are unable to be dosed in high enough concentration to provide therapeutic
benefit to the lung due to the systemic nature (oral or IV dosing) of the drug leading to toxicity of the kidney, lungs and other
systemic safety concerns. We believe our TFF platform has the potential to take these difficult to formulate drugs and develop
products to be delivered directly to the lung for treatment of lung diseases and disorders. This direct dosing may reduce plasma
levels and has the potential to increase efficacy while reducing side effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that all of the above potential drug candidates are off-patent drugs for which we would directly pursue the development
of a dry powder formulation through the FDA&rsquo;s 505(b)(2) regulatory pathway. However, not all of our drug product candidates
will target off-patent drugs. For example, we do not expect our proposed dry powder formulation of CBD to be off-patent and our
proposed dry powder formulation of aluminum salt vaccines may not be off-patent. We also expect that our dry powder formulation
of a CBD drug product will likely require a full NDA through the FDA&rsquo;s 505(b)(1) regulatory pathway and that our dry powder
formulation of aluminum salt vaccines will require a biological license application, or BLA, which is very similar to a full NDA
through the FDA&rsquo;s 505(b)(1) regulatory pathway.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Licenses
and Intellectual Property Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
hold rights to our TFF technology pursuant to a patent license agreement entered into in July 2015, between University of Texas
at Austin, or UT, and our former parent, LTI, which LTI assigned to us in March 2018, as amended by UT and us on November 30,
2018. UT is the owner of 42 U.S. and international patents and patent applications with claims covering the TFF platform. Pursuant
to the amended patent license agreement, we hold an exclusive worldwide, royalty bearing license to the rights to the aforementioned
patents, including any divisionals, continuations and extensions, in all fields of use.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required to pay royalties to UT in the amount of 2% of net sales received by us from the sale of products covered by the licensed
patent rights. We will also be required to make certain milestone payments to UT in connection with the certain regulatory submissions
and approvals and pay fees in connection with any assignments or sublicenses, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$50,000
    upon each approval of an IND for the first indication of each product candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$100,000
    upon submission of a final Phase II report (or a foreign equivalent) on the first product candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$250,000
    upon submission of a final Phase III report (or a foreign equivalent) on the first product candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$500,000
    upon regulatory approval in the U.S. (or a foreign equivalent) on the first product candidate;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$500,000
    upon regulatory approval in the U.S. (or a foreign equivalent) on the second product candidate or on the second indication
    of the first product candidate; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
    issuance to UT of one percent (1%) of our outstanding common stock, calculated on a fully-diluted basis, upon and as of our
    first IND approval for a product candidate.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Pursuant
to the UT patent license agreement, UT has agreed to consult with us concerning the development and implementation of a strategy
for the prosecution and maintenance of the licensed patent rights, including any infringement of the licensed patents rights by
third-parties. However, UT has retained control and final decision-making authority over such matters. We are responsible for
the payment of all fees and expenses involved in the prosecution and maintenance of the licensed patent rights and are obligated
to negotiate in good faith with UT over the funding and allocation of any recovery involved in any patent infringement action
brought to enforce the licensed patent rights, which are presently scheduled to expire over a period of time commencing in 2023
and ending in 2035. The term of the UT patent license agreement is co-terminus with the licensed patent rights. However, UT has
the right to terminate the patent license agreement, or any part of the licensed patent rights or field of use, in the event of
our breach of any provision of the patent license agreement that remains uncured after UT&rsquo;s written notice of breach and
an applicable cure period or in the event we initiate any proceeding to challenge the validity or scope of the licensed patent
rights. The agreement also contains customary representations, warranties, covenants and indemnities by the parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to the licensed patent rights, we also rely on our trade secrets, know-how and continuing technological innovation to
develop and maintain our proprietary position. We will vigorously defend our intellectual property to preserve our rights and
gain the benefit of our technological investments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Government
Regulations and Funding</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pharmaceutical
companies are subject to extensive regulation by foreign, federal, state and local agencies, such as the U.S. FDA, and various
similar agencies in most countries worldwide. The manufacture, distribution, marketing and sale of pharmaceutical products are
subject to government regulation in the U.S. and various foreign countries. Additionally, in the U.S., we must follow rules and
regulations established by the FDA requiring the presentation of data indicating that our product candidates are safe and efficacious
and are manufactured in accordance with cGMP regulations. If we do not comply with applicable requirements, we may be fined, the
government may refuse to approve our marketing applications or allow us to manufacture or market our product candidates, and we
may be criminally prosecuted. We, our manufacturers and clinical research organizations, may also be subject to regulations under
other foreign, federal, state and local laws, including, but not limited to, the U.S. Occupational Safety and Health Act, the
Resource Conservation and Recovery Act, the Clean Air Act and import, export and customs regulations as well as the laws and regulations
of other countries. The U.S. government has increased its enforcement activity regarding illegal marketing practices domestically
and internationally. As a result, pharmaceutical companies must ensure their compliance with the Foreign Corrupt Practices Act
and federal healthcare fraud and abuse laws, including the False Claims Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
regulatory requirements impact our operations and differ from one country to another, so that securing the applicable regulatory
approvals of one country does not imply the approval of another country. The approval procedures involve high costs and are manpower
intensive, usually extend over many years and require highly skilled and professional resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FDA
Market Approval Process</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
steps usually required to be taken before a new drug may be marketed in the U.S. generally include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of pre-clinical laboratory and animal testing;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">completion
    of required chemistry, manufacturing and controls testing;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    submission to the FDA of an IND, which must be evaluated and found acceptable by the FDA before human clinical trials may
    commence;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">performance
    of adequate and well-controlled human clinical trials to establish the safety, pharmacokinetics and efficacy of the proposed
    drug for its intended use;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">submission
    and approval of an NDA;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successful
    pre-approval inspection of the manufacturer and analytical testing facilities; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">agreement
    with FDA of the label language, including the prescribing information insert.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
studies are conducted under protocols detailing, among other things, the objectives of the study, what types of patients may enter
the study, schedules of tests and procedures, drugs, dosages, and length of study, as well as the parameters to be used in monitoring
safety, and the efficacy criteria to be evaluated. A protocol for each clinical study and any subsequent protocol amendments must
be submitted to the FDA as part of the IND process.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials are usually conducted in three phases. Phase I clinical trials are normally conducted in small groups of healthy volunteers
to assess safety and tolerability of various dosing regimens and pharmacokinetics. After a safe dose has been established, in
Phase II clinical trials the drug is administered to small populations of sick patients to look for initial signs of efficacy
via dose ranging studies in treating the targeted disease or condition and to continue to assess safety and the effective doses
to be studied in larger trials in Phase III. In the case of vaccines, the participants are healthy and the signs of efficacy can
be obtained in early Phase I, therefore this Phase is defined as Phase I/II. Phase III clinical trials are usually multi-center,
double-blind controlled trials in hundreds or even thousands of subjects at various sites to assess as fully as possible both
the safety and effectiveness of the drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
trials must be conducted in accordance with the FDA&rsquo;s good clinical practice, or GCP, requirements. The FDA may order the
temporary or permanent discontinuation of a clinical study at any time or impose other sanctions if it believes that the clinical
study is not being conducted in accordance with FDA requirements or that the participants are being exposed to an unacceptable
health risk. An institutional review board, or IRB, generally must approve the clinical trial design and patient informed consent
at study sites that the IRB oversees and also may halt a study, either temporarily or permanently, for failure to comply with
the IRB&rsquo;s requirements, or may impose other conditions. Additionally, some clinical studies are overseen by an independent
group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board or committee. This
group recommends whether or not a trial may move forward at designated check points based on access to certain data from the study.
The clinical study sponsor may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive
climate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a product candidate moves through the clinical testing phases, manufacturing processes are further defined, refined, controlled
and validated. The level of control and validation required by the FDA increases as clinical studies progress. We and the third-party
manufacturers on which we rely for the manufacture of our product candidates and their respective components (including the API)
are subject to requirements that drugs be manufactured, packaged and labeled in conformity with cGMPs. To comply with cGMP requirements,
manufacturers must continue to spend time, money and effort to meet requirements relating to personnel, facilities, equipment,
production and process, labeling and packaging, quality control, recordkeeping and other requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assuming
completion of all required testing in accordance with all applicable regulatory requirements, detailed information on the product
candidate is submitted to the FDA in the form of an NDA, requesting approval to market the product for one or more indications,
together with payment of a user fee, unless waived. An NDA includes all relevant data available from pertinent nonclinical and
clinical studies, including negative or ambiguous results as well as positive findings, together with detailed information on
the chemistry, manufacture, controls and proposed labeling, among other things. To support marketing approval, the data submitted
must be sufficient in quality and quantity to establish the safety and efficacy of the product candidate for its intended use
to the satisfaction of the FDA. The FDA also conducts a pre-approval inspection of the manufacturer and laboratory prior to approval
of the NDA.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an NDA submission is accepted for filing, the FDA begins an in-depth review of the NDA. Under the Prescription Drug User Fee Act,
or PDUFA, the FDA&rsquo;s goal is to complete its initial review and respond to the applicant within ten months of submission,
unless the application relates to an unmet medical need, or is for a serious or life-threatening indication, in which case the
goal may be within six months of NDA submission. However, PDUFA goal dates are not legal mandates and the FDA response often occurs
several months beyond the original PDUFA goal date. Further, the review process and the target response date under PDUFA may be
extended if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding information
already provided in the NDA. The NDA review process can, accordingly, be very lengthy. During its review of an NDA, the FDA may
refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should
be approved. The FDA is not bound by the recommendation of an advisory committee, but it typically follows such recommendations.
Data from clinical studies are not always conclusive and the FDA and/or any advisory committee it appoints may interpret data
differently than the applicant.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
the FDA evaluates the NDA and inspects manufacturing facilities where the drug product and/or its API will be produced and tested,
it will either approve commercial marketing of the drug product with prescribing information for specific indications or issue
a complete response letter indicating that the application is not ready for approval and stating the conditions that must be met
in order to secure approval of the NDA. If the complete response letter requires additional data and the applicant subsequently
submits that data, the FDA nevertheless may ultimately decide that the NDA does not satisfy its criteria for approval. The FDA
could also approve the NDA with a Risk Evaluation and Mitigation Strategies, or REMS, plan to mitigate risks, which could include
medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient
registries and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed
labeling, development of adequate controls and specifications, or a commitment to conduct post-marketing testing. Such post-marketing
testing may include Phase IV clinical trials and surveillance to further assess and monitor the product&rsquo;s safety and efficacy
after approval. Regulatory approval of products for serious or life-threatening indications may require that participants in clinical
studies be followed for long periods to determine the overall survival benefit of the drug.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
the FDA approves one of our product candidates, we will be required to comply with a number of post-approval regulatory requirements.
We would be required to report, among other things, certain adverse reactions and production problems to the FDA, provide updated
safety and efficacy information and comply with requirements concerning advertising and promotional labeling for any of our product
candidates. Also, quality control and manufacturing procedures must continue to conform to cGMPs after approval, and the FDA periodically
inspects manufacturing facilities to assess compliance with cGMPs, which imposes extensive procedural, substantive and record
keeping requirements. If we seek to make certain changes to an approved product, such as certain manufacturing changes, we may
need FDA review and approval before the change can be implemented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
physicians may use products for indications that have not been approved by the FDA, we may not label or promote the product for
an indication that has not been approved. Securing FDA approval for new indications is similar to the process for approval of
the original indication and requires, among other things, submitting data from adequate and well-controlled studies that demonstrate
the product&rsquo;s safety and efficacy in the new indication. Even if such studies are conducted, the FDA may not approve any
change in a timely fashion, or at all.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA may also require post-marketing testing, or Phase IV testing, as well as risk minimization action plans and surveillance to
monitor the effects of an approved product or place conditions or an approval that could otherwise restrict the distribution or
use of the product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section&nbsp;505(b)(2)
New Drug Applications</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to submit applications for both of our lead therapeutic candidates via the 505(b)(2) regulatory pathway. As an alternate
path for FDA approval of new indications or new formulations of previously-approved products, a company may file a Section&nbsp;505(b)(2)
NDA, instead of a &ldquo;stand-alone&rdquo; or &ldquo;full&rdquo; NDA. Section&nbsp;505(b)(2) of the FDCA was enacted as part
of the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Amendments. Section&nbsp;505(b)(2)
permits the submission of an NDA where at least some of the information required for approval comes from studies not conducted
by or for the applicant and for which the applicant has not obtained a right of reference. Some examples of products that may
be allowed to follow a 505(b)(2) path to approval are drugs that have a new dosage form, strength, route of administration, formulation
or indication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Hatch-Waxman Amendments permit the applicant to rely upon certain published nonclinical or clinical studies conducted for an approved
product or the FDA&rsquo;s conclusions from prior review of such studies. The FDA may require companies to perform additional
studies or measurements to support any changes from the approved product. The FDA may then approve the new product for all or
some of the labeled indications for which the reference product has been approved, as well as for any new indication supported
by the Section 505(b)(2) application. While references to nonclinical and clinical data not generated by the applicant or for
which the applicant does not have a right of reference are allowed, all development, process, stability, qualification and validation
data related to the manufacturing and quality of the new product must be included in an NDA submitted under Section&nbsp;505(b)(2).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the extent that the Section&nbsp;505(b)(2) applicant is relying on the FDA&rsquo;s conclusions regarding studies conducted for
an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product
in the FDA&rsquo;s&nbsp;Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book. Specifically, the applicant
must certify that: (i)&nbsp;the required patent information has not been filed; (ii)&nbsp;the listed patent has expired; (iii)&nbsp;the
listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or (iv)&nbsp;the
listed patent is invalid or will not be infringed by the new product. The Section&nbsp;505(b)(2) application also will not be
approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the
Orange Book for the reference product has expired. If the Orange Book certifications outlined above are not accomplished, the
Section&nbsp;505(b)(2) applicant may invest a significant amount of time and expense in the development of its products only to
be subject to significant delay and patent litigation before its products may be commercialized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Orphan
Drugs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan designation to a drug intended to treat a rare disease or condition affecting fewer
than 200,000 individuals in the United States, or in other limited cases. Orphan drug designation (ODD) provides for seven years
of market exclusivity, independent of patent protection, to the company with ODD that brings a particular product to market. In
addition, companies developing orphan drugs are eligible for certain incentives, including tax credits for qualified clinical
testing. In addition, an NDA for a product that has received orphan drug designation is not subject to a prescription drug user
fee unless the application includes an indication other than the rare disease or condition for which the drug was designated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
gain exclusivity, if a product that has orphan drug designation subsequently receives the first FDA approval for the disease or
condition for which it has such designation, the product is entitled to the orphan drug exclusivity, which means that the FDA
may not approve any other applications to market the same active moiety for the same indication for seven years, except in limited
circumstances, such as another drug&rsquo;s showing of clinical superiority over the drug with orphan exclusivity. Competitors,
however, may receive approval of different active moieties for the same indication or obtain approval for the same active moiety
for a different indication. In addition, doctors may prescribe products for off-label uses and undermine our exclusivity. Orphan
drug exclusivity could block the approval of one of our product candidates for seven years if a competitor obtains approval for
the same active moiety for the same indication before we do, unless we are able to demonstrate that our product is clinically
superior.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may plan to pursue orphan drug designation and exclusivity for some of our product candidates in the United States, European Union,
and other geographies of interest for specific products. We cannot guarantee that we will obtain orphan drug designation for any
products in any jurisdiction. Even if we are able to obtain orphan drug designation for a product, we cannot be sure that such
product will be approved, that we will be able to obtain orphan drug exclusivity upon approval, if ever, or that we will be able
to maintain any exclusivity that is granted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Continuing
Regulation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a drug is approved for marketing and enters the marketplace, numerous regulatory requirements continue to apply. These include,
but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA&rsquo;s cGMP regulations require manufacturers, including third party manufacturers, to follow stringent requirements
    for the methods, facilities and controls used in manufacturing, processing and packing of a drug product;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">labeling
    regulations and the FDA prohibitions against the promotion of drugs for unapproved uses (known as off-label uses), as well
    as requirements to provide adequate information on both risks and benefits during promotion of the drug;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">approval
    of product modifications or use of a drug for an indication other than approved in an NDA;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">adverse
    drug experience regulations, which require us to report information on adverse events during pre-market testing and post-approval
    safety reporting;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NDA
    quarterly reporting for the first three years, then annual reporting thereafter, of changes in chemistry, manufacturing and
    control or CMC, labeling, clinical studies and findings, and toxicology studies from the data submitted in the NDA;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">post-market
    testing and surveillance requirements, including Phase IV trials, when necessary to protect the public health or to provide
    additional safety and effectiveness data for the drug; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    FDA&rsquo;s recall authority, whereby it can ask, or under certain conditions order, drug manufacturers to recall from the
    market a product that is in violation of governing laws and regulation. After a drug receives approval, any modification in
    conditions of use, active ingredient(s), route of administration, dosage form, strength or bioavailability, will require a
    new approval, for which it may be possible to submit a 505(b)(2), accompanied by additional clinical data necessary to demonstrate
    the safety and effectiveness of the product with the proposed changes. Additional clinical studies may be required for proposed
    changes.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
U.S. Healthcare Laws and Compliance Requirements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
products distributed in the United States, we will also be subject to additional healthcare regulation and enforcement by the
federal government and the states in which we conduct our business. Applicable federal and state healthcare laws and regulations
include the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal healthcare anti-kickback statute prohibits, among other things, persons from knowingly and willfully soliciting, offering,
    receiving, or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral
    of an individual for, or the purchase, order, or recommendation of, any good or service, for which payment may be made under
    federal healthcare programs such as Medicare and Medicaid;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Ethics in Patient Referrals Act, commonly referred to as the Stark Law, and its corresponding regulations, prohibit physicians
    from referring patients for designated health services (including outpatient drugs) reimbursed under the Medicare or Medicaid
    programs to entities with which the physicians or their immediate family members have a financial relationship or an ownership
    interest, subject to narrow regulatory exceptions, and prohibits those entities from submitting claims to Medicare or Medicaid
    for payment of items or services provided to a referred beneficiary;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    federal False Claims Act imposes criminal and civil penalties, including civil whistleblower or qui tam actions, against individuals
    or entities for knowingly presenting, or causing to be presented, to the federal government claims for payment that are false
    or fraudulent or making a false statement to avoid, decrease, or conceal an obligation to pay money to the federal government;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Health
    Insurance Portability and Accountability Act of 1996, imposes criminal and civil liability for executing a scheme to defraud
    any healthcare benefit program and also imposes obligations, including mandatory contractual terms, with respect to safeguarding
    the privacy, security and transmission of individually identifiable health information. This statute also prohibits knowingly
    and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection
    with the delivery of or payment for healthcare benefits, items, or services; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Analogous
    state laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements
    and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers,
    and some state laws require pharmaceutical companies to comply with the pharmaceutical industry&rsquo;s voluntary compliance
    guidelines and the relevant compliance guidance promulgated by the federal government.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Reimbursement</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sales
of our product candidates in the United States may depend, in part, on the extent to which the costs of the product candidates
will be covered by third-party payers, such as government health programs, commercial insurance and managed health care organizations.
These third-party payers are increasingly challenging the prices charged for medical products and services. Additionally, the
containment of health care costs has become a priority of federal and state governments, and the prices of drugs have been a focus
in this effort. The United States government, state legislatures and foreign governments have shown significant interest in implementing
cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic
products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions
with existing controls and measures, could further limit our net revenue and results. If these third-party payers do not consider
our product candidates to be cost-effective compared to other available therapies, they may not cover our product candidates after
approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our product
candidates on a profitable basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, imposes new requirements for the distribution
and pricing of prescription drugs for Medicare beneficiaries and includes a major expansion of the prescription drug benefit under
Medicare Part D. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which
will provide coverage of outpatient prescription drugs. Part&nbsp;D plans include both stand-alone prescription drug benefit plans
and prescription drug coverage as a supplement to Medicare Advantage plans. Unlike Medicare Parts A and B, Part D coverage is
not standardized. Part&nbsp;D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each drug
plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription
drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily
all the drugs in each category or class. Any formulary used by a Part D prescription drug plan must be developed and reviewed
by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for
product candidates for which we receive marketing approval. However, any negotiated prices for our product candidates covered
by a Part D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies
only to drug benefits for Medicare beneficiaries, private payers often follow Medicare coverage policy and payment limitations
in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments
from non-governmental payers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 17, 2009, the American Recovery and Reinvestment Act of 2009 was signed into law. This law provides funding for the federal
government to compare the effectiveness of different treatments for the same illness. A plan for the research will be developed
by the Department of Health and Human Services, the Agency for Healthcare Research and Quality and the National Institutes of
Health, and periodic reports on the status of the research and related expenditures will be made to Congress. Although the results
of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payers, it is not
clear how such a result could be avoided and what if any effect the research will have on the sales of our product candidates,
if any such product or the condition that it is intended to treat is the subject of a study. It is also possible that comparative
effectiveness research demonstrating benefits in a competitor&rsquo;s product could adversely affect the sales of our product
candidates. Decreases in third-party reimbursement for our product candidates or a decision by a third-party payer to not cover
our product candidates could reduce physician usage of the product candidates and have a material adverse effect on our sales,
results of operations and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees
and Human Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of the date of this report, we have four employees, including our executive officers, and several consultants providing technical,
financial and general administrative services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our&nbsp;human&nbsp;capital&nbsp;resources
objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees,
advisors and consultants. The principal purposes of our equity incentive plans are to attract, retain and reward personnel through
the granting of stock-based compensation awards, in order to increase stockholder value and the success of our company by motivating
such individuals to perform to the best of their abilities and achieve our objectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Available
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
website is located at www.tffpharma.com. The information on or accessible through our website is not part of this annual report
on Form&nbsp;10-K. A copy of this annual report on Form&nbsp;10-K is located at the SEC&rsquo;s Public Reference Room at 100 F
Street, NE, Washington, D.C. 20549. Information on the operation of the Public Reference Room can be obtained by calling the SEC
at 1-800-SEC-0330. The SEC also maintains an internet site that contains reports and other information regarding our filings at
www.sec.gov.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="a_003"></A>Item
1A. Risk Factors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Investing
in our common stock involves a high degree of risk. Before purchasing our common stock, you should read and consider carefully
the following risk factors as well as all other information contained in this report, including our financial statements and the
related notes. Each of these risk factors, either alone or taken together, could adversely affect our business, operating results
and financial condition, as well as adversely affect the value of an investment in our common stock. There may be additional risks
that we do not presently know of or that we currently believe are immaterial, which could also impair our business and financial
position. If any of the events described below were to occur, our financial condition, our ability to access capital resources,
our results of operations and/or our future growth prospects could be materially and adversely affected and the market price of
our common stock could decline. As a result, you could lose some or all of any investment you may make in our common stock.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are a clinical-stage biopharmaceutical company with limited operating history</I></B>. We are a biopharmaceutical company, newly-formed
in January 2018, and have limited operating history. We have not commenced revenue-producing operations. In November 2019, we
initiated Phase I human clinical trials for our TFF VIP product candidate and in June 2020, we initiated Phase I human clinical
trials for our TFF TIP product candidate, however, to date, our operations have otherwise consisted of preliminary research and
development, drug formulation and characterization and testing of our initial product candidates. Our limited operating history
makes it difficult for potential investors to evaluate our technology or prospective operations. As a development stage biopharmaceutical
company, we are subject to all the risks inherent in the organization, financing, expenditures, complications and delays involved
with a new business. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties
frequently encountered by companies in the early stages of development, especially clinical-stage biopharmaceutical companies
such as ours. Potential investors should carefully consider the risks and uncertainties that a company with a limited operating
history will face. In particular, potential investors should consider that we may be unable to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    implement or execute our business plan, or ensure that our business plan is sound;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    complete pre-clinical and clinical trials and obtain regulatory approval for the marketing of our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    demonstrate a favorable differentiation between our dry powder candidates and the current products on the market;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">successfully
    contract for the manufacture of our clinical drug products and establish a commercial drug supply;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">secure
    market exclusivity and/or adequate intellectual property protection for our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">attract
    and retain an experienced management and advisory team; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">raise
    sufficient funds in the capital markets to effectuate our business plan, including product and clinical development, regulatory
    approval and commercialization for our product candidates.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Investors
should evaluate an investment in us in light of the uncertainties encountered by developing companies in a competitive environment.
There can be no assurance that our efforts will be successful or that we will ultimately be able to attain profitability. If we
cannot successfully execute any one of the foregoing, our business may not succeed and your investment will be adversely affected.
You must be prepared to lose all of your investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have a history of significant operating losses and anticipate continued operating losses for the foreseeable future</I></B>. For
the fiscal years ended December 31, 2020 and 2019, we incurred a net loss applicable to common stockholders of $18.6 million and
$36.7 million, respectively. As of December 31, 2020, we had an accumulated deficit of $34.3&nbsp;million. We expect to continue
to incur substantial expenses without any corresponding revenues unless and until we are able to obtain regulatory approval and
successfully commercialize at least one of our product candidates. However, there can be no assurance we will be able to obtain
regulatory approval for any of our product candidates. Even if we are able to obtain regulatory approval and subsequently commercialize
our product candidates, there can be no assurance that we will generate significant revenues or ever achieve profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to have significant research, regulatory and development expenses as we advance our product candidates towards commercialization.
As a result, we expect to incur substantial losses for the foreseeable future, and these losses will be increasing. We are uncertain
when or if we will be able to achieve or sustain profitability. If we achieve profitability in the future, we may not be able
to sustain profitability in subsequent periods. Failure to become and remain profitable may impair our ability to sustain operations
and adversely affect our business and our ability to raise capital. If we are unable to generate positive cash flow within a reasonable
period of time, we may be unable to further pursue our business plan or continue operations, in which case you may lose your entire
investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect we will need additional financing to execute our business plan and fund operations, which additional financing may not
be available on reasonable terms or at all.</I></B>&nbsp;As of December 31, 2020, we had total assets of approximately $38.7&nbsp;million
and working capital of approximately $36.2&nbsp;million. As of December 31, 2020, our liquidity included approximately $35.3&nbsp;million
of cash and cash equivalents. We believe that our cash on-hand as of the date of this report is sufficient to fund our proposed
operating plan for, at least, the 12 months following the date of this report. However, as of the date of this report, we believe
that we will need additional capital to fund our operations through to the marketing approval for TFF VIP and TFF TIP, assuming
such approval can be obtained at all, and to engage in the substantial development of any other of our drug candidates, such as
formulation, early stage animal testing and formal toxicology studies. We intend to seek additional funds through various financing
sources, including the sale of our equity and debt securities, licensing fees for our technology and co-development and joint
ventures with industry partners, with a preference towards licensing fees for our technology and co-development and joint ventures
with industry partners. In addition, we will consider alternatives to our current business plan that may enable to us to achieve
revenue producing operations and meaningful commercial success with a smaller amount of capital. However, there can be no guarantees
that such funds will be available on commercially reasonable terms, if at all. If such financing is not available on satisfactory
terms, we may be unable to further pursue our business plan and we may be unable to continue operations, in which case you may
lose your entire investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business model is entirely dependent on certain patent rights licensed to us from the University of Texas at Austin, and the loss
of those license rights would, in all likelihood, cause our business, as presently contemplated, to fail.</I></B> In July 2015,
the University of Texas at Austin, or UT, granted to our former parent, LTI, an exclusive worldwide, royalty bearing license to
the patent rights for the TFF platform in all fields of use, other than vaccines. In March 2018, LTI assigned to us all of its
interest to the TFF platform, including the patent license agreement with UT. In November 2018, we and UT amended the patent license
agreement such that our exclusive patent rights to the TFF platform were expanded to all fields of use. Our current business model,
which focuses exclusively on the development of drugs using the TFF technology, is based entirely on the availability of the patent
rights licensed to us by UT under the patent license agreement. The patent license agreement requires us to pay royalties and
milestone payments and conform to a variety of covenants and agreements, and in the event of our breach of the agreement, UT may
elect to terminate the agreement. As of the date of this report, we believe we are in compliance with the patent license agreement
and consider our relationship with UT to be excellent. However, in the event of our breach of the patent license agreement for
any reason, and our inability to cure such breach within any cure period or obtain a waiver from UT, we could lose the patent
license agreement, which would result in our loss of all rights to the TFF technology.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
business may be adversely affected by the recent COVID-19 outbreak.</I></B> In December 2019, a novel strain of coronavirus, COVID-19,
was reported to have surfaced in Wuhan, China. In January 2020, this coronavirus spread to other countries, including the United
States, and efforts to contain the spread of COVID-19 have intensified. At this time, the United States and certain other countries
are the subject of lock-downs and self-isolation procedures, which have significantly limited business operations and restricted
internal and external meetings. We had expected to commence Phase 1 clinical trials our TFF formulation of Tacrolimus, or TFF
TIP, in Australia in the first quarter of 2020, and on March 13, 2020 we had received the approval of the Australian Human Research
Ethics Committee to commence Phase 1 trials. However, later in March 2020, our contract research organization partner in Australia
informed us that because of the spread of the COVID-19 virus in Australia, there would be a delay in initiating the trials. One contributing factor is that Tacrolimus is an immunosuppressant drug and, given the threat of the COVID-19 virus, we were concerned
that even though we would be dosing healthy volunteers the inhalation of an immunosuppressant could increase the risk of severe
complications if a volunteer was to contract COVID-19. In June 2020, we were able to begin dosing in the Phase I trial our
TFF TIP in Melbourne, however, in July 2020, due to the resurgence of COVID-19 in the Melbourne area, the Phase I trials were
delayed. With the flaring of COVID-19 in the Melbourne area and in order to remain dynamic, a second clinical trial site in Brisbane,
Queensland, Australia was opened and we resumed dosing in the Phase I clinical trials during the third quarter of 2020. Further,
the outbreak and any preventative or protective actions that we or our customers may take in respect of COVID-19 may result in
a period of disruption to other work in progress. Our customers&rsquo; businesses could be disrupted, and our future costs and
potential revenues and technology evaluations could be negatively affected. Any resulting financial impact cannot be reasonably
estimated at this time but may materially affect our business and financial condition. The extent to which COVID-19 impacts our
results will depend on future developments, which are highly uncertain and cannot be predicted, including new information which
may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.45in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
currently have no sales and marketing organization. If we are unable to establish satisfactory sales and marketing capabilities
or secure a third-party sales and marketing relationship, we may not be able to successfully commercialize any of our product
candidates</I></B>. At present, we have no sales or marketing personnel. Upon and subject to initial receipt of the requisite
regulatory approvals for one or more of our drug products, we intend to commercialize our drug products through a combination
of our internal direct sales force, third-party marketing and distribution relationships. In some cases, such as involving the
development of combination drugs or the development of dry powder formulations of patented drugs, we intend to pursue the licensing
of our TFF technology or enter into a joint development arrangement. If we are not successful in recruiting sales and marketing
personnel and building a sales and marketing infrastructure or entering into appropriate collaboration arrangements with third
parties, we will have difficulty successfully commercializing our product candidates, which would adversely affect our business,
operating results and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we enter into third-party marketing and distribution arrangements, we may have limited or no control over the sales, marketing
and distribution activities of these third parties. Our future revenues may depend heavily on the success of the efforts of these
third parties. In terms of establishing a sales and marketing infrastructure, we will have to compete with established and well-funded
pharmaceutical and biotechnology companies to recruit, hire, train and retain sales and marketing personnel. Factors that may
inhibit our efforts to build an internal sales organization or enter into collaboration arrangements with third parties include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    inability to recruit and retain adequate numbers of effective sales and marketing personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe any of our product
    candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to
    companies with more extensive product lines; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">unforeseen
    costs and expenses associated with creating an internal sales and marketing organization.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will be completely dependent on third parties to manufacture our product candidates, and the commercialization of our product
candidates could be halted, delayed or made less profitable if those third parties fail to obtain manufacturing approval from
the FDA or comparable foreign regulatory authorities fail to provide us with sufficient quantities of our product candidates or
fail to do so at acceptable quality levels or prices</I></B>. We do not currently have, nor do we plan to acquire, the capability
or infrastructure to manufacture our drug candidates for use in our clinical trials or for commercial sales, if any. As a result,
we will be obligated to rely on contract manufacturers, if and when any of our product candidates are approved for commercialization.
We have entered into short-term contract manufacturing agreements with IriSys, Inc. and CoreRx, Inc. for their provision of certain
product testing, development and clinical manufacturing services for our TFF VIP and TFF TIP product candidates, respectively,
and we are currently in discussion with several contract manufacturers for the commercial supply of any drug candidates we are
able to bring to market. However, we have not entered into agreements with any contract manufacturers for commercial supply and
may not be able to engage contract manufacturers for commercial supply of any of our product candidates on favorable terms to
us, or at all, should the need arise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
facilities used by our current and future contract manufacturers to manufacture our product candidates must be approved by the
FDA or comparable foreign regulatory authorities. Such approvals are subject to inspections that will be conducted after we submit
a New Drug Application, or NDA, or Biologics License Application, or BLA, to the FDA or their equivalents to other relevant regulatory
authorities. We will not control the manufacturing process of our product candidates, and will be completely dependent on our
contract manufacturing partners for compliance with Current Good Manufacturing Practices, or cGMPs, for manufacture of both active
drug substances and finished drug products. These cGMP regulations cover all aspects of the manufacturing, testing, quality control,
storage, distribution and record keeping relating to our product candidates. If our contract manufacturers do not successfully
manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we will
not be able to secure or maintain regulatory approval for product made at their manufacturing facilities. If the FDA or a comparable
foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws
any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our
ability to develop, manufacture, obtain regulatory approval for or market our product candidates, if approved. Likewise, we could
be negatively impacted if any of our contract manufacturers elect to discontinue their business relationship with us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contract manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign
agencies for compliance with cGMPs and similar regulatory requirements. We will not have control over our contract manufacturers&rsquo;
compliance with these regulations and standards. Failure by any of our contract manufacturers to comply with applicable regulations
could result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure to grant approval to market
any of our product candidates, delays, suspensions or withdrawals of approvals, inability to supply product, operating restrictions
and criminal prosecutions, any of which could significantly and adversely affect our business. In addition, we will not have control
over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel.
Failure by our contract manufacturers to comply with or maintain any of these standards could adversely affect our ability to
develop, manufacture, obtain regulatory approval for or market any of our product candidates, if approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If,
for any reason, these third parties are unable or unwilling to perform we may not be able to locate alternative manufacturers
or formulators or enter into favorable agreements with them and we cannot be certain that any such third parties will have the
manufacturing capacity to meet future requirements. If these manufacturers or any alternate manufacturer of finished drug product
experiences any significant difficulties in its respective manufacturing processes for our active pharmaceutical ingredients,
or APIs, or finished products or should cease doing business with us for any reason, we could experience significant interruptions
in the supply of any of our product candidates or may not be able to create a supply of our product candidates at all. Were we
to encounter manufacturing difficulties, our ability to produce a sufficient supply of any of our product candidates might be
negatively affected. Our inability to coordinate the efforts of our third-party manufacturing partners, or the lack of capacity
available at our third-party manufacturing partners, could impair our ability to supply any of our product candidates at required
levels. Because of the significant regulatory requirements that we would need to satisfy in order to qualify a new bulk drug substance
or finished product manufacturer, if we face these or other difficulties with our then current manufacturing partners, we could
experience significant interruptions in the supply of any of our product candidates if we decided to transfer the manufacture
of any of our product candidates to one or more alternative manufacturers in an effort to deal with such difficulties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Any manufacturing problem
or the loss of a contract manufacturer could be disruptive to our operations and result in development delays and lost sales. Additionally,
we will rely on third parties to supply the raw materials needed to manufacture our product candidates. Any such reliance on suppliers
may involve several risks, including a potential inability to obtain critical materials and reduced control over production costs,
delivery schedules, reliability and quality. Any unanticipated disruption to the operation of one of our contract manufacturers
caused by problems with suppliers could delay shipment of any of our product candidates, increase our cost of goods sold and result
in lost sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>If product liability
lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product
candidates</I></B>. We will face a potential risk of product liability as a result of the clinical testing of our product candidates
and will face an even greater risk of such liability if we commercialize any of our product candidates. For example, we may be
sued if any product we develop, including any of our product candidates, or any materials that we use in our product candidates
allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such
product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent
in the product, negligence, strict liability and a breach of warranties. In the U.S., claims could also be asserted against us
under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur
substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense of these claims
would require us to employ significant financial and management resources. Regardless of the merits or eventual outcome, liability
claims may result in:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">decreased demand for any of our product candidates or any future products that we may develop;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">injury to our reputation;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">failure to obtain regulatory approval for our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">withdrawal of participants in our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">costs associated with our defense of the related litigation;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a diversion of our management&rsquo;s time and our resources;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">substantial monetary awards to trial participants or patients;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">product recalls, withdrawals or labeling, marketing or promotional restrictions;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the inability to commercialize some or all of our product candidates; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a decline in the value of our stock.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">As of the date of this
report, we have procured insurance coverage for our human clinical trials, which we consider adequate for our current level of
clinical testing and development, however we do not carry product liability insurance. We intend to obtain product liability insurance
at the time we commence commercial sale of our initial product. Our inability to obtain and retain sufficient product liability
insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization
of products we develop. Although we will endeavor to obtain and maintain such insurance in coverage amounts we deem adequate, any
claim that may be brought against us could result in a court judgment or settlement in an amount that is not covered, in whole
or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies would also have
various exclusions, and we may be subject to a product liability claim for which we have no coverage. As a result, we may have
to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered
by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Our business
operations could suffer in the event of information technology systems&rsquo; failures or security breaches</I></B>. While we believe
that we have implemented adequate security measures within our internal information technology and networking systems, our information
technology systems may be subject to security breaches, damages from computer viruses, natural disasters, terrorism, and telecommunication
failures. Any system failure or security breach could cause interruptions in our operations in addition to the possibility of losing
proprietary information and trade secrets. To the extent that any disruption or security breach results in inappropriate disclosure
of our confidential information, our competitive position may be adversely affected and we may incur liability or additional costs
to remedy the damages caused by these disruptions or security breaches.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Sales of counterfeit
versions of our product candidates, as well as unauthorized sales of our product candidates, may have adverse effects on our revenues,
business, results of operations and damage our brand and reputation</I></B>. Our product candidates may become subject to competition
from counterfeit pharmaceutical products, which are pharmaceutical products sold under the same or very similar brand names and/or
having a similar appearance to genuine products, but which are sold without proper licenses or approvals. Such products divert
sales from genuine products, often are of lower cost and quality (having different ingredients or formulations, for example), and
have the potential to damage the reputation for quality and effectiveness of the genuine product. Obtaining regulatory approval
for our product candidates is a complex and lengthy process. If during the period while the regulatory approval is pending illegal
sales of counterfeit products begin, consumers may buy such counterfeit products, which could have an adverse impact on our revenues,
business and results of operations. In addition, if illegal sales of counterfeits result in adverse side effects to consumers,
we may be associated with any negative publicity resulting from such incidents. Although pharmaceutical regulation, control and
enforcement systems throughout the world have been increasingly active in policing counterfeit pharmaceuticals, we may not be able
to prevent third parties from manufacturing, selling or purporting to sell counterfeit products competing with our product candidates.
Such sales may also be occurring without our knowledge. The existence and any increase in production or sales of counterfeit products
or unauthorized sales could negatively impact our revenues, brand reputation, business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><B>Risks Related to Product Regulation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Our success is
entirely dependent on our ability to obtain the marketing approval for our product candidates by the FDA and the regulatory authorities
in foreign jurisdictions in which we intend to market our product candidates, of which there can be no assurance.</I></B> We are
not permitted to market our product candidates as prescription pharmaceutical products in the United States until we receive approval
of an NDA from the FDA, or in any foreign countries until we receive the requisite approval from such countries. In the United
States, the FDA generally requires the completion of clinical trials of each drug to establish its safety and efficacy and extensive
pharmaceutical development to ensure its quality before an NDA is approved. Of the large number of drugs in development, only a
small percentage result in the submission of an NDA to the FDA and even fewer are eventually approved for commercialization. As
of the date of this report, we have not submitted an NDA to the FDA or comparable applications to other regulatory authorities
for any of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Because our initial
dry powder drug candidates, TFF VIP and TFF TIP, will be established drugs that are off-patent, we believe that our initial drug
product candidates will qualify for FDA approval through the FDA&rsquo;s 505(b)(2) regulatory pathway and in corresponding regulatory
paths in other foreign jurisdictions. The 505(b)(2) pathway sometimes does not require clinical trials other than a bioequivalence
trial; however, to the extent we claim that our drug product candidates target a new indication or offer improved safety compared
to the existing approved products, and it is our present expectation that we will do so in many cases, it is likely that we will
be required to conduct additional clinical trials in order to obtain marketing approval. For example, based on separate pre-IND
meetings with the FDA concerning TFF VIP and TFF TIP, we believe we will need to conduct Phase I and Phase II studies prior to
filing for marketing approval for TFF VIP and Phase I and Phase IIb/IIIa studies prior to filing for marketing approval for TFF
TIP. However, there can be no assurance that the FDA will not ask for additional clinical data for either TFF VIP or TFF TIP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our business model
is to pursue the development of off-patent drugs for which we would directly pursue the development of a dry powder formulation
through the FDA&rsquo;s 505(b)(2) regulatory pathway; however, not all of our product candidates will target off-patent drugs and,
at least in the case of a dry powder formulation of CBD, our product candidate may not be a drug. We do not expect any dry powder
formulation of a CBD drug product to be off-patent and our proposed dry powder formulation of aluminum salt vaccines may not be
off-patent. We also expect that our dry powder formulation of a CBD drug product will likely require a full NDA through the FDA&rsquo;s
505(b)(1) regulatory pathway; however, a non-pharmaceutical CBD dry powder formulation may not require FDA approval. We expect
that our dry powder formulation of aluminum salt vaccines will require a biological license application, or BLA, which is very
similar to a full NDA through the FDA&rsquo;s 505(b)(1) regulatory pathway.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our success depends
on our receipt of the regulatory approvals described above, and the issuance of such regulatory approvals is uncertain and subject
to a number of risks, including the following:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the results of toxicology studies may not support the filing of an IND for our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the FDA or comparable foreign regulatory authorities or Institutional Review Boards, or IRB, may disagree with the design or implementation of our clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">we may not be able to provide acceptable evidence of our product candidates&rsquo; safety and efficacy;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the results of our clinical trials may not be satisfactory or may not meet the level of statistical or clinical significance required by the FDA, European Medicines Agency, or EMA, or other regulatory agencies for us to receive marketing approval for any of our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the dosing of our product candidates in a particular clinical trial may not be at an optimal level;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">patients in our clinical trials may suffer adverse effects for reasons that may or may not be related to our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the data collected from clinical trials may not be sufficient to support the submission of an NDA, BLA or other submission or to obtain regulatory approval in the United States or elsewhere;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval of our product candidates.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The process of obtaining
regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially based upon,
among other things, the type, complexity and novelty of the product candidates involved, the jurisdiction in which regulatory approval
is sought and the substantial discretion of the regulatory authorities. Changes in regulatory approval policies during the development
period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for a submitted product
application may cause delays in the approval or rejection of an application. Regulatory approval obtained in one jurisdiction does
not necessarily mean that a product candidate will receive regulatory approval in all jurisdictions in which we may seek approval,
but the failure to obtain approval in one jurisdiction may negatively impact our ability to seek approval in a different jurisdiction.
Failure to obtain regulatory approval for our product candidates for the foregoing, or any other reasons, will prevent us from
commercializing our product candidates, and our ability to generate revenue will be materially impaired.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Clinical testing
is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome</I></B>. Our
business model depends entirely on the successful development, regulatory approval and commercialization of our product candidates,
which may never occur. In November 2019, we initiated Phase I human clinical trials for our TFF VIP product candidate and initiated
Phase I human clinical trials for our TFF TIP product candidate in June 2020. However, as of the date of this report, we have not
otherwise progressed any of our product candidates beyond performance characterization and animal testing. We may not be successful
in obtaining approval from the FDA or comparable foreign regulatory authorities to start clinical trials for any other of our product
candidates. If we do not obtain such approvals as presently planned, the time in which we expect to commence clinical programs
for any product candidate will be extended and such extension will increase our expenses, delay our potential receipt of any revenues,
and increase our need for additional capital. Moreover, there is no guarantee that we will receive approval to commence human clinical
trials or, if we do receive approval, that our clinical trials will be successful or that we will continue clinical development
in support of an approval from the FDA or comparable foreign regulatory authorities for any indication. We note that most product
candidates never reach the clinical development stage and even those that do commence clinical development have only a small chance
of successfully completing clinical development and gaining regulatory approval. Success in early phases of pre-clinical and clinical
trials does not ensure that later clinical trials will be successful, and interim results of a clinical trial do not necessarily
predict final results. A failure of one or more of our clinical trials can occur at any stage of testing. We may experience numerous
unforeseen events during, or as a result of, the clinical trial process that could delay or prevent our ability to receive regulatory
approval or commercialize our product candidates. Therefore, our business currently depends entirely on the successful development,
regulatory approval and commercialization of our product candidates, which may never occur.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Even if we receive
regulatory approval for any of our product candidates, we may not be able to successfully commercialize the product and the revenue
that we generate from its sales, if any, may be limited.</I></B> If approved for marketing, the commercial success of our product
candidates will depend upon each product&rsquo;s acceptance by the medical community, including physicians, patients and health
care payors. The degree of market acceptance for any of our product candidates will depend on a number of factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">demonstration of clinical safety and efficacy;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">relative convenience, dosing burden and ease of administration;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the prevalence and severity of any adverse effects;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the willingness of physicians to prescribe our product candidates, and the target patient population to try new therapies;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>


<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">efficacy of our product candidates compared to competing products;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the introduction of any new products that may in the future become available targeting indications for which our product candidates may be approved;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">new procedures or therapies that may reduce the incidences of any of the indications in which our product candidates may show utility;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">pricing and cost-effectiveness;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the inclusion or omission of our product candidates in applicable therapeutic and vaccine guidelines;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the effectiveness of our own or any future collaborators&rsquo; sales and marketing strategies;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limitations or warnings contained in approved labeling from regulatory authorities;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care programs, including Medicare and Medicaid, private health insurers and other third-party payors or to receive the necessary pricing approvals from government bodies regulating the pricing and usage of therapeutics; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement or government pricing approvals.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If any of our product
candidates are approved, but do not achieve an adequate level of acceptance by physicians, health care payors, and patients, we
may not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to educate the medical
community and third-party payors on the benefits of our product candidates may require significant resources and may never be successful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, even if
we obtain regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize our product
candidates successfully. For example, if the approval process takes too long, we may miss market opportunities and give other companies
the ability to develop competing products or establish market dominance. Any regulatory approval we ultimately obtain may be limited
or subject to restrictions or post-approval commitments that render our product candidates not commercially viable. For example,
regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not
approve the price we intend to charge for any of our product candidates, may grant approval contingent on the performance of costly
post-marketing clinical trials, or may approve any of our product candidates with a label that does not include the labeling claims
necessary or desirable for the successful commercialization of that indication. Further, the FDA or comparable foreign regulatory
authorities may place conditions on approvals or require risk management plans or a Risk Evaluation and Mitigation Strategy, or
REMS, to assure the safe use of the drug. Moreover, product approvals may be withdrawn for non-compliance with regulatory standards
or if problems occur following the initial marketing of the product. Any of the foregoing scenarios could materially harm the commercial
success of our product candidates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Even if we obtain
marketing approval for any of our product candidates, we will be subject to ongoing obligations and continued regulatory review,
which may result in significant additional expense. Additionally, our product candidates could be subject to labeling and other
restrictions and withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements
or if we experience unanticipated problems with our product candidates.</I></B> Even if we obtain regulatory approval for any of
our product candidates for an indication, the FDA or foreign equivalent may still impose significant restrictions on their indicated
uses or marketing or the conditions of approval, or impose ongoing requirements for potentially costly and time-consuming post-approval
studies, including Phase&nbsp;4 clinical trials, and post-market surveillance to monitor safety and efficacy. Our product candidates
will also be subject to ongoing regulatory requirements governing the manufacturing, labeling, packaging, storage, distribution,
safety surveillance, advertising, promotion, recordkeeping and reporting of adverse events and other post-market information. These
requirements include registration with the FDA, as well as continued compliance with current Good Clinical Practices regulations,
or cGCPs, for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities
are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with current
cGMPs, requirements relating to quality control, quality assurance and corresponding maintenance of records and documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The FDA has the authority
to require a REMS as part of an NDA or after approval, which may impose further requirements or restrictions on the distribution
or use of an approved drug, such as limiting prescribing to certain physicians or medical centers that have undergone specialized
training, limiting treatment to patients who meet certain safe-use criteria or requiring patient testing, monitoring and/or enrollment
in a registry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">With respect to sales
and marketing activities related to our product candidates, advertising and promotional materials must comply with FDA rules in
addition to other applicable federal, state and local laws in the United States and similar legal requirements in other countries.
In the United States, the distribution of product samples to physicians must comply with the requirements of the U.S. Prescription
Drug Marketing Act. Application holders must obtain FDA approval for product and manufacturing changes, depending on the nature
of the change. We may also be subject, directly or indirectly through our customers and partners, to various fraud and abuse laws,
including, without limitation, the U.S. Anti-Kickback Statute, U.S. False Claims Act, and similar state laws, which impact, among
other things, our proposed sales, marketing, and scientific/educational grant programs. If we participate in the U.S. Medicaid
Drug Rebate Program, the Federal Supply Schedule of the U.S. Department of Veterans Affairs, or other government drug programs,
we will be subject to complex laws and regulations regarding reporting and payment obligations. All of these activities are also
potentially subject to U.S. federal and state consumer protection and unfair competition laws. Similar requirements exist in many
of these areas in other countries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, if any
of our product candidates are approved for a particular indication, our product labeling, advertising and promotion would be subject
to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that may be made
about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected
in the product&rsquo;s approved labeling. If we receive marketing approval for our product candidates, physicians may nevertheless
legally prescribe our products to their patients in a manner that is inconsistent with the approved label. If we are found to have
promoted such off-label uses, we may become subject to significant liability and government fines. The FDA and other agencies actively
enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted
off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against
companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also
requested that companies enter into consent decrees of permanent injunctions under which specified promotional conduct is changed
or curtailed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If we or a regulatory
agency discover previously unknown problems with a product candidate, such as adverse events of unanticipated severity or frequency,
problems with the facility where the product is manufactured, or we or our manufacturers fail to comply with applicable regulatory
requirements, we may be subject to the following administrative or judicial sanctions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">issuance of warning letters or untitled letters;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">clinical holds;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">injunctions or the imposition of civil or criminal penalties or monetary fines;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">suspension or withdrawal of regulatory approval;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">suspension of any ongoing clinical trials;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refusal to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">suspension or imposition of restrictions on operations, including costly new manufacturing requirements; or</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">product seizure or detention or refusal to permit the import or export of product.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The occurrence of any
event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue. Adverse
regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase our product
liability exposure.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Obtaining and
maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining
regulatory approval of our product candidates in other jurisdictions.</I></B> Obtaining and maintaining regulatory approval of
our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in
any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect
on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable
regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate
in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods
different from those in the United States, including additional preclinical studies or clinical trials, as clinical studies conducted
in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United
States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some
cases, the price that we intend to charge for our products is also subject to approval.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Obtaining foreign regulatory
approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us
and could delay or prevent the introduction of our product candidates in certain countries. If we fail to comply with the regulatory
requirements in international markets and/ or to receive applicable marketing approvals, our target market will be reduced and
our ability to realize the full market potential of our product candidates will be harmed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Even though we
may apply for orphan drug designation for a product candidate, we may not be able to obtain orphan drug marketing exclusivity.</I></B>
We believe that in some cases our dry powder drug products may qualify for the FDA&rsquo;s orphan drug status. There is no guarantee
that the FDA will grant any future application for orphan drug designation for any of our product candidates, which would make
us ineligible for the additional exclusivity and other benefits of orphan drug designation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Under the Orphan Drug
Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease
or condition that affects fewer than 200,000 individuals in the United States and for which there is no reasonable expectation
that the cost of developing and making a drug available in the United States for this type of disease or condition will be recovered
from sales of the product. Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug
designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan product
designation does not convey any advantage in or shorten the duration of regulatory review and approval process. In addition to
the potential period of exclusivity, orphan designation makes a company eligible for grant funding of up to $400,000 per year for
four years to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential exemption from
the FDA application user fee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If a product that has
orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation,
the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other applications to market the same
drug for the same indication for seven years, except in limited circumstances, such as (i) the drug&rsquo;s orphan designation
is revoked; (ii) its marketing approval is withdrawn; (iii) the orphan exclusivity holder consents to the approval of another applicant&rsquo;s
product; (iv) the orphan exclusivity holder is unable to assure the availability of a sufficient quantity of drug; or (v) a showing
of clinical superiority to the product with orphan exclusivity by a competitor product. If a drug designated as an orphan product
receives marketing approval for an indication broader than what is designated, it may not be entitled to orphan drug exclusivity.
There can be no assurance that we will receive orphan drug designation for any of our product candidates in the indications for
which we think they might qualify, if we elect to seek such applications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Current and future
legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates
and affect the prices we may obtain.</I></B> In the United States and some foreign jurisdictions, there have been a number of legislative
and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval for
our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell our product candidates.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities
for pharmaceutical products. We do not know whether additional legislative changes will be enacted, or whether the FDA regulations,
guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates,
if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&rsquo;s approval process may significantly delay
or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In the United States,
the Medicare Modernization Act, or MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded
Medicare coverage for drug purchases by the elderly and introduced a new reimbursement methodology based on average sales prices
for drugs. In addition, this legislation authorized Medicare Part&nbsp;D prescription drug plans to use formularies where they
can limit the number of drugs that will be covered in any therapeutic class. As a result of this legislation and the expansion
of federal coverage of drug products, we expect that there will be additional pressure to contain and reduce costs. These cost
reduction initiatives and other provisions of this legislation could decrease the coverage and price that we receive for our product
candidates and could seriously harm our business. While the MMA applies only to drug benefits for Medicare beneficiaries, private
payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates, and any reduction
in reimbursement that results from the MMA may result in a similar reduction in payments from private payors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Patient Protection
and Affordable Care&nbsp;Act, as amended by the Health Care and Education Affordability Reconciliation&nbsp;Act of 2010 or, collectively,
the Health Care Reform Law, is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of
healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for healthcare and health insurance
industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The Health Care Reform
Law revised the definition of &ldquo;average manufacturer price&rdquo; for reporting purposes, which could increase the amount
of Medicaid drug rebates to states. Further, the law imposed a significant annual fee on companies that manufacture or import branded
prescription drug products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The Health Care Reform
Law remains subject to legislative efforts to repeal, modify or delay the implementation of the law. If the Health Care Reform
Law is repealed or modified, or if implementation of certain aspects of the Health Care Reform Law are delayed, such repeal, modification
or delay may materially adversely impact our business, strategies, prospects, operating results or financial condition. We are
unable to predict the full impact of any repeal, modification or delay in the implementation of the Health Care Reform Law on us
at this time. Due to the substantial regulatory changes that will need to be implemented by Centers for Medicare &amp; Medicaid
Services, or CMS, and others, and the numerous processes required to implement these reforms, we cannot predict which healthcare
initiatives will be implemented at the federal or state level, the timing of any such reforms, or the effect such reforms or any
other future legislation or regulation will have on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, other
legislative changes have been proposed and adopted in the United States since the Health Care Reform Law was enacted. We expect
that additional federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal
and state governments will pay for healthcare products and services, and in turn could significantly reduce the projected value
of certain development projects and reduce or eliminate our profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Any termination
or suspension of, or delays in the commencement or completion of, any necessary studies of any of our product candidates for any
indications could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial
prospects</I></B>. The commencement and completion of clinical studies can be delayed for a number of reasons, including delays
related to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the FDA or a comparable foreign regulatory authority failing to grant permission to proceed and placing the clinical study on hold;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">subjects for clinical testing failing to enroll or remain enrolled in our trials at the rate we expect;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a facility manufacturing any of our product candidates being ordered by the FDA or other government or regulatory authorities to temporarily or permanently shut down due to violations of cGMP requirements or other applicable requirements, or cross-contaminations of product candidates in the manufacturing process;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any changes to our manufacturing process that may be necessary or desired;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">subjects choosing an alternative treatment for the indications for which we are developing our product candidates, or participating in competing clinical studies;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">subjects experiencing severe or unexpected drug-related adverse effects;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reports from clinical testing on similar technologies and products raising safety and/or efficacy concerns;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">third-party clinical investigators losing their license or permits necessary to perform our clinical trials, not performing our clinical trials on our anticipated schedule or employing methods consistent with the clinical trial protocol, cGMP requirements, or other third parties not performing data collection and analysis in a timely or accurate manner;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">inspections of clinical study sites by the FDA, comparable foreign regulatory authorities, or IRBs finding regulatory violations that require us to undertake corrective action, result in suspension or termination of one or more sites or the imposition of a clinical hold on the entire study, or that prohibit us from using some or all of the data in support of our marketing applications;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or any of the data produced by such contractors in support of our marketing applications;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">one or more IRBs refusing to approve, suspending or terminating the study at an investigational site, precluding enrollment of additional subjects, or withdrawing its approval of the trial; reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">deviations of the clinical sites from trial protocols or dropping out of a trial;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">adding new clinical trial sites;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the inability of the CRO to execute any clinical trials for any reason; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">government or regulatory delays or &ldquo;clinical holds&rdquo; requiring suspension or termination of a trial.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Product development
costs for any of our product candidates will increase if we have delays in testing or approval or if we need to perform more or
larger clinical studies than planned. Additionally, changes in regulatory requirements and policies may occur and we may need to
amend study protocols to reflect these changes. Amendments may require us to resubmit our study protocols to the FDA, comparable
foreign regulatory authorities, and IRBs for reexamination, which may impact the costs, timing or successful completion of that
study. If we experience delays in completion of, or if we, the FDA or other regulatory authorities, the IRB, or other reviewing
entities, or any of our clinical study sites suspend or terminate any of our clinical studies of any of our product candidates,
its commercial prospects may be materially harmed and our ability to generate product revenues will be delayed. Any delays in completing
our clinical trials will increase our costs, slow down our development and approval process and jeopardize our ability to commence
product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly.
In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion
of, clinical studies may also ultimately lead to the denial of regulatory approval of our product candidates. In addition, if one
or more clinical studies are delayed, our competitors may be able to bring competing products to market before we do, and the commercial
viability of any of our affected product candidates could be significantly reduced.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Third-party coverage
and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues.</I></B>
Our ability to successfully market our product candidates will depend in part on the level of reimbursement that government health
administration authorities, private health coverage insurers and other organizations provide for the cost of our product candidates
and related treatments. Countries in which any of our product candidates are sold through reimbursement schemes under national
health insurance programs frequently require that manufacturers and sellers of pharmaceutical products obtain governmental approval
of initial prices and any subsequent price increases. In certain countries, including the United States, government-funded and
private medical care plans can exert significant indirect pressure on prices. We may not be able to sell our product candidates
profitably if adequate prices are not approved or coverage and reimbursement is unavailable or limited in scope. Increasingly,
third-party payors attempt to contain health care costs in ways that are likely to impact our development of products including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">failing to approve or challenging the prices charged for health care products;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">introducing reimportation schemes from lower priced jurisdictions;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limiting both coverage and the amount of reimbursement for new therapeutic products;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">denying or limiting coverage for products that are approved by the regulatory agencies but are considered to be experimental or investigational by third-party payors; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">refusing to provide coverage when an approved product is used in a way that has not received regulatory marketing approval.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Any product candidates
we develop that incorporate CBD will be subject to U.S. controlled substance laws and regulations and failure to comply with these
laws and regulations, or the cost of compliance with these laws and regulations, may adversely affect the results of our business
operations, both during clinical development and post approval, and our financial condition.</I></B> We believe that our TFF platform
could be used to formulate a dry powder version of cannabidiol, or CBD, and we are in the early stages of developing a dry powder
form of CBD. CBD is a controlled substance as defined in the federal Controlled Substances Act of 1970, or CSA. Controlled substances
are subject to a high degree of regulation under the CSA, which establishes, among other things, certain registration, manufacturing
quotas, security, recordkeeping, reporting, import, export and other requirements administered by the federal Drug Enforcement
Agency, or DEA. The DEA classifies controlled substances into five schedules: Schedule I, II, III, IV or V substances. Schedule
I substances by definition have a high potential for abuse, have no currently &ldquo;accepted medical use&rdquo; in the United
States, lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the United States.
Pharmaceutical products approved for use in the United States may be listed as Schedule II, III, IV or V, with Schedule II substances
considered to present the highest potential for abuse or dependence and Schedule V substances the lowest relative risk of abuse
among such substances. Schedule I and II drugs are subject to the strictest controls under the CSA, including manufacturing and
procurement quotas, security requirements and criteria for importation. In addition, dispensing of Schedule II drugs is further
restricted. For example, they may not be refilled without a new prescription.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">While cannabis and
certain of its derivatives, including CBD, are Schedule I controlled substances, products approved for medical use in the United
States that contain cannabis or cannabis extracts must be placed in Schedules II through V, since approval by the FDA satisfies
the &ldquo;accepted medical use&rdquo; requirement. In 2018, the FDA approved Epidiolex, a sesame oil oral solution of CBD, and
the DEA scheduled Epidiolex to Schedule V. To our knowledge, Epidiolex is the only CBD-based drug to have received FDA marketing
approval. If we are able to develop a CBD-based dry powder drug candidate, and the FDA provides market approval for such drug candidate,
of which there can be no assurance, the DEA will make a scheduling determination and place our dry powder CBD-based drug candidate
in a schedule other than Schedule I in order for it to be prescribed to patients in the United States. If we are able to develop
a CBD-based dry powder drug candidate, we would be able to favorably cite Epidiolex for purposes of DEA scheduling; however, there
can be no assurance that any CBD-based drug candidate we develop will be listed by the DEA as a Schedule V controlled substance.
Furthermore, if the FDA, DEA or any foreign regulatory authority determines that any of our CBD-based drug candidates may have
potential for abuse, it may require us to generate more clinical data than would otherwise be required, which could increase the
cost or delay the launch of such drug candidate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Facilities conducting
research, manufacturing, distributing, importing or exporting, or dispensing controlled substances must be registered (licensed)
to perform these activities and have the security, control, recordkeeping, reporting and inventory mechanisms required by the DEA
to prevent drug loss and diversion. All these facilities must renew their registrations annually, except dispensing facilities,
which must renew every three years. The DEA conducts periodic inspections of certain registered establishments that handle controlled
substances. Obtaining the necessary registrations may result in delay of the importation, manufacturing or distribution of any
CBD-based drug candidates we may develop. Furthermore, failure to maintain compliance with the CSA, particularly non-compliance
resulting in loss or diversion, can result in regulatory action that could have a material adverse effect on our business, financial
condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings
to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Individual states have
also established controlled substance laws and regulations. Though state-controlled substance laws often mirror federal law, because
the states are separate jurisdictions, they may separately schedule our product candidates as well. While some states automatically
schedule a drug based on federal action, other states schedule drugs through rulemaking or a legislative action. State scheduling
may delay commercial sale of any product for which we obtain federal regulatory approval and adverse scheduling could have a material
adverse effect on the commercial attractiveness of such product. We must also obtain separate state registrations, permits or licenses
in order to be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale, and failure
to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those from the
DEA or otherwise arising under federal law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>The passage of
the 2018 Farm Bill will impact our development of a dry powder version of CBD.</I></B> The Agriculture Improvement Act of 2018,
or the 2018 Farm Bill, was signed into law on December 20, 2018. This new law excludes hemp from the definition of marijuana for
purposes of the CSA, and legalizes the cultivation and commercial sale of hemp in the United States, subject to state regulation
and continuing oversight by federal regulatory agencies. However, the 2018 Farm Bill does not legalize hemp-derived CBDs. CBDs
generally remain a Schedule I controlled substance under the CSA and the 2018 Farm Bill provides that a CBD will be removed from
Schedule I status if, among other requirements, the CBD is derived from hemp produced by a licensed grower in a manner consistent
with the 2018 Farm Bill and associated federal and state regulations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, the 2018
Farm Bill did not alter the FDA&rsquo;s authority to regulate products containing cannabis or cannabis-derived compounds, including
CBD, under the Federal Food, Drug, and Cosmetic Act. Hemp products, including CBDs, that qualify as drugs, food, dietary supplements,
veterinary products, and cosmetics will continue to be regulated by the FDA under the applicable regulatory frameworks. Following
passage of the 2018 Farm Bill, the FDA reaffirmed its enforcement authority and reiterated the requirement that a CBD product (hemp-derived
or otherwise) that is marketed with a claim of therapeutic benefit, or with any other disease claim, be approved by the FDA for
its intended use before it may be introduced into interstate commerce. However, we believe that hemp-derived CBD products that
are not marketed with a claim of therapeutic benefit, or with any other disease claim, may not require FDA pre-marketing approval.
While we believe that recent legislation, most notably the 2018 Farm Bill, has reduced the amount of DEA regulation of CBDs, this
is a rapidly evolving area of law and there remains some uncertainty surrounding future state regulation of CBDs. In addition,
as of the date of this report, the FDA has approved for marketing only one CBD-based drug product, Epidiolex, and there can be
no assurance that we will not encounter increased costs or delays in pursuing FDA market approval of a CBD-based dry powder formula,
assuming we can obtain approval at all.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify"><B>Risks Relating to Our Intellectual Property
Rights</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>We are dependent
on rights to certain technologies licensed to us. We do not have complete control over these technologies and any loss of our rights
to them could prevent us from selling our product candidates.</I></B> As noted above, our business model is entirely dependent
on certain patent rights licensed to us by the University of Texas at Austin, or UT. See, &ldquo;<I>Risk Factors &mdash; Risks
Relating to Our Business &mdash; Our business model is entirely dependent on certain patent rights licensed to us from the University
of Texas at Austin, and the loss of those license rights would, in all likelihood, cause our business, as presently contemplated,
to fail.&rdquo;</I> Because we will hold those rights as a licensee, we have limited control over certain important aspects of
those patent rights. Pursuant to the patent license agreement, UT has reserved the right to control all decisions concerning the
prosecution and maintenance of all U.S. and foreign patents, as well as all decisions concerning the enforcement of any actions
against potential infringers of the patent rights. We believe that UT shares a common interest in these matters with us, and UT
has agreed to consult with us on the prosecution and enforcement of possible infringement claims as well as other matters for which
UT has retained control. However, there can be no assurance that UT will agree with our views as to how best to prosecute, maintain
and defend the patent rights subject to the patent license agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>It is difficult
and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights.</I></B> Our commercial
success will depend, in part, on our ability to successfully defend the patent rights subject to our patent license agreement with
UT against third-party challenges and successfully enforcing these patent rights against third party competitors. The patent positions
of pharmaceutical companies can be highly uncertain and involve complex legal, scientific and factual questions for which important
legal principles remain unresolved. Changes in either the patent laws or in interpretations of patent laws may diminish the value
of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowable or enforceable in the
patent applications subject to the UT patent license agreement. The patents and patent applications relating to our TFF platform
and related technologies may be challenged, invalidated or circumvented by third parties and might not protect us against competitors
with similar products or technologies.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The degree of future
protection afforded by the patent rights licensed to us is uncertain, because legal means afford only limited protection and may
not adequately protect our rights, permit us to gain or keep our competitive advantage, or provide us with any competitive advantage
at all. We cannot be certain that any patent application owned by a third party will not have priority over patent applications
in which we hold license rights or that we will not be involved in interference, opposition or invalidity proceedings before United
States or foreign patent offices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Additionally, if UT
were to initiate legal proceedings against a third party to enforce a patent covering any of our product candidates, the defendant
could counterclaim that such patent is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims
alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include alleged failures to meet
any of several statutory requirements, including lack of novelty, obviousness or non-enablement. Grounds for unenforceability assertions
include allegations that someone connected with prosecution of the patent withheld relevant information from the United States
Patent and Trademark Office, or the U.S. PTO, or made a misleading statement, during prosecution. Third parties may also raise
similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms
include re-examination, post grant review and equivalent proceedings in foreign jurisdictions, e.g. opposition proceedings. Such
proceedings could result in revocation or amendment of UT&rsquo;s patents in such a way that they no longer cover our product candidates
or competitive products. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect
to validity, for example, we cannot be certain that there is no invalidating prior art, of which UT and the patent examiner were
unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would
lose at least part, and perhaps all, of the patent protection on any of our product candidates. Such a loss of patent protection
would have a material adverse impact on our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In the future, we may
rely on know-how and trade secrets to protect technology, especially in cases in which we believe patent protection is not appropriate
or obtainable. However, know-how and trade secrets are difficult to protect. While we intend to require employees, academic collaborators,
consultants and other contractors to enter into confidentiality agreements, we may not be able to adequately protect our trade
secrets or other proprietary or licensed information. Typically, research collaborators and scientific advisors have rights to
publish data and information in which we may have rights. Enforcing a claim that a third party illegally obtained and is using
any of our trade secrets is expensive and time consuming, and the outcome is unpredictable. In addition, courts are sometimes less
willing to protect trade secrets than patents. Moreover, our competitors may independently develop equivalent knowledge, methods
and know-how.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">If we fail to obtain
or maintain patent protection or trade secret protection for our product candidates or our technologies, third parties could use
our proprietary information, which could impair our ability to compete in the market and adversely affect our ability to generate
revenues and attain profitability.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Our product candidates
may infringe the intellectual property rights of others, which could increase our costs and delay or prevent our development and
commercialization efforts.</I></B> Our success depends in part on avoiding infringement of the proprietary technologies of others.
The pharmaceutical industry has been characterized by frequent litigation regarding patent and other intellectual property rights.
Identification of third-party patent rights that may be relevant to our proprietary technology is difficult because patent searching
is imperfect due to differences in terminology among patents, incomplete databases and the difficulty in assessing the meaning
of patent claims. Additionally, because patent applications are maintained in secrecy until the application is published, we may
be unaware of third-party patents that may be infringed by commercialization of any of our product candidates or any future product
candidate. There may be certain issued patents and patent applications claiming subject matter that we may be required to license
in order to research, develop or commercialize any of our product candidates, and we do not know if such patents and patent applications
would be available to license on commercially reasonable terms, or at all. Any claims of patent infringement asserted by third
parties would be time-consuming and may:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">result in costly litigation;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">divert the time and attention of our technical personnel and management;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">prevent us from commercializing a product until the asserted patent expires or is held finally invalid or not infringed in a court of law;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">require us to cease or modify our use of the technology and/or develop non-infringing technology; or</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">require us to enter into royalty or licensing agreements.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Third parties may hold
proprietary rights that could prevent any of our product candidates from being marketed. Any patent-related legal action against
us claiming damages and seeking to enjoin commercial activities relating to any of our product candidates or our processes could
subject us to potential liability for damages and require us to obtain a license to continue to manufacture or market any of our
product candidates or any future product candidates. We cannot predict whether we would prevail in any such actions or that any
license required under any of these patents would be made available on commercially acceptable terms, if at all. In addition, we
cannot be sure that we could redesign our product candidates or any future product candidates or processes to avoid infringement,
if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary
licenses, could prevent us from developing and commercializing any of our product candidates or a future product candidate, which
could harm our business, financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We expect that there
are other companies, including major pharmaceutical companies, working in the areas competitive to our product candidates which
either has resulted, or may result, in the filing of patent applications that may be deemed related to our activities. If we were
to challenge the validity of these or any issued United States patent in court, we would need to overcome a statutory presumption
of validity that attaches to every issued United States patent. This means that, in order to prevail, we would have to present
clear and convincing evidence as to the invalidity of the patent&rsquo;s claims. If we were to challenge the validity of these
or any issued United States patent in an administrative trial before the Patent Trial and Appeal Board in the U.S. PTO, we would
have to prove that the claims are unpatentable by a preponderance of the evidence. There is no assurance that a jury and/or court
would find in our favor on questions of infringement, validity or enforceability. Even if we are successful, litigation could result
in substantial costs and be a distraction to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>We may be subject
to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed
alleged confidential information or trade secrets of their former employers.</I></B> As is commonplace in our industry, we will
employ individuals who were previously employed at other pharmaceutical companies, including our competitors or potential competitors.
Although no claims against us are currently pending, we may be subject in the future to claims that our employees or prospective
employees are subject to a continuing obligation to their former employers (such as non-competition or non-solicitation obligations)
or claims that our employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information
of their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against
these claims, litigation could result in substantial costs and be a distraction to management.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Risks Related to Owning Our Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>The market price
of our shares may be subject to fluctuation and volatility. You could lose all or part of your investment</I></B>. The market price
of our common stock is subject to wide fluctuations in response to various factors, some of which are beyond our control. Since
shares of our common stock were sold in our initial public offering in October 2019 at a price of $5.00 per share, the reported
high and low sales prices of our common stock have ranged from $3.44 to $21.14 through December 31, 2020. The market price of our
shares on the NASDAQ Global Market may fluctuate as a result of a number of factors, some of which are beyond our control, including,
but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">actual or anticipated variations in our and our competitors&rsquo; results of operations and financial condition;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">market acceptance of our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in earnings estimates or recommendations by securities analysts, if our shares are covered by analysts;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">development of technological innovations or new competitive products by others;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">announcements of technological innovations or new products by us;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">publication of the results of preclinical or clinical trials for our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">failure by us to achieve a publicly announced milestone;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">delays between our expenditures to develop and market new or enhanced products and the generation of sales from those products;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">developments concerning intellectual property rights, including our involvement in litigation brought by or against us;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in our expenditures to promote our product candidates;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">our sale or proposed sale, or the sale by our significant stockholders, of our shares or other securities in the future;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">changes in key personnel;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">success or failure of our research and development projects or those of our competitors;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the trading volume of our shares; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">general economic and market conditions and other factors, including factors unrelated to our operating performance.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">These factors and any
corresponding price fluctuations may materially and adversely affect the market price of our shares and result in substantial losses
being incurred by our investors. In the past, following periods of market volatility, public company stockholders have often instituted
securities class action litigation. If we were involved in securities litigation, it could impose a substantial cost upon us and
divert the resources and attention of our management from our business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>If securities
or industry analysts do not continue to publish research or publish inaccurate or unfavorable research about our business, our
stock price and trading volume could decline. </I></B>The trading market for our common stock depends in part on the research and
reports that securities or industry analysts publish about us or our business. If industry analysts cease coverage of us, the trading
price for our common stock would be negatively affected. If one or more of the analysts who cover us downgrade our common stock
or publish inaccurate or unfavorable research about our business, our common stock price would likely decline. If one or more of
these analysts cease coverage of us or fail to publish reports on us regularly, demand for our common stock could decrease, which
might cause our common stock price and trading volume to decline. In addition, independent industry analysts may provide reviews
of our product candidates and our TFF platform&rsquo;s capabilities, as well as those of our competitors, and perception of our
offerings in the marketplace may be significantly influenced by these reviews. We have no control over what these industry analysts
report, and because industry analysts may influence current and potential customers, our brand could be harmed if they do not provide
a positive review of our products and platform capabilities or view us as a market leader.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24.75pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Future capital
raises may dilute your ownership and/or have other adverse effects on our operations</I></B>. If we raise additional capital by
issuing equity securities, our existing stockholders&rsquo; percentage ownership will be reduced and these stockholders may experience
substantial dilution. If we raise additional funds by issuing debt securities, these debt securities would have rights senior to
those of our common stock and the terms of the debt securities issued could impose significant restrictions on our operations,
including liens on our assets. If we raise additional funds through collaborations and licensing arrangements, we may be required
to relinquish some rights to our intellectual property or candidate products, or to grant licenses on terms that are not favorable
to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>We are an &ldquo;emerging
growth company&rdquo; under the JOBS Act of 2012 and we cannot be certain if the reduced disclosure requirements applicable to
emerging growth companies will make our common stock less attractive to investors</I></B>. We are an &ldquo;emerging growth company,&rdquo;
as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and we may take advantage of certain exemptions from
various reporting requirements that are applicable to other public companies that are not &ldquo;emerging growth companies&rdquo;
including, but not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">extended transition periods available for complying with new or revised accounting standards.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We have chosen to take
advantage of all of the benefits available under the JOBS Act, including the exemptions discussed above. We cannot predict if investors
will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less
attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We will remain an &ldquo;emerging
growth company&rdquo; for up to five years, although we will lose that status sooner if our revenues exceed $1.07 billion, if we
issue more than $1 billion in non-convertible debt in a three year period, or if the market value of our common stock that is held
by non-affiliates exceeds $700 million as of June 30 in any future year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>If we fail to
maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial
results or prevent fraud</I></B>. Commencing with our annual report on Form 10-K for the fiscal year ended December 31, 2020, we
will be required to provide a report on management&rsquo;s assessment of our internal control over financial reporting. Once we
are neither an emerging growth company nor a non-accelerated filed, we will be required to obtain an attestation from our independent
registered public accounting firm on our internal control report. Effective internal controls over financial reporting are necessary
for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent
fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause
us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section&nbsp;404 of the
Sarbanes-Oxley Act, or the subsequent testing by our independent registered public accounting firm when required, may reveal deficiencies
in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or
retrospective changes to our financial statements or identify other areas for further attention or improvement. Inferior internal
controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect
on the trading price of our common shares. There is also a risk that neither we nor our independent registered public accounting
firm (when applicable in the future) will be able to conclude within the prescribed timeframe that internal controls over financial
reporting is effective as required by Section 404. As a result, investors could lose confidence in our financial and other public
reporting, which would harm our business and the trading price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>We have not paid
dividends in the past and have no immediate plans to pay dividends</I></B>. We plan to reinvest all of our earnings, to the extent
we have earnings, to cover operating costs and otherwise become and remain competitive. We do not plan to pay any cash dividends
with respect to our securities in the foreseeable future. We cannot assure you that we would, at any time, generate sufficient
surplus cash that would be available for distribution to the holders of our common stock as a dividend. Therefore, you should not
expect to receive cash dividends on our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>We may be at
an increased risk of securities class action litigation.</I></B> Historically, securities class action litigation has often been
brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because
biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we were to be
sued, it could result in substantial costs and a diversion of management&rsquo;s attention and resources, which could harm our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Our charter documents
and Delaware law may inhibit a takeover that stockholders consider favorable.</I></B> The provisions of our second amended and
restated certificate of incorporation, or Certificate, and amended and restated bylaws and applicable provisions of Delaware law
may delay or discourage transactions involving an actual or potential change in control or change in our management, including
transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might
otherwise deem to be in their best interests. The provisions in our Certificate and amended and restated bylaws:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">limit who may call stockholder meetings;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">do not provide for cumulative voting rights; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">provide that all board vacancies may be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In addition, Section
203 of the Delaware General Corporation Law may limit our ability to engage in any business combination with a person who beneficially
owns 15% or more of our outstanding voting stock unless certain conditions are satisfied. This restriction lasts for a period of
three years following the share acquisition. These provisions may have the effect of entrenching our management team and may deprive
you of the opportunity to sell your shares to potential acquirers at a premium over prevailing prices. This potential inability
to obtain a control premium could reduce the price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><B><I>Our Certificate
and amended and restated bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain
litigation that may be initiated by our stockholders, which could limit our stockholders&rsquo; ability to obtain a favorable judicial
forum for disputes with us or our directors, officers or other employees</I></B>. Provisions in our Certificate and amended and
restated bylaws provide that the Court of Chancery of the State of Delaware will, to the fullest extent permitted by law, be the
sole and exclusive forum for:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any derivative action or proceeding brought on our behalf;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any action asserting a claim of breach of a fiduciary duty owed to us or our stockholders by any of our directors, officers or other employees;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any action asserting a claim against us or any of our directors, officers or other employees arising pursuant to any provision of Delaware law or our charter documents; or</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine, but excluding actions to enforce a duty or liability created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">These exclusive forum
provisions do not apply to claims under the Securities Act or the Exchange Act. These exclusive forums provisions, however, do
provide that if no state court located in the State of Delaware has jurisdiction, the federal district court for the District of
Delaware shall be the exclusive forum. By becoming a stockholder in our company, you will be deemed to have notice of and have
consented to the provisions of our Certificate and amended and restated bylaws related to choice of forum, but will not be deemed
to have waived our compliance with the federal securities laws and the rules and regulations thereunder. The choice of forum provisions
in our Certificate and amended and restated bylaws may limit our stockholders&rsquo; ability to obtain a favorable judicial forum
for disputes with us or any of our directors, officers or other employees, which may discourage lawsuits with respect to such claims.
Alternatively, if a court were to find the choice of forum provision contained in our Certificate and amended and restated bylaws
to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other
jurisdictions, which could harm our business, results of operations and financial condition.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><A NAME="a_025"></A>Item 1B. Unresolved Staff Comments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_026"></A>Item 2. Properties</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Our former parent,
LTI, currently provides us with office space and certain administrative services and equipment for no charge. Those offices are
located at 2600&nbsp;Via Fortuna, Suite 360 Austin, Texas, 78746; telephone number (737) 802-1975. We also lease 1,500 square feet
of office space in Doylestown, Pennsylvania. The lease agreement is for one year and expires October 31, 2021, subject to our option
to renew for an additional year. The monthly lease rate is $3,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_027"></A>Item 3. Legal Proceedings</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As of the date of this
report, there are no legal proceedings to which we or our properties are subject. We may be involved, from time to time, in legal
proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties and outcomes
and are not predictable with assurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><A NAME="a_028"></A>Item 4. Mine Safety Disclosures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_004"></A>PART II</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><A NAME="a_005"></A>Item 5. Market for Registrant&rsquo;s
Common Equity, Related Stockholder Matters and Issuer Repurchases of Equity Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Market Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our common stock has
traded on the NASDAQ Stock Market under the symbol &ldquo;TFFP,&rdquo; since our initial public offering on October 25, 2019. Since
then, our common stock common stock has experienced, and is expected to experience in the future, significant price and volume
volatility. The following table shows the reported high and low closing prices per share for our common stock based on information
provided by the NASDAQ Stock Market for the periods indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left"><B>Fiscal Year&nbsp;Ended&nbsp;December&nbsp;31,
    2019</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid"><B>High</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><B>&nbsp;</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center; border-bottom: Black 1.5pt solid"><B>Low</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Fourth Quarter (commencing on October 25, 2019)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5.40</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4.71</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; text-align: left"><B>Fiscal Year&nbsp;Ended&nbsp;December&nbsp;31,
    2020</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><B>&nbsp;</B></TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><B>&nbsp;</B></TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; width: 76%">First Quarter</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">$</TD><TD STYLE="text-align: right; width: 9%">5.36</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: left; width: 1%">&nbsp;</TD><TD STYLE="text-align: right; width: 9%">3.51</TD><TD STYLE="text-align: left; width: 1%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Second Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.08</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.79</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Third Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18.47</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.86</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Fourth Quarter</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18.49</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12.74</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Holders of Record</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">As of March 5, 2021,
there were 14 holders of record of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Dividend Policy</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We have never declared
or paid cash dividends on our common stock. We presently intend to retain earnings to finance the operation and expansion of our
business.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Equity Compensation Plan Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We have adopted the
TFF Pharmaceuticals, Inc. 2018 Stock Incentive Plan providing for the grant of non-qualified stock options and incentive stock
options to purchase shares of our common stock and for the grant of restricted and unrestricted share grants. We reserved
3,284,480 shares of our common stock under the 2018 Plan. All officers, directors, employees and consultants to our
company are eligible to participate under the plan. The purpose of the plan is to provide eligible participants with
an opportunity to acquire an ownership interest in our company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The following table
sets forth certain information as of December 31, 2020 about our stock plans under which our equity securities are authorized for
issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Plan Category</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(a)<BR>
Number of Securities to be Issued Upon Exercise of Outstanding Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(b)<BR>
Weighted-Average Exercise Price of Outstanding Options</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">(c)<BR>
Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities Reflected In Column (a))</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 64%; text-align: left">Equity compensation plans approved by security holders</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,610,495</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">5.63</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">673,985</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Equity compensation plans not approved by security holders</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,610,495</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5.63</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">673,985</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Unregistered Sales of Equity Securities and Use of Proceeds</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On August 10, 2020,
we entered into a Securities Purchase Agreement, or the Purchase Agreement, and a Registration Rights Agreement with certain institutional
and other accredited investors, pursuant to which the investors purchased 3,048,654 shares of our common stock at a price of $8.50
per share for the approximate gross proceeds of $25.91 million, before deducting placement agent and other offering expenses. The
Purchase Agreement included customary representations, warranties, and covenants by the investors and us, and an indemnity from
us in favor of the investors. Pursuant to the terms of the Registration Rights Agreement, we filed a resale registration statement
with the SEC on September 9, 2020 for purposes of registering the resale of the shares sold to the investors. The sale of our shares
to the investors was exempt under Section 4(a)(2) of the Securities Act of 1933 and Rule 506 there under. All of the investors
were accredited investors, as such term is defined in Rule 501 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><A NAME="a_006"></A>Item 6. Selected Financial Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><A NAME="a_007"></A>Item 7. Management&rsquo;s Discussion
and Analysis of Financial Condition and Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We were formed as a
Delaware corporation on January 24, 2018 for the purpose of developing and commercializing innovative drug products based on our
patented Thin Film Freezing, or TFF, technology platform&rdquo;. Since our formation, we have focused on the development of our
initial drug candidates, the establishment of strategic relationships with established pharmaceutical companies for the licensing
of our TFF technology platform and the pursuit of additional working capital. We have not commenced revenue-producing operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Since our organization
in 2018, we have engaged in the following financing transactions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><I>Series A Preferred
Stock Placements</I>. In March 2018, we conducted a private placement of 5,662,000 shares of our Series A preferred stock, at an
offering price of $2.50 per share, for the gross proceeds of approximately $14.2 million, and in May 2019 we conducted a private
placement of 3,268,000 shares of our Series&nbsp;A preferred stock, at an offering price of $2.50 per share, for the gross proceeds
of approximately $8.2&nbsp;million<I>.</I> The shares of our Series A preferred stock accumulated dividends at the rate of 6% per
annum<I>.</I> The shares of Series A preferred stock, including all accrued but unpaid dividends on the Series A preferred stock,
which totaled $1,603,709, automatically converted into 9,571,692 shares of our common stock concurrent with the completion of our
initial public offering at the conversion price of $2.50<I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><I>Initial Public Offering</I>.
On October 25, 2019, we conducted an initial public offering of 4,400,000 shares of common stock at a public offering price of
$5.00 per share. After the payment of underwriter discounts and offering expenses, and after giving effect to the underwriters&rsquo;
exercise of its overallotment option on November&nbsp;20, 2019 to purchase an additional 479,300 shares of our common stock at
the offering price of $5.00 per share, we received net proceeds of approximately $21.8 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"><I>August 2020 Private
Placement</I>. On August 13, 2020, we conducted a private placement of 3,048,654 shares of common stock, at a purchase price per
share of $8.50, for aggregate gross proceeds of approximately $25,914,000, before deducting selling commissions and other offering
expenses. After deducting the placement agent and other offering expenses, we received net proceeds of approximately $24,280,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Results of Operations</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.45in">We were formed in
January 2018 and have not commenced revenue-producing operations. To date, our operations have consisted of the development and
early-stage testing of our initial product candidates. In connection with our organization on January 24, 2018, we entered into
a Contribution and Subscription Agreement with Lung Therapeutics, Inc., or LTI, our former parent, pursuant to which we agreed
to acquire from LTI certain of LTI&rsquo;s non-core intellectual property rights and other assets, or the Acquired Assets, all
of which relate to our Thin Film Freezing technology. We closed on the acquisition of the Acquired Assets concurrent with the close
of the initial Series A preferred stock financing in March 2018.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.45in">In December 2019,
the Company established a wholly-owned Australian subsidiary, TFF Pharmaceuticals Australia Pty Ltd. in order to conduct clinical
research.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.45in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.45in">On March 11, 2020,
the World Health Organization declared a novel strain of coronavirus disease (&ldquo;COVID-19&rdquo;) a global pandemic. We had
expected to commence Phase I clinical trials our TFF formulation of Tacrolimus in Australia in the first quarter of 2020, and on
March 13, 2020 we had received the approval of the Australian Human Research Ethics Committee to commence Phase I trials, however
later in March 2020 our contract research organization in Australia informed us that because of the spread of the COVID-19 virus
in Australia, there would be a delay in initiating the trial. During the second quarter of 2020, we were able to begin dosing in
the Phase I Tacrolimus trial in Melbourne, Victoria, Australia. However, due to the resurgence of COVID-19 in the Melbourne area,
in July 2020 the Phase I trials were delayed. With the flaring of COVID-19 in the Melbourne area and in order to remain dynamic,
we opened a second clinical trial site in Brisbane, Queensland, Australia and dosing in the Phase 1 clinical trial resumed in Australia
during the third quarter 2020. We expect that dosing in this trial will be completed early in the second quarter of 2021. Any financial
impact cannot be reasonably estimated at this time, but may materially affect our business and financial condition. The extent
to which COVID-19 impacts our results will depend on future developments, which are highly uncertain and cannot be predicted, including
new information which may emerge concerning the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among
others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.45in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">During the fiscal years
ended December 31, 2020 and 2019, we incurred $10.7&nbsp;million and $8.8&nbsp;million of research and development expenses and
$8.0&nbsp;million and $3.2&nbsp;million of general and administrative expenses, respectively. The increase in research and development
expenses during 2020 was due to the ramp-up of research and development activities following the completion of our IPO in October
2019. The ramp up includes our preliminary analysis and testing of dry powder formulations of certain drugs and vaccines we believe
have the potential to become product candidates. We expect our spending on research and development activities to continue to increase
in upcoming quarters. The increase in general and administrative expenses in 2020 from the prior year was mainly a result of public-company
related increases in expenses of approximately $1,250,000, increased expenses related to consulting and business development activities
of approximately $1,274,000, payroll and related expense increases of approximately $827,000 and an increase in stock-based compensation
of approximately $1,457,000. While we expect our general and administrative expenses to continue to increase over the next few
years, we anticipate the rate of increase will be less than the increase from 2019 to 2020. We incurred a net loss applicable to
common stockholders of $18.6&nbsp;million and $36.7&nbsp;million for the fiscal years ended December 31, 2020 and 2019, respectively.
The decrease in net loss applicable to common stockholders was due to a deemed dividend of $24.0 million upon the conversion of
our Series A preferred stock in October 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Financial Condition</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">As of December 31,
2020, we had total assets of approximately $38.7&nbsp;million and working capital of approximately $36.2&nbsp;million. As of December
31, 2020, our liquidity included approximately $35.3&nbsp;million of cash and cash equivalents. We believe that our cash on-hand
as of the date of this report is sufficient to fund our proposed operating plan for, at least, the 12 months following the date
of this report. However, as of the date of this report, we believe that we will need additional capital to fund our operations
through to the marketing approval for TFF VIP and TFF TIP, assuming such approval can be obtained at all, and to engage in the
substantial development of any other of our drug candidates, such as formulation, early stage animal testing and formal toxicology
studies. If we encounter unforeseen delays or expenses, we have the ability to curtail our presently planned level of operations.
We intend to seek additional funds through various financing sources, including the sale of our equity and debt securities, licensing
fees for our technology and co-development and joint ventures with industry partners, with a preference towards licensing fees
for our technology and co-development and joint ventures with industry partners. In addition, we will consider alternatives to
our current business plan that may enable to us to achieve revenue producing operations and meaningful commercial success with
a smaller amount of capital. However, there can be no guarantees that such funds will be available on commercially reasonable terms,
if at all. If such financing is not available on satisfactory terms, we may be unable to further pursue our business plan and we
may be unable to continue operations, in which case you may lose your entire investment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Cash Flows</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The following table
sets forth a summary of our cash flows for the years ended December 31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<BR>December&nbsp;31,<BR> 2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year ended<BR>December&nbsp;31,<BR> 2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left">Net cash used in operating activities</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(16,615,589</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(11,216,122</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash used in investing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,102,808</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash flows provided by financing activities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,994,665</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,049,387</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Effect of exchange rate changes</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(70,399</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Net increase in cash and cash equivalents</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">7,205,869</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">17,833,265</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The increase in cash
used in operating activities is primarily a result of higher operating losses in 2020 due to our business expansion, including
additional personnel and increased product candidate development activity. The financing activity primarily consists of the October
2019 initial public offering, or IPO, and the August 2020 private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Critical Accounting Policies</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our consolidated financial
statements are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP. The
preparation of our consolidated financial statements and related disclosures requires us to make estimates and judgments that affect
the reported amounts of assets, liabilities, costs and expenses in our consolidated financial statements. We base our estimates
on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily
apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from
these estimates under different assumptions or conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">While our significant
accounting policies are described in more detail in Note 3 to our consolidated financial statements included herein, we believe
that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated
financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Stock-Based Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We compute stock-based
compensation in accordance with authoritative guidance. We use the Black-Scholes-Merton option-pricing model to determine the fair
value of its stock options. The Black-Scholes-Merton option-pricing model includes various assumptions, including the fair market
value of our common stock, expected life of stock options, the expected volatility and the expected risk-free interest rate, among
others. These assumptions reflect our best estimates, but they involve inherent uncertainties based on market conditions generally
outside our control.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">As a result, if other
assumptions had been used, stock-based compensation cost, as determined in accordance with authoritative guidance, could have been
materially impacted. Furthermore, if we use different assumptions on future grants, stock-based compensation cost could be materially
affected in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">For grants prior to
the IPO, the fair value of the common stock was determined by the board of directors based on a variety of factors, including valuations
prepared by third parties, our financial position, the status of our development efforts, the current climate in the marketplace
and the prospects of a liquidity event, among others. For grants after the IPO, we use the closing stock price on the date of grant
as the fair value of the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Research and Development Expenses</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">In accordance with
authoritative guidance, we charge research and development costs to operations as incurred. Research and development expenses consist
of personnel costs for the design, development, testing and enhancement of our technology, and certain other allocated costs, such
as depreciation and other facilities related expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Common Stock Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We classify as equity
any warrants that (i) require physical settlement or net-share settlement or (ii)&nbsp;provides us with a choice of net-cash settlement
or settlement in its own shares (physical settlement or net-share settlement). We classify as assets or liabilities any contracts
that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event
is outside our control), (ii) gives the counterparty a choice of net-cash settlement or settlement in shares (physical settlement
or net-share settlement) or (iii) that contain reset provisions that do not qualify for the scope exception. We assess classification
of its common stock warrants and other freestanding derivatives at each reporting date to determine whether a change in classification
between assets and liabilities is required. Our freestanding derivatives consist of warrants to purchase common stock that were
issued in connection with services provided to us. We evaluated these warrants to assess their proper classification and determined
that the common stock warrants meet the criteria for equity classification in the consolidated balance sheet. Such warrants are
measured at fair value, which we determine using the Black-Scholes-Merton option-pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Beneficial Conversion Feature</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">On the date of the
IPO, the outstanding Series A preferred stock, and related accrued and unpaid dividends, automatically converted into shares of
our common stock. The conversion share calculation was based on the $2.50 initial issuance price for the Series A preferred stock
plus any accrued but unpaid dividends and converted to common stock using a stated divisor conversion price equal to 50% of the
IPO price to the public, which was $5.00 per share. In accordance with relevant accounting literature, since the stated terms of
the conversion option did not permit us to compute the additional number of shares that it would need to issue upon conversion
of the Series A preferred stock when the contingent event occurred, we recorded the beneficial conversion amount as a deemed dividend
at the date of the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Off Balance Sheet Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We do not have any
off-balance sheet transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><A NAME="a_008"></A>Item 7A. Quantitative and Qualitative
Disclosures About Market Risk</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B><A NAME="a_009"></A>Item 8. Financial
Statements and Supplementary Data</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Index to Consolidated Financial Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 90%; text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><A HREF="#b_001">Report of Independent Registered Public Accounting Firm</A></FONT></TD>
    <TD STYLE="width: 1%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center"><FONT STYLE="font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><A HREF="#b_002">Consolidated Balance Sheets as of December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><A HREF="#b_003">Consolidated Statements of Operations for the years ended December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><A HREF="#b_004">Consolidated Statements of Stockholders&rsquo; Equity for the years ended December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><A HREF="#b_005">Consolidated Statements of Cash Flows for the years ended December 31, 2020 and 2019</A></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt"><A HREF="#b_006">Notes to Consolidated Financial Statements</A></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">F-7</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<!-- Field: Page; Sequence: 44; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_001"></A>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
the Shareholders and Board of Directors of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TFF
Pharmaceuticals, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Opinion
on the Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of TFF Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) as of December
31, 2020 and 2019, the related consolidated statements of operations, stockholders&rsquo; equity and cash flows for each of the
two years in the period ended December 31, 2020, and the related notes (collectively referred to as the &ldquo;financial statements&rdquo;).
In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of
December 31, 2020 and 2019, and the results of its operations and its cash flows for each of the two years in the period ended
December 31, 2020, in conformity with accounting principles generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Basis
for Opinion</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express an opinion on
the Company&rsquo;s financial statements based on our audits. We are a public accounting firm registered with the Public Company
Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent with respect to the Company
in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission
and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not
for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that our audits provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Marcum
<FONT STYLE="font-variant: small-caps">llp</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&rsquo;s auditor since 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, NY<BR>
March 10, 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_002"></A>TFF
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
BALANCE SHEETS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">ASSETS</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Current assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 76%; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">35,300,805</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">28,094,936</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Prepaid assets and other current assets</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,258,229</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,092,462</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Total current assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">37,559,034</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">29,187,398</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Property and equipment, net</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,102,808</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 4pt">Total assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">38,661,842</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">29,187,398</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">LIABILITIES AND STOCKHOLDERS&rsquo; EQUITY</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Current liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,297,725</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">410,638</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Deferred research grant revenue</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,315</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left">Total current liabilities</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,322,040</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">410,638</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Accrued research and development expense (see Note 5)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,132,013</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Total liabilities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,322,040</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,542,651</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Commitments and contingencies (see Note 4)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Common stock; $0.001 par value, 45,000,000 shares authorized; 22,534,874 and 18,450,992 shares issued and outstanding as of December 31, 2020 and 2019, respectively</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">22,535</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,451</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Additional paid-in capital</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">71,648,453</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,338,710</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left">Accumulated other comprehensive loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51,538</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Accumulated deficit</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(34,279,648</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(15,712,414</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Total stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">37,339,802</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">27,644,747</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 4pt">Total liabilities and stockholders&rsquo; equity</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">38,661,842</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">29,187,398</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_003"></A>TFF
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD COLSPAN="9" STYLE="vertical-align: bottom; font-weight: bold; text-align: center"><U>CONSOLIDATED STATEMENTS OF OPERATIONS</U></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Year Ended</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Year Ended</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">December&nbsp;31,</TD><TD STYLE="text-align: center; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Operating expenses:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; width: 76%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">10,681,565</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">8,822,226</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">8,012,085</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">3,165,331</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Total operating expenses</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">18,693,650</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">11,987,557</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Loss from operations</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,693,650</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,987,557</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Other income:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.25in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Interest income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">126,416</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">117,329</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.375in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Total other income</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">126,416</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">117,329</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(18,567,234</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(11,870,228</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Preferred stock dividend</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(875,359</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Deemed dividend for beneficial conversion feature of Series A Preferred Stock</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(23,929,751</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 4pt">Net loss applicable to common stock</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(18,567,234</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(36,675,338</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 4pt">Net loss applicable to common stock per share, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(0.91</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(5.31</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 4pt">Weighted average common shares outstanding, basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">20,425,162</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,904,983</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD COLSPAN="9" STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-decoration: underline; text-align: left">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; font-weight: bold; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Net loss</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(18,567,234</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">(11,870,228</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Other comprehensive loss:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Foreign currency translation adjustments</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(51,538</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 4pt">Comprehensive loss</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(18,618,772</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(11,870,228</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_004"></A>TFF
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF STOCKHOLDERS&rsquo; EQUITY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE YEARS ENDED DECEMBER 31, 2020 AND 2019</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Common Stock</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Additional Paid in</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Accumulated Other Comprehensive</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Accumulated</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center">Total Stockholders&rsquo;</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Shares</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Capital</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Loss</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Deficit</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Equity</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; width: 28%; text-align: left">Balance, January 1, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4,000,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">596,724</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">-</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(3,842,186</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(3,241,462</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Issuance of common stock in connection with IPO, including underwriter&rsquo;s over- allotment, net of offering costs and underwriter&rsquo;s discount</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,879,300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4,879</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,748,969</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,753,848</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">590,041</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">590,041</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Dividends on preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(875,359</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(875,359</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Conversion of Series A Preferred Stock (including accrued dividends) to common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,571,692</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9,572</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,278,335</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,287,907</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,870,228</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,870,228</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Balance, December 31, 2019</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,450,992</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">18,451</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">43,338,710</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(15,712,414</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">27,644,747</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Sale of common stock, net of offering costs</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,048,654</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,048</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,277,235</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,280,283</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Issuance of common stock for accrued research and development expense</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">220,666</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">221</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,131,792</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,132,013</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Issuance of common stock for stock option exercises</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">285,003</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">285</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">714,097</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">714,382</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Issuance of common stock in connection with cashless warrant exercises</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">529,559</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">530</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(530</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Stock-based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,187,149</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,187,149</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">Foreign currency translation adjustment</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51,538</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(51,538</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 1.5pt">Net loss</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(18,567,234</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(18,567,234</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; vertical-align: top; text-align: left; padding-bottom: 4pt">Balance, December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">22,534,874</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">22,535</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">71,648,453</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(51,538</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">(34,279,648</TD><TD STYLE="padding-bottom: 2pt; text-align: left">)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">37,339,802</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><A NAME="b_005"></A>TFF
PHARMACEUTICALS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONSOLIDATED
STATEMENTS OF CASH FLOWS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December&nbsp;31,<BR> 2020</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD><TD STYLE="text-align: center; font-weight: bold; padding-bottom: 1.5pt; vertical-align: bottom">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="vertical-align: bottom; font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December&nbsp;31,<BR> 2019</TD><TD STYLE="text-align: center; padding-bottom: 1.5pt; font-weight: bold; vertical-align: bottom">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash flows from operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; width: 76%; text-align: left">Net loss</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(18,567,234</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(11,870,228</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Adjustment to reconcile net loss to net cash used in operating activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Stock based compensation</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,187,149</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">590,041</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.375in; text-align: left">Changes in operating assets and liabilities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.5in; text-align: left">Prepaid assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,122,495</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1,080,397</TD><TD STYLE="text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.5in; text-align: left">Accounts payable</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">862,676</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">12,449</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.5in; text-align: left">Deferred research grant revenue</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,315</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.5in; text-align: left; padding-bottom: 1.5pt">Accrued research and development expense</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,132,013</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net cash used in operating activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(16,615,589</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(11,216,122</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash flows from investing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Purchases of property and equipment</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,102,808</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net cash used in investing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(1,102,808</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Cash flows from financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net proceeds from issuance of common stock in connection with IPO</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">21,851,160</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net proceeds from issuance of preferred stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,198,227</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left">Net proceeds from issuance of common stock</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">24,280,283</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Proceeds from issuance of common stock for stock option exercises</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">714,382</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Net cash provided by financing activities</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">24,994,665</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">29,049,387</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 1.5pt">Effect of exchange rate changes on cash and cash equivalents</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(70,399</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Net increase in cash and cash equivalents</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">7,205,869</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">17,833,265</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Cash and cash equivalents at beginning of year</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">28,094,936</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">10,261,671</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Cash and cash equivalents at end of year</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">35,300,805</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">28,094,936</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.125in; text-align: left">Supplemental disclosure of non-cash investing and financing activities:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Accrued dividend</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">875,359</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Conversion of Series A Preferred Stock (including accrued dividends) to common stock</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">21,287,907</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Offering costs netted with proceeds from IPO</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">97,312</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Deemed dividend for beneficial conversion feature of Series A Preferred Stock</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">23,929,751</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Cashless exercise of warrants</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">530</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="vertical-align: bottom; text-indent: -0.125in; padding-left: 0.25in; text-align: left; padding-bottom: 4pt">Issuance of common stock for accrued research and development expense</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">1,132,013</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
accompanying notes are an integral part of these consolidated financial statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="b_006"></A>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 1 &ndash; ORGANIZATION AND DESCRIPTION OF BUSINESS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">TFF Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;)
was incorporated in the State of Delaware on January 24, 2018 by Lung Therapeutics, Inc. (&ldquo;LTI&rdquo;), at which time the
Company and LTI entered into a Contribution and Subscription Agreement (&ldquo;Contribution Agreement&rdquo;) pursuant to which
LTI agreed to transfer to the Company certain of LTI&rsquo;s non-core intellectual property rights and other assets, including
LTI&rsquo;s rights under a patent license agreement with the University of Texas at Austin (see Note 5), in exchange for 4,000,000
shares of the Company&rsquo;s common stock. The transactions under the Contribution Agreement closed in March 2018. LTI&rsquo;s
basis in such assets were minimal. LTI is an early-stage biotechnology company focused on the development of certain technologies
in the pulmonary field. The Company&rsquo;s initial focus is on the development of inhaled dry powder drugs to enhance the treatment
of pulmonary diseases and conditions. In December 2019, the Company established a wholly-owned Australian subsidiary, TFF Pharmaceuticals
Australia Pty Ltd (&ldquo;TFF Australia&rdquo;), in order to conduct clinical research. TFF Pharmaceuticals, Inc., along with TFF
Australia, are collectively referred to as the &ldquo;Company&rdquo;. The Company is in the development stage and is devoting substantially
all of its efforts toward technology research and development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>October 2019 Initial Public Offering</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In October 2019, the Company completed
an initial public offering (&ldquo;IPO&rdquo;), selling 4,400,000 shares of common stock at an offering price of $5.00 per share.
The Company received gross proceeds of approximately $22,000,000. In addition, the Company granted the underwriter a 45-day option
to purchase an additional 660,000 shares of common stock at the initial public offering price, less underwriting discounts and
commissions. The option was exercised in November 2019 and the underwriter purchased an additional 479,300 shares of common stock
and the Company received additional gross proceeds of approximately $2,397,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>August 2020 Private Placement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 13, 2020, the Company conducted
a private placement of 3,048,654 shares of its common stock, at a purchase price per share of $8.50, for aggregate gross proceeds
to the Company of approximately $25,914,000, before deducting selling commissions and other offering expenses payable by the Company.
After deducting the placement agent and other offering expenses, the Company received net proceeds of approximately $24,280,000.
See Note 6 for additional details of the private placement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>COVID-19</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On March 11, 2020, the World Health Organization
declared a novel strain of coronavirus disease (&ldquo;COVID-19&rdquo;) a global pandemic. At this time, the United States and
certain other countries are the subject of lock-downs and self-isolation procedures, which have significantly limited business
operations and restricted internal and external meetings.&nbsp;The Company had expected to commence Phase I clinical trials of
its thin film freezing, or TFF, formulation of Tacrolimus in Australia in the first quarter of 2020, and on March 13, 2020 the
Company received the approval of the Alfred Hospital Human Research Ethics Committee to commence Phase I trials, however, later
in March 2020, the Company&rsquo;s contract research organization in Australia informed the Company that because of the spread
of the COVID-19 virus in Australia, there would be a delay in initiating the trial. During the second quarter of 2020, the Company
was able to begin dosing in the Phase I Tacrolimus trial in Melbourne, Victoria, Australia. However, due to the resurgence of COVID-19
in the Melbourne area, in July 2020 the Phase I trials were delayed. With the flaring of COVID-19 in the Melbourne area and in
order to remain dynamic, the Company opened a second clinical trial site in Brisbane, Queensland, Australia. and dosing in the
Phase 1 clinical trial resumed in Australia during the third quarter 2020. We expect that dosing in this trial will be completed
early in the second quarter of 2021. Any financial impact from the COVID-19 global pandemic cannot be reasonably estimated at this
time, but may materially affect our business and financial condition. The extent to which COVID-19 impacts our results will depend
on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning
the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 2 &ndash; LIQUIDITY AND MANAGEMENT&rsquo;S PLANS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2020, the Company had
cash and cash equivalents of approximately $35,301,000 and a working capital surplus of approximately $36,237,000. The Company
has not generated revenues since inception and has incurred recurring operating losses. The Company expects to continue incurring
losses for the foreseeable future and may need to raise additional capital to pursue its product development.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to further increase
its research and development activities, which will increase the amount of cash utilized subsequent to December 31, 2020. Specifically,
the Company expects increased spending on research and development activities and higher payroll expenses as it increases its professional
and scientific staff and continues to prepare for anticipated manufacturing activities. If we encounter unforeseen delays or expenses,
we have the ability to curtail our presently planned level of operations. The Company currently believes its existing cash and
cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12
months from the date of issuance of these consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 3 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Basis of Presentation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company&rsquo;s consolidated financial
statements are presented in accordance with accounting principles generally accepted in the United States of America (&ldquo;GAAP&rdquo;)
and the rules and regulations of the Securities and Exchange Commission (&ldquo;SEC&rdquo;) and reflect the financial position,
results of operations and cash flows for all periods presented.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Principles of Consolidation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The consolidated financial statements include
the accounts of TFF Pharmaceuticals, Inc. and its wholly-owned subsidiary, TFF Australia. All material intercompany accounts and
transactions have been eliminated in consolidation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Foreign Currency</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The currency of TFF Australia, the Company&rsquo;s
international subsidiary, is in Australian dollars. Foreign currency denominated assets and liabilities are translated into U.S.
dollars using the exchange rates in effect at each balance sheet date. Results of operations and cash flows are translated using
the average exchange rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities
is included as a separate component of stockholders&rsquo; equity in accumulated other comprehensive income (loss).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Geographic Concentrations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company conducts business in the U.S.
and Australia. As of December 31, 2020, the Company maintained 100% of its net property and equipment in the U.S. There was no
property and equipment as of December 31, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Deferred Offering Costs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company complies with the requirements
of Accounting Standards Codification (&ldquo;ASC&rdquo;) 340, <I>Other Assets and Deferred Costs</I>. Deferred offering costs of
consisted primarily of legal, accounting and filing fees that were related to the Company&rsquo;s IPO and were charged to capital
upon completion of the IPO in October 2019. There are no deferred offering costs as of December&nbsp;31, 2020 and 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Cash and Cash Equivalents</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company maintains its operating accounts
in financial institutions in the U.S. and in Australia. The balances are insured up to specified limits. The Company&rsquo;s cash
is maintained in checking accounts and money market funds with maturities of less than three months when purchased, which are readily
convertible to known amounts of cash, and which in the opinion of management are subject to insignificant risk of loss in value.
As of December 31, 2020 and 2019, the Company had cash in Australia of AUD$214,240 (US$165,092) and $0, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 3 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Property and Equipment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Property and equipment are stated at cost
less accumulated depreciation and amortization. The Company calculates depreciation using the straight-line method over the estimated
useful lives of the assets, which range from&nbsp;two&nbsp;to&nbsp;five&nbsp;years for furniture, fixtures, lab and computer equipment
and software. Assets held within construction in progress are not depreciated. Construction in progress is related to the construction
or development of property and equipment that have not yet been placed in service for its intended use. As of December 31, 2020,
all of the Company&rsquo;s property and equipment consist of lab equipment that are considered construction in progress. Expenditures
for repairs and maintenance of assets are charged to expense as incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Fair Value of Financial Instruments</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Authoritative guidance requires disclosure
of the fair value of financial instruments. The Company&rsquo;s financial instruments consist of cash and cash equivalents and
accounts payable, the carrying amounts of which approximate their estimated fair values primarily due to the short-term nature
of the instruments or based on information obtained from market sources and management estimates. The Company measures the fair
value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality
and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value which
is not equivalent to cost will be classified and disclosed in one of the following three categories:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Level 1 &mdash; Quoted prices (unadjusted)
in active markets for identical assets and liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Level 2 &mdash; Inputs other than Level
1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted
quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market
data for substantially the full term of the assets or liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Level 3 &mdash; Unobservable inputs that
are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Income Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In accordance with authoritative guidance,
deferred tax assets and liabilities are recorded for temporary differences between the financial reporting and tax bases of assets
and liabilities using the current enacted tax rate expected to be in effect when the differences are expected to reverse. A valuation
allowance is recorded on deferred tax assets unless realization is considered more likely than not.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company evaluates its tax positions
taken or expected to be taken in the course of preparing the Company&rsquo;s tax returns to determine whether the tax positions
are &ldquo;more-likely-than-not&rdquo; of being sustained by the applicable tax authority. Tax positions not deemed to meet the
&ldquo;more-likely-than-not&rdquo; threshold are not recorded as a tax benefit or expense in the current year. The Company recognizes
interest and penalties, if any, related to uncertain tax positions in interest expense. No interest and penalties related to uncertain
tax positions were accrued at either December&nbsp;31, 2020 or 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company follows authoritative guidance
which requires the evaluation of existing tax positions. The Company files in the federal and various state jurisdictions. Management
has analyzed all open tax years, as defined by the statute of limitations, for all major jurisdictions. Open tax years are those
that are open for examination by taxing authorities. The Company was incorporated during 2018 which is the only open year at this
time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Revenue Recognition</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company entered into a feasibility
and material transfer agreement (&ldquo;Feasibility Agreement&rdquo;) with a third party that provided the Company funds in return
for certain research and development activities. Revenue from the Feasibility Agreement will be recognized in the period during
which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Feasibility
Agreement have been met.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 3 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued</U></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Feasibility Agreement is on a best-effort
basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable.
The costs associated with the agreement are expensed as incurred and will be reflected as a component of research and development
expense in the accompanying consolidated statements of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Funds received from the Feasibility Agreement
will be recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Feasibility
Agreement are part of the Company&rsquo;s development programs. In those instances where the Company first receives consideration
in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company
provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt
of consideration, the Company records a grant receivable. As of December 31, 2020 and 2019, the Company had deferred grant revenue
of $24,315 and $0, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Research and Development Expenses</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In accordance with authoritative guidance,
the Company charges research and development costs to operations as incurred. Research and development expenses consist of personnel
costs for the design, development, testing and enhancement of the Company&rsquo;s technology, and certain other allocated costs,
such as depreciation and other facilities related expenditures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Basic and Diluted Earnings per Common Share</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share
is computed by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding
for the period, determined using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods
presented, all potentially dilutive securities are anti-dilutive. Basic weighted average shares outstanding for the years ended
December 31, 2020 and 2019 include 400,000 shares underlying a warrant to purchase common shares. As the shares underlying this
warrant can be issued for little consideration (an aggregate exercise price of $0.01 per share), these shares are deemed to be
issued for purposes of basic earnings per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For the years ended December 31, 2020 and
2019, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of
diluted net loss per common share because inclusion thereof would be anti-dilutive:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Stock Options</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,610,495</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">2,139,078</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Warrants</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">417,355</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,076,463</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,027,850</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3,215,541</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Common Stock Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company classifies as equity any warrants
that (i) require physical settlement or net-share settlement or (ii)&nbsp;provide the Company with a choice of net-cash settlement
or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities
any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs
and if that event is outside the Company&rsquo;s control), (ii) gives the counterparty a choice of net-cash settlement or settlement
in shares (physical settlement or net-share settlement) or (iii) that contain reset provisions that do not qualify for the scope
exception. The Company assesses classification of its common stock warrants and other freestanding derivatives at each reporting
date to determine whether a change in classification between assets and liabilities is required. The Company&rsquo;s freestanding
derivatives consist of warrants to purchase common stock that were issued in connection with services provided to the Company.
The Company evaluated these warrants to assess their proper classification and determined that the common stock warrants meet the
criteria for equity classification in the consolidated balance sheet. Such warrants are measured at fair value, which the Company
determines using the Black-Scholes-Merton option-pricing model.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 3 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Beneficial Conversion Feature</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On the date of the IPO, the outstanding
Series A Convertible Preferred Stock (&ldquo;Series A Preferred Stock&rdquo;), and related accrued and unpaid dividends, automatically
converted into shares of the Company&rsquo;s common stock. The conversion share calculation was based on the $2.50 initial issuance
price for the Series A Preferred Stock plus any accrued but unpaid dividends and converted to common stock using a stated divisor
conversion price equal to 50% of the IPO price to the public, which was $5.00 per share. In accordance with relevant accounting
literature, since the stated terms of the conversion option did not permit the Company to compute the additional number of shares
that it would need to issue upon conversion of the Series A Preferred Stock when the contingent event occurred, the Company recorded
the beneficial conversion amount of approximately $23,930,000 as a deemed dividend at the date of the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Stock-Based Compensation</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company computes stock-based compensation
in accordance with authoritative guidance. The Company uses the Black-Scholes-Merton option-pricing model to determine the fair
value of its stock options. The Black-Scholes-Merton option-pricing model includes various assumptions, including the fair market
value of the common stock of the Company, expected life of stock options, the expected volatility and the expected risk-free interest
rate, among others. These assumptions reflect the Company&rsquo;s best estimates, but they involve inherent uncertainties based
on market conditions generally outside the control of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As a result, if other assumptions had been
used, stock-based compensation cost, as determined in accordance with authoritative guidance, could have been materially impacted.
Furthermore, if the Company uses different assumptions on future grants, stock-based compensation cost could be materially affected
in future periods.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Use of Estimates</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The preparation of consolidated financial
statements in conformity with GAAP requires the Company&rsquo;s management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and
the reported amounts of expenses during the reporting period. Significant estimates include the fair value of stock-based compensation
and warrants, valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Recent Accounting Standards</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In February 2016, the Financial Accounting
Standards Board (&ldquo;FASB&rdquo;) issued Accounting Standards Update (&ldquo;ASU&rdquo;) No. 2016-02, <I>Leases (Topic 842)</I>.
This ASU will require lessees to recognize a right-of-use asset and lease liability on the consolidated balance sheet for leases
with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern
of expense recognition in the income statement. ASU No. 2016-02 supersedes the lease accounting requirements of ASC Topic 840,
<I>Leases.</I> The Company adopted this standard on January 1, 2020, using the modified retrospective approach, which did not cause
adjustments to prior comparative periods. The new standard provides a number of optional practical expedients in transition. The
Company has elected the following &ldquo;package of practical expedients&rdquo; when assessing the transition impact as the lessee
as of January 1, 2020: (1) not to reassess whether any expired or existing contracts, contain leases; (2) not to reassess the lease
classification for any expired or existing leases; and (3) not to reassess initial direct costs for any existing leases. Leases
with an initial term of 12 months or less are considered short-term leases and are not recorded on the balance sheet as the Company
recognizes lease expense for these leases on a straight-line basis over the lease term. The Company reviewed all contracts that
may contain leases and has determined that there was no impact related to the adoption of ASU 2016-02 as the only contract that
contains a lease on the adoption date is for office space in Doylestown, Pennsylvania, which is considered a short-term lease.
See Note 4 for more information regarding the leased office space.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 3 &ndash; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, continued</U></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In July 2017, the FASB issued ASU 2017-11,
<I>Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815):
I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily
Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with
a Scope Exception</I>, (ASU 2017-11). Part I of this update addresses the complexity of accounting for certain financial instruments
with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result
in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost
and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features
that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses
the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content
in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements
about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling
interests. The amendments in Part II of this update do not have an accounting effect. This guidance is effective for public business
entities for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and effective
for all other entities for fiscal years beginning after December 15, 2019 and interim periods within fiscal years beginning after
December 15, 2020. The adoption of this standard did not have a material effect on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In June 2018, the FASB issued ASU No. 2018-07,
<I>Compensation &mdash; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</I>. The guidance
in this ASU expands the scope of ASC Topic 718 to include all share-based payment arrangements related to the acquisition of goods
and services from both nonemployees and employees. This guidance is effective for public business entities for fiscal years beginning
after December 15, 2018, including interim periods within those fiscal years, and effective for all other entities for fiscal years
beginning after December 15, 2019 and interim periods within fiscal years beginning after December 15, 2020. The adoption of this
standard did not have a material effect on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In August 2018, the FASB issued ASU 2018-13,
&ldquo;<I>Fair Value Measurement</I> (Topic 820), - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value
Measurement,&rdquo; which makes a number of changes meant to add, modify or remove certain disclosure requirements associated with
the movement amongst or hierarchy associated with Level 1, Level 2 and Level&nbsp;3 fair value measurements. This guidance is effective
for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The adoption of this standard
did not have a material effect on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In December 2019, the FASB issued ASU 2019-12,&nbsp;<I>Income
Taxes (Topic 740), Simplifying the Accounting for Income Taxes,&nbsp;</I>which clarifies and simplifies certain aspects of the
accounting for income taxes.&nbsp;The standard is effective&nbsp;for years beginning after December&nbsp;15, 2020, and interim
periods within annual periods beginning after December&nbsp;15, 2020. The adoption of this standard on January 1, 2021 is not expected
to have a material impact on the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In January 2020,
the FASB issued ASU 2020-01, <I>Investments &ndash; Equity Securities, Investments &ndash; Equity Method and Joint Ventures, and
Derivatives and Hedging &ndash; Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815</I>, intended to clarify
the interactions between ASC 321, ASC 323 and ASC 815. The new standard addresses accounting for the transition into and out of
the equity method and measurement of certain purchased options and forward contracts to acquire investments. The standard is effective
for annual and interim periods beginning after December 15, 2020, with early adoption permitted. Adoption of the standard requires
changes to be made prospectively. The adoption of this standard on January 1, 2021 is not expected to have a material impact on
the Company&rsquo;s consolidated financial statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 4 &ndash; COMMITMENTS AND CONTINGENCIES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Operating Leases</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In October 2018, the Company entered into
a lease agreement for office space in Doylestown, Pennsylvania. The lease commenced on October 15, 2018, the Company exercised
a one-year lease renewal in October 2019, and another one-year lease renewal in October 2020 that will expire on October 31, 2021.
The lease has an additional one-year option for renewal, and the base rent is $36,000 per year. The Company has determined that
the lease agreement is considered a short-term lease under ASC 842 and has not recorded a right-of-use asset or liability. The
Company rents another office space on a month-to-month basis with no long-term commitment, which is considered a short-term lease
as well. Short-term lease expense for the years ended December 31, 2020 and 2019 was approximately $59,000 and $28,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Approximate future minimum lease payments
required under the operating lease, as amended, are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year ending December 31,</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">2021</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">30,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Legal</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company may be involved, from time
to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties
and outcomes and are not predictable with assurance. While management believes that such matters are currently insignificant, matters
arising in the ordinary course of business for which the Company is or could become involved in litigation may have a material
adverse effect on its business and financial condition. To the Company&rsquo;s knowledge, neither the Company nor any of its properties
are subject to any pending legal proceedings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 5 &ndash; LICENSE AND AGREEMENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In July 2015, the University of Texas at
Austin (&ldquo;UT&rdquo;) granted to the Company&rsquo;s former parent, LTI, an exclusive worldwide, royalty bearing license to
the patent rights for the TFF platform in all fields of use, other than vaccines for which LTI received a non-exclusive worldwide,
royalty bearing license to the patent rights for the TFF platform. In March 2018, LTI completed an assignment to the Company all
of its interest to the TFF platform, including the patent license agreement with UT, at which time the Company paid UT an assignment
fee of $100,000 in accordance with the patent license agreement. In November 2018, the Company and UT entered into an amendment
to the patent license agreement pursuant to which, among other things, the Company&rsquo;s exclusive patent rights to the TFF platform
were expanded to all fields of use. The patent license agreement requires the Company to pay royalties and milestone payments and
conform to a variety of covenants and agreements, and in the event of the Company&rsquo;s breach of agreement, UT may elect to
terminate the agreement. During the year ended December 31, 2019, the Company achieved one milestone by gaining IND approval on
first indication of a licensed product on November 24, 2019. The milestone fee associated with this achievement to be paid is $50,000
and the Company must issue UT common shares equal to 1% of the Company&rsquo;s outstanding shares of common stock, on a fully diluted
basis, as of 30 days after IND approval, which was December 24, 2019. The total amount of common shares due and payable on December
31, 2019 to UT were 220,666 common shares, which have a fair value of approximately $1,132,000 based on the closing stock price
of $5.13 on December 24, 2019. As of December 31, 2019, the Company had not paid the $50,000 or issued the shares and has included
the $50,000 in accounts payable and the share amount due as a research and development expense payable. The Company paid the $50,000
and issued the shares in January 2020. As of the date of these consolidated financial statements, the Company is in compliance
with the patent license agreement as all required amounts have been paid in accordance with the agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In May 2018, the Company entered into a
master services agreement and associated individual study contracts with ITR Canada, Inc. (&ldquo;ITR&rdquo;) to provide initial
contract pre-clinical research and development services for the Company&rsquo;s drug product candidates. The fees payable for pre-clinical
research and development services under these study contracts totaled $1,790,000, with no minimum fee requirement. In January 2019,
the Company cancelled all of the individual study contracts with ITR and entered into a contract with 11036114 Canada Inc. (initially
dba VJO Non-Clinical Development and now dba Strategy Point Innovations (&ldquo;SPI&rdquo;)) to complete additional pre-clinical
research and development services in order to take advantage of eligible Canadian Tax Credits. The services related to the contract
with SPI were sub-contracted to ITR under substantially the same terms as the initial contract with ITR, with fees payable for
services under statements of work that are currently open totaling $4,582,000, as amended. During the years ended December 31,
2020 and 2019, the Company recorded research and development costs of approximately $1,177,000 and $2,746,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 5 &ndash; LICENSE AND AGREEMENTS,
continued</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In April 2019, the Company entered into
a master services agreement with Irisys, LLC to provide contract manufacturing services for one of the Company&rsquo;s drug product
candidates, Voriconazole. The fees payable for open contract manufacturing services under this agreement total approximately $3,220,000,
as amended, with additional pass-through costs. During the years ended December 31, 2020 and 2019, the Company recorded research
and development costs of approximately $1,837,000 and $867,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In June 2019, the Company entered into
a master services agreement with CoreRx to provide contract manufacturing services for one of the Company&rsquo;s drug product
candidates, Tacrolimus. The fees payable for open contract manufacturing services under this agreement total approximately $1,103,000,
as amended, with additional pass-through costs. During the years ended December 31, 2020 and 2019, the Company recorded research
and development costs of approximately $839,000 and $290,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In August 2019, the Company entered into
a master services agreement and associated individual study contracts with Conform Clinical Development, Inc. and its affiliates,
Les Entreprises Envie Inc. (dba Envie Ventures) and Desire Ventures LLC, which sub-contracted with Inflamax Research Limited (dba
Cliantha Research) to perform a Phase I study of one of the Company&rsquo;s drug candidates, Voriconazole. The fees payable for
the open services under this contract total approximately $1,484,000, as amended. During the years ended December 31, 2020 and
2019, the Company recorded research and development costs of approximately $1,824,000 and $977,000, respectively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In January 2020, TFF Australia entered
into a master consultancy agreement with Novotech (Australia) Pty Ltd. (formally known as Clinical Network Services Pty Ltd.) to
provide initial contract clinical research and development services for the Company&rsquo;s drug product candidates. The fees payable
for clinical research and development services under these open study contracts totaled AUD$1,942,981 (US$1,355,580), as amended.
During the year ended December 31, 2020, the Company recorded research and development costs of approximately AUD$590,000 (US$407,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In May 2020, TFF Australia entered into
an amended clinical trial research agreement with Nucleus Network Pty Ltd. to provide a Phase I study of one of the Company&rsquo;s
drug candidates, Tacrolimus. The fees payable for services under this contract totaled AUD$1,392,805 (US$953,388), as amended.
During the year ended December 31, 2020, the Company recorded research and development costs of approximately AUD$489,000 (US$337,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In August 2020, TFF Australia entered into
a clinical trial research agreement with Q-Pharm Pty Ltd. to provide a Phase I study of one of the Company&rsquo;s drug candidates,
Tacrolimus. The fees payable for services under this contract totaled AUD$704,600 (US$505,488). During the year ended December
31, 2020, the Company recorded research and development costs of approximately AUD$557,000 (US$384,000).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 12, 2020, the Company entered
into a licensing and collaboration agreement with UNION therapeutics A/S in which UNION acquired an option to obtain a worldwide
exclusive license for the TFF technology in combination with niclosamide. Pursuant to the terms of the license agreement, UNION
can exercise its option to obtain the license within 45 days after the complete data has been received by UNION from investigator-initiated
trials. Upon exercise of the option, UNION shall be responsible to pay all expenses incurred in the development of any licensed
product. The Company will be eligible to receive milestone payments upon the achievement of certain milestones in the development
the licensed products, based on completion of clinical trials, pre-marketing approvals and/or the receipt of at least $25,000,000
of grant funding. The Company will receive a single-digit tiered royalty on net sales. The Company will also be entitled to receive
sales-related milestone payments based on the commercial success of the licensed products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 6 &ndash; STOCKHOLDERS&rsquo;
EQUITY</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Common Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><U>IPO</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In October 2019, the Company completed
an IPO, selling 4,400,000 shares of common stock at an offering price of $5.00 per share. The Company received gross proceeds of
approximately $22,000,000. In addition, the Company granted the underwriter a 45-day option to purchase an additional 660,000 shares
of common stock at the initial public offering price. The option was exercised and the underwriter purchased an additional 479,300
shares of common stock and the Company received additional gross proceeds of approximately $2,397,000. The Company received net
proceeds from the IPO and the underwriter&rsquo;s purchase of additional shares of approximately $21,754,000, after deducting underwriting
discounts and commissions and offering-related expenses. Warrants for 317,155 shares of the Company&rsquo;s common stock were issued
to the IPO underwriter at an exercise price of $6.25 per share as part of the underwriter&rsquo;s compensation for the IPO. The
estimated fair value of the warrants of approximately $977,000 was considered an offering cost and netted against additional paid-in
capital.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In conjunction with the IPO, the Company&rsquo;s
outstanding shares of Series A Preferred Stock automatically converted into 9,571,692 shares of its common stock (see below). Also
in conjunction with the issuance of shares in the IPO, the Company granted options to officers and directors to purchase 627,984
shares of common stock at an exercise price of $5.00.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><U>UT Agreement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In November 2019, the Company achieved
a milestone in connection with the UT agreement (see Note 5). As a result of the milestone, the Company owed UT 220,666 shares
of common stock, which had a fair value of approximately $1,132,000, which was accrued in accrued research and development expense
as of December 31, 2019. In January 2020, the Company issued the 220,666 shares of common stock to UT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><U>August 2020 Private Placement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 10, 2020, the Company entered
into a Securities Purchase Agreement (the &ldquo;Purchase Agreement&rdquo;) and a Registration Rights Agreement (the &ldquo;Registration
Rights Agreement&rdquo;) with certain institutional and other accredited investors pursuant to which the Company issued and sold
to the investors 3,048,654 shares of the Company&rsquo;s common stock at a price of $8.50 per share for gross proceeds of approximately
$25.91 million, before deducting placement agent and other offering expenses. After deducting the placement agent and other offering
expenses, the Company received net proceeds of approximately $24.28 million. The Purchase Agreement included customary representations,
warranties, and covenants by the investors and the Company, and an indemnity from the Company in favor of the investors. Jefferies
LLC acted as placement agent for the private placement and the private placement closed on August 13, 2020. Pursuant to the terms
of the Registration Rights Agreement, the Company filed a resale registration statement on Form S-1 with the SEC that was declared
effective on September 15, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><U>Stock Option Exercises</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During November and December 2020, 285,003
shares of common stock were issued in connection with the exercise of stock options for total proceeds of $714,382.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><U>Cashless Warrant Exercises</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During August through December 2020, 529,559
shares of common stock were issued in connection with the cashless exercise of 659,108 common stock warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Series A Convertible Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Prior to our initial public offering in
October 2019, the Company&rsquo;s amended and restated certificate of incorporation authorized the Company to issue up to 10,000,000
shares of preferred stock, all of which was designated as Series A preferred stock and there were 8,930,000&nbsp;shares of Series
A preferred stock issued and outstanding immediately prior to the Company&rsquo;s initial public offering. Pursuant to the Company&rsquo;s
amended and restated certificate of incorporation, all outstanding shares of Series A preferred stock automatically converted to
common stock at the close of our initial public offering and thereafter the Company was no longer authorized to issue any preferred
stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Series A Preferred Stock ranked senior
to common stock with respect to dividends rights and liquidation preferences and had full voting rights. The Series A Preferred
Stock accrued a dividend at a rate of 6% per annum, and $875,359 of dividends accrued during the year ended December 31, 2019.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 6 &ndash; STOCKHOLDERS&rsquo;
EQUITY (DEFICIT), continued</U></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Pursuant to the Company&rsquo;s amended
and restated certificate of incorporation, holders of the Series&nbsp;A Preferred Stock had the following methods of conversion:
(i) automatic conversion into common stock upon the consummation of an IPO at a conversion price of 50% of the IPO price, (ii)
automatic conversion into common stock upon the consummation of a subsequent private placement of securities at a conversion price
of 50% of the purchase price of the securities being sold by the Company approved by the holders of the Series&nbsp;A preferred
stock, and (iii) at any time after the issuance date and until ten calendar days prior to the consummation of an IPO, each holder
shall be entitled to convert into common stock at a conversion price of $2.50 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Series A Preferred Stock automatically
converted into 9,571,692 common shares upon completion of the IPO in October 2019, based on the number of shares of Series A Preferred
Stock outstanding as of the date of the IPO. The conversion share calculation was based on the $2.50 initial issue price for the
Series A Preferred Stock plus $1,603,709 of accrued and unpaid dividends and automatically converted into shares of the Company&rsquo;s
common stock using a stated divisor conversion price equal to 50% of the IPO price to the public which was $5.00 per share.&nbsp;In
accordance with relevant accounting literature, since the terms of the conversion option did not permit the Company to compute
the additional number of shares that it would need to issue upon conversion of the Series A Preferred when the contingent event
occurred, the Company recorded the beneficial conversion amount of approximately $23,930,000 as a deemed dividend at the date of
the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><U>2019 Private Placement</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In May 2019, the Company entered into a
securities purchase agreement with various accredited investors to raise gross proceeds of $8.2 million in a private placement
(the &ldquo;2019 Private Placement&rdquo;), issuing 3,268,000 shares of its Series A Preferred Stock. The shares of the Series
A Preferred Stock were sold for $2.50 per share. The Company received net proceeds of approximately $7.2 million from the 2019
Private Placement, after paying placement agent fees and offering expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 7 &ndash; WARRANTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On March 13, 2018 and March 22, 2018, the
Company issued to National Securities Corporation warrants to purchase shares of the Company&rsquo;s common stock in an amount
equal to 10% of the shares of common stock issuable upon conversion of 5,662,000 shares of the Company&rsquo;s Series&nbsp;A Preferred
Stock. In connection with the conversion of the Series A Preferred Stock as a result of the IPO, the Company issued additional
warrants to purchase 53,679 shares of common stock. The additional warrants were considered offering costs and netted with the
proceeds from the IPO.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On May 16, 2019 and May 23, 2019, the Company
issued to National Securities Corporation 326,800 warrants to purchase shares of the Company&rsquo;s common stock. The fair value
of the warrants on the grant date was estimated using the Black-Scholes-Merton option pricing model with a common stock value of
$1.67 per share, a contractual life of 5 years, a dividend yield of 0%, a volatility of 89.6% and an assumed risk-free interest
rate of 2.11%. The fair value of the warrants was determined to be approximately $347,000 and was included in general and administrative
expenses in the statement of operations. On September 13, 2019, these warrants were cancelled by the individual warrant holders
and the Company determined that the related expense should be reversed. The reversal of the expense was recorded during the three
months ended September 30, 2019, when the warrants were cancelled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 7 &ndash; WARRANTS, continued</U></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On October 29, 2019, the Company issued
a ten-year warrant to purchase 43,794 shares of common stock at $5.00 per share to BP Directors, LP (&ldquo;BP&rdquo;). The warrant
represented consideration for board service from Dr. Aaron Fletcher. The fair value of the warrant on the grant date was estimated
using the Black-Scholes-Merton option pricing model with a common stock value of $5.01 per share, a contractual life of 6.0 years,
a dividend yield of 0%, a volatility of 88.48% and an assumed risk-free interest rate of 1.70%. The warrant is subject to a 25%
cliff vesting at one year from the date of grant and the balance vesting quarterly over the following two years. The fair value
of the warrant was determined to be $161,419 and is being amortized in general and administrative expenses in the consolidated
statements of operations over the vesting term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On November 26, 2019, the Company issued
to National Securities Corporation and its representatives underwriter warrants to purchase 317,155 shares of the Company&rsquo;s
common stock in connection with the IPO. The exercise price of the warrants is $6.25 per share, each has a contractual life of
5 years and they were not exercisable for one year from the date of grant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On November 29, 2019, the Company issued
a ten-year warrant to purchase 3,623 shares of common stock at $5.00 per share to BP. The warrant represented consideration for
board service from Dr. Aaron Fletcher. The fair value of the warrant on the grant date was estimated using the Black-Scholes-Merton
option pricing model with a common stock value of $5.26 per share, a contractual life of 6.0 years, a dividend yield of 0%, a volatility
of 90.16% and an assumed risk-free interest rate of 1.68%. The warrant is subject to a 25% cliff vesting at one year from the date
of grant and the balance vesting quarterly over the following two years. The fair value of the warrant was determined to be $14,300
and is being amortized in general and administrative expenses in the consolidated statements of operations over the vesting term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In determining the fair value for warrants,
the expected life of the Company&rsquo;s warrants was determined using the contractual life. The methodology in determining all
other inputs to calculate the fair value utilizing the Black-Scholes-Merton option pricing model is the same as the stock option
methodology described in Note 8 for stock options.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A summary of warrant activity for the years
ended December 31, 2020 and 2019 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Range of Exercise Prices</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average Exercise Prices</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average Remaining Life</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt">Outstanding at January 1, 2019</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,058,212</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right"><FONT STYLE="font-size: 10pt">0.01 &ndash; $2.50</FONT></TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">1.56</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">4.6</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt">Issued</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">745,051</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.67 &ndash; 6.25</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.26</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt">Cancelled</FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(326,800</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.50</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.50</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt">Outstanding at December 31, 2019</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,476,463</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.01 &ndash; 6.25</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.71</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">4.1</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt">Exercised</FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(659,108</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right"><FONT STYLE="font-size: 10pt">2.50 &ndash; 6.25</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2.75</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-bottom: 2pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><FONT STYLE="font-size: 10pt">Outstanding at December 31, 2020</FONT></TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">817,355</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right"><FONT STYLE="font-size: 10pt">0.01 &ndash; $6.25</FONT></TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2.68</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3.7</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The warrants outstanding at December 31,
2020 had an aggregate intrinsic value of approximately $9,511,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 8 &ndash; STOCK BASED COMPENSATION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In January 2018, the Company&rsquo;s board
of directors approved its 2018 Stock Incentive Plan (&ldquo;2018 Plan&rdquo;). The 2018 Plan provides for the grant of non-qualified
stock options and incentive stock options to purchase shares of the Company&rsquo;s common stock, the grant of restricted and unrestricted
share awards and grant of restricted stock units. The Company initially reserved 1,630,000 shares of its common stock under the
2018 Plan; however, upon completion of the Company&rsquo;s IPO the number of shares reserved for issuance under the 2018 Plan increased
to 3,284,480, representing 15% of the Company&rsquo;s outstanding shares of common stock calculated on a fully diluted basis upon
the close of the IPO. All of the Company&rsquo;s employees and any subsidiary employees (including officers and directors who are
also employees), as well as all of the Company&rsquo;s nonemployee directors and other consultants, advisors and other persons
who provide services to the Company will be eligible to receive incentive awards under the 2018 Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 8 &ndash; STOCK BASED COMPENSATION,
continued</U></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following table summarizes the stock-based
compensation expense recorded in the Company&rsquo;s results of operations during the years ended December 31, 2020 and 2019 for
stock options and warrants:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center">Year Ended</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR>
2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR>
2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Research and development</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">140,278</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,046,871</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">590,041</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,187,149</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">590,041</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2020, there was approximately
$9,074,000 of total unrecognized compensation expense related to non-vested share-based compensation arrangements that are expected
to vest. This cost is expected to be recognized over a weighted-average period of 2.4 years.</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company records compensation expense
for employee awards with graded vesting using the straight-line method. The Company records compensation expense for nonemployee
awards with graded vesting using the accelerated expense attribution method. The Company recognizes compensation expense over the
requisite service period applicable to each individual award, which generally equals the vesting term. The Company estimates the
fair value of each option award using the Black-Scholes-Merton option pricing model. Forfeitures are recognized when realized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company estimated the fair value of
employee and non-employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options
is being amortized on a straight-line basis over the requisite service periods of the respective awards. The fair value of stock
options issued was estimated using the following assumptions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December&nbsp;31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<BR> December&nbsp;31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted average exercise price</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">10.42</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">4.42</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted average grant date fair value</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">9.25</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.08</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Assumptions</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Expected volatility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">87-91</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">88-90</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Expected term (in years)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">6.3-10</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6.3</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Risk-free interest rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">0.36-1.47</FONT></TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">1.68-2.31</FONT></TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Expected dividend yield</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The risk-free interest rate was obtained
from U.S. Treasury rates for the applicable periods. The Company&rsquo;s expected volatility was based upon the historical volatility
for industry peers and used an average of those volatilities. The expected life of the Company&rsquo;s options was determined using
the simplified method as a result of limited historical data regarding the Company&rsquo;s activity for employee awards and the
contractual term for nonemployee awards. The dividend yield considers that the Company has not historically paid dividends, and
does not expect to pay dividends in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For grants prior to the IPO, the fair value
of the common stock was determined by the board of directors based on a variety of factors, including valuations prepared by third
parties, the Company&rsquo;s financial position, the status of development efforts within the Company, the current climate in the
marketplace and the prospects of a liquidity event, among others. For grants after the IPO, the Company uses the closing stock
price on the date of grant as the fair value of the common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 8 &ndash; STOCK BASED COMPENSATION,
continued</U></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following table summarizes stock option
activity during the years ended December 31, 2020 and 2019:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average<BR> Exercise Prices</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average Remaining
    Contractual Term (In&nbsp;Years)</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic Value</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 52%; text-align: left"><FONT STYLE="font-size: 10pt">Outstanding at January 1, 2019</FONT></TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">1,073,082</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">9.64</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">&mdash;</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Granted</FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">1,065,996</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.42</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Outstanding at December 31, 2019</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2,139,078</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">3.46</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">9.17</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">4,052,512</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Granted</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">782,045</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">10.42</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><FONT STYLE="font-size: 10pt">Exercised</FONT></TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(285,003</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">2.74</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"><FONT STYLE="font-size: 10pt">Cancelled</FONT></TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(25,625</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4.86</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">&mdash;</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 10pt">Outstanding at December 31, 2020</FONT></TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">2,610,495</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">5.63</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8.60</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">22,789,233</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt; text-align: left"><FONT STYLE="font-size: 10pt">Exercisable at December 31, 2020</FONT></TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">755,885</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">3.25</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8.04</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">8,365,946</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 9 &ndash; INCOME TAXES</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company had no income tax expense due
to operating losses incurred for the years ended December&nbsp;31, 2020 and 2019. The Company accounts for income taxes in accordance
with ASC 740, which requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded
as an asset to the extent that management assesses that realization is &ldquo;more likely than not.&rdquo; Realization of the future
tax benefits is dependent on the Company&rsquo;s ability to generate sufficient taxable income within the carryforward period.
Because of the Company&rsquo;s recent history of operating losses, management believes that recognition of the deferred tax assets
arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a full
valuation allowance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company&rsquo;s income tax expense
for the years ended December 31, 2020 and 2019 are summarized below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Current:</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: center">&nbsp;</TD><TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Federal</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">State</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Foreign</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total current</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deferred:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">Federal</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(4,502,016</TD><TD STYLE="width: 1%; text-align: left">)</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">(2,952,519</TD><TD STYLE="width: 1%; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">State</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Foreign</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(480,666</TD><TD STYLE="text-align: left">)</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">-</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">4,982,682</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">2,952,519</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total deferred</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">-</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Income tax provision (benefit)</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 9 &ndash; INCOME TAXES, continued</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company&rsquo;s deferred tax assets
are as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deferred tax assets:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">Net operating loss carryforwards</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">6,807,300</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">2,789,541</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Research and development tax credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">1,092,345</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">532,711</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Intangibles</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">136,226</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">105,580</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Stock compensation</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">761,741</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">387,098</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-indent: -0.125in; text-align: left">Total deferred tax assets</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">8,797,612</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3,814,930</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Valuation allowances</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(8,797,612</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(3,814,930</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Net deferred tax assets</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The effective tax rate of the Company&rsquo;s
provision (benefit) for income taxes differs from the federal statutory rate as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2020</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&nbsp;31,<BR> 2019</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Statutory rate</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">21.00</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 9%; text-align: right">21.00</TD><TD STYLE="width: 1%; text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">State rate</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Foreign</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(1.81</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">0.00</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Permanent book/tax differences</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.26</TD><TD STYLE="text-align: left">)%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">(0.12</TD><TD STYLE="text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Research and development credit</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">5.09</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">3.99</TD><TD STYLE="text-align: left">%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Changes in valuation allowance</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24.02</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(24.87</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)%</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">-</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2020 and 2019, the Company
had gross federal income tax net operating loss (&ldquo;NOL&rdquo;) carryforwards of $30,126,830 and $13,283,530, respectively,
and federal research tax credits of $1,486,704 and $690,525, respectively. Additionally, the Company had gross foreign income tax
net operating loss carryforwards of $1,602,220 as of December 31, 2020. The federal and foreign NOL have an indefinite life while
the federal research tax credits will expire by 2040.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Utilization of U.S. net operating losses
and tax credit carryforwards may be limited by &ldquo;ownership change&rdquo; rules, as defined in Sections&nbsp;382 and 383 of
the Code. Similar rules may apply under state tax laws. The Company has not conducted a study to-date to assess whether a limitation
would apply under Sections&nbsp;382 and 383 of the Code as and when it starts utilizing its net operating losses and tax credits.
The Company will continue to monitor activities in the future. In the event the Company previously experienced an ownership change,
or should experience an ownership change in the future, the amount of net operating losses and research and development credit
carryovers available in any taxable year could be limited and may expire unutilized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>TFF PHARMACEUTICALS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>For The Years Ended December 31, 2020
and 2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 9 &ndash; INCOME TAXES, continued</U></B></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The CARES Act was signed into law on March
27, 2020 as a response to the economic challenges facing U.S. businesses caused by the COVID-19 global pandemic. The CARES Act
allowed net operating loss incurred in 2018-2020 to be carried back five years or carried forward indefinitely, and to be fully
utilized without being subjected to the 80% taxable income limitation. Net operating losses incurred after December 31, 2020 will
be subjected to the 80% taxable income limitation. In assessing the realization of deferred tax assets, management considers whether
it is more likely than not that some portion, or all, of the deferred tax asset will be realized. The ultimate realization of deferred
tax assets is dependent upon the Company attaining future taxable income during periods in which those temporary differences become
deductible.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Due to the uncertainty surrounding the
realization of the benefits of its deferred assets, including NOL carryforwards, the Company has provided a 100% valuation allowance
on its deferred tax assets at December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company accounts for uncertain tax
positions in accordance with the provisions of ASC 740, <I>Income Taxes</I>. When uncertain tax positions exist, the Company recognizes
the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to
whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as
consideration of the available facts and circumstances. As of December 31, 2020, the Company had a reserve for uncertain tax positions
of $394,358, and no interest or penalties have been charged to the Company for the years ended December 31, 2020 and 2019. If incurred,
the Company will classify any interest and penalties as a component of interest expense and operating expense, respectively. If
recognized, $394,358 of the reserve for uncertain tax positions would favorably affect the Company&rsquo;s effective tax rate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A reconciliation of the change in the unrecognized
tax positions for the year ended December 31, 2020 is as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Federal and State</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">Balance at December 31, 2019</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 9%; text-align: right">157,814</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Additions for tax positions related to current year</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">318,374</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Decreases for tax positions related to prior years</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(81,830</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Balance at December 31, 2020</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">$</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">394,358</TD><TD STYLE="padding-bottom: 2pt; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><U>NOTE 10 &ndash; SUBSEQUENT EVENTS</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has performed an evaluation
of events occurring subsequent to December 31, 2020 through the filing date of this Annual Report. Based on its evaluation, nothing
other than the events described below need to be disclosed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between January 1, 2021 and March 10,
2021, 444,751 shares of common stock were issued in connection with the exercise of warrants and 160,275 shares of common stock
were issued in connection with the exercise of stock options. The Company received total cash proceeds from the exercises of $585,700.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><A NAME="a_010"></A>Item 9. Changes in and Disagreements with Accountants on
Accounting and Financial Disclosure</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in"><B><A NAME="a_011"></A>Item 9A.
Controls and Procedures</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Evaluation of Disclosure Controls and Procedures</I>.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our management, with
the participation of our chief executive officer and chief financial officer evaluated the effectiveness of our disclosure controls
and procedures pursuant to Rule 13a-15(e) and 15d-15(e) under the Exchange Act. Based upon that evaluation, our management, including
our chief executive officer and chief financial officer, concluded that our disclosure controls and procedures were effective as
of December 31, 2020 in ensuring all material information required to be filed has been made known in a timely manner.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt"><I>(b)</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Changes in internal control over financial reporting.</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">There were no changes
to our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred
during the quarter ended December 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal
control over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt"><I>(c)</I></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><I>Management&rsquo;s report on internal controls over financial reporting.</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our management is responsible
for establishing and maintaining adequate internal controls over financial reporting, as defined under Rule 15a-15(f) under the
Exchange Act. Our management has assessed the effectiveness of our internal controls over financial reporting as of December 31,
2020 based on the framework established in Internal Control - Integrated Framework issued by the Committee of Sponsoring Organizations
of the Treadway Commission (2013 Framework) (&ldquo;COSO&rdquo;). Our internal control system was designed to provide reasonable
assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements.
An internal control material weakness is a significant deficiency, or aggregation of deficiencies, that does not reduce to a relatively
low level the risk that material misstatements in financial statements will be prevented or detected on a timely basis by employees
in the normal course of their work. Our management assessed the effectiveness of our internal control over financial reporting
as of December 31, 2020, and based on that evaluation, management concluded that our internal control over financial reporting
was effective as of December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">This report does not
include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management&rsquo;s
report was not subject to attestation by our registered public accounting firm pursuant to the rules of the Securities and Exchange
Commission that permit us to provide only management&rsquo;s report in this Annual Report.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><A NAME="a_012"></A>Item 9B. Other Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 65; Options: NewSection; Value: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_013"></A>PART&nbsp;III</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The information required
by Part III is omitted from this report because we will file a definitive proxy statement within 120 days after the end of our
2020 fiscal year pursuant to Regulation 14A for our 2020 Annual Meeting of Stockholders, or the 2020 Proxy Statement, and the information
to be included in the 2021 Proxy Statement is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><A NAME="a_014"></A>Item 10. Directors, Executive Officers
and Corporate Governance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The information required
by this item will be contained in the 2021 Proxy Statement and is hereby incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><A NAME="a_015"></A>Item 11. Executive Compensation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The information required
by this item will be contained in the 2021 Proxy Statement and is hereby incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><A NAME="a_016"></A>Item 12. Security Ownership of Certain
Beneficial Owners and Management and Related Stockholder Matters</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The information required
by this item will be contained in the 2021 Proxy Statement and is hereby incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><A NAME="a_017"></A>Item 13. Certain Relationships and Related
Transactions, and Director Independence</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The information required
by this item will be contained in the 2021 Proxy Statement and is hereby incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><A NAME="a_018"></A>Item 14. Principal Accountant Fees and
Services</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The information required
by this item will be contained in the 2021 Proxy Statement and is hereby incorporated by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>



<!-- Field: Page; Sequence: 66; Value: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_019"></A>PART&nbsp;IV</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><A NAME="a_020"></A>Item 15. Exhibits and Financial Statement
Schedules</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(a) Financial statements</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Reference is made to
the Index and Financial Statements under Item 8 in Part&nbsp;II hereof where these documents are listed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(b) Financial statement
schedules</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Financial statement
schedules are either not required or the required information is included in the consolidated financial statements or notes thereto
filed under Item 8 in Part&nbsp;II hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">(c) Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The exhibits to this
Annual Report on Form&nbsp;10-K are set forth below. The exhibit index indicates each management contract or compensatory plan
or arrangement required to be filed as an exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 45%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit Description</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 44%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Method of Filing</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex3-1_tffpharm.htm">Second Amended and Restated Certificate of Incorporation of the Registrant</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on August 20, 2019.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex3-3_tffpharm.htm">Amended and Restated Bylaws of the Registrant</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on August 20, 2019.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019019208/fs12019a1ex4-1_tffpharm.htm">Specimen Certificate representing shares of common stock of Registrant</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on September 27, 2019.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390020007544/f10k2019ex4-7_tffpharma.htm">Warrant dated October 29, 2019 issued to National Securities Corporation</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">Incorporated by reference from the Registrant&rsquo;s Annual Report on Form 10-K filed on March 27, 2020. </TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390020007544/f10k2019ex4-8_tffpharma.htm">Warrant dated November 20, 2019 issued to National Securities Corporation</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Incorporated
by reference from the Registrant&rsquo;s Annual Report on Form 10-K filed on March 27, 2020.</P></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="f10k2020ex4-4_tffpharma.htm"><FONT STYLE="font-size: 10pt">Description of Capital Stock</FONT></A></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex10-5_tffpharm.htm">Patent License Agreement dated July 8, 2015 between Lung Therapeutics, Inc. and The University of Texas at Austin</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on August 20, 2019.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">10.2*</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex10-6_tffpharm.htm">TFF Pharmaceuticals, Inc. 2018 Stock Incentive Plan</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on August 20, 2019.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">10.3*</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex10-7_tffpharm.htm">Amended and Restated Consulting Agreement dated December 20, 2018 between Robert Mills and the Registrant</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on August 20, 2019.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">10.4*</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019019208/fs12019a1ex10-8_tffpharm.htm"><FONT STYLE="font-size: 10pt">Consulting Agreement effective as of January 24, 2018 between Dr. Brian Windsor and the Registrant, as amended on December 20, 2018 and September 26, 2019</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on September&nbsp;27, 2019</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex10-10_tffpharm.htm">Lease Agreement dated October 19, 2018</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on August 20, 2019.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">10.6*</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex10-11_tffpharm.htm">Executive Employment Agreement dated December 20, 2018 between Glenn Mattes and the Registrant</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on August 20, 2019.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex10-13_tffpharm.htm">Amendment No. 1 to Patent License Agreement dated November 30, 2018 between the Registrant and The University of Texas at Austin</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on August 20, 2019.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 67; Value: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 45%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit Description</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; vertical-align: bottom; width: 44%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Method of Filing</B></FONT></TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">10.8*</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390019016393/fs12019ex10-14_tffpharm.htm">Employment Agreement dated February 15, 2019, by and between the Registrant and Kirk Coleman</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Incorporated by reference from the Registrant&rsquo;s Registration Statement on Form S-1 filed on August 20, 2019.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">10.9</P></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">
<A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390020021315/ea125332ex10-2_tffpharma.htm">Form of Registration Rights Agreement dated August 10, 2020 between the Company and investors named therein</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Incorporated
by reference from the Registrant&rsquo;s Current Report on Form 8-K filed on August 11, 2020</P></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">10.10</P></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">
        <A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390020021865/f10q0620ex10-1_tffpharma.htm">Amendment No.&nbsp;1 Dated May 14, 2020 to Executive Employment Agreement Between Glenn Mattes and Registrant</A></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Incorporated
by reference from the Registrant&rsquo;s Quarterly Report on Form 10-Q filed on August 13, 2020.</P></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">10.11*</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="f10k2020ex10-11_tffpharma.htm">Employment Agreement dated September 24, 2020 by and between the Registrant and Christopher Cano</A></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">21.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="http://www.sec.gov/Archives/edgar/data/1733413/000121390020007544/f10k2019ex21-1_tffpharma.htm">List of Subsidiaries</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Incorporated
by reference from the Registrant&rsquo;s Annual Report on Form 10-K filed on March 27, 2020.</P></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt"><A HREF="f10k2020ex23-1_tffpharma.htm">Consent of Marcum LLP</A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">31.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="f10k2020ex31-1_tffpharma.htm"><FONT STYLE="font-size: 10pt">Certification under Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">31.2</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="f10k2020ex31-2_tffpharma.htm"><FONT STYLE="font-size: 10pt">Certification under Section 302 of the Sarbanes-Oxley Act of 2002.</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">32.1</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><A HREF="f10k2020ex32-1_tffpharma.htm"><FONT STYLE="font-size: 10pt">Certifications Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350.</FONT></A></TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith.</FONT></TD></TR>
<TR STYLE="background-color: White">
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">101.INS</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Instance Document</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">101.SCH</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Schema Document</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">101.CAL</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Calculation Linkbase Document</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">101.LAB</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Label Linkbase Document</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">101.PRE</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Presentation Linkbase Document</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">101.DEF</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">XBRL Taxonomy Extension Definition Linkbase Document</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Filed electronically herewith</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 15%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>
<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0in; margin-bottom: 0in; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Indicates management compensatory
plan, contract or arrangement.</FONT></TD>
</TR></TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 68; Value: 41 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><A NAME="a_021"></A>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Pursuant to the requirements of Section&nbsp;13
or 15(d)&nbsp;of the Securities Exchange Act of 1934, the Registrant has duly caused this annual report on Form&nbsp;10-K to be
signed on its behalf by the undersigned, thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>TFF PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-size: 10pt">Date:&nbsp;March 10, 2021</FONT></TD>
    <TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ <I>Glenn Mattes</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Glenn Mattes,</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities
and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: bottom; width: 45%; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 35%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 1%; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 18%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ <I>Glenn Mattes</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Chief Executive Officer and Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Glenn Mattes</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt"><I>(Principal Executive Officer)</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ <I>Kirk Coleman</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Chief Financial Officer</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Kirk Coleman</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: left"><I>(Principal
Financial and Accounting Officer)</I></P></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ <I>Aaron Fletcher</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Chairman of the Board</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Aaron Fletcher, Ph. D</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ <I>Brian Windsor</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Brian Windsor, Ph. D</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ <I>Robert S. Mills, Jr.</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Robert S. Mills, Jr.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ <I>Stephen Rocamboli</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Stephen Rocamboli</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ <I>Harlan Weisman, M.D.</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Harlan Weisman, M.D.</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ <I>Randy Thurman</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Randy Thurman</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: bottom; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ <I>Malcolm Fairbairn</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center"><FONT STYLE="font-size: 10pt">March 10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Malcolm Fairbairn</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">45</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.4
<SEQUENCE>2
<FILENAME>f10k2020ex4-4_tffpharma.htm
<DESCRIPTION>DESCRIPTION OF CAPITAL STOCK
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>EXHIBIT 4.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>DESCRIPTION OF THE CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">TFF Pharmaceuticals,
Inc. (&ldquo;Company&rdquo;, &ldquo;we&rdquo;, &ldquo;us&rdquo; and &ldquo;our&rdquo;) has one class of securities registered under
Section 12 of the Securities Exchange Act of 1934, as amended, namely our common stock, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">The following is a
summary of the rights of our common and of certain provisions of our Second Amended and Restated Certificate of Incorporation (&ldquo;Certificate
of Incorporation&rdquo;) and Amended and Restated Bylaws (&ldquo;Bylaws&rdquo;). For more detailed information, please see our
Certificate of Incorporation and Bylaws, which are incorporated by reference as exhibits to the Annual Report on Form 10-K to which
this description is an exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Our Certificate of Incorporation
authorizes us to issue up to 45,000,000&nbsp;shares of common stock, $0.001 par value per share. As of March [&#9679;], 2021, we
had 23,063,491 shares of common stock outstanding, held by [&#9679;] stockholders of record.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Holders of shares of
common stock are entitled to one vote per share on all matters to be voted upon by the stockholders generally. Stockholders are
entitled to receive such dividends as may be declared from time to time by the Board out of funds legally available therefore,
and in the event of liquidation, dissolution or winding up of the company to share ratably in all assets remaining after payment
of liabilities. The holders of shares of common stock have no preemptive, conversion, subscription rights or cumulative voting
rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">Prior to our initial
public offering in October 2019, our Certificate of Incorporation authorized us to issue up to 10,000,000 shares of preferred stock,
all of which was designated as Series A preferred stock and there were 8,930,000&nbsp;shares of Series A preferred stock issued
and outstanding immediately prior to our initial public offering. Pursuant to our Certificate of Incorporation, all outstanding
shares of Series A preferred stock automatically converted to common stock at the close of our initial public offering and thereafter
we were no longer authorized to issue any preferred stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Dividends</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We have never paid cash
dividends on our common stock and we do not anticipate the payment of cash dividends on our common stock in the foreseeable future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Anti-Takeover Effects of Certain Provisions of Delaware Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 0.5in">We are subject to the
provisions of Section 203 of the Delaware General Corporation Law, or DGCL, an anti-takeover law. In general, Section 203 prohibits
a publicly held Delaware corporation from engaging in a &ldquo;business combination&rsquo;&rsquo; with an &ldquo;interested stockholder&rsquo;&rsquo;
for a period of three years after the date of the transaction in which such stockholder became an interested stockholder, unless
the business combination is approved in a prescribed manner. For purposes of Section 203, a &ldquo;business combination&rsquo;&rsquo;
includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder, and an &ldquo;interested
stockholder&rsquo;&rsquo; is a stockholder who, together with affiliates and associates, owns, or within three years prior, did
own, 15% or more of the voting stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-indent: 0.5in; text-align: justify">The transfer agent and registrar for our
common stock is Philadelphia Stock Transfer, 2320 Haverford Road, Suite 230, Ardmore, PA 19003.</P>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>f10k2020ex10-11_tffpharma.htm
<DESCRIPTION>EMPLOYMENT AGREEMENT DATED SEPTEMBER 24, 2020 BY AND BETWEEN THE REGISTRANT AND CHRISTOPHER CANO
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.11</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">AMENDED AND RESTATED EMPLOYMENT AGREEMENT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This Amended and Restated
Employment Agreement (this &ldquo;<B><I>Agreement</I></B>&rdquo;) is made and entered into as of September 24, 2020, to be effective
as of September 15, 2020 (the &ldquo;<B><I>Effective Date</I></B>&rdquo;), by and between TFF Pharmaceuticals, Inc., a Delaware
corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), and Christopher Cano, an individual (&ldquo;<B><I>Employee</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">RECITALS</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Employee has
been serving as the Director of Business Development to the Company pursuant to that certain employment agreement (&ldquo;<B><I>Original
Employment Agreement</I></B>&rdquo;) dated December 18, 2019 between the Company and Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, the Company
now desires to hire Employee as its Chief Operating Officer and Vice President of Business Development and Employee desires to
become so employed by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">WHEREAS, Employee and
Company desire to amend and restate the Original Employment Agreement on the terms and conditions set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">NOW, THEREFORE, in
consideration of the promises and the mutual covenants contained herein, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-weight: normal">AGREEMENT</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -0.5in">1. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><U>EMPLOYMENT
TERMS AND DUTIES</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.1. <U>Employment</U>.
The Company hereby employs Employee, and Employee hereby accepts employment by the Company, effective as of the Effective Date,
upon the terms and conditions set forth in this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.2. <U>Duties
and Reporting</U>. Commencing as of the Effective Date, Employee shall serve as Chief Operating Officer and Vice President of Business
Development of the Company, reporting to the Chief Executive Officer. Employee shall perform all reasonable duties <FONT STYLE="font-weight: normal">and
have such authority as assigned by the Chief Executive Officer</FONT>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.2.1. <U>Full
Working Time</U>. Employee shall devote his full working time and efforts to the performance of his duties and the furtherance
of the interests of the Company and shall not engage in any other business activity or serve in any industry, trade, professional,
governmental or academic position during the term of this Agreement, except as may be expressly approved in advance by the Chief
Executive Officer in writing, provided that Employee may (i) engage in activities that involve a de minimis amount of time or that
are conducted on non-business time, in each case, without the prior written approval of the Chief Executive Officer, (ii) make
and manage personal investments of his choice without the prior written approval of the Chief Executive Officer, and (iii) serve
on the board of directors of one&nbsp;(1) for profit enterprise with the prior written approval of the Chief Executive Officer,
which approval shall not be unreasonably withheld, so long as such activities listed in clauses (i), (ii), and (iii), either separately
or collectively, do not materially interfere with Employee&rsquo;s duties and responsibilities hereunder and are not inconsistent
with the terms of any conflict of interest, securities trading or similar material written policies of the Company applicable to
Employee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.2.2. <U>Compliance
With Policies</U>. Employee shall comply with all policies, practices and procedures, and all codes of ethics or business conduct
of the Company applicable to Employee&rsquo;s position, as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.2.3. <U>Duty
of Loyalty</U>. Employee acknowledges that Employee owes a duty of care and loyalty to the Company, as well as a duty to perform
Employee&rsquo;s duties in a manner that is in the best interests of the Company. Employee owes such duties to the Company in addition
to duties imposed upon Employee under applicable law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.3. <U>Term</U>.
Subject to earlier termination as set forth herein, Employee&rsquo;s employment hereunder shall be for a term of three (3) years,
commencing on the December 18, 2019 (&ldquo;<B><I>Commencement Date</I></B>&rdquo;). Beginning on the third (3rd) anniversary of
the Commencement Date, and on each subsequent anniversary of the Commencement Date, the term shall automatically, without further
action by Employee or the Company, be extended for one (1) year; provided, however, that either Employee or the Company may, by
notice to the other given not less than ninety (90) days prior to the scheduled expiration of the term, cause the term to cease
to extend automatically. The term of this Agreement is hereafter referred to as the &ldquo;<B><I>Employment Term</I></B>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.4. <U>Compensation
and Benefits</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.4.1. <U>Base
Salary</U>. In consideration of the services rendered to the Company hereunder by Employee and Employee&rsquo;s covenants hereunder,
the Company shall, effective as of the Effective Date and during the remaining Employment Term, pay Employee a base salary (the
&ldquo;<B><I>Base Salary</I></B>&rdquo;) of Twenty-Seven Thousand Eighty-Three Dollars and 33 cents ($27,083.33) per month, less
statutory deductions and withholdings, payable in accordance with the Company&rsquo;s regular payroll practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.4.2. <U>Commission
Compensation</U>. During the Employment Term, the Company shall pay Employee a sales commission (&ldquo;<B><I>Sales Commission</I></B>&rdquo;)
based on the Net Proceeds (as defined below) actually received by the Company, up to a maximum of $1,000,000 of Sales Commissions
per calendar year, from sublicensees of the patent rights to the Company&rsquo;s thin film freezing platform during the term of
this Agreement. The Sales Commission rate shall be one percent (1%) of Net Proceeds, except for any Net Proceeds with respect to
which the Company is obligated to pay any third-party a commission, finder&rsquo;s fee or the like, in which case the Sales Commission
rate shall be one-half of one percent (.5%) of Net Proceeds. The term &ldquo;<B><I>Net Proceeds</I></B>&rdquo; means cash payments
to the Company from sublicensees in the form of sublicensing fees, milestone payments and running royalty payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.4.3. <U>Annual
Bonus</U>. For each full fiscal year completed during the Employment Term commencing with the fiscal year ending December 31, 2020,
Executive shall be eligible to earn a discretionary annual bonus (the &ldquo;<B><I>Annual Bonus</I></B>&rdquo;). The target for
the Annual Bonus awarded to Executive will be twenty percent (20%) of the Base Salary in effect for the applicable year, and if
Executive&rsquo;s salary varies during a fiscal year, the applicable Base Salary shall be the highest Base Salary during that year.
The Annual Bonus shall be based upon Executive&rsquo;s individual performance and the performance of the Company, with reference
to performance goals to be provided at the beginning of each fiscal year by the Company&rsquo;s Chief Executive Officer or the
Board, as the case may be. In order to earn the Annual Bonus under this Section for any fiscal year, Executive must be employed
by the Company, and not have provided notice of resignation, as of the date payment of the Annual Bonus is made. Any Annual Bonus
due to Executive hereunder will be payable at the time bonuses, if any, are paid to other executives, but in all events not later
than the March 15th following the end of the fiscal year for which any such Annual Bonus is awarded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.4.4. <U>Employee
Benefits</U>. During the Employment Term, Employee will be entitled to participate in the employee benefit plans currently and
hereafter maintained by the Company of general applicability to other senior executives of the Company, including, without limitation,
the Company's group medical, dental, vision, disability, life insurance and flexible-spending account plans. The Company reserves
the right to cancel or change the benefit plans and programs it offers to its employees at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.4.5. <U>Vacation</U>.
Employee shall be entitled to paid vacation in accordance with the Company&rsquo;s vacation policy, with the timing and duration
of specific vacations mutually and reasonably agreed to by Employee and the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.4.6. <U>Business
Expenses</U>. During the Employment Term, the Company will reimburse Employee for reasonable travel, entertainment or other expenses
incurred by Employee in the furtherance of or in connection with the performance of Employee's duties hereunder, in accordance
with the Company's expense reimbursement policy as in effect from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.5. <U>Stock
Options</U>. Employee will be eligible to participate in and receive stock option or equity award grants under the Company&rsquo;s
equity incentive plans from time to time in the discretion of the Board of Directors (&ldquo;<B><I>Board</I></B>&rdquo;) of the
Company, and in accordance with the terms and conditions of such plans.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.6. <U>Termination</U>.
Employee&rsquo;s employment and this Agreement (except as otherwise provided hereunder) shall terminate upon the occurrence of
any of the following, at the time set forth therefor (the &ldquo;<B><I>Termination Date</I></B>&rdquo;):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.6.1. <U>Death
or Disability</U>. Immediately upon the death of Employee or a determination by the Company that Employee has ceased to be able
to perform the essential functions of his duties, with or without reasonable accommodation, for a period of not less than <FONT STYLE="font-weight: normal">one
hundred and twenty (120</FONT>) days in the aggregate within a one-year period, due to a mental or physical illness or incapacity
(&ldquo;<B><I>Disability</I></B>&rdquo;) (termination pursuant to this <U>Section 1.6.1</U> being referred to herein as termination
for &ldquo;<B><I>Death or Disability</I></B>&rdquo;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.6.2. <U>Voluntary
Termination</U>. Ninety (90) days following Employee&rsquo;s written notice to the Company of termination of employment; <U>provided,
however</U>, that the Company may waive all or a portion of the ninety (90) days&rsquo; notice and accelerate the effective date
of such termination (and the Termination Date) (termination pursuant to this <U>Section 1.6.2</U> being referred to herein as &ldquo;<B><I>Voluntary
Termination</I></B>&rdquo;); or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.6.3. <U>Termination
For Cause</U>. Immediately following notice of termination for &ldquo;Cause&rdquo; (as defined below), specifying such Cause, given
by the Company (termination pursuant to this <U>Section 1.6.3</U> being referred to herein as &ldquo;<B><I>Termination for Cause</I></B>&rdquo;).
As used herein, &ldquo;<B><I>Cause</I></B>&rdquo; means (i) termination based on Employee&rsquo;s conviction or plea of &ldquo;guilty&rdquo;
or &ldquo;no contest&rdquo; to any crime constituting a felony in the jurisdiction in which committed, any crime involving moral
turpitude (whether or not a felony), or any other violation of criminal law involving dishonesty or willful misconduct that injures
the Company&rsquo;s interests or reputation (whether or not a felony); (ii) Employee&rsquo;s substance abuse that in any manner
interferes with the performance of his duties; (iii) Employee&rsquo;s failure or refusal to perform his duties at all or in an
acceptable manner in the reasonable judgment of the Board or to follow the lawful and proper directives of the Board that are within
the scope of Employee&rsquo;s duties; (iv) Employee&rsquo;s <FONT STYLE="font-weight: normal">material </FONT>breach of this Agreement
<FONT STYLE="font-weight: normal">which, if curable, is not cured within fifteen (15) days after receipt of written notice of such
material breach</FONT>; (v) Employee&rsquo;s <FONT STYLE="font-weight: normal">material</FONT> breach of the PIIA; (vi)&nbsp;misconduct
by Employee that has or could discredit or damage the Company; (vii) Employee&rsquo;s indictment for a felony violation of the
federal securities laws; or (viii) Employee&rsquo;s chronic absence from work for reasons other than illness.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.6.4. <U>Termination
Without Cause</U>. Notwithstanding any other provisions contained herein, including, but not limited to <U>Section 1.3</U> above,
the Company may terminate Employee&rsquo;s employment thirty (30) days following notice of termination without Cause given by the
Company; provided, however, that during any such thirty (30) day notice period, the Company may suspend, with no reduction in pay
or benefits, Employee from his duties as set forth herein (including, without limitation, Employee&rsquo;s position as a representative
and agent of the Company) (termination pursuant to this <U>Section 1.6.4</U> being referred to herein as &ldquo;<B><I>Termination
Without Cause</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.6.5. <U>Resignation
for &ldquo;Good Reason&rdquo;</U>. Notwithstanding any other provisions contained herein, Employee may resign his position for
good reason if any one of the following occurs, without Employee&rsquo;s consent: (i) a reduction in Employee&rsquo;s Base Salary
greater than 10% and material or significant reduction in benefits from those in effect at the time the change is indicated, other
than reductions in salary and/or benefits that are applied to all executive officers of the Company, or (ii) relocation of Employee&rsquo;s
office farther than 50 miles from Employee&rsquo;s office location at the commencement of this Agreement; provided, however, that
with respect to either of the foregoing clauses (i) &ndash; (ii), Employee has provided written notice to the Company of the existence
of the condition or conditions constituting Good Reason within ninety (90) days of the condition or conditions first occurring,
and the Company has failed to cure the condition or conditions specified in such notice despite having been given at least thirty
(30) days after receipt of such notice to cure such condition or conditions (termination pursuant to this <U>Section 1.6.5</U>
being referred herein to &ldquo;<B><I>Resignation for Good Reason</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.6.6. <U>Other
Remedies</U>. Termination pursuant to this section above shall be in addition to and without prejudice to any other right or remedy
to which the Company may be entitled at law, in equity, or under this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.7. <U>Severance
and Termination</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.7.1. <U>Voluntary
Termination, Termination for Cause, Termination for Death or Disability</U>. In the case of a termination of Employee&rsquo;s employment
hereunder for Death or Disability in accordance with <U>Section 1.6.1</U> above, or Employee&rsquo;s Voluntary Termination in accordance
with <U>Section 1.6.2</U> above, or a termination of Employee&rsquo;s employment hereunder for Cause in accordance with <U>Section
1.6.3</U> above, (i) Employee shall not be entitled to receive payment of, and the Company shall have no obligation to pay, any
severance or similar compensation attributable to such termination, other than base salary earned but unpaid and any unreimbursed
expenses pursuant to <U>Section 1.4.5</U> hereof incurred by Employee as of the termination date, and (ii) the Company&rsquo;s
obligations under this Agreement shall immediately cease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.7.2. <U>Termination
Without Cause and Resignation for Good Reason</U>. Subject to the provisions set forth in this Agreement, in the case of a Termination
Without Cause of Employee&rsquo;s employment hereunder in accordance with <U>Section 1.6.4</U> or Resignation for Good Reason in
accordance with <U>Section 1.6.5</U> above, the Company shall pay Employee twelve (12) months&rsquo; base salary then in effect
(hereinafter the &ldquo;<B><I>Severance Payments</I></B>&rdquo;), less statutory deductions and withholdings, payable in the form
of salary continuation and pursuant to the Company&rsquo;s normal payroll cycle. The Company&rsquo;s obligation to make Severance
Payments is conditioned upon Employee timely signing and returning to the Company (and not revoking) a release agreement in a form
satisfactory to the Company (which shall include, but not be limited to, a full release of claims of Employee&rsquo;s claims against
the Company) and on Employee&rsquo;s continued compliance with Employee&rsquo;s obligations to the Company that survive termination
of his employment in this Agreement in and in the PIIA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">1.8. <U>Timing
of Payments and Section 409A</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.8.1. Notwithstanding
anything to the contrary in this Agreement, if at the time of Employee&rsquo;s termination of employment, Employee is a &ldquo;specified
employee,&rdquo; as defined below, any and all amounts payable under this Section 1 on account of such separation from service,
to the extent required in order to avoid accelerated taxation and/or tax penalties under Section 409A of the Code (&ldquo;<B><I>Section
409A</I></B>&rdquo;) that constitute deferred compensation and would (but for this provision) be payable within six (6) months
following the date of termination, shall instead be paid on the next business day following the expiration of such six (6) month
period or, if earlier, upon Employee&rsquo;s death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.8.2. For
purposes of this Agreement, all references to &ldquo;termination of employment&rdquo; and correlative phrases shall be construed
to require a &ldquo;separation from service&rdquo; (as defined in Section 1.409A-1(h) of the Treasury regulations after giving
effect to the presumptions contained therein), and the term &ldquo;specified employee&rdquo; means an individual determined by
the Company to be a specified employee under Treasury Regulation Section 1.409A-1(i).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.8.3. Each
payment made under this Agreement shall be treated as a separate payment and the right to a series of installment payments under
this Agreement is to be treated as a right to a series of separate payments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.8.4. Any
reimbursement for expenses or provision of in-kind benefits that would constitute nonqualified deferred compensation subject to
Section 409A shall be subject to the following additional rules: (i) the amount of expenses eligible for reimbursement, or the
in-kind benefits to be provided, during any taxable year shall not affect the amount of expenses eligible for reimbursement, or
in-kind benefits to be provided, in any other taxable year; (ii)&nbsp;reimbursement of the expense shall be made, if at all, promptly,
but not later than the end of the calendar year following the calendar year in which the expense was incurred; and (iii) the right
to reimbursement or to in-kind benefits shall not be subject to liquidation or exchange for any other benefit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">1.8.5. The
parties hereto agree that their intent is that payments and benefits under this Agreement comply with or be exempt from Section
409A to the extent applicable. This Agreement shall be interpreted to comply with or be exempt from Section 409A, and all provisions
of this Agreement shall be construed in a manner consistent with the requirements for avoiding taxes or penalties under Section
409A.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.25in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -0.5in">2. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><U>PROTECTION
OF COMPANY&rsquo;S PROPRIETARY INFORMATION AND INVENTIONS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">This Agreement, and Employee&rsquo;s
employment hereunder, is subject to the Proprietary Information and Inventions Agreement (&ldquo;<B><I>PIIA</I></B>&rdquo;) dated
November 30, 2018 between the Company and Employee, which is incorporated herein by this reference. The PIIA survives the termination
of the Original Employment Agreement and shall also survive the termination of this Agreement, the Employment Term and/or Employee&rsquo;s
employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -0.5in">3. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><U>REPRESENTATIONS
AND WARRANTIES BY EMPLOYEE</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.4. <U>No
Contrary Agreements or Claims</U>. Employee represents and warrants to the Company that (i) unless otherwise provided in writing
prior to signing this <FONT STYLE="font-weight: normal">Agreement</FONT>, Employee is not bound by or subject to any contractual
or other obligation that would be violated by his execution or performance of this Agreement, including, but not limited to, any
non-competition or non-solicitation agreement presently in effect, and (ii) Employee is not subject to any pending or, to Employee&rsquo;s
knowledge, threatened claim, action, judgment, order, or investigation that could adversely affect his ability to perform his obligations
under this Agreement or the business reputation of the Company. Employee has not entered into, and agrees that he will not enter
into, any agreement either written or oral in conflict herewith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.5. <U>Cooperation</U>.
Employee agrees to cooperate with the Company in connection with matters arising out of Employee&rsquo;s service to the Company
and assist the Company and its attorneys in the prosecution or defense of any litigation or similar proceedings to which the Company
is a party, or matters concerning which litigation or similar proceedings subsequently arise, relating to any matter falling within
Employee&rsquo;s knowledge or former area of responsibility. Employee agrees to provide reasonable assistance and completely truthful
testimony in such matters, including, without limitation, consulting on matters relating to Employee&rsquo;s service to the Company,
facilitating and assisting in the preparation of any underlying defense, responding to discovery requests, preparing for and attending
deposition(s), as well as appearing in court to provide truthful testimony. The Company shall reimburse Employee any reasonable
out-of-pocket expenses necessary for Employee to comply with the obligations under this <U>Section 3.5</U> (including, without
limitation, reasonable travel expenses, lodging and meals) in accordance with the Company&rsquo;s expense reimbursement policies
and, if such policies only permit reimbursement of expenses for active employees, to the same extent Employee would have been reimbursed
if he were an active employee at the time such expenses were incurred.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">3.6. <U>Non-Disparagement</U>.
Employee shall not, at any time during or following his employment, make statements or representations, or otherwise communicate,
directly or, if undertaken at the direction of Employee, indirectly, in writing, orally, or otherwise, or take any action which,
directly or indirectly, disparages any member of the Company, or their respective officers, equityholders, general partners, limited
partners, members, managers, directors, employees, or advisors, or the businesses or reputations of any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -0.5in">4. <FONT STYLE="font-family: Times New Roman, Times, Serif; font-weight: normal"><U>MISCELLANEOUS</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-transform: uppercase; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.4. <U>Notices</U>.
Any and all notices, requests, demands and other communications provided for by this Agreement shall be in writing and shall be
deemed given (a) upon actual receipt by the party to which such notice shall be directed if delivered by hand or electronic mail;
(b) three (3) business days after the date of deposit in the U.S. mail, postage prepaid, registered or certified; or (c) on the
next business day, if sent by prepaid reputable national overnight courier service, in each case addressed to as provided below,
or to such other address as either party hereto may specify by notice to the other in the manner set forth above:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">If to the Company, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">TFF Pharmaceuticals, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">2600 Via Fortuna, Suite 360</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Austin, Texas 78746</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: kcoleman@tffpharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">If to Employee, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Christopher Cano</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">24 Woodfield Lane</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Lawrenceville, New Jersey 08648</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Email: ccano@tffpharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.5. <U>Authorization
to be Employed</U>. This Agreement, and Employee&rsquo;s employment hereunder, is subject to Employee providing the Company with
legally required proof of Employee&rsquo;s authorization to be employed in the United States of America within three days of the
commencement of Employee&rsquo;s employment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.6. <U>Entire
Agreement</U>. This Agreement, the PIIA, together with any equity-based written agreements between Employee and the Company, supersede
all prior discussions and agreements among the parties with respect to the subject matter hereof and contain the sole and entire
agreement between the parties hereto with respect thereto. The Original Employment Agreement is hereby terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.7. <U>Survival</U>.
The respective rights and obligations of the parties in this Agreement and the PIIA that are designed to last beyond the employment
relationship <FONT STYLE="font-weight: normal">hereto</FONT> shall survive the termination of this Agreement, the Employment Term
and/or <FONT STYLE="font-weight: normal">Employee</FONT>&rsquo;s employment with the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.8. <U>Waiver</U>.
Any term or condition of this Agreement may be waived at any time by the party that is entitled to the benefit thereof, but no
such waiver shall be effective unless set forth in a written instrument duly executed by or on behalf of the party waiving such
term or condition. No waiver by any party hereto of any term or condition of this Agreement, in any one or more instances, shall
be deemed to be or construed as a waiver of the same or any other term or condition of this Agreement on any future occasion. All
remedies, either under this Agreement or by law or otherwise afforded, will be cumulative and not alternative.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.9. <U>Amendment</U>.
This Agreement may be amended, supplemented, or modified only by a written instrument duly executed by or on behalf of each party
hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.10. <U>Recovery
of Attorney&rsquo;s Fees</U>. In the event of any litigation arising from or relating to this Agreement, the prevailing party in
such litigation proceedings shall be entitled to recover, from the non-prevailing party, the prevailing party&rsquo;s reasonable
costs and attorney&rsquo;s fees, in addition to all other legal or equitable remedies to which it may otherwise be entitled.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.11. <U>No
Assignment; Binding Effect</U>. This Agreement shall inure to the benefit of any successors or assigns of the Company. Employee
shall not be entitled to assign his obligations under this Agreement. <FONT STYLE="font-weight: normal">The Company shall have
the right at any time to assign this Agreement to its successors and assigns; provided, however, that the assignee or transferee
is the successor to all or substantially all of the business assets of the Company and such assignee or transferee expressly assumes
all of the obligations, duties, and liabilities of the company set forth in this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.12. <U>Headings</U>.
The headings used in this Agreement have been inserted for convenience of reference only and do not define or limit the provisions
hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.13. <U>Severability</U>.
The Company and Employee intend all provisions of this Agreement to be enforced to the fullest extent permitted by law. Accordingly,
if a court of competent jurisdiction determines that the scope and/or operation of any provision of this Agreement is too broad
to be enforced as written, the Company and Employee intend that the court should reform such provision to such narrower scope and/or
operation as it determines to be enforceable. If, however, any provision of this Agreement is held to be illegal, invalid, or unenforceable
under present or future law, and not subject to reformation, then (i) such provision shall be fully severable, (ii) this Agreement
shall be construed and enforced as if such provision was never a part of this Agreement, and (iii) the remaining provisions of
this Agreement shall remain in full force and effect and shall not be affected by illegal, invalid, or unenforceable provisions
or by their severance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.14. <U>Governing
Law</U>. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF TEXAS APPLICABLE TO CONTRACTS
EXECUTED AND PERFORMED IN SUCH STATE WITHOUT GIVING EFFECT TO CONFLICTS OF LAWS PRINCIPLES.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.15. <U>Jurisdiction
and Venue</U>. With respect to any suit, action, or other proceeding arising from (or relating to) this Agreement, the Company
and Employee hereby irrevocably agree to the exclusive personal jurisdiction and venue of the United States District Court for
the Western District of Texas, Austin Division (and any Texas State Court within Travis County, Texas).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.16. <U>Counterparts</U>.
This Agreement may be executed in any number of counterparts and by facsimile, each of which will be deemed an original, but all
of which together will constitute one and the same instrument.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">4.17. <FONT STYLE="font-weight: normal"><U>Construction</U>.
The parties acknowledge that this Agreement is the result of arm&rsquo;s length negotiations between sophisticated parties each
afforded representation by legal counsel. Each and every provision of this Agreement shall be construed as though both parties
participated equally in the drafting of same, and any rule of construction that a document shall be construed against the drafting
party shall not be applicable to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[SIGNATURE PAGE TO AMENDED AND RESTATED
EMPLOYMENT AGREEMENT FOLLOWS]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><B>IN WITNESS WHEREOF</B>,
the parties hereto have caused this Agreement to be executed on the date first written above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&ldquo;<B>Company&rdquo;</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>TFF Pharmaceuticals, Inc.,</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">a Delaware corporation</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; width: 60%">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1.5pt; width: 5%">By:</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; padding-bottom: 1.5pt; width: 35%"><I>/s/ Glenn Mattes</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Glenn Mattes,</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&ldquo;<B>Employee&rdquo;</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1.5pt solid"><I>/s/ Christopher Cano</I>
</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Christopher Cano</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>f10k2020ex23-1_tffpharma.htm
<DESCRIPTION>CONSENT OF MARCUM LLP
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; margin: 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><U>Independent
Registered Public Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">We consent to the incorporation by reference
in the Registration Statement of TFF Pharmaceuticals, Inc. on Form S-3 (File No. 333-249870) and Form S-8 (File No. 333-249364)
of our report dated March 10, 2021, with respect to our audits of the consolidated financial statements of TFF Pharmaceuticals,
Inc. as of December 31, 2020 and 2019 and for each of the two years in the period ended December 31, 2020, which report is included
in this Annual Report on Form 10-K of TFF Pharmaceuticals, Inc. for the year ended December 31, 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">/s/ Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Marcum <FONT STYLE="font-variant: small-caps">llp</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">New York, NY</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">March 10, 2021</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>f10k2020ex31-1_tffpharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>EXHIBIT 31.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">I, Glenn Mattes, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this annual report on Form&nbsp;10-K of TFF Pharmaceuticals, Inc.;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the company and have:</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left"></TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>TFF PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-size: 10pt">Date: March 10, 2021</FONT></TD>
    <TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/&nbsp;<I>Glenn Mattes</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Glenn Mattes, Chief Executive Officer</FONT></TD></TR>
</TABLE>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>f10k2020ex31-2_tffpharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>EXHIBIT 31.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">I, Kirk Coleman, certify that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">I have reviewed this annual report on Form&nbsp;10-K of TFF Pharmaceuticals, Inc.;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(3)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(4)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s)&nbsp;and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&nbsp;13a-15(e)&nbsp;and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&nbsp;13a-15(f)&nbsp;and 15d-15(f)) for the company and have:</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the period covered by this report based on such evaluation; and</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s most recent quarter (the registrant&rsquo;s fourth quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(5)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The registrant&rsquo;s other certifying officer(s)&nbsp;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors and the audit committee of registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial information; and</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; text-align: left">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left"><FONT STYLE="font-size: 10pt"><B>TFF PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: left"><FONT STYLE="font-size: 10pt">Date: March 10, 2021</FONT></TD>
    <TD STYLE="width: 4%; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 36%; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ <I>Kirk
    Coleman</I></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">Kirk Coleman, Chief Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left"><FONT STYLE="font-size: 10pt">(Principal Financial Officer)</FONT></TD></TR>
</TABLE>


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>f10k2020ex32-1_tffpharma.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>EXHIBIT 32.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CERTIFICATION
PURSUANT TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>18 U.S.C. ss.1350,</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>AS ADOPTED PURSUANT
TO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECTION&nbsp;906 OF THE SARBANES-OXLEY
ACT OF 2002</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In connection with the Annual Report of
TFF Pharmaceuticals, Inc. (the &ldquo;Company&rdquo;) on Form&nbsp;10-K for the period ended December&nbsp;31, 2020 as filed with
the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), I, Glenn Mattes, the Chief Executive Officer,
and Kirk Coleman, the Chief Financial Officer, of the Company, respectively, certify, pursuant to 18 U.S.C. &sect;1350, as adopted
pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Report fully complies with the requirements of Section&nbsp;13(a)&nbsp;or 15(d)&nbsp;of the Securities Exchange Act of 1934; and</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in; text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR>
    <TD STYLE="vertical-align: top; width: 5%; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; width: 35%; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ <I>Glenn Mattes</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 5%; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 55%; text-align: left"><FONT STYLE="font-size: 10pt">Dated:&nbsp;March 10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Glenn Mattes</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left">Chief Executive Officer <BR>
(Principal Executive Officer)</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: top; border-bottom: black 1.5pt solid; text-align: left"><FONT STYLE="font-size: 10pt">/s/ <I>Kirk Coleman</I></FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Dated:&nbsp;March 10, 2021</FONT></TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Kirk Coleman</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; text-align: left"><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: left">Chief Financial Officer <BR> (Principal Financial and Accounting Officer)</TD>
    <TD STYLE="vertical-align: bottom; text-align: left">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">This certification is made solely for the
purposes of 18 U.S.C. Section&nbsp;1350, subject to the knowledge standard contained therein, and not for any other purpose.</P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>img_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "4 .$# 2(  A$! Q$!_\0
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M;B6,G >.%F'Y@5:P:M=R%[7R/K3^T;+_ )_+?_OZO^-']H61.!=VY)["5?\
M&OD[^QM2_P"@9>?^ [_X59T[2-175;)CIMV +B,DFW;@;Q[4/"12OS#]J^Q]
M62W,%OCSIHX]W3>P7/YU'_:-E_S^6_\ W]7_ !KRGX[@&UT+(_Y:S?R6O&X;
M>2XD$<$+RR'HD:%B?P%12PJG#FN$JEG:Q]=?VC9?\_EO_P!_5_QH_M&R_P"?
MRW_[^K_C7R=_8^I?] N\_P# =_\ "C^QM2_Z!EY_X#O_ (5?U./\PO:OL?6T
M4\4ZEH94D4'!*,"/TJ2O-O@M;3VOA6]2>WEA8WC$+(A4D;5YP:])KDJ1Y9.)
MJG=7"BBBH&%%%% !1110 4444 %%%% !1110 4444 %%%% 'RIXO_P"1SUK_
M *_)/YU[#\$?^1-N_P#K^?\ ] 2O'O%__(YZU_U^2?SKV'X)?\B;=_\ 7\__
M * E>EB/X"^1A#XV>E4445YIN?)&M?\ (?U+_K[E_P#0S7O?P>_Y)Y;?]=YO
M_0S7@FM?\A_4O^OJ7_T,UZU\-O''AS0?!D%CJ>II;W*S2L8S&YP"V1T!%>GB
M8N5)61STW:3/7:*Y#_A:/@S_ *#<?_?F3_XFM;0_%6B^)&G72+Y;DP;3)A&7
M;G..H'H:\]PDE=HWNCSKX[_\>NA?]=9OY+7&_";_ )*1IW_7.;_T6:[+X[?\
M>NA?]=9OY+7 ?#O5K'1/&]EJ&HSB"UC24/(03@E"!P.>M=])7PS2\S&7\0^G
M:*Y#_A:/@S_H-Q_]^9/_ (FG1_$WP=+*D::U&7=@JCRI.23@?PUP>SGV9MS+
MN=;1114#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^5/%__(YZ
MU_U^2?SKV'X)?\B;=_\ 7\__ * E>/>+_P#D<]:_Z_)/YU[#\$O^1-N_^OY_
M_0$KTL1_ 7R,(?&STJBBBO--SY(UK_D/ZE_U]R_^AFMC1/ 'B/Q#IJ:AIMI%
M+;.S*&:95.0<'@UCZU_R']2_Z^Y?_0S7O?P>_P"2>VW_ %WF_P#0S7K5JCIT
MTT<T8J4K,\L_X5+XR_Z!\'_@2E>B?"KPAK7A>;56U:VCA%PL0CVRA\[=V>G3
MJ*]+HKAGB9SCRLV5-)W/(?CO_P >NA?]=9OY+7DVCZ/>Z]JD6G:=&LEU*&**
MS!00!D\GV%>L_'?_ (]="_ZZS?R6N-^$W_)2-._ZYS?^BS771DXX?F72YE-7
MG87_ (5+XR_Z!\'_ ($I_C4UI\*?&$5];2OI\(1)D=C]I3H&!-?1-%<WURH:
M>RB%%%%<IH%%%% !144=S#+/+#'(K218\Q0<E<],U+0 4444 %%%% !1110
M4444 %%%% !1110!\J>+_P#D<]:_Z_)/YU[#\$O^1-N_^OY__0$KGM=^$.O:
MIX@U"_AO+!8KFX>5 S-D G//%=Y\._"U[X2T">POI89)9+EI0822,%5'?Z5W
MUZL)4DD]=#&$6I79U]%%%<!L?)&M?\A_4O\ K[E_]#->]_![_DGMM_U\3?\
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M^$--\-Q;H%\V[88>XD'S'V'H*)QPV&_O2"$\7C/[D?Q,7P9X$32"FHZF%EU
M\HA^80_CW;WKNJ**\^I5E4ES2/4HT848\D$%%%%9FH4444 %%%% !1110 5G
MZQK-GH6GO>7LFV->%4?><^@'<UH5S?B/P=:>);RUGNKNXC2 ;?*C(VL,Y[]#
M[U=-0<ESO0SJN:@_9J[.&":]\2=0)+&TTF)^/[J__%M^@KT70O#&F>'H EE
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I** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>img_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %Y XH# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOY5X??-J6F1V=B+LM*H/G2$YS6G T\5IYIN\AOXB:.;#?RL/9XS^9?<>N_\
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M -?)_O'^= 6/$12T8HKE.H**** "BBB@ HHQ10 4444 %%%% !1110 4444
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MS76"P'9Z]@\!9'A]01@ACQ7DUI86JZK+*EL)"D9"W']VO6? 7/A]3ZL:[/\
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M,D;X=\GHQZB@#G% +X[5K:1(]HR31DA]W ]:WM'\#PW6@_;[Z[-O)+GRE/\
M6ET/P3J-]=/#/)Y,$?(EQG/TH L:K.\US 9@,,O3WK<\/V,&E:7<:O=IO#]5
M_P!FK$7AJ)+Z"&23[3$HYDQTJMXACF@O8;>!F-ED90?Q"@#4M]/@\0ZEI\D
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MDNYQ\HQ]P^E7-"T+5=!LX?[2B(D)^:0'C![4S5]/TUM0>ZOHE$T8S#(QPN*
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M\_,7_?8H^W6G_/U%_P!]BN3^R6__ #R%'V2W_P">0K3V9'M#K/MUI_S\Q?\
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M74)KT0K)>QC:8GZ\]Z] M;[0=!U>:YGTX&54^:3;D*.]<?/>QZ3$9A*+>=@
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M*8@I*6B@8+]\5R4W^OD_WC_.NN7[XKD9O]?)_O'^=!)XE12T5RG6)0.M+10
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M*.*&S8^7(ZCYB1UQ4NCZI9AS<RW?F18*!0<YS5+1;*VB@U6!W)MY"TR.?X*
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M^AY^8;0]3.EU?4XO#UYI?AW_ $FXF4XR> .Y'O7(>#OA[=0ZE)<ZR,7&-RP
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MRL /WC[&N0[UL>2[-4T#59T43*T;E6<*=K#W->@:=XKET_P_#JBVHFN#($(
MR%]Z])M-0TG5/MEFMA!+$B'Y609./?O7"6E_8&:5(-/5;-I"K1G^ T#,74+F
M%M5-[)\MQ='((&2:9+K4VFZC%'-:N8WQ^^88KJ[W3=/2&&Y9%C2U?<KM_$/2
MNIM;+2?$^A3QW*1XBB\R(XQB@#DK/Q#8^9\\0.X8;CM70V%Y>VL932YR+:3H
MK#.S-><^([B+1[%+>,*UU*>&]%KJ? .H/K6@2"2<1&'Y)"!DF@#SK4H;P:U>
MB9I&<RD^:>AK1TZ[#0B!Y#YRGKZUW6K>$T:SE:"?S(@<ES6(?!;22V[I<I'\
MP'UH ;HD"I=SWDZY=1A-W;WJ)O$Z+?/&8'D0'#/C('O7<ZYX=CTCP].8)UN+
ME%!D4#I]*X#PE</*^HV\EJ#:RC:TCKR/84 ='8:BQC<Q$R6\P*CC@9KRB>T^
MS^(WLV)1O.+ ^Q->EW>KV&GVRV\,T44,8P%)YKB=2U72-4UZ*0!C-D*K+T)H
M ]-T6^"I EVJ,R@>43T8CUK-U?2-)7Q%)KEQ*L<TN (L\*WL*V+'2=/L+.W:
MX=Y)U&\#/ S6;<^';.^\2QZC-=/+$6!$&.!B@#&US1;J:6RU*)7<V[_<'IUS
M71P:]:ZG936EQ#L4J-V_U]JVY+FU75G2-<1QQ_,IZ-7G][J-BVJ?8Y,I,9,[
M>@4YXH -7\<IX<D6UCC,LFW)7L*NZ%XROM<TS,]M&BEB=P'0"N(\?Z48;B/4
MPY;SCL<8Z&H_!/B!K.Y32Y(P\<YPI],T =>;[P_KE^][>?O(K?Y7W'CCTK(L
MQ!J?B(S^'U:&VMF#&0#CZ4W7/#LFGZ;>6ML!AY=Y^A[4NBZW+X>M&M[6U1HY
M5^<D=#0!U%SXOMX89Y9R/M,0)*)SN/:L*P\0VE_IESJ\MNLFI ,  ,E!VJCH
M>FBZUJ2^E3]T<M(K'@UM0_V18P74D<*1S3'YCV(]J )O"G@^35_#SW\^H-'<
M7S$L!U ]*[72? %N+$6<VHR&"#YF)')]C6#X>L[S1D35I[D#3W_Y8C^'WJ]X
M@\4W MGFC<QPO\JA>-WO0!T-]9V$C);V\[PQ)@($Z&O-];O_  WHWBGR(K5[
MK46(7?UV$T^P\91Z59.MV6N2"?+8'D'WKE;&RU9_$RZ_)8/-')(6/XT >F+(
MUO!)+*,NH+ -SN&*B\/W4NMZ5/?M 8AYFP(.,CUJ6)X[JV:\G!2<?($/3'>N
M9U_6GL-<MH+>7R$0 K&O1_K0!O:%.MEJ]]H]U)M@G^>'=ZUIVNE74DUR9[MV
M3K#'GH1Z5QOCW46G2T,">3<-'N9Q_#70^$8[QM$TZXDOF=@2TC-Z4 =;KE_?
M7_@EI4C"RP+LE?/.T5P?PHU8RV>J6$T[-^^+(';) JUXK\6S>'_#>H:8]N9#
M>,0DX/0&J_A+PI_8WAVUU.+?)=WL1=F]!Z4 4=:M]6@UBWBMF?[%YI,F3\M)
MJKV]C:M++N+@'RD7DEJZ:>-I[ +(>,\DG&*I7&G#;#>/L A!P6Y&* /)M%LM
M3U'67OA.\!#%F8]3[5UJ^(;:\F>SD&R9!CS#T:GWNF&U4ZG!<CR'8[E/'XBN
M-O%CDDD$9P[-\I]2: /4=#-MIFG?:1"\MS=-L#*,E1]:Z.&\M(3):W101-&3
M)NZ@4WPQI\^D^#+&.6+S;UOFVGL#7/>,];L5MI[2WLR^H[=LLH/&#VH&BCX=
M\0QZM>WELF (G(C_ -I!7MG@+_D7EYYW&O / WARYBNY=4F7RXTC("]^:]_\
M!'.@*?5C78O]U?J>8_\ ?5Z'4T445QGI!7*ZP637'?RI&0Q*-RKFNII.<4)V
M8FKHXWS_ /IC/_W[-)]H_P"F,_\ W[-=IS1S6GM&1[-'%_:/^F,__?LT>?\
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M0!K>)+FV,"VX"N0<Y'45S/IGFE+%I&8YRQSS10!/9?\ (3L_^NZ_SKZ]M?\
MCTA_ZYK_ "KY"L/^0E9_]=U_G7U[:_\ 'I#_ -<U_E0!+1110 4AZ&EI#T-
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MNV^^>HQ[U6^Q&X$BVZ",.I.%7@'UIFH^+M&T^Q-Q%!)<R$[>F!3+C6Y'TK?
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M]:\QO]&ETB]*W3"9WY67.0U '1:%XKU33Y+:W@B%T8_N1]Q73S76MZ[=M=-
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MD^0Q$9QCN:DO=/N;0/YB;D[,M4Y,")<\Y%>?.$H.TM#UJ=2-17@[F%J#;KS
M((]:@44L@VW#@\^E+M8 9!&?6HN:/3H*!BE^E I>E,!,&@CC%.S[49]J -2R
M$<MLK28<QGA:BU- 7#AEY'W5_AJ@&93PQ7Z4'DDDDF@!N*7%&<TM "<T<TM%
M  .*/KTHHH : 0Y7MU%.I#TW#J*4_P![L: )[#_D)V9_Z;+_ #KZ]M?^/2'_
M *YK_*OD*P_Y"5G_ -=E_G7U[:_\>D/_ %S7^5 $M%%% !1110 TUY7XDR?&
M$X'7*X_*O5#7E?B;/_"7S;1D\8_*NK![R]#S\PVAZG/0^)8KS79K0OM>/Y,'
MI70>%HKJUU6Y\R<2P%6*N#GMTKSCQQX:U'1I4U% ?LUP^24'*FK'PWOM:,]S
M Q;[#U,LO7-<IWHZ6WM[B*^?S87$3.2N>G6JEYXPN?"&NBWU&$-#=#; X_A!
MZ5VGE--+%;W$\8A!X8GK7*>*O!IU3Q"MSJ,C/:HH%NB=J!CK6""[F6X6T0W)
M/,@'7-=AIUG]G5+F5A%'%RY/\JJ:/HR:78/=W4HC@C3">9QD]JX;2_B1Y^M7
M6E:PD;6\3EEFC[CT- &WXNO]+U3P[JD]ND+W2D_9X\<^YQ7SZMK=-,D+0.DK
MG@,,9KTO4M1TRT\027[3&..Y^9$[!17$>)?$K:OJBR6X5(8.(V P30 Q-#N_
M/Q(F4S@E:T &LI(TA9C,Q"E#]:T/#^H6UU;$,Y,ZIDKZGUJ(VD^I:BJ0P2FX
M#C:RB@#M[J^_X1/0/*A+_;+C!Z<#BLOP7KEW=:G=).^5"[@3UW5U=]<6C:=!
M!=0K<26R@RKCDU@6&K:/J]Q/_9<(AG3.Y,<B@#5U3QQ'X=N+6,HLDK\S*@Z_
M6K-YK4>J^3+"&6-^=K=JPM(\'02W$^I:O?"YE+95 >%':MB6SMX(]ZR#:!A6
MSTH I2^(+:\OSHEN2I _>-G@^U<SJ7AG4IM3FMM)N7BMU7<PW<-5G1O"EU;>
M)_MMU/G<Q9"O?T!KH+>YT_1/$DEA?B6>]NCG:#PBT <SX/\ #=[=K>VPG6+'
MRRJW\Z]1LM*LM.MXK.U=O-AC^9NH)^E8TSV]LSSZ?LM6!_>EC]X51TV/4+;6
M+G6(]3#I,NT0MT'O0!;\>>(YM&\/P2(#OEF".P'"BH) L4,7B*-RR2PXF8]A
MBKT=O9Z_I#Z=JIW*S\N.N:Y'QA/>Z-,?".F1O=Q/&'W@=%]* ,/P]JT=WXT@
MFNQO@\PLI ZBMKQQJ+:OJUQ/8Q.]LJ;4C09VGUKF/#T,O_"0V[1Q,5MR1+QP
MOM7I&GSPV$MQ<6,.WSC\^\9% "0WL6I_"K['*K!!A2,8(;UKC-3M$FTJW@F5
MB(L 'N178#4?]&N(C&HB<[MH%8.C:E::KXL@@V?N0< MTR* .ST.VM-%T&..
MP3RF"@R/W)-$%S--?[I<SJBY/M5K5IX+'1+J[*_Z/ _[R0=SV%9?A?78->@G
M^QQ&#Y/F8]Q0 W4-1C$C2W$HCB7[NX\57\'^.-.M];.FRR^7%.^Y)6./FKB?
M&>LI>:W]@MF!M;;^(=VKC]2*[E8<,O((ZT >L?$74)[36XI-,G4SR3D>4N")
M!ZUO6^H2P:8\DCM'>K'N\OMFO$K/4&%S;WLMRQDMSG#G) KT?6I;J]T>VOK.
M9HVE  3N<]Z .5M_'>LS:Q-)<R>?.'($;'@#VK5T35;5KW4-3U&39=N,!7X
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M#7K-EN#.R 2$?/CIFNR\!_\ (OK_ +QKEKV[AOO#D=[;R"6-^"PYQ74^ O\
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M_L^6*\B,GD@F)^Y]C7D>C:A<2:O)JJ,8G?.T \"MAM=U:!Y;M+EY9!QY>>*
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MM##%>0@JORR,?TK7OK*UN=:@U*W<0F+F6//WC1<:[;QWPMKFY*-<']V">IH
MPHO"^G:)X>(N;1+N?<#+*HYSZ"I3:V<VH6U_/&^8DVQQ'HHK8ACNIK[R$*_,
M.0>E49]-U"Z\1-IP41QJH9K@_=% &???#X>,+V2\DGCCLX5^5%/S,:Y'2[37
M?">KW,$%M<2V4O[N,$>M>PV'A.\TO1IYDU!;A"VX,IZ5G3:Q,EN847<V"%8K
MWH Y3X@6Z1>#=/M;Q8TOBX=)HQD@>A-<9H>L75HD]W:3;5A.UT8?ZW\*]=TK
M4=)?3_L[?9[J[#$RK+\Q4^V:=_9^E-NN&LH49OX%48H K>'=4EUK2$O38);J
MIQM/ 8UA7UV\GB&&6:!7DDF5 HZXS75M,UOI$EK9B-YG/[N,\!:H:-:NES!=
M:FD23PL?E7G=Z4 ='K5_YJRV[;3&B]/H.E<IHNJVGB.Y;3F@62,9#1O_  @5
MU=EX?DO8KZ?[0AN)%)52>%S7D\5[>^"?$US;7]NL;3#/R]2/6@#LM;T317MU
MT_8WSG$3Y^X:YC0['7=%EN[)[1VM"<QRD8 ]Q7=0:9:Z]8VKVLVVZ8;T#5R&
MK_%66QNKC3)K0O+;@PGCC/K0-$<&H&TU%--?SG:4%B[<BO8? 8QH"CKAC7C7
MAW4UU^"2Y<HLD!QM/7FO9? 7_(OK_O&NQ?[L_4\Q_P"^KT.IHHHKC/2$J.6%
M)HFBE4,C#!!J6DH"US#?PS;D_NII(E[ 'I2?\(Q'VNY:WJ*?,Q<J,'_A&4_Y
M^Y:/^$93_G[EK>-)1S,.5&%_PC*?\_<M'_",I_S]RUNT4<S#E1A?\(RG_/W+
M1_PC*?\ /W+6[13YF'*C"'AF/()NI2/2N7\+Q7&KZSKEI=7;F.SF"0X'0&O1
M:X'P%_R,_BG_ *^%_K1S,.5'0_\ ",I_S]RT?\(RG_/W+6[12YF'*C"_X1E/
M^?N6C_A&4_Y^Y:W:*.9ARHPO^$93_G[EH_X1E/\ G[EK=HHYF'*C"_X1E/\
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M.J_!ZG-*YR]-P* %..U+M(%(,"E[Y_2@ XHXI"N>124 .HI** %I1UIN#2T
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M[%D?[4\G^L!X89ZUZ'XWN;[PGI=JT,OVJ6? =L<1GTJ+7/$,>D3V$LR@S!P
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MD!5A\VU3[5WEOI]MH=MI""S2XL5.WS>ZR>M;]YJRV6E7-V\B-GY45AQBN0]
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M*&^>XD$-K"PVQ,/O-Z5VUK8:%J&M)8ZC;QK<)\IV+@@5S&A6GB?POKC,?*:
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M ,*I\&?] 6+\S1_PJGP9_P! 6+\S0!\:45]E_P#"J?!G_0%B_,T?\*I\&?\
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M%+*XA*31*O$;#H0/>O1_^%6+C_D"0_\ ?5'_  JU?^@+#_WU3^JK^9!]??\
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M +ZH_P"%6C_H"P_]]4OJJ_F0?7W_ ",^;J*^D?\ A5H_Z L/_?5'_"K1_P!
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MNBHH YV\\'Z9>7"RLKQ?*%<1-@.!ZUK2:?;R:8^GM'BV>,Q%!_=(QBKE% &
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MRA^%&/:K_P#8%S_S]C\J/[ N?^?H?E1[2(>S90Q[48]JO_V!<_\ /V/RI/[
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MW\D@BEDW06\C;FA7TSWKJ!TI/XC2K]V@!:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
ABB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>10
<FILENAME>tffp-20201231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Mar 09 20:01:28 EST 2021 -->
<xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:compsci="http://compsciresources.com" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:tffp="http://tffp.com/20201231" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:type="simple" xlink:href="tffp-20201231.xsd"/>
  <context id="c0_From1Jan2020To31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c1_AsOf5Mar2021">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2021-03-05</instant>
    </period>
  </context>
  <context id="c2_AsOf30Jun2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2020-06-30</instant>
    </period>
  </context>
  <context id="c3_AsOf31Dec2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c4_AsOf31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c5_From1Jan2019To31Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c6_AsOf31Dec2018_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c7_AsOf31Dec2018_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c8_AsOf31Dec2018_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c9_AsOf31Dec2018_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c10_AsOf31Dec2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c11_From1Jan2019To31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c12_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c13_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c14_From1Jan2019To31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c15_AsOf31Dec2019_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c16_AsOf31Dec2019_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c17_AsOf31Dec2019_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c18_AsOf31Dec2019_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c19_From1Jan2020To31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c20_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c21_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c22_From1Jan2020To31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c23_AsOf31Dec2020_CommonStockMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c24_AsOf31Dec2020_AdditionalPaidInCapitalMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c25_AsOf31Dec2020_AccumulatedOtherComprehensiveIncomeMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c26_AsOf31Dec2020_RetainedEarningsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c27_AsOf24Jan2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2018-01-24</instant>
    </period>
  </context>
  <context id="c28_From1Oct2019To31Oct2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <startDate>2019-10-01</startDate>
      <endDate>2019-10-31</endDate>
    </period>
  </context>
  <context id="c29_AsOf31Oct2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2019-10-31</instant>
    </period>
  </context>
  <context id="c30_From1Aug2020To13Aug2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <startDate>2020-08-01</startDate>
      <endDate>2020-08-13</endDate>
    </period>
  </context>
  <context id="c31_AsOf13Aug2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2020-08-13</instant>
    </period>
  </context>
  <context id="c32_From1Jan2020To31Dec2020_MinimumMember_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c33_From1Jan2020To31Dec2020_MinimumMember_ComputerEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c34_From1Jan2020To31Dec2020_MaximumMember_FurnitureAndFixturesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c35_From1Jan2020To31Dec2020_MaximumMember_ComputerEquipmentMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c36_From1Jan2020To31Dec2020_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c37_From1Jan2019To31Dec2019_StockOptionMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c38_From1Jan2020To31Dec2020_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c39_From1Jan2019To31Dec2019_WarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c40_AsOf31Mar2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2018-03-31</instant>
    </period>
  </context>
  <context id="c41_AsOf24Dec2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2019-12-24</instant>
    </period>
  </context>
  <context id="c42_AsOf31May2018_MasterServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:MasterServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-05-31</instant>
    </period>
  </context>
  <context id="c43_From1Jan2019To31Jan2019_MasterServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:MasterServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-01-31</endDate>
    </period>
  </context>
  <context id="c44_AsOf31Jan2019_MasterServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:MasterServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-01-31</instant>
    </period>
  </context>
  <context id="c45_From1Jan2020To31Dec2020_MasterServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:MasterServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c46_From1Jan2019To31Dec2019_MasterServicesMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:MasterServicesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c47_AsOf30Apr2019_IrisysLlcMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:IrisysLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-04-30</instant>
    </period>
  </context>
  <context id="c48_From1Jan2020To31Dec2020_IrisysLlcMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:IrisysLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c49_From1Jan2019To31Dec2019_IrisysLlcMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:IrisysLlcMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c50_AsOf30Jun2019_CoreRxMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:CoreRxMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-06-30</instant>
    </period>
  </context>
  <context id="c51_From1Jan2020To31Dec2020_CoreRxMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:CoreRxMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c52_From1Jan2019To31Dec2019_CoreRxMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:CoreRxMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c53_AsOf31Aug2020_ConformClinicalDevelopmentIncMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:ConformClinicalDevelopmentIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-08-31</instant>
    </period>
  </context>
  <context id="c54_AsOf31Jan2020_NovotechAustraliaPtyLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:NovotechAustraliaPtyLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-01-31</instant>
    </period>
  </context>
  <context id="c55_From1Jan2020To31Dec2020_NovotechAustraliaPtyLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:NovotechAustraliaPtyLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c56_AsOf31May2020_NucleusNetworkPtyLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:NucleusNetworkPtyLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c57_AsOf31May2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2020-05-31</instant>
    </period>
  </context>
  <context id="c58_From1Jan2020To31Dec2020_NucleusNetworkPtyLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:NucleusNetworkPtyLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c59_AsOf31Aug2020_QPharmPtyLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:QPharmPtyLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-08-31</instant>
    </period>
  </context>
  <context id="c60_From1Jan2020To31Dec2020_QPharmPtyLtdMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">tffp:QPharmPtyLtdMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c61_From1Oct2019To31Oct2019_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-10-01</startDate>
      <endDate>2019-10-31</endDate>
    </period>
  </context>
  <context id="c62_AsOf31Oct2019_SeriesAPreferredStockMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-10-31</instant>
    </period>
  </context>
  <context id="c63_AsOf31Oct2019_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-10-31</instant>
    </period>
  </context>
  <context id="c64_AsOf31Jan2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2020-01-31</instant>
    </period>
  </context>
  <context id="c65_AsOf10Aug2020_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-08-10</instant>
    </period>
  </context>
  <context id="c66_From2Aug2020To10Aug2020_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-08-02</startDate>
      <endDate>2020-08-10</endDate>
    </period>
  </context>
  <context id="c67_From1Nov2020To30Nov2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <startDate>2020-11-01</startDate>
      <endDate>2020-11-30</endDate>
    </period>
  </context>
  <context id="c68_From1May2019To31May2019_SeriesAPreferredStockMember_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-05-01</startDate>
      <endDate>2019-05-31</endDate>
    </period>
  </context>
  <context id="c69_AsOf31May2019_SeriesAPreferredStockMember_PrivatePlacementMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-31</instant>
    </period>
  </context>
  <context id="c70_From20Feb2018To13Mar2018_NationalSecuritiesCorporationsWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:NationalSecuritiesCorporationsWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-20</startDate>
      <endDate>2018-03-13</endDate>
    </period>
  </context>
  <context id="c71_AsOf13Mar2018_SeriesAPreferredStockMember_NationalSecuritiesCorporationsWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:NationalSecuritiesCorporationsWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-03-13</instant>
    </period>
  </context>
  <context id="c72_AsOf13Mar2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2018-03-13</instant>
    </period>
  </context>
  <context id="c73_AsOf22Mar2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2018-03-22</instant>
    </period>
  </context>
  <context id="c74_AsOf16May2019_NationalSecuritiesCorporationsWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:NationalSecuritiesCorporationsWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-05-16</instant>
    </period>
  </context>
  <context id="c75_From20Apr2019To16May2019_NationalSecuritiesCorporationsWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:NationalSecuritiesCorporationsWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-04-20</startDate>
      <endDate>2019-05-16</endDate>
    </period>
  </context>
  <context id="c76_From19Apr2019To23May2019_NationalSecuritiesCorporationsWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:NationalSecuritiesCorporationsWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-04-19</startDate>
      <endDate>2019-05-23</endDate>
    </period>
  </context>
  <context id="c77_AsOf29Aug2019_TenYearsWarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:TenYearsWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-08-29</instant>
    </period>
  </context>
  <context id="c78_AsOf29Aug2019_BPDirectorsMember_TenYearsWarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">tffp:BPDirectorsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:TenYearsWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-08-29</instant>
    </period>
  </context>
  <context id="c79_From2Aug2019To29Aug2019_TenYearsWarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:TenYearsWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-08-02</startDate>
      <endDate>2019-08-29</endDate>
    </period>
  </context>
  <context id="c80_AsOf26Nov2019_NationalSecuritiesCorporationsWarrantsMember_IPOMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:NationalSecuritiesCorporationsWarrantsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-11-26</instant>
    </period>
  </context>
  <context id="c81_AsOf26Nov2019_NationalSecuritiesCorporationsWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:NationalSecuritiesCorporationsWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-11-26</instant>
    </period>
  </context>
  <context id="c82_From3Nov2019To26Nov2019_NationalSecuritiesCorporationsWarrantsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:NationalSecuritiesCorporationsWarrantsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-11-03</startDate>
      <endDate>2019-11-26</endDate>
    </period>
  </context>
  <context id="c83_AsOf29Nov2019_TenYearsWarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:TenYearsWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-11-29</instant>
    </period>
  </context>
  <context id="c84_AsOf29Nov2019_TenYearsWarrantMember_BPDirectorsMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:TenYearsWarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">tffp:BPDirectorsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-11-29</instant>
    </period>
  </context>
  <context id="c85_AsOf29Nov2019">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <instant>2019-11-29</instant>
    </period>
  </context>
  <context id="c86_From4Nov2019To29Nov2019_TenYearsWarrantMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">tffp:TenYearsWarrantMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-11-04</startDate>
      <endDate>2019-11-29</endDate>
    </period>
  </context>
  <context id="c87_AsOf31Dec2018_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c88_AsOf31Dec2018_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-12-31</instant>
    </period>
  </context>
  <context id="c89_From1Jan2019To31Dec2019_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c90_From1Jan2019To31Dec2019_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c91_AsOf31Dec2019_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c92_AsOf31Dec2019_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c93_From1Jan2020To31Dec2020_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c94_From1Jan2020To31Dec2020_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c95_AsOf31Dec2020_MinimumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c96_AsOf31Dec2020_MaximumMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c97_From1Jan2018To31Jan2018">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-01-31</endDate>
    </period>
  </context>
  <context id="c98_From1Jan2020To31Dec2020_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c99_From1Jan2019To31Dec2019_ResearchAndDevelopmentExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c100_From1Jan2020To31Dec2020_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c101_From1Jan2019To31Dec2019_GeneralAndAdministrativeExpenseMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2019-01-01</startDate>
      <endDate>2019-12-31</endDate>
    </period>
  </context>
  <context id="c102_From3Mar2020To27Mar2020">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
    </entity>
    <period>
      <startDate>2020-03-03</startDate>
      <endDate>2020-03-27</endDate>
    </period>
  </context>
  <context id="c103_From1Jan2020To31Dec2020_EffectiveTaxRateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tffp:EffectiveTaxRateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c104_AsOf31Dec2020_EffectiveTaxRateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">tffp:EffectiveTaxRateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c105_AsOf31Dec2019_FederalAndStateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tffp:FederalAndStateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2019-12-31</instant>
    </period>
  </context>
  <context id="c106_From1Jan2020To31Dec2020_FederalAndStateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tffp:FederalAndStateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2020-01-01</startDate>
      <endDate>2020-12-31</endDate>
    </period>
  </context>
  <context id="c107_AsOf31Dec2020_FederalAndStateMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">tffp:FederalAndStateMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2020-12-31</instant>
    </period>
  </context>
  <context id="c108_AsOf10Mar2021_WarrantMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-10</instant>
    </period>
  </context>
  <context id="c109_AsOf10Mar2021_OptionMember_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:OptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2021-03-10</instant>
    </period>
  </context>
  <context id="c110_From1Jan2021To10Mar2021_SubsequentEventMember">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001733413</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2021-01-01</startDate>
      <endDate>2021-03-10</endDate>
    </period>
  </context>
  <unit id="shares">
    <measure>xbrli:shares</measure>
  </unit>
  <unit id="usd">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="usdPershares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>xbrli:shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="pure">
    <measure>xbrli:pure</measure>
  </unit>
  <unit id="aud">
    <measure>iso4217:AUD</measure>
  </unit>
  <dei:AmendmentFlag contextRef="c0_From1Jan2020To31Dec2020">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="c0_From1Jan2020To31Dec2020">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="c0_From1Jan2020To31Dec2020">FY</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="c0_From1Jan2020To31Dec2020">2020</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="c0_From1Jan2020To31Dec2020">2020-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="c0_From1Jan2020To31Dec2020">10-K</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="c0_From1Jan2020To31Dec2020">0001733413</dei:EntityCentralIndexKey>
  <dei:EntityCurrentReportingStatus contextRef="c0_From1Jan2020To31Dec2020">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityEmergingGrowthCompany contextRef="c0_From1Jan2020To31Dec2020">true</dei:EntityEmergingGrowthCompany>
  <dei:EntityExTransitionPeriod contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityExTransitionPeriod>
  <dei:EntityFileNumber contextRef="c0_From1Jan2020To31Dec2020">001-39102</dei:EntityFileNumber>
  <dei:EntityFilerCategory contextRef="c0_From1Jan2020To31Dec2020">Non-accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityIncorporationStateCountryCode contextRef="c0_From1Jan2020To31Dec2020">DE</dei:EntityIncorporationStateCountryCode>
  <dei:EntityInteractiveDataCurrent contextRef="c0_From1Jan2020To31Dec2020">Yes</dei:EntityInteractiveDataCurrent>
  <dei:EntityRegistrantName contextRef="c0_From1Jan2020To31Dec2020">TFF Pharmaceuticals, Inc.</dei:EntityRegistrantName>
  <dei:EntityShellCompany contextRef="c0_From1Jan2020To31Dec2020">false</dei:EntityShellCompany>
  <dei:EntitySmallBusiness contextRef="c0_From1Jan2020To31Dec2020">true</dei:EntitySmallBusiness>
  <dei:EntityVoluntaryFilers contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="c0_From1Jan2020To31Dec2020">No</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityCommonStockSharesOutstanding unitRef="shares" contextRef="c1_AsOf5Mar2021" decimals="INF">23139900</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat unitRef="usd" contextRef="c2_AsOf30Jun2020" decimals="0">83662145</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">35300805</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">28094936</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:PrepaidExpenseAndOtherAssets unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">2258229</us-gaap:PrepaidExpenseAndOtherAssets>
  <us-gaap:PrepaidExpenseAndOtherAssets unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">1092462</us-gaap:PrepaidExpenseAndOtherAssets>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">37559034</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">29187398</us-gaap:AssetsCurrent>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1102808</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:Assets unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">38661842</us-gaap:Assets>
  <us-gaap:Assets unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">29187398</us-gaap:Assets>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1297725</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">410638</us-gaap:AccountsPayableCurrent>
  <us-gaap:OtherLiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">24315</us-gaap:OtherLiabilitiesCurrent>
  <us-gaap:OtherLiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1322040</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">410638</us-gaap:LiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesNoncurrent unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:OtherAccruedLiabilitiesNoncurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">1132013</us-gaap:OtherAccruedLiabilitiesNoncurrent>
  <us-gaap:Liabilities unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1322040</us-gaap:Liabilities>
  <us-gaap:Liabilities unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">1542651</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:CommitmentsAndContingencies unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">22535</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">18451</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">71648453</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">43338710</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">-51538</us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">-34279648</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">-15712414</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">37339802</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">27644747</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">38661842</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">29187398</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare unitRef="usdPershares" contextRef="c4_AsOf31Dec2019" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">45000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">45000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">22534874</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">18450992</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">22534874</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">18450992</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">10681565</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">8822226</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">8012085</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">3165331</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">18693650</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">11987557</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-18693650</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">-11987557</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestIncomeExpenseNet unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">126416</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:InterestIncomeExpenseNet unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">117329</us-gaap:InterestIncomeExpenseNet>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">126416</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">117329</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-18567234</us-gaap:ProfitLoss>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">-11870228</us-gaap:ProfitLoss>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:PreferredStockDividendsIncomeStatementImpact unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">875359</us-gaap:PreferredStockDividendsIncomeStatementImpact>
  <us-gaap:OtherPreferredStockDividendsAndAdjustments unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:OtherPreferredStockDividendsAndAdjustments unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">23929751</us-gaap:OtherPreferredStockDividendsAndAdjustments>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-18567234</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">-36675338</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">-0.91</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted unitRef="usdPershares" contextRef="c5_From1Jan2019To31Dec2019" decimals="2">-5.31</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">20425162</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted unitRef="shares" contextRef="c5_From1Jan2019To31Dec2019" decimals="INF">6904983</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-18567234</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">-11870228</us-gaap:NetIncomeLoss>
  <tffp:ForeignCurrencyTranslationAdjustments unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">51538</tffp:ForeignCurrencyTranslationAdjustments>
  <tffp:ForeignCurrencyTranslationAdjustments unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:OtherComprehensiveIncomeLossTax unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-18618772</us-gaap:OtherComprehensiveIncomeLossTax>
  <us-gaap:OtherComprehensiveIncomeLossTax unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">-11870228</us-gaap:OtherComprehensiveIncomeLossTax>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c6_AsOf31Dec2018_CommonStockMember" decimals="INF">4000000</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c6_AsOf31Dec2018_CommonStockMember" decimals="0">4000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c7_AsOf31Dec2018_AdditionalPaidInCapitalMember" decimals="0">596724</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c8_AsOf31Dec2018_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c9_AsOf31Dec2018_RetainedEarningsMember" decimals="0">-3842186</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c10_AsOf31Dec2018" decimals="0">-3241462</us-gaap:StockholdersEquity>
  <tffp:IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares unitRef="shares" contextRef="c11_From1Jan2019To31Dec2019_CommonStockMember" decimals="INF">4879300</tffp:IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares>
  <tffp:IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount unitRef="usd" contextRef="c11_From1Jan2019To31Dec2019_CommonStockMember" decimals="0">4879</tffp:IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount>
  <tffp:IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount unitRef="usd" contextRef="c12_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="0">21748969</tffp:IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount>
  <tffp:IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount unitRef="usd" contextRef="c13_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <tffp:IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount unitRef="usd" contextRef="c14_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <tffp:IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">21753848</tffp:IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c11_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c12_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="0">590041</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c13_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c14_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">590041</us-gaap:ShareBasedCompensation>
  <us-gaap:DividendsPreferredStockStock unitRef="usd" contextRef="c11_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:DividendsPreferredStockStock unitRef="usd" contextRef="c12_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="0">875359</us-gaap:DividendsPreferredStockStock>
  <us-gaap:DividendsPreferredStockStock unitRef="usd" contextRef="c13_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:DividendsPreferredStockStock unitRef="usd" contextRef="c14_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:DividendsPreferredStockStock unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">875359</us-gaap:DividendsPreferredStockStock>
  <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities unitRef="shares" contextRef="c11_From1Jan2019To31Dec2019_CommonStockMember" decimals="INF">9571692</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c11_From1Jan2019To31Dec2019_CommonStockMember" decimals="0">9572</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c12_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" decimals="0">21278335</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c13_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c14_From1Jan2019To31Dec2019_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">21287907</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c11_From1Jan2019To31Dec2019_CommonStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c12_From1Jan2019To31Dec2019_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c13_From1Jan2019To31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c14_From1Jan2019To31Dec2019_RetainedEarningsMember" decimals="0">-11870228</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c15_AsOf31Dec2019_CommonStockMember" decimals="INF">18450992</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c15_AsOf31Dec2019_CommonStockMember" decimals="0">18451</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c16_AsOf31Dec2019_AdditionalPaidInCapitalMember" decimals="0">43338710</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c17_AsOf31Dec2019_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c18_AsOf31Dec2019_RetainedEarningsMember" decimals="0">-15712414</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesOther unitRef="shares" contextRef="c19_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">3048654</us-gaap:StockIssuedDuringPeriodSharesOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c19_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">3048</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c20_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">24277235</us-gaap:StockIssuedDuringPeriodValueOther>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c21_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodValueOther unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">24280283</us-gaap:StockIssuedDuringPeriodValueOther>
  <tffp:IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense unitRef="shares" contextRef="c19_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">220666</tffp:IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense>
  <us-gaap:ProceedsFromIssuanceOfWarrants unitRef="usd" contextRef="c19_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">221</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ProceedsFromIssuanceOfWarrants unitRef="usd" contextRef="c20_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">1131792</us-gaap:ProceedsFromIssuanceOfWarrants>
  <us-gaap:ProceedsFromIssuanceOfWarrants unitRef="usd" contextRef="c21_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfWarrants unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfWarrants unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1132013</us-gaap:ProceedsFromIssuanceOfWarrants>
  <tffp:IssuanceOfCommonStockForStockOptionExercisesShares unitRef="shares" contextRef="c19_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">285003</tffp:IssuanceOfCommonStockForStockOptionExercisesShares>
  <tffp:IssuanceOfCommonStockForStockOptionExercises unitRef="usd" contextRef="c19_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">285</tffp:IssuanceOfCommonStockForStockOptionExercises>
  <tffp:IssuanceOfCommonStockForStockOptionExercises unitRef="usd" contextRef="c20_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">714097</tffp:IssuanceOfCommonStockForStockOptionExercises>
  <tffp:IssuanceOfCommonStockForStockOptionExercises unitRef="usd" contextRef="c21_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <tffp:IssuanceOfCommonStockForStockOptionExercises unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <tffp:IssuanceOfCommonStockForStockOptionExercises unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">714382</tffp:IssuanceOfCommonStockForStockOptionExercises>
  <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares unitRef="shares" contextRef="c19_From1Jan2020To31Dec2020_CommonStockMember" decimals="INF">529559</tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares>
  <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises unitRef="usd" contextRef="c19_From1Jan2020To31Dec2020_CommonStockMember" decimals="0">530</tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises>
  <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises unitRef="usd" contextRef="c20_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">-530</tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises>
  <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises unitRef="usd" contextRef="c21_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c19_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c20_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" decimals="0">2187149</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c21_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">2187149</us-gaap:ShareBasedCompensation>
  <tffp:ForeignCurrencyTranslationAdjustment unitRef="usd" contextRef="c19_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <tffp:ForeignCurrencyTranslationAdjustment unitRef="usd" contextRef="c20_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <tffp:ForeignCurrencyTranslationAdjustment unitRef="usd" contextRef="c21_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-51538</tffp:ForeignCurrencyTranslationAdjustment>
  <tffp:ForeignCurrencyTranslationAdjustment unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_RetainedEarningsMember" xs:nil="true"/>
  <tffp:ForeignCurrencyTranslationAdjustment unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-51538</tffp:ForeignCurrencyTranslationAdjustment>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c19_From1Jan2020To31Dec2020_CommonStockMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c20_From1Jan2020To31Dec2020_AdditionalPaidInCapitalMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c21_From1Jan2020To31Dec2020_AccumulatedOtherComprehensiveIncomeMember" xs:nil="true"/>
  <us-gaap:ProfitLoss unitRef="usd" contextRef="c22_From1Jan2020To31Dec2020_RetainedEarningsMember" decimals="0">-18567234</us-gaap:ProfitLoss>
  <us-gaap:SharesOutstanding unitRef="shares" contextRef="c23_AsOf31Dec2020_CommonStockMember" decimals="INF">22534874</us-gaap:SharesOutstanding>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c23_AsOf31Dec2020_CommonStockMember" decimals="0">22535</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c24_AsOf31Dec2020_AdditionalPaidInCapitalMember" decimals="0">71648453</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c25_AsOf31Dec2020_AccumulatedOtherComprehensiveIncomeMember" decimals="0">-51538</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity unitRef="usd" contextRef="c26_AsOf31Dec2020_RetainedEarningsMember" decimals="0">-34279648</us-gaap:StockholdersEquity>
  <tffp:StockBasedCompensation unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">2187149</tffp:StockBasedCompensation>
  <tffp:StockBasedCompensation unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">590041</tffp:StockBasedCompensation>
  <us-gaap:IncreaseDecreaseInPrepaidExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1122495</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInPrepaidExpense unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">1080397</us-gaap:IncreaseDecreaseInPrepaidExpense>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">862676</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">12449</us-gaap:IncreaseDecreaseInAccountsPayable>
  <tffp:IncreaseDecreaseDeferredResearchGrantRevenue unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-24315</tffp:IncreaseDecreaseDeferredResearchGrantRevenue>
  <tffp:IncreaseDecreaseDeferredResearchGrantRevenue unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <tffp:IncreaseDecreaseInAccruedResearchAndDevelopmentExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <tffp:IncreaseDecreaseInAccruedResearchAndDevelopmentExpense unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">1132013</tffp:IncreaseDecreaseInAccruedResearchAndDevelopmentExpense>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-16615589</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">-11216122</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1102808</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-1102808</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfCommonStock unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">21851160</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">7198227</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
  <tffp:ProceedsFromIssuanceOfCommonStockValue unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">24280283</tffp:ProceedsFromIssuanceOfCommonStockValue>
  <tffp:ProceedsFromIssuanceOfCommonStockValue unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <tffp:ProceedsFromIssuanceOfCommonStockForStockOptionExercises unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-714382</tffp:ProceedsFromIssuanceOfCommonStockForStockOptionExercises>
  <tffp:ProceedsFromIssuanceOfCommonStockForStockOptionExercises unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">24994665</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">29049387</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <tffp:EffectOfExchangeRateChangesOnCashAndCashEquivalent unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-70399</tffp:EffectOfExchangeRateChangesOnCashAndCashEquivalent>
  <tffp:EffectOfExchangeRateChangesOnCashAndCashEquivalent unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">7205869</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">17833265</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue unitRef="usd" contextRef="c10_AsOf31Dec2018" decimals="0">10261671</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <tffp:AccruedDividend unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <tffp:AccruedDividend unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">875359</tffp:AccruedDividend>
  <tffp:ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <tffp:ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">21287907</tffp:ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock>
  <tffp:OfferingCostsNettedWithProceedsFromIPO unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <tffp:OfferingCostsNettedWithProceedsFromIPO unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">97312</tffp:OfferingCostsNettedWithProceedsFromIPO>
  <tffp:DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <tffp:DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">23929751</tffp:DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock>
  <tffp:CashlessExerciseOfWarrants unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">530</tffp:CashlessExerciseOfWarrants>
  <tffp:CashlessExerciseOfWarrants unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <tffp:ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1132013</tffp:ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock>
  <tffp:ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;NOTE 1 &amp;#x2013; ORGANIZATION AND DESCRIPTION OF BUSINESS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;TFF Pharmaceuticals, Inc. (the &amp;#x201c;Company&amp;#x201d;)
was incorporated in the State of Delaware on January 24, 2018 by Lung Therapeutics, Inc. (&amp;#x201c;LTI&amp;#x201d;), at which time the
Company and LTI entered into a Contribution and Subscription Agreement (&amp;#x201c;Contribution Agreement&amp;#x201d;) pursuant to which
LTI agreed to transfer to the Company certain of LTI&amp;#x2019;s non-core intellectual property rights and other assets, including
LTI&amp;#x2019;s rights under a patent license agreement with the University of Texas at Austin (see Note 5), in exchange for 4,000,000
shares of the Company&amp;#x2019;s common stock. The transactions under the Contribution Agreement closed in March 2018. LTI&amp;#x2019;s
basis in such assets were minimal. LTI is an early-stage biotechnology company focused on the development of certain technologies
in the pulmonary field. The Company&amp;#x2019;s initial focus is on the development of inhaled dry powder drugs to enhance the treatment
of pulmonary diseases and conditions. In December 2019, the Company established a wholly-owned Australian subsidiary, TFF Pharmaceuticals
Australia Pty Ltd (&amp;#x201c;TFF Australia&amp;#x201d;), in order to conduct clinical research. TFF Pharmaceuticals, Inc., along with TFF
Australia, are collectively referred to as the &amp;#x201c;Company&amp;#x201d;. The Company is in the development stage and is devoting substantially
all of its efforts toward technology research and development.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;October 2019 Initial Public Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In October 2019, the Company completed
an initial public offering (&amp;#x201c;IPO&amp;#x201d;), selling 4,400,000 shares of common stock at an offering price of $5.00 per share.
The Company received gross proceeds of approximately $22,000,000. In addition, the Company granted the underwriter a 45-day option
to purchase an additional 660,000 shares of common stock at the initial public offering price, less underwriting discounts and
commissions. The option was exercised in November 2019 and the underwriter purchased an additional 479,300 shares of common stock
and the Company received additional gross proceeds of approximately $2,397,000.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;August 2020 Private Placement&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;On August 13, 2020, the Company conducted
a private placement of 3,048,654 shares of its common stock, at a purchase price per share of $8.50, for aggregate gross proceeds
to the Company of approximately $25,914,000, before deducting selling commissions and other offering expenses payable by the Company.
After deducting the placement agent and other offering expenses, the Company received net proceeds of approximately $24,280,000.
See Note 6 for additional details of the private placement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;COVID-19&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;On March 11, 2020, the World Health Organization
declared a novel strain of coronavirus disease (&amp;#x201c;COVID-19&amp;#x201d;) a global pandemic. At this time, the United States and
certain other countries are the subject of lock-downs and self-isolation procedures, which have significantly limited business
operations and restricted internal and external meetings.&amp;#xa0;The Company had expected to commence Phase I clinical trials of
its thin film freezing, or TFF, formulation of Tacrolimus in Australia in the first quarter of 2020, and on March 13, 2020 the
Company received the approval of the Alfred Hospital Human Research Ethics Committee to commence Phase I trials, however, later
in March 2020, the Company&amp;#x2019;s contract research organization in Australia informed the Company that because of the spread
of the COVID-19 virus in Australia, there would be a delay in initiating the trial. During the second quarter of 2020, the Company
was able to begin dosing in the Phase I Tacrolimus trial in Melbourne, Victoria, Australia. However, due to the resurgence of COVID-19
in the Melbourne area, in July 2020 the Phase I trials were delayed. With the flaring of COVID-19 in the Melbourne area and in
order to remain dynamic, the Company opened a second clinical trial site in Brisbane, Queensland, Australia. and dosing in the
Phase 1 clinical trial resumed in Australia during the third quarter 2020. We expect that dosing in this trial will be completed
early in the second quarter of 2021. Any financial impact from the COVID-19 global pandemic cannot be reasonably estimated at this
time, but may materially affect our business and financial condition. The extent to which COVID-19 impacts our results will depend
on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning
the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others.&lt;/p&gt;&lt;br/&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <tffp:ExchangeOfCommonStock unitRef="shares" contextRef="c27_AsOf24Jan2018" decimals="INF">4000000</tffp:ExchangeOfCommonStock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c28_From1Oct2019To31Oct2019" decimals="INF">4400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c29_AsOf31Oct2019" decimals="2">5.00</us-gaap:SharePrice>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c28_From1Oct2019To31Oct2019" decimals="0">22000000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <tffp:OrganizationAndDescriptionsOfBusinessDescription contextRef="c28_From1Oct2019To31Oct2019">the underwriter a 45-day option to purchase an additional 660,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The option was exercised in November 2019 and the underwriter purchased an additional 479,300 shares of common stock and the Company received additional gross proceeds of approximately $2,397,000.</tffp:OrganizationAndDescriptionsOfBusinessDescription>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c30_From1Aug2020To13Aug2020" decimals="INF">3048654</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharePrice unitRef="usdPershares" contextRef="c31_AsOf13Aug2020" decimals="2">8.50</us-gaap:SharePrice>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues unitRef="usd" contextRef="c30_From1Aug2020To13Aug2020" decimals="0">25914000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <tffp:ReceivedNetProceeds unitRef="usd" contextRef="c30_From1Aug2020To13Aug2020" decimals="0">24280000</tffp:ReceivedNetProceeds>
  <tffp:LiquidityAndManagementsPlansTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;NOTE 2 &amp;#x2013; LIQUIDITY AND MANAGEMENT&amp;#x2019;S PLANS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;As of December 31, 2020, the Company had
cash and cash equivalents of approximately $35,301,000 and a working capital surplus of approximately $36,237,000. The Company
has not generated revenues since inception and has incurred recurring operating losses. The Company expects to continue incurring
losses for the foreseeable future and may need to raise additional capital to pursue its product development.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company expects to further increase
its research and development activities, which will increase the amount of cash utilized subsequent to December 31, 2020. Specifically,
the Company expects increased spending on research and development activities and higher payroll expenses as it increases its professional
and scientific staff and continues to prepare for anticipated manufacturing activities. If we encounter unforeseen delays or expenses,
we have the ability to curtail our presently planned level of operations. The Company currently believes its existing cash and
cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12
months from the date of issuance of these consolidated financial statements.&lt;/p&gt;&lt;br/&gt;</tffp:LiquidityAndManagementsPlansTextBlock>
  <us-gaap:PreconfirmationCashAndCashEquivalents unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">35301000</us-gaap:PreconfirmationCashAndCashEquivalents>
  <us-gaap:SurplusNotes unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">36237000</us-gaap:SurplusNotes>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZox5kKltS1j4H1Hm6x5rsVySu3GvyFidfKO4jLCc6vqlIAk2/hDR2bzzoxw5NX+h9OcfjdvrLHYAuwh2Zi7sQ0UOAQ0i8qn20R76xjgd36yBDZMSKJy6UF8YlRJlhDvltYdDBaXR3sWPsW9VT/9h3wyKkqYRK0lALx3+SAcoHi554Ul7Qas6aWvZyHzgVs3yX9Gb+02gkuacFI5RGEMTGa] CSR-->
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;NOTE 3 &amp;#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company&amp;#x2019;s consolidated financial
statements are presented in accordance with accounting principles generally accepted in the United States of America (&amp;#x201c;GAAP&amp;#x201d;)
and the rules and regulations of the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) and reflect the financial position,
results of operations and cash flows for all periods presented.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The consolidated financial statements include
the accounts of TFF Pharmaceuticals, Inc. and its wholly-owned subsidiary, TFF Australia. All material intercompany accounts and
transactions have been eliminated in consolidation.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Foreign Currency&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The currency of TFF Australia, the Company&amp;#x2019;s
international subsidiary, is in Australian dollars. Foreign currency denominated assets and liabilities are translated into U.S.
dollars using the exchange rates in effect at each balance sheet date. Results of operations and cash flows are translated using
the average exchange rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities
is included as a separate component of stockholders&amp;#x2019; equity in accumulated other comprehensive income (loss).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Geographic Concentrations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company conducts business in the U.S.
and Australia. As of December 31, 2020, the Company maintained 100% of its net property and equipment in the U.S. There was no
property and equipment as of December 31, 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company complies with the requirements
of Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) 340, &lt;i&gt;Other Assets and Deferred Costs&lt;/i&gt;. Deferred offering costs of
consisted primarily of legal, accounting and filing fees that were related to the Company&amp;#x2019;s IPO and were charged to capital
upon completion of the IPO in October 2019. There are no deferred offering costs as of December&amp;#xa0;31, 2020 and 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company maintains its operating accounts
in financial institutions in the U.S. and in Australia. The balances are insured up to specified limits. The Company&amp;#x2019;s cash
is maintained in checking accounts and money market funds with maturities of less than three months when purchased, which are readily
convertible to known amounts of cash, and which in the opinion of management are subject to insignificant risk of loss in value.
As of December 31, 2020 and 2019, the Company had cash in Australia of AUD$214,240 (US$165,092) and $0, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Property and equipment are stated at cost
less accumulated depreciation and amortization. The Company calculates depreciation using the straight-line method over the estimated
useful lives of the assets, which range from&amp;#xa0;two&amp;#xa0;to&amp;#xa0;five&amp;#xa0;years for furniture, fixtures, lab and computer equipment
and software. Assets held within construction in progress are not depreciated. Construction in progress is related to the construction
or development of property and equipment that have not yet been placed in service for its intended use. As of December 31, 2020,
all of the Company&amp;#x2019;s property and equipment consist of lab equipment that are considered construction in progress. Expenditures
for repairs and maintenance of assets are charged to expense as incurred.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Authoritative guidance requires disclosure
of the fair value of financial instruments. The Company&amp;#x2019;s financial instruments consist of cash and cash equivalents and
accounts payable, the carrying amounts of which approximate their estimated fair values primarily due to the short-term nature
of the instruments or based on information obtained from market sources and management estimates. The Company measures the fair
value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality
and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value which
is not equivalent to cost will be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Level 1 &amp;#x2014; Quoted prices (unadjusted)
in active markets for identical assets and liabilities.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Level 2 &amp;#x2014; Inputs other than Level
1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted
quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market
data for substantially the full term of the assets or liabilities.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Level 3 &amp;#x2014; Unobservable inputs that
are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In accordance with authoritative guidance,
deferred tax assets and liabilities are recorded for temporary differences between the financial reporting and tax bases of assets
and liabilities using the current enacted tax rate expected to be in effect when the differences are expected to reverse. A valuation
allowance is recorded on deferred tax assets unless realization is considered more likely than not.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company evaluates its tax positions
taken or expected to be taken in the course of preparing the Company&amp;#x2019;s tax returns to determine whether the tax positions
are &amp;#x201c;more-likely-than-not&amp;#x201d; of being sustained by the applicable tax authority. Tax positions not deemed to meet the
&amp;#x201c;more-likely-than-not&amp;#x201d; threshold are not recorded as a tax benefit or expense in the current year. The Company recognizes
interest and penalties, if any, related to uncertain tax positions in interest expense. No interest and penalties related to uncertain
tax positions were accrued at either December&amp;#xa0;31, 2020 or 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company follows authoritative guidance
which requires the evaluation of existing tax positions. The Company files in the federal and various state jurisdictions. Management
has analyzed all open tax years, as defined by the statute of limitations, for all major jurisdictions. Open tax years are those
that are open for examination by taxing authorities. The Company was incorporated during 2018 which is the only open year at this
time.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company entered into a feasibility
and material transfer agreement (&amp;#x201c;Feasibility Agreement&amp;#x201d;) with a third party that provided the Company funds in return
for certain research and development activities. Revenue from the Feasibility Agreement will be recognized in the period during
which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Feasibility
Agreement have been met.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Feasibility Agreement is on a best-effort
basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable.
The costs associated with the agreement are expensed as incurred and will be reflected as a component of research and development
expense in the accompanying consolidated statements of operations.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Funds received from the Feasibility Agreement
will be recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Feasibility
Agreement are part of the Company&amp;#x2019;s development programs. In those instances where the Company first receives consideration
in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company
provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt
of consideration, the Company records a grant receivable. As of December 31, 2020 and 2019, the Company had deferred grant revenue
of $24,315 and $0, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In accordance with authoritative guidance,
the Company charges research and development costs to operations as incurred. Research and development expenses consist of personnel
costs for the design, development, testing and enhancement of the Company&amp;#x2019;s technology, and certain other allocated costs,
such as depreciation and other facilities related expenditures.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Earnings per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share
is computed by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding
for the period, determined using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods
presented, all potentially dilutive securities are anti-dilutive. Basic weighted average shares outstanding for the years ended
December 31, 2020 and 2019 include 400,000 shares underlying a warrant to purchase common shares. As the shares underlying this
warrant can be issued for little consideration (an aggregate exercise price of $0.01 per share), these shares are deemed to be
issued for purposes of basic earnings per share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;For the years ended December 31, 2020 and
2019, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of
diluted net loss per common share because inclusion thereof would be anti-dilutive:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Year Ended&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Year Ended&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Stock Options&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2,610,495&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2,139,078&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Warrants&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;417,355&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1,076,463&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,027,850&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,215,541&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Common Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company classifies as equity any warrants
that (i) require physical settlement or net-share settlement or (ii)&amp;#xa0;provide the Company with a choice of net-cash settlement
or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities
any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs
and if that event is outside the Company&amp;#x2019;s control), (ii) gives the counterparty a choice of net-cash settlement or settlement
in shares (physical settlement or net-share settlement) or (iii) that contain reset provisions that do not qualify for the scope
exception. The Company assesses classification of its common stock warrants and other freestanding derivatives at each reporting
date to determine whether a change in classification between assets and liabilities is required. The Company&amp;#x2019;s freestanding
derivatives consist of warrants to purchase common stock that were issued in connection with services provided to the Company.
The Company evaluated these warrants to assess their proper classification and determined that the common stock warrants meet the
criteria for equity classification in the consolidated balance sheet. Such warrants are measured at fair value, which the Company
determines using the Black-Scholes-Merton option-pricing model.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Beneficial Conversion Feature&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;On the date of the IPO, the outstanding
Series A Convertible Preferred Stock (&amp;#x201c;Series A Preferred Stock&amp;#x201d;), and related accrued and unpaid dividends, automatically
converted into shares of the Company&amp;#x2019;s common stock. The conversion share calculation was based on the $2.50 initial issuance
price for the Series A Preferred Stock plus any accrued but unpaid dividends and converted to common stock using a stated divisor
conversion price equal to 50% of the IPO price to the public, which was $5.00 per share. In accordance with relevant accounting
literature, since the stated terms of the conversion option did not permit the Company to compute the additional number of shares
that it would need to issue upon conversion of the Series A Preferred Stock when the contingent event occurred, the Company recorded
the beneficial conversion amount of approximately $23,930,000 as a deemed dividend at the date of the IPO.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company computes stock-based compensation
in accordance with authoritative guidance. The Company uses the Black-Scholes-Merton option-pricing model to determine the fair
value of its stock options. The Black-Scholes-Merton option-pricing model includes various assumptions, including the fair market
value of the common stock of the Company, expected life of stock options, the expected volatility and the expected risk-free interest
rate, among others. These assumptions reflect the Company&amp;#x2019;s best estimates, but they involve inherent uncertainties based
on market conditions generally outside the control of the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;As a result, if other assumptions had been
used, stock-based compensation cost, as determined in accordance with authoritative guidance, could have been materially impacted.
Furthermore, if the Company uses different assumptions on future grants, stock-based compensation cost could be materially affected
in future periods.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The preparation of consolidated financial
statements in conformity with GAAP requires the Company&amp;#x2019;s management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and
the reported amounts of expenses during the reporting period. Significant estimates include the fair value of stock-based compensation
and warrants, valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In February 2016, the Financial Accounting
Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) No. 2016-02, &lt;i&gt;Leases (Topic 842)&lt;/i&gt;.
This ASU will require lessees to recognize a right-of-use asset and lease liability on the consolidated balance sheet for leases
with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern
of expense recognition in the income statement. ASU No. 2016-02 supersedes the lease accounting requirements of ASC Topic 840,
&lt;i&gt;Leases.&lt;/i&gt; The Company adopted this standard on January 1, 2020, using the modified retrospective approach, which did not cause
adjustments to prior comparative periods. The new standard provides a number of optional practical expedients in transition. The
Company has elected the following &amp;#x201c;package of practical expedients&amp;#x201d; when assessing the transition impact as the lessee
as of January 1, 2020: (1) not to reassess whether any expired or existing contracts, contain leases; (2) not to reassess the lease
classification for any expired or existing leases; and (3) not to reassess initial direct costs for any existing leases. Leases
with an initial term of 12 months or less are considered short-term leases and are not recorded on the balance sheet as the Company
recognizes lease expense for these leases on a straight-line basis over the lease term. The Company reviewed all contracts that
may contain leases and has determined that there was no impact related to the adoption of ASU 2016-02 as the only contract that
contains a lease on the adoption date is for office space in Doylestown, Pennsylvania, which is considered a short-term lease.
See Note 4 for more information regarding the leased office space.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In July 2017, the FASB issued ASU 2017-11,
&lt;i&gt;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815):
I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily
Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with
a Scope Exception&lt;/i&gt;, (ASU 2017-11). Part I of this update addresses the complexity of accounting for certain financial instruments
with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result
in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost
and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features
that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses
the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content
in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements
about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling
interests. The amendments in Part II of this update do not have an accounting effect. This guidance is effective for public business
entities for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and effective
for all other entities for fiscal years beginning after December 15, 2019 and interim periods within fiscal years beginning after
December 15, 2020. The adoption of this standard did not have a material effect on the Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In June 2018, the FASB issued ASU No. 2018-07,
&lt;i&gt;Compensation &amp;#x2014; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&lt;/i&gt;. The guidance
in this ASU expands the scope of ASC Topic 718 to include all share-based payment arrangements related to the acquisition of goods
and services from both nonemployees and employees. This guidance is effective for public business entities for fiscal years beginning
after December 15, 2018, including interim periods within those fiscal years, and effective for all other entities for fiscal years
beginning after December 15, 2019 and interim periods within fiscal years beginning after December 15, 2020. The adoption of this
standard did not have a material effect on the Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In August 2018, the FASB issued ASU 2018-13,
&amp;#x201c;&lt;i&gt;Fair Value Measurement&lt;/i&gt; (Topic 820), - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value
Measurement,&amp;#x201d; which makes a number of changes meant to add, modify or remove certain disclosure requirements associated with
the movement amongst or hierarchy associated with Level 1, Level 2 and Level&amp;#xa0;3 fair value measurements. This guidance is effective
for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The adoption of this standard
did not have a material effect on the Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In December 2019, the FASB issued ASU 2019-12,&amp;#xa0;&lt;i&gt;Income
Taxes (Topic 740), Simplifying the Accounting for Income Taxes,&amp;#xa0;&lt;/i&gt;which clarifies and simplifies certain aspects of the
accounting for income taxes.&amp;#xa0;The standard is effective&amp;#xa0;for years beginning after December&amp;#xa0;15, 2020, and interim
periods within annual periods beginning after December&amp;#xa0;15, 2020. The adoption of this standard on January 1, 2021 is not expected
to have a material impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In January 2020,
the FASB issued ASU 2020-01, &lt;i&gt;Investments &amp;#x2013; Equity Securities, Investments &amp;#x2013; Equity Method and Joint Ventures, and
Derivatives and Hedging &amp;#x2013; Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815&lt;/i&gt;, intended to clarify
the interactions between ASC 321, ASC 323 and ASC 815. The new standard addresses accounting for the transition into and out of
the equity method and measurement of certain purchased options and forward contracts to acquire investments. The standard is effective
for annual and interim periods beginning after December 15, 2020, with early adoption permitted. Adoption of the standard requires
changes to be made prospectively. The adoption of this standard on January 1, 2021 is not expected to have a material impact on
the Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;&lt;br/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company&amp;#x2019;s consolidated financial
statements are presented in accordance with accounting principles generally accepted in the United States of America (&amp;#x201c;GAAP&amp;#x201d;)
and the rules and regulations of the Securities and Exchange Commission (&amp;#x201c;SEC&amp;#x201d;) and reflect the financial position,
results of operations and cash flows for all periods presented.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The consolidated financial statements include
the accounts of TFF Pharmaceuticals, Inc. and its wholly-owned subsidiary, TFF Australia. All material intercompany accounts and
transactions have been eliminated in consolidation.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:ForeignCurrencyDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Foreign Currency&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The currency of TFF Australia, the Company&amp;#x2019;s
international subsidiary, is in Australian dollars. Foreign currency denominated assets and liabilities are translated into U.S.
dollars using the exchange rates in effect at each balance sheet date. Results of operations and cash flows are translated using
the average exchange rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities
is included as a separate component of stockholders&amp;#x2019; equity in accumulated other comprehensive income (loss).&lt;/p&gt;</us-gaap:ForeignCurrencyDisclosureTextBlock>
  <tffp:GeographicConcentrationsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Geographic Concentrations&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company conducts business in the U.S.
and Australia. As of December 31, 2020, the Company maintained 100% of its net property and equipment in the U.S. There was no
property and equipment as of December 31, 2019.&lt;/p&gt;</tffp:GeographicConcentrationsPolicyTextBlock>
  <tffp:MaintenanceOfPropertyAndEquipment unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">1.00</tffp:MaintenanceOfPropertyAndEquipment>
  <us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Deferred Offering Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company complies with the requirements
of Accounting Standards Codification (&amp;#x201c;ASC&amp;#x201d;) 340, &lt;i&gt;Other Assets and Deferred Costs&lt;/i&gt;. Deferred offering costs of
consisted primarily of legal, accounting and filing fees that were related to the Company&amp;#x2019;s IPO and were charged to capital
upon completion of the IPO in October 2019. There are no deferred offering costs as of December&amp;#xa0;31, 2020 and 2019.&lt;/p&gt;</us-gaap:CapitalizationOfDeferredPolicyAcquisitionCostsPolicy>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company maintains its operating accounts
in financial institutions in the U.S. and in Australia. The balances are insured up to specified limits. The Company&amp;#x2019;s cash
is maintained in checking accounts and money market funds with maturities of less than three months when purchased, which are readily
convertible to known amounts of cash, and which in the opinion of management are subject to insignificant risk of loss in value.
As of December 31, 2020 and 2019, the Company had cash in Australia of AUD$214,240 (US$165,092) and $0, respectively.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:Cash unitRef="aud" contextRef="c3_AsOf31Dec2020" decimals="0">214240</us-gaap:Cash>
  <us-gaap:Cash unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">165092</us-gaap:Cash>
  <us-gaap:Cash unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">0</us-gaap:Cash>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Property and equipment are stated at cost
less accumulated depreciation and amortization. The Company calculates depreciation using the straight-line method over the estimated
useful lives of the assets, which range from&amp;#xa0;two&amp;#xa0;to&amp;#xa0;five&amp;#xa0;years for furniture, fixtures, lab and computer equipment
and software. Assets held within construction in progress are not depreciated. Construction in progress is related to the construction
or development of property and equipment that have not yet been placed in service for its intended use. As of December 31, 2020,
all of the Company&amp;#x2019;s property and equipment consist of lab equipment that are considered construction in progress. Expenditures
for repairs and maintenance of assets are charged to expense as incurred.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c32_From1Jan2020To31Dec2020_MinimumMember_FurnitureAndFixturesMember">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c33_From1Jan2020To31Dec2020_MinimumMember_ComputerEquipmentMember">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c34_From1Jan2020To31Dec2020_MaximumMember_FurnitureAndFixturesMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c35_From1Jan2020To31Dec2020_MaximumMember_ComputerEquipmentMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Authoritative guidance requires disclosure
of the fair value of financial instruments. The Company&amp;#x2019;s financial instruments consist of cash and cash equivalents and
accounts payable, the carrying amounts of which approximate their estimated fair values primarily due to the short-term nature
of the instruments or based on information obtained from market sources and management estimates. The Company measures the fair
value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality
and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value which
is not equivalent to cost will be classified and disclosed in one of the following three categories:&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Level 1 &amp;#x2014; Quoted prices (unadjusted)
in active markets for identical assets and liabilities.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Level 2 &amp;#x2014; Inputs other than Level
1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted
quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market
data for substantially the full term of the assets or liabilities.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Level 3 &amp;#x2014; Unobservable inputs that
are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In accordance with authoritative guidance,
deferred tax assets and liabilities are recorded for temporary differences between the financial reporting and tax bases of assets
and liabilities using the current enacted tax rate expected to be in effect when the differences are expected to reverse. A valuation
allowance is recorded on deferred tax assets unless realization is considered more likely than not.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company evaluates its tax positions
taken or expected to be taken in the course of preparing the Company&amp;#x2019;s tax returns to determine whether the tax positions
are &amp;#x201c;more-likely-than-not&amp;#x201d; of being sustained by the applicable tax authority. Tax positions not deemed to meet the
&amp;#x201c;more-likely-than-not&amp;#x201d; threshold are not recorded as a tax benefit or expense in the current year. The Company recognizes
interest and penalties, if any, related to uncertain tax positions in interest expense. No interest and penalties related to uncertain
tax positions were accrued at either December&amp;#xa0;31, 2020 or 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company follows authoritative guidance
which requires the evaluation of existing tax positions. The Company files in the federal and various state jurisdictions. Management
has analyzed all open tax years, as defined by the statute of limitations, for all major jurisdictions. Open tax years are those
that are open for examination by taxing authorities. The Company was incorporated during 2018 which is the only open year at this
time.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company entered into a feasibility
and material transfer agreement (&amp;#x201c;Feasibility Agreement&amp;#x201d;) with a third party that provided the Company funds in return
for certain research and development activities. Revenue from the Feasibility Agreement will be recognized in the period during
which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Feasibility
Agreement have been met.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Feasibility Agreement is on a best-effort
basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable.
The costs associated with the agreement are expensed as incurred and will be reflected as a component of research and development
expense in the accompanying consolidated statements of operations.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Funds received from the Feasibility Agreement
will be recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Feasibility
Agreement are part of the Company&amp;#x2019;s development programs. In those instances where the Company first receives consideration
in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company
provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt
of consideration, the Company records a grant receivable. As of December 31, 2020 and 2019, the Company had deferred grant revenue
of $24,315 and $0, respectively.&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <tffp:DeferredResearchGrantRevenue unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">24315</tffp:DeferredResearchGrantRevenue>
  <tffp:DeferredResearchGrantRevenue unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">0</tffp:DeferredResearchGrantRevenue>
  <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In accordance with authoritative guidance,
the Company charges research and development costs to operations as incurred. Research and development expenses consist of personnel
costs for the design, development, testing and enhancement of the Company&amp;#x2019;s technology, and certain other allocated costs,
such as depreciation and other facilities related expenditures.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Basic and Diluted Earnings per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share
is computed by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding
for the period, determined using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods
presented, all potentially dilutive securities are anti-dilutive. Basic weighted average shares outstanding for the years ended
December 31, 2020 and 2019 include 400,000 shares underlying a warrant to purchase common shares. As the shares underlying this
warrant can be issued for little consideration (an aggregate exercise price of $0.01 per share), these shares are deemed to be
issued for purposes of basic earnings per share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;For the years ended December 31, 2020 and
2019, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of
diluted net loss per common share because inclusion thereof would be anti-dilutive:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Year Ended&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Year Ended&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Stock Options&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2,610,495&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2,139,078&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Warrants&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;417,355&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1,076,463&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,027,850&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,215,541&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <tffp:CommonStockWarrantsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Common Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company classifies as equity any warrants
that (i) require physical settlement or net-share settlement or (ii)&amp;#xa0;provide the Company with a choice of net-cash settlement
or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities
any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs
and if that event is outside the Company&amp;#x2019;s control), (ii) gives the counterparty a choice of net-cash settlement or settlement
in shares (physical settlement or net-share settlement) or (iii) that contain reset provisions that do not qualify for the scope
exception. The Company assesses classification of its common stock warrants and other freestanding derivatives at each reporting
date to determine whether a change in classification between assets and liabilities is required. The Company&amp;#x2019;s freestanding
derivatives consist of warrants to purchase common stock that were issued in connection with services provided to the Company.
The Company evaluated these warrants to assess their proper classification and determined that the common stock warrants meet the
criteria for equity classification in the consolidated balance sheet. Such warrants are measured at fair value, which the Company
determines using the Black-Scholes-Merton option-pricing model.&lt;/p&gt;</tffp:CommonStockWarrantsPolicyTextBlock>
  <tffp:BeneficialConversionFeaturePolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Beneficial Conversion Feature&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;On the date of the IPO, the outstanding
Series A Convertible Preferred Stock (&amp;#x201c;Series A Preferred Stock&amp;#x201d;), and related accrued and unpaid dividends, automatically
converted into shares of the Company&amp;#x2019;s common stock. The conversion share calculation was based on the $2.50 initial issuance
price for the Series A Preferred Stock plus any accrued but unpaid dividends and converted to common stock using a stated divisor
conversion price equal to 50% of the IPO price to the public, which was $5.00 per share. In accordance with relevant accounting
literature, since the stated terms of the conversion option did not permit the Company to compute the additional number of shares
that it would need to issue upon conversion of the Series A Preferred Stock when the contingent event occurred, the Company recorded
the beneficial conversion amount of approximately $23,930,000 as a deemed dividend at the date of the IPO.&lt;/p&gt;</tffp:BeneficialConversionFeaturePolicyTextBlock>
  <us-gaap:DebtInstrumentConvertibleConversionPrice1 unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">2.50</us-gaap:DebtInstrumentConvertibleConversionPrice1>
  <tffp:ConversionPricePercentage unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.50</tffp:ConversionPricePercentage>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">5.00</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">23930000</us-gaap:DebtInstrumentConvertibleBeneficialConversionFeature>
  <us-gaap:CompensationRelatedCostsPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company computes stock-based compensation
in accordance with authoritative guidance. The Company uses the Black-Scholes-Merton option-pricing model to determine the fair
value of its stock options. The Black-Scholes-Merton option-pricing model includes various assumptions, including the fair market
value of the common stock of the Company, expected life of stock options, the expected volatility and the expected risk-free interest
rate, among others. These assumptions reflect the Company&amp;#x2019;s best estimates, but they involve inherent uncertainties based
on market conditions generally outside the control of the Company.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;As a result, if other assumptions had been
used, stock-based compensation cost, as determined in accordance with authoritative guidance, could have been materially impacted.
Furthermore, if the Company uses different assumptions on future grants, stock-based compensation cost could be materially affected
in future periods.&lt;/p&gt;</us-gaap:CompensationRelatedCostsPolicyTextBlock>
  <us-gaap:UseOfEstimates contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The preparation of consolidated financial
statements in conformity with GAAP requires the Company&amp;#x2019;s management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and
the reported amounts of expenses during the reporting period. Significant estimates include the fair value of stock-based compensation
and warrants, valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Recent Accounting Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In February 2016, the Financial Accounting
Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) No. 2016-02, &lt;i&gt;Leases (Topic 842)&lt;/i&gt;.
This ASU will require lessees to recognize a right-of-use asset and lease liability on the consolidated balance sheet for leases
with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern
of expense recognition in the income statement. ASU No. 2016-02 supersedes the lease accounting requirements of ASC Topic 840,
&lt;i&gt;Leases.&lt;/i&gt; The Company adopted this standard on January 1, 2020, using the modified retrospective approach, which did not cause
adjustments to prior comparative periods. The new standard provides a number of optional practical expedients in transition. The
Company has elected the following &amp;#x201c;package of practical expedients&amp;#x201d; when assessing the transition impact as the lessee
as of January 1, 2020: (1) not to reassess whether any expired or existing contracts, contain leases; (2) not to reassess the lease
classification for any expired or existing leases; and (3) not to reassess initial direct costs for any existing leases. Leases
with an initial term of 12 months or less are considered short-term leases and are not recorded on the balance sheet as the Company
recognizes lease expense for these leases on a straight-line basis over the lease term. The Company reviewed all contracts that
may contain leases and has determined that there was no impact related to the adoption of ASU 2016-02 as the only contract that
contains a lease on the adoption date is for office space in Doylestown, Pennsylvania, which is considered a short-term lease.
See Note 4 for more information regarding the leased office space.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In July 2017, the FASB issued ASU 2017-11,
&lt;i&gt;Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815):
I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily
Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with
a Scope Exception&lt;/i&gt;, (ASU 2017-11). Part I of this update addresses the complexity of accounting for certain financial instruments
with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result
in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost
and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features
that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses
the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content
in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements
about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling
interests. The amendments in Part II of this update do not have an accounting effect. This guidance is effective for public business
entities for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and effective
for all other entities for fiscal years beginning after December 15, 2019 and interim periods within fiscal years beginning after
December 15, 2020. The adoption of this standard did not have a material effect on the Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In June 2018, the FASB issued ASU No. 2018-07,
&lt;i&gt;Compensation &amp;#x2014; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting&lt;/i&gt;. The guidance
in this ASU expands the scope of ASC Topic 718 to include all share-based payment arrangements related to the acquisition of goods
and services from both nonemployees and employees. This guidance is effective for public business entities for fiscal years beginning
after December 15, 2018, including interim periods within those fiscal years, and effective for all other entities for fiscal years
beginning after December 15, 2019 and interim periods within fiscal years beginning after December 15, 2020. The adoption of this
standard did not have a material effect on the Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In August 2018, the FASB issued ASU 2018-13,
&amp;#x201c;&lt;i&gt;Fair Value Measurement&lt;/i&gt; (Topic 820), - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value
Measurement,&amp;#x201d; which makes a number of changes meant to add, modify or remove certain disclosure requirements associated with
the movement amongst or hierarchy associated with Level 1, Level 2 and Level&amp;#xa0;3 fair value measurements. This guidance is effective
for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The adoption of this standard
did not have a material effect on the Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In December 2019, the FASB issued ASU 2019-12,&amp;#xa0;&lt;i&gt;Income
Taxes (Topic 740), Simplifying the Accounting for Income Taxes,&amp;#xa0;&lt;/i&gt;which clarifies and simplifies certain aspects of the
accounting for income taxes.&amp;#xa0;The standard is effective&amp;#xa0;for years beginning after December&amp;#xa0;15, 2020, and interim
periods within annual periods beginning after December&amp;#xa0;15, 2020. The adoption of this standard on January 1, 2021 is not expected
to have a material impact on the Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In January 2020,
the FASB issued ASU 2020-01, &lt;i&gt;Investments &amp;#x2013; Equity Securities, Investments &amp;#x2013; Equity Method and Joint Ventures, and
Derivatives and Hedging &amp;#x2013; Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815&lt;/i&gt;, intended to clarify
the interactions between ASC 321, ASC 323 and ASC 815. The new standard addresses accounting for the transition into and out of
the equity method and measurement of certain purchased options and forward contracts to acquire investments. The standard is effective
for annual and interim periods beginning after December 15, 2020, with early adoption permitted. Adoption of the standard requires
changes to be made prospectively. The adoption of this standard on January 1, 2021 is not expected to have a material impact on
the Company&amp;#x2019;s consolidated financial statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Year Ended&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Year Ended&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Stock Options&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2,610,495&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2,139,078&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Warrants&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;417,355&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1,076,463&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,027,850&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3,215,541&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c36_From1Jan2020To31Dec2020_StockOptionMember" decimals="INF">2610495</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c37_From1Jan2019To31Dec2019_StockOptionMember" decimals="INF">2139078</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c38_From1Jan2020To31Dec2020_WarrantMember" decimals="INF">417355</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c39_From1Jan2019To31Dec2019_WarrantMember" decimals="INF">1076463</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">3027850</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount unitRef="shares" contextRef="c5_From1Jan2019To31Dec2019" decimals="INF">3215541</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;NOTE 4 &amp;#x2013; COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Operating Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In October 2018, the Company entered into
a lease agreement for office space in Doylestown, Pennsylvania. The lease commenced on October 15, 2018, the Company exercised
a one-year lease renewal in October 2019, and another one-year lease renewal in October 2020 that will expire on October 31, 2021.
The lease has an additional one-year option for renewal, and the base rent is $36,000 per year. The Company has determined that
the lease agreement is considered a short-term lease under ASC 842 and has not recorded a right-of-use asset or liability. The
Company rents another office space on a month-to-month basis with no long-term commitment, which is considered a short-term lease
as well. Short-term lease expense for the years ended December 31, 2020 and 2019 was approximately $59,000 and $28,000, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Approximate future minimum lease payments
required under the operating lease, as amended, are as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left&quot;&gt;Year ending December 31,&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Amount&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;30,000&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Legal&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company may be involved, from time
to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties
and outcomes and are not predictable with assurance. While management believes that such matters are currently insignificant, matters
arising in the ordinary course of business for which the Company is or could become involved in litigation may have a material
adverse effect on its business and financial condition. To the Company&amp;#x2019;s knowledge, neither the Company nor any of its properties
are subject to any pending legal proceedings.&lt;/p&gt;&lt;br/&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <tffp:ExpireDate contextRef="c0_From1Jan2020To31Dec2020">The lease commenced on October 15, 2018, the Company exercised a one-year lease renewal in October 2019, and another one-year lease renewal in October 2020 that will expire on October 31, 2021.</tffp:ExpireDate>
  <us-gaap:LeaseAndRentalExpense unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">36000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:OperatingLeaseCost unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">59000</us-gaap:OperatingLeaseCost>
  <us-gaap:OperatingLeaseCost unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">28000</us-gaap:OperatingLeaseCost>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left&quot;&gt;Year ending December 31,&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center&quot;&gt;Amount&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left&quot;&gt;2021&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;30,000&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">30000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <tffp:LicenseAndAgreementsDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;NOTE 5 &amp;#x2013; LICENSE AND AGREEMENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In July 2015, the University of Texas at
Austin (&amp;#x201c;UT&amp;#x201d;) granted to the Company&amp;#x2019;s former parent, LTI, an exclusive worldwide, royalty bearing license to
the patent rights for the TFF platform in all fields of use, other than vaccines for which LTI received a non-exclusive worldwide,
royalty bearing license to the patent rights for the TFF platform. In March 2018, LTI completed an assignment to the Company all
of its interest to the TFF platform, including the patent license agreement with UT, at which time the Company paid UT an assignment
fee of $100,000 in accordance with the patent license agreement. In November 2018, the Company and UT entered into an amendment
to the patent license agreement pursuant to which, among other things, the Company&amp;#x2019;s exclusive patent rights to the TFF platform
were expanded to all fields of use. The patent license agreement requires the Company to pay royalties and milestone payments and
conform to a variety of covenants and agreements, and in the event of the Company&amp;#x2019;s breach of agreement, UT may elect to
terminate the agreement. During the year ended December 31, 2019, the Company achieved one milestone by gaining IND approval on
first indication of a licensed product on November 24, 2019. The milestone fee associated with this achievement to be paid is $50,000
and the Company must issue UT common shares equal to 1% of the Company&amp;#x2019;s outstanding shares of common stock, on a fully diluted
basis, as of 30 days after IND approval, which was December 24, 2019. The total amount of common shares due and payable on December
31, 2019 to UT were 220,666 common shares, which have a fair value of approximately $1,132,000 based on the closing stock price
of $5.13 on December 24, 2019. As of December 31, 2019, the Company had not paid the $50,000 or issued the shares and has included
the $50,000 in accounts payable and the share amount due as a research and development expense payable. The Company paid the $50,000
and issued the shares in January 2020. As of the date of these consolidated financial statements, the Company is in compliance
with the patent license agreement as all required amounts have been paid in accordance with the agreement.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In May 2018, the Company entered into a
master services agreement and associated individual study contracts with ITR Canada, Inc. (&amp;#x201c;ITR&amp;#x201d;) to provide initial
contract pre-clinical research and development services for the Company&amp;#x2019;s drug product candidates. The fees payable for pre-clinical
research and development services under these study contracts totaled $1,790,000, with no minimum fee requirement. In January 2019,
the Company cancelled all of the individual study contracts with ITR and entered into a contract with 11036114 Canada Inc. (initially
dba VJO Non-Clinical Development and now dba Strategy Point Innovations (&amp;#x201c;SPI&amp;#x201d;)) to complete additional pre-clinical
research and development services in order to take advantage of eligible Canadian Tax Credits. The services related to the contract
with SPI were sub-contracted to ITR under substantially the same terms as the initial contract with ITR, with fees payable for
services under statements of work that are currently open totaling $4,582,000, as amended. During the years ended December 31,
2020 and 2019, the Company recorded research and development costs of approximately $1,177,000 and $2,746,000, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In April 2019, the Company entered into
a master services agreement with Irisys, LLC to provide contract manufacturing services for one of the Company&amp;#x2019;s drug product
candidates, Voriconazole. The fees payable for open contract manufacturing services under this agreement total approximately $3,220,000,
as amended, with additional pass-through costs. During the years ended December 31, 2020 and 2019, the Company recorded research
and development costs of approximately $1,837,000 and $867,000, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In June 2019, the Company entered into
a master services agreement with CoreRx to provide contract manufacturing services for one of the Company&amp;#x2019;s drug product
candidates, Tacrolimus. The fees payable for open contract manufacturing services under this agreement total approximately $1,103,000,
as amended, with additional pass-through costs. During the years ended December 31, 2020 and 2019, the Company recorded research
and development costs of approximately $839,000 and $290,000, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In August 2019, the Company entered into
a master services agreement and associated individual study contracts with Conform Clinical Development, Inc. and its affiliates,
Les Entreprises Envie Inc. (dba Envie Ventures) and Desire Ventures LLC, which sub-contracted with Inflamax Research Limited (dba
Cliantha Research) to perform a Phase I study of one of the Company&amp;#x2019;s drug candidates, Voriconazole. The fees payable for
the open services under this contract total approximately $1,484,000, as amended. During the years ended December 31, 2020 and
2019, the Company recorded research and development costs of approximately $1,824,000 and $977,000, respectively.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In January 2020, TFF Australia entered
into a master consultancy agreement with Novotech (Australia) Pty Ltd. (formally known as Clinical Network Services Pty Ltd.) to
provide initial contract clinical research and development services for the Company&amp;#x2019;s drug product candidates. The fees payable
for clinical research and development services under these open study contracts totaled AUD$1,942,981 (US$1,355,580), as amended.
During the year ended December 31, 2020, the Company recorded research and development costs of approximately AUD$590,000 (US$407,000).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In May 2020, TFF Australia entered into
an amended clinical trial research agreement with Nucleus Network Pty Ltd. to provide a Phase I study of one of the Company&amp;#x2019;s
drug candidates, Tacrolimus. The fees payable for services under this contract totaled AUD$1,392,805 (US$953,388), as amended.
During the year ended December 31, 2020, the Company recorded research and development costs of approximately AUD$489,000 (US$337,000).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In August 2020, TFF Australia entered into
a clinical trial research agreement with Q-Pharm Pty Ltd. to provide a Phase I study of one of the Company&amp;#x2019;s drug candidates,
Tacrolimus. The fees payable for services under this contract totaled AUD$704,600 (US$505,488). During the year ended December
31, 2020, the Company recorded research and development costs of approximately AUD$557,000 (US$384,000).&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;On August 12, 2020, the Company entered
into a licensing and collaboration agreement with UNION therapeutics A/S in which UNION acquired an option to obtain a worldwide
exclusive license for the TFF technology in combination with niclosamide. Pursuant to the terms of the license agreement, UNION
can exercise its option to obtain the license within 45 days after the complete data has been received by UNION from investigator-initiated
trials. Upon exercise of the option, UNION shall be responsible to pay all expenses incurred in the development of any licensed
product. The Company will be eligible to receive milestone payments upon the achievement of certain milestones in the development
the licensed products, based on completion of clinical trials, pre-marketing approvals and/or the receipt of at least $25,000,000
of grant funding. The Company will receive a single-digit tiered royalty on net sales. The Company will also be entitled to receive
sales-related milestone payments based on the commercial success of the licensed products.&lt;/p&gt;&lt;br/&gt;</tffp:LicenseAndAgreementsDisclosureTextBlock>
  <us-gaap:DebtInstrumentFeeAmount unitRef="usd" contextRef="c40_AsOf31Mar2018" decimals="0">100000</us-gaap:DebtInstrumentFeeAmount>
  <tffp:MilestoneFee unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">50000</tffp:MilestoneFee>
  <tffp:CommonShareOutstandingPricePercentage unitRef="pure" contextRef="c3_AsOf31Dec2020" decimals="2">0.01</tffp:CommonShareOutstandingPricePercentage>
  <tffp:AmountOfCommonShareDuePayable unitRef="shares" contextRef="c5_From1Jan2019To31Dec2019" decimals="INF">220666</tffp:AmountOfCommonShareDuePayable>
  <us-gaap:FairValueOptionReasonsForElection contextRef="c5_From1Jan2019To31Dec2019">$1,132,000</us-gaap:FairValueOptionReasonsForElection>
  <tffp:ClosingStockPrice unitRef="usdPershares" contextRef="c41_AsOf24Dec2019" decimals="2">5.13</tffp:ClosingStockPrice>
  <tffp:DescriptionOfLicenseAndAgreements contextRef="c5_From1Jan2019To31Dec2019">As of December 31, 2019, the Company had not paid the $50,000 or issued the shares and has included the $50,000 in accounts payable and the share amount due as a research and development expense payable. The Company paid the $50,000 and issued the shares in January 2020.</tffp:DescriptionOfLicenseAndAgreements>
  <us-gaap:DebtInstrumentFeeAmount unitRef="usd" contextRef="c42_AsOf31May2018_MasterServicesMember" decimals="0">1790000</us-gaap:DebtInstrumentFeeAmount>
  <tffp:AgreementTremDescription contextRef="c43_From1Jan2019To31Jan2019_MasterServicesMember">In January 2019, the Company cancelled all of the individual study contracts with ITR and entered into a contract with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba Strategy Point Innovations (&amp;#x201c;SPI&amp;#x201d;)) to complete additional pre-clinical research and development services in order to take advantage of eligible Canadian Tax Credits.</tffp:AgreementTremDescription>
  <us-gaap:DebtInstrumentFeeAmount unitRef="usd" contextRef="c44_AsOf31Jan2019_MasterServicesMember" decimals="0">4582000</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c45_From1Jan2020To31Dec2020_MasterServicesMember" decimals="0">1177000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c46_From1Jan2019To31Dec2019_MasterServicesMember" decimals="0">2746000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:DebtInstrumentFeeAmount unitRef="usd" contextRef="c47_AsOf30Apr2019_IrisysLlcMember" decimals="0">3220000</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c48_From1Jan2020To31Dec2020_IrisysLlcMember" decimals="0">1837000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c49_From1Jan2019To31Dec2019_IrisysLlcMember" decimals="0">867000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:DebtInstrumentFeeAmount unitRef="usd" contextRef="c50_AsOf30Jun2019_CoreRxMember" decimals="0">1103000</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c51_From1Jan2020To31Dec2020_CoreRxMember" decimals="0">839000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c52_From1Jan2019To31Dec2019_CoreRxMember" decimals="0">290000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:DebtInstrumentFeeAmount unitRef="usd" contextRef="c53_AsOf31Aug2020_ConformClinicalDevelopmentIncMember" decimals="0">1484000</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:ResearchAndDevelopmentInProcess unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">1824000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ResearchAndDevelopmentInProcess unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">977000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:DebtInstrumentFeeAmount unitRef="aud" contextRef="c54_AsOf31Jan2020_NovotechAustraliaPtyLtdMember" decimals="0">1942981</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:DebtInstrumentFeeAmount unitRef="usd" contextRef="c54_AsOf31Jan2020_NovotechAustraliaPtyLtdMember" decimals="0">1355580</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="aud" contextRef="c55_From1Jan2020To31Dec2020_NovotechAustraliaPtyLtdMember" decimals="0">590000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c55_From1Jan2020To31Dec2020_NovotechAustraliaPtyLtdMember" decimals="0">407000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:DebtInstrumentFeeAmount unitRef="aud" contextRef="c56_AsOf31May2020_NucleusNetworkPtyLtdMember" decimals="0">1392805</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:DebtInstrumentFeeAmount unitRef="usd" contextRef="c57_AsOf31May2020" decimals="0">953388</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="aud" contextRef="c58_From1Jan2020To31Dec2020_NucleusNetworkPtyLtdMember" decimals="0">489000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c58_From1Jan2020To31Dec2020_NucleusNetworkPtyLtdMember" decimals="0">337000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:DebtInstrumentFeeAmount unitRef="aud" contextRef="c59_AsOf31Aug2020_QPharmPtyLtdMember" decimals="0">704600</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:DebtInstrumentFeeAmount unitRef="usd" contextRef="c59_AsOf31Aug2020_QPharmPtyLtdMember" decimals="0">505488</us-gaap:DebtInstrumentFeeAmount>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="aud" contextRef="c60_From1Jan2020To31Dec2020_QPharmPtyLtdMember" decimals="0">557000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c60_From1Jan2020To31Dec2020_QPharmPtyLtdMember" decimals="0">384000</us-gaap:OtherResearchAndDevelopmentExpense>
  <tffp:PremarketingApprovals unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">25000000</tffp:PremarketingApprovals>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;NOTE 6 &amp;#x2013; STOCKHOLDERS&amp;#x2019;
EQUITY&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;IPO&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In October 2019, the Company completed
an IPO, selling 4,400,000 shares of common stock at an offering price of $5.00 per share. The Company received gross proceeds of
approximately $22,000,000. In addition, the Company granted the underwriter a 45-day option to purchase an additional 660,000 shares
of common stock at the initial public offering price. The option was exercised and the underwriter purchased an additional 479,300
shares of common stock and the Company received additional gross proceeds of approximately $2,397,000. The Company received net
proceeds from the IPO and the underwriter&amp;#x2019;s purchase of additional shares of approximately $21,754,000, after deducting underwriting
discounts and commissions and offering-related expenses. Warrants for 317,155 shares of the Company&amp;#x2019;s common stock were issued
to the IPO underwriter at an exercise price of $6.25 per share as part of the underwriter&amp;#x2019;s compensation for the IPO. The
estimated fair value of the warrants of approximately $977,000 was considered an offering cost and netted against additional paid-in
capital.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In conjunction with the IPO, the Company&amp;#x2019;s
outstanding shares of Series A Preferred Stock automatically converted into 9,571,692 shares of its common stock (see below). Also
in conjunction with the issuance of shares in the IPO, the Company granted options to officers and directors to purchase 627,984
shares of common stock at an exercise price of $5.00.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;UT Agreement&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In November 2019, the Company achieved
a milestone in connection with the UT agreement (see Note 5). As a result of the milestone, the Company owed UT 220,666 shares
of common stock, which had a fair value of approximately $1,132,000, which was accrued in accrued research and development expense
as of December 31, 2019. In January 2020, the Company issued the 220,666 shares of common stock to UT.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;August 2020 Private Placement&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;On August 10, 2020, the Company entered
into a Securities Purchase Agreement (the &amp;#x201c;Purchase Agreement&amp;#x201d;) and a Registration Rights Agreement (the &amp;#x201c;Registration
Rights Agreement&amp;#x201d;) with certain institutional and other accredited investors pursuant to which the Company issued and sold
to the investors 3,048,654 shares of the Company&amp;#x2019;s common stock at a price of $8.50 per share for gross proceeds of approximately
$25.91 million, before deducting placement agent and other offering expenses. After deducting the placement agent and other offering
expenses, the Company received net proceeds of approximately $24.28 million. The Purchase Agreement included customary representations,
warranties, and covenants by the investors and the Company, and an indemnity from the Company in favor of the investors. Jefferies
LLC acted as placement agent for the private placement and the private placement closed on August 13, 2020. Pursuant to the terms
of the Registration Rights Agreement, the Company filed a resale registration statement on Form S-1 with the SEC that was declared
effective on September 15, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Stock Option Exercises&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;During November and December 2020, 285,003
shares of common stock were issued in connection with the exercise of stock options for total proceeds of $714,382.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;Cashless Warrant Exercises&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;During August through December 2020, 529,559
shares of common stock were issued in connection with the cashless exercise of 659,108 common stock warrants.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;i&gt;Series A Convertible Preferred Stock&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Prior to our initial public offering in
October 2019, the Company&amp;#x2019;s amended and restated certificate of incorporation authorized the Company to issue up to 10,000,000
shares of preferred stock, all of which was designated as Series A preferred stock and there were 8,930,000&amp;#xa0;shares of Series
A preferred stock issued and outstanding immediately prior to the Company&amp;#x2019;s initial public offering. Pursuant to the Company&amp;#x2019;s
amended and restated certificate of incorporation, all outstanding shares of Series A preferred stock automatically converted to
common stock at the close of our initial public offering and thereafter the Company was no longer authorized to issue any preferred
stock.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Series A Preferred Stock ranked senior
to common stock with respect to dividends rights and liquidation preferences and had full voting rights. The Series A Preferred
Stock accrued a dividend at a rate of 6% per annum, and $875,359 of dividends accrued during the year ended December 31, 2019.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Pursuant to the Company&amp;#x2019;s amended
and restated certificate of incorporation, holders of the Series&amp;#xa0;A Preferred Stock had the following methods of conversion:
(i) automatic conversion into common stock upon the consummation of an IPO at a conversion price of 50% of the IPO price, (ii)
automatic conversion into common stock upon the consummation of a subsequent private placement of securities at a conversion price
of 50% of the purchase price of the securities being sold by the Company approved by the holders of the Series&amp;#xa0;A preferred
stock, and (iii) at any time after the issuance date and until ten calendar days prior to the consummation of an IPO, each holder
shall be entitled to convert into common stock at a conversion price of $2.50 per share.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Series A Preferred Stock automatically
converted into 9,571,692 common shares upon completion of the IPO in October 2019, based on the number of shares of Series A Preferred
Stock outstanding as of the date of the IPO. The conversion share calculation was based on the $2.50 initial issue price for the
Series A Preferred Stock plus $1,603,709 of accrued and unpaid dividends and automatically converted into shares of the Company&amp;#x2019;s
common stock using a stated divisor conversion price equal to 50% of the IPO price to the public which was $5.00 per share.&amp;#xa0;In
accordance with relevant accounting literature, since the terms of the conversion option did not permit the Company to compute
the additional number of shares that it would need to issue upon conversion of the Series A Preferred when the contingent event
occurred, the Company recorded the beneficial conversion amount of approximately $23,930,000 as a deemed dividend at the date of
the IPO.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;2019 Private Placement&lt;/font&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In May 2019, the Company entered into a
securities purchase agreement with various accredited investors to raise gross proceeds of $8.2 million in a private placement
(the &amp;#x201c;2019 Private Placement&amp;#x201d;), issuing 3,268,000 shares of its Series A Preferred Stock. The shares of the Series
A Preferred Stock were sold for $2.50 per share. The Company received net proceeds of approximately $7.2 million from the 2019
Private Placement, after paying placement agent fees and offering expenses.&lt;/p&gt;&lt;br/&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <tffp:StockholdersEquityDescription contextRef="c61_From1Oct2019To31Oct2019_IPOMember">the Company completed an IPO, selling 4,400,000 shares of common stock at an offering price of $5.00 per share. The Company received gross proceeds of approximately $22,000,000. In addition, the Company granted the underwriter a 45-day option to purchase an additional 660,000 shares of common stock at the initial public offering price. The option was exercised and the underwriter purchased an additional 479,300 shares of common stock and the Company received additional gross proceeds of approximately $2,397,000. The Company received net proceeds from the IPO and the underwriter&amp;#x2019;s purchase of additional shares of approximately $21,754,000, after deducting underwriting discounts and commissions and offering-related expenses. Warrants for 317,155 shares of the Company&amp;#x2019;s common stock were issued to the IPO underwriter at an exercise price of $6.25 per share as part of the underwriter&amp;#x2019;s compensation for the IPO. The estimated fair value of the warrants of approximately $977,000 was considered an offering cost and netted against additional paid-in capital.</tffp:StockholdersEquityDescription>
  <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion unitRef="shares" contextRef="c62_AsOf31Oct2019_SeriesAPreferredStockMember_IPOMember" decimals="INF">9571692</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues unitRef="shares" contextRef="c61_From1Oct2019To31Oct2019_IPOMember" decimals="INF">627984</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <tffp:FairValueAssumptionExercisePrice unitRef="usdPershares" contextRef="c63_AsOf31Oct2019_IPOMember" decimals="2">5.00</tffp:FairValueAssumptionExercisePrice>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">1132000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c64_AsOf31Jan2020" decimals="INF">220666</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued unitRef="shares" contextRef="c65_AsOf10Aug2020_PrivatePlacementMember" decimals="INF">3048654</us-gaap:CommonStockSharesIssued>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c65_AsOf10Aug2020_PrivatePlacementMember" decimals="2">8.50</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement unitRef="usd" contextRef="c66_From2Aug2020To10Aug2020_PrivatePlacementMember" decimals="-4">25910000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <tffp:NetProceeds unitRef="usd" contextRef="c66_From2Aug2020To10Aug2020_PrivatePlacementMember" decimals="-4">24280000</tffp:NetProceeds>
  <tffp:IssuanceOfCommonStockForStockOptionExerciseShares unitRef="shares" contextRef="c67_From1Nov2020To30Nov2020" decimals="INF">285003</tffp:IssuanceOfCommonStockForStockOptionExerciseShares>
  <tffp:IssuanceOfCommonStockForStockOptionExerciseShares unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">285003</tffp:IssuanceOfCommonStockForStockOptionExerciseShares>
  <tffp:StockOptionExercisesTotalProceeds unitRef="usd" contextRef="c67_From1Nov2020To30Nov2020" decimals="0">714382</tffp:StockOptionExercisesTotalProceeds>
  <tffp:StockOptionExercisesTotalProceeds unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">714382</tffp:StockOptionExercisesTotalProceeds>
  <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">529559</tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise>
  <tffp:IssuanceOfCommonStockWarrant unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">659108</tffp:IssuanceOfCommonStockWarrant>
  <us-gaap:PreferredStockSharesAuthorized unitRef="shares" contextRef="c29_AsOf31Oct2019" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c29_AsOf31Oct2019" decimals="INF">8930000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:PreferredStockDividendRatePercentage unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="2">0.06</us-gaap:PreferredStockDividendRatePercentage>
  <us-gaap:DividendsPayableCurrent unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">875359</us-gaap:DividendsPayableCurrent>
  <us-gaap:ConversionOfStockDescription contextRef="c0_From1Jan2020To31Dec2020">Pursuant to the Company&amp;#x2019;s amended and restated certificate of incorporation, holders of the Series A Preferred Stock had the following methods of conversion: (i) automatic conversion into common stock upon the consummation of an IPO at a conversion price of 50% of the IPO price, (ii) automatic conversion into common stock upon the consummation of a subsequent private placement of securities at a conversion price of 50% of the purchase price of the securities being sold by the Company approved by the holders of the Series A preferred stock, and (iii) at any time after the issuance date and until ten calendar days prior to the consummation of an IPO, each holder shall be entitled to convert into common stock at a conversion price of $2.50 per share.</us-gaap:ConversionOfStockDescription>
  <us-gaap:ConvertiblePreferredStockTermsOfConversion contextRef="c0_From1Jan2020To31Dec2020">The Series A Preferred Stock automatically converted into 9,571,692 common shares upon completion of the IPO in October 2019, based on the number of shares of Series A Preferred Stock outstanding as of the date of the IPO. The conversion share calculation was based on the $2.50 initial issue price for the Series A Preferred Stock plus $1,603,709 of accrued and unpaid dividends and automatically converted into shares of the Company&amp;#x2019;s common stock using a stated divisor conversion price equal to 50% of the IPO price to the public which was $5.00 per share. In accordance with relevant accounting literature, since the terms of the conversion option did not permit the Company to compute the additional number of shares that it would need to issue upon conversion of the Series A Preferred when the contingent event occurred, the Company recorded the beneficial conversion amount of approximately $23,930,000 as a deemed dividend at the date of the IPO.</us-gaap:ConvertiblePreferredStockTermsOfConversion>
  <us-gaap:ProceedsFromIssuanceOfPrivatePlacement unitRef="usd" contextRef="c68_From1May2019To31May2019_SeriesAPreferredStockMember_PrivatePlacementMember" decimals="-5">8200000</us-gaap:ProceedsFromIssuanceOfPrivatePlacement>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c69_AsOf31May2019_SeriesAPreferredStockMember_PrivatePlacementMember" decimals="INF">3268000</us-gaap:PreferredStockSharesIssued>
  <us-gaap:SaleOfStockPricePerShare unitRef="usdPershares" contextRef="c69_AsOf31May2019_SeriesAPreferredStockMember_PrivatePlacementMember" decimals="2">2.50</us-gaap:SaleOfStockPricePerShare>
  <tffp:NetProceeds unitRef="usd" contextRef="c68_From1May2019To31May2019_SeriesAPreferredStockMember_PrivatePlacementMember" decimals="-5">7200000</tffp:NetProceeds>
  <tffp:WarrantsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;NOTE 7 &amp;#x2013; WARRANTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;On March 13, 2018 and March 22, 2018, the
Company issued to National Securities Corporation warrants to purchase shares of the Company&amp;#x2019;s common stock in an amount
equal to 10% of the shares of common stock issuable upon conversion of 5,662,000 shares of the Company&amp;#x2019;s Series&amp;#xa0;A Preferred
Stock. In connection with the conversion of the Series A Preferred Stock as a result of the IPO, the Company issued additional
warrants to purchase 53,679 shares of common stock. The additional warrants were considered offering costs and netted with the
proceeds from the IPO.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;On May 16, 2019 and May 23, 2019, the Company
issued to National Securities Corporation 326,800 warrants to purchase shares of the Company&amp;#x2019;s common stock. The fair value
of the warrants on the grant date was estimated using the Black-Scholes-Merton option pricing model with a common stock value of
$1.67 per share, a contractual life of 5 years, a dividend yield of 0%, a volatility of 89.6% and an assumed risk-free interest
rate of 2.11%. The fair value of the warrants was determined to be approximately $347,000 and was included in general and administrative
expenses in the statement of operations. On September 13, 2019, these warrants were cancelled by the individual warrant holders
and the Company determined that the related expense should be reversed. The reversal of the expense was recorded during the three
months ended September 30, 2019, when the warrants were cancelled.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;On October 29, 2019, the Company issued
a ten-year warrant to purchase 43,794 shares of common stock at $5.00 per share to BP Directors, LP (&amp;#x201c;BP&amp;#x201d;). The warrant
represented consideration for board service from Dr. Aaron Fletcher. The fair value of the warrant on the grant date was estimated
using the Black-Scholes-Merton option pricing model with a common stock value of $5.01 per share, a contractual life of 6.0 years,
a dividend yield of 0%, a volatility of 88.48% and an assumed risk-free interest rate of 1.70%. The warrant is subject to a 25%
cliff vesting at one year from the date of grant and the balance vesting quarterly over the following two years. The fair value
of the warrant was determined to be $161,419 and is being amortized in general and administrative expenses in the consolidated
statements of operations over the vesting term.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;On November 26, 2019, the Company issued
to National Securities Corporation and its representatives underwriter warrants to purchase 317,155 shares of the Company&amp;#x2019;s
common stock in connection with the IPO. The exercise price of the warrants is $6.25 per share, each has a contractual life of
5 years and they were not exercisable for one year from the date of grant.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;On November 29, 2019, the Company issued
a ten-year warrant to purchase 3,623 shares of common stock at $5.00 per share to BP. The warrant represented consideration for
board service from Dr. Aaron Fletcher. The fair value of the warrant on the grant date was estimated using the Black-Scholes-Merton
option pricing model with a common stock value of $5.26 per share, a contractual life of 6.0 years, a dividend yield of 0%, a volatility
of 90.16% and an assumed risk-free interest rate of 1.68%. The warrant is subject to a 25% cliff vesting at one year from the date
of grant and the balance vesting quarterly over the following two years. The fair value of the warrant was determined to be $14,300
and is being amortized in general and administrative expenses in the consolidated statements of operations over the vesting term.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In determining the fair value for warrants,
the expected life of the Company&amp;#x2019;s warrants was determined using the contractual life. The methodology in determining all
other inputs to calculate the fair value utilizing the Black-Scholes-Merton option pricing model is the same as the stock option
methodology described in Note 8 for stock options.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;A summary of warrant activity for the years
ended December 31, 2020 and 2019 is as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number of Shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Range of Exercise Prices&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-Average Exercise Prices&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-Average Remaining Life&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Outstanding at January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,058,212&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;0.01 &amp;#x2013; $2.50&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.56&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.6&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Issued&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;745,051&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;1.67 &amp;#x2013; 6.25&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.26&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(326,800&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2.50&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2.50&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Outstanding at December 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,476,463&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;0.01 &amp;#x2013; 6.25&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.71&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.1&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Exercised&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(659,108&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;2.50 &amp;#x2013; 6.25&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2.75&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 2pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Outstanding at December 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;817,355&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;0.01 &amp;#x2013; $6.25&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2.68&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3.7&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The warrants outstanding at December 31,
2020 had an aggregate intrinsic value of approximately $9,511,000.&lt;/p&gt;&lt;br/&gt;</tffp:WarrantsTextBlock>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent unitRef="pure" contextRef="c70_From20Feb2018To13Mar2018_NationalSecuritiesCorporationsWarrantsMember" decimals="2">0.10</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:PreferredStockSharesIssued unitRef="shares" contextRef="c71_AsOf13Mar2018_SeriesAPreferredStockMember_NationalSecuritiesCorporationsWarrantsMember" decimals="INF">5662000</us-gaap:PreferredStockSharesIssued>
  <tffp:WarrantToPurchaseSharesOfCommonStock unitRef="shares" contextRef="c72_AsOf13Mar2018" decimals="INF">53679</tffp:WarrantToPurchaseSharesOfCommonStock>
  <tffp:WarrantToPurchaseSharesOfCommonStock unitRef="shares" contextRef="c73_AsOf22Mar2018" decimals="INF">53679</tffp:WarrantToPurchaseSharesOfCommonStock>
  <tffp:WarrantToPurchaseSharesOfCommonStock unitRef="shares" contextRef="c74_AsOf16May2019_NationalSecuritiesCorporationsWarrantsMember" decimals="INF">326800</tffp:WarrantToPurchaseSharesOfCommonStock>
  <tffp:FairValueAssumptionsCommonStockValue unitRef="usdPershares" contextRef="c75_From20Apr2019To16May2019_NationalSecuritiesCorporationsWarrantsMember" decimals="2">1.67</tffp:FairValueAssumptionsCommonStockValue>
  <tffp:FairValueAssumptionsCommonStockValue unitRef="usdPershares" contextRef="c76_From19Apr2019To23May2019_NationalSecuritiesCorporationsWarrantsMember" decimals="2">1.67</tffp:FairValueAssumptionsCommonStockValue>
  <tffp:FairValueAssumptionsExpectedTerms contextRef="c75_From20Apr2019To16May2019_NationalSecuritiesCorporationsWarrantsMember">P5Y</tffp:FairValueAssumptionsExpectedTerms>
  <tffp:FairValueAssumptionsExpectedDividendRates unitRef="pure" contextRef="c75_From20Apr2019To16May2019_NationalSecuritiesCorporationsWarrantsMember" decimals="2">0.00</tffp:FairValueAssumptionsExpectedDividendRates>
  <tffp:FairValueAssumptionsExpectedDividendRates unitRef="pure" contextRef="c76_From19Apr2019To23May2019_NationalSecuritiesCorporationsWarrantsMember" decimals="2">0.00</tffp:FairValueAssumptionsExpectedDividendRates>
  <tffp:FairValueAssumptionExpectedVolatilityRate unitRef="pure" contextRef="c75_From20Apr2019To16May2019_NationalSecuritiesCorporationsWarrantsMember" decimals="3">0.896</tffp:FairValueAssumptionExpectedVolatilityRate>
  <tffp:FairValueAssumptionExpectedVolatilityRate unitRef="pure" contextRef="c76_From19Apr2019To23May2019_NationalSecuritiesCorporationsWarrantsMember" decimals="3">0.896</tffp:FairValueAssumptionExpectedVolatilityRate>
  <tffp:FairValueAssumptionRiskFreeInterestRate unitRef="pure" contextRef="c75_From20Apr2019To16May2019_NationalSecuritiesCorporationsWarrantsMember" decimals="4">0.0211</tffp:FairValueAssumptionRiskFreeInterestRate>
  <tffp:FairValueAssumptionRiskFreeInterestRate unitRef="pure" contextRef="c76_From19Apr2019To23May2019_NationalSecuritiesCorporationsWarrantsMember" decimals="4">0.0211</tffp:FairValueAssumptionRiskFreeInterestRate>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c75_From20Apr2019To16May2019_NationalSecuritiesCorporationsWarrantsMember" decimals="0">347000</us-gaap:OtherResearchAndDevelopmentExpense>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c76_From19Apr2019To23May2019_NationalSecuritiesCorporationsWarrantsMember" decimals="0">347000</us-gaap:OtherResearchAndDevelopmentExpense>
  <tffp:WarrantToPurchaseSharesOfCommonStock unitRef="shares" contextRef="c77_AsOf29Aug2019_TenYearsWarrantMember" decimals="INF">43794</tffp:WarrantToPurchaseSharesOfCommonStock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c78_AsOf29Aug2019_BPDirectorsMember_TenYearsWarrantMember" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <tffp:FairValueAssumptionsCommonStockValue unitRef="usdPershares" contextRef="c79_From2Aug2019To29Aug2019_TenYearsWarrantMember" decimals="2">5.01</tffp:FairValueAssumptionsCommonStockValue>
  <tffp:FairValueAssumptionsExpectedTerms contextRef="c79_From2Aug2019To29Aug2019_TenYearsWarrantMember">P6Y</tffp:FairValueAssumptionsExpectedTerms>
  <tffp:FairValueAssumptionsExpectedDividendRates unitRef="pure" contextRef="c79_From2Aug2019To29Aug2019_TenYearsWarrantMember" decimals="2">0.00</tffp:FairValueAssumptionsExpectedDividendRates>
  <tffp:FairValueAssumptionExpectedVolatilityRate unitRef="pure" contextRef="c79_From2Aug2019To29Aug2019_TenYearsWarrantMember" decimals="4">0.8848</tffp:FairValueAssumptionExpectedVolatilityRate>
  <tffp:FairValueAssumptionRiskFreeInterestRate unitRef="pure" contextRef="c79_From2Aug2019To29Aug2019_TenYearsWarrantMember" decimals="4">0.0170</tffp:FairValueAssumptionRiskFreeInterestRate>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c79_From2Aug2019To29Aug2019_TenYearsWarrantMember" decimals="0">161419</us-gaap:OtherResearchAndDevelopmentExpense>
  <tffp:WarrantToPurchaseSharesOfCommonStock unitRef="shares" contextRef="c80_AsOf26Nov2019_NationalSecuritiesCorporationsWarrantsMember_IPOMember" decimals="INF">317155</tffp:WarrantToPurchaseSharesOfCommonStock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c81_AsOf26Nov2019_NationalSecuritiesCorporationsWarrantsMember" decimals="2">6.25</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <tffp:FairValueAssumptionsExpectedTerms contextRef="c82_From3Nov2019To26Nov2019_NationalSecuritiesCorporationsWarrantsMember">P5Y</tffp:FairValueAssumptionsExpectedTerms>
  <tffp:WarrantToPurchaseSharesOfCommonStock unitRef="shares" contextRef="c83_AsOf29Nov2019_TenYearsWarrantMember" decimals="INF">3623</tffp:WarrantToPurchaseSharesOfCommonStock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 unitRef="usdPershares" contextRef="c84_AsOf29Nov2019_TenYearsWarrantMember_BPDirectorsMember" decimals="2">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare unitRef="usdPershares" contextRef="c85_AsOf29Nov2019" decimals="2">5.26</tffp:IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare>
  <tffp:FairValueAssumptionsExpectedTerms contextRef="c86_From4Nov2019To29Nov2019_TenYearsWarrantMember">P6Y</tffp:FairValueAssumptionsExpectedTerms>
  <tffp:FairValueAssumptionsExpectedDividendRates unitRef="pure" contextRef="c86_From4Nov2019To29Nov2019_TenYearsWarrantMember" decimals="2">0.00</tffp:FairValueAssumptionsExpectedDividendRates>
  <tffp:FairValueAssumptionExpectedVolatilityRate unitRef="pure" contextRef="c86_From4Nov2019To29Nov2019_TenYearsWarrantMember" decimals="4">0.9016</tffp:FairValueAssumptionExpectedVolatilityRate>
  <tffp:FairValueAssumptionRiskFreeInterestRate unitRef="pure" contextRef="c86_From4Nov2019To29Nov2019_TenYearsWarrantMember" decimals="4">0.0168</tffp:FairValueAssumptionRiskFreeInterestRate>
  <us-gaap:OtherResearchAndDevelopmentExpense unitRef="usd" contextRef="c86_From4Nov2019To29Nov2019_TenYearsWarrantMember" decimals="0">14300</us-gaap:OtherResearchAndDevelopmentExpense>
  <tffp:WarrantOutstandingAggregateIntrinsicValue unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">9511000</tffp:WarrantOutstandingAggregateIntrinsicValue>
  <tffp:ScheduleOfWarrantActivity contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number of Shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Range of Exercise Prices&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-Average Exercise Prices&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-Average Remaining Life&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Outstanding at January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,058,212&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;0.01 &amp;#x2013; $2.50&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1.56&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.6&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Issued&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;745,051&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;1.67 &amp;#x2013; 6.25&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.26&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(326,800&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2.50&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2.50&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Outstanding at December 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,476,463&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;0.01 &amp;#x2013; 6.25&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.71&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4.1&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Exercised&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(659,108&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;2.50 &amp;#x2013; 6.25&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2.75&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-bottom: 2pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Outstanding at December 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;817,355&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;0.01 &amp;#x2013; $6.25&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2.68&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3.7&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</tffp:ScheduleOfWarrantActivity>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c10_AsOf31Dec2018" decimals="INF">1058212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice unitRef="usdPershares" contextRef="c87_AsOf31Dec2018_MinimumMember" decimals="2">0.01</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice unitRef="usdPershares" contextRef="c88_AsOf31Dec2018_MaximumMember" decimals="2">2.50</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c10_AsOf31Dec2018" decimals="2">1.56</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c5_From1Jan2019To31Dec2019">P4Y219D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross unitRef="shares" contextRef="c5_From1Jan2019To31Dec2019" decimals="INF">745051</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice unitRef="usdPershares" contextRef="c89_From1Jan2019To31Dec2019_MinimumMember" decimals="2">1.67</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice unitRef="usdPershares" contextRef="c90_From1Jan2019To31Dec2019_MaximumMember" decimals="2">6.25</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c5_From1Jan2019To31Dec2019" decimals="2">4.26</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross unitRef="shares" contextRef="c5_From1Jan2019To31Dec2019" decimals="INF">-326800</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled unitRef="usdPershares" contextRef="c5_From1Jan2019To31Dec2019" decimals="2">2.50</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c5_From1Jan2019To31Dec2019" decimals="2">2.50</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">1476463</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice unitRef="usdPershares" contextRef="c91_AsOf31Dec2019_MinimumMember" decimals="2">0.01</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice unitRef="usdPershares" contextRef="c92_AsOf31Dec2019_MaximumMember" decimals="2">6.25</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c4_AsOf31Dec2019" decimals="2">2.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <tffp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="c5_From1Jan2019To31Dec2019">P4Y36D</tffp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">-659108</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised unitRef="usdPershares" contextRef="c93_From1Jan2020To31Dec2020_MinimumMember" decimals="2">2.50</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised unitRef="usdPershares" contextRef="c94_From1Jan2020To31Dec2020_MaximumMember" decimals="2">6.25</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised>
  <tffp:ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">2.75</tffp:ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">817355</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice unitRef="usdPershares" contextRef="c95_AsOf31Dec2020_MinimumMember" decimals="2">0.01</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice unitRef="usdPershares" contextRef="c96_AsOf31Dec2020_MaximumMember" decimals="2">6.25</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">2.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <tffp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="c0_From1Jan2020To31Dec2020">P3Y255D</tffp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;NOTE 8 &amp;#x2013; STOCK BASED COMPENSATION&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;In January 2018, the Company&amp;#x2019;s board
of directors approved its 2018 Stock Incentive Plan (&amp;#x201c;2018 Plan&amp;#x201d;). The 2018 Plan provides for the grant of non-qualified
stock options and incentive stock options to purchase shares of the Company&amp;#x2019;s common stock, the grant of restricted and unrestricted
share awards and grant of restricted stock units. The Company initially reserved 1,630,000 shares of its common stock under the
2018 Plan; however, upon completion of the Company&amp;#x2019;s IPO the number of shares reserved for issuance under the 2018 Plan increased
to 3,284,480, representing 15% of the Company&amp;#x2019;s outstanding shares of common stock calculated on a fully diluted basis upon
the close of the IPO. All of the Company&amp;#x2019;s employees and any subsidiary employees (including officers and directors who are
also employees), as well as all of the Company&amp;#x2019;s nonemployee directors and other consultants, advisors and other persons
who provide services to the Company will be eligible to receive incentive awards under the 2018 Plan.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The following table summarizes the stock-based
compensation expense recorded in the Company&amp;#x2019;s results of operations during the years ended December 31, 2020 and 2019 for
stock options and warrants:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Year Ended&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Year Ended&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt;
2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt;
2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Research and development&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;140,278&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;General and administrative&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,046,871&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;590,041&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,187,149&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;590,041&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;As of December 31, 2020, there was approximately
$9,074,000 of total unrecognized compensation expense related to non-vested share-based compensation arrangements that are expected
to vest. This cost is expected to be recognized over a weighted-average period of 2.4 years.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company records compensation expense
for employee awards with graded vesting using the straight-line method. The Company records compensation expense for nonemployee
awards with graded vesting using the accelerated expense attribution method. The Company recognizes compensation expense over the
requisite service period applicable to each individual award, which generally equals the vesting term. The Company estimates the
fair value of each option award using the Black-Scholes-Merton option pricing model. Forfeitures are recognized when realized.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company estimated the fair value of
employee and non-employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options
is being amortized on a straight-line basis over the requisite service periods of the respective awards. The fair value of stock
options issued was estimated using the following assumptions:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Year Ended&lt;br/&gt; December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Year Ended&lt;br/&gt; December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Weighted average exercise price&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;10.42&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.42&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.25&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.08&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Assumptions&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;87-91&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;88-90&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;6.3-10&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.3&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;0.36-1.47&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;1.68-2.31&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The risk-free interest rate was obtained
from U.S. Treasury rates for the applicable periods. The Company&amp;#x2019;s expected volatility was based upon the historical volatility
for industry peers and used an average of those volatilities. The expected life of the Company&amp;#x2019;s options was determined using
the simplified method as a result of limited historical data regarding the Company&amp;#x2019;s activity for employee awards and the
contractual term for nonemployee awards. The dividend yield considers that the Company has not historically paid dividends, and
does not expect to pay dividends in the foreseeable future.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;For grants prior to the IPO, the fair value
of the common stock was determined by the board of directors based on a variety of factors, including valuations prepared by third
parties, the Company&amp;#x2019;s financial position, the status of development efforts within the Company, the current climate in the
marketplace and the prospects of a liquidity event, among others. For grants after the IPO, the Company uses the closing stock
price on the date of grant as the fair value of the common stock.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The following table summarizes stock option
activity during the years ended December 31, 2020 and 2019:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number of Shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-Average&lt;br/&gt; Exercise Prices&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-Average Remaining
    Contractual Term (In&amp;#xa0;Years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Intrinsic Value&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 52%; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Outstanding at January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,073,082&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.50&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;9.64&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1,065,996&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4.42&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Outstanding at December 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,139,078&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.46&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.17&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4,052,512&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;782,045&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;10.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Exercised&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(285,003&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.74&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(25,625&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4.86&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Outstanding at December 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,610,495&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5.63&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8.60&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;22,789,233&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Exercisable at December 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;755,885&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3.25&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8.04&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8,365,946&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:DeferredCompensationArrangementsOverallDescription contextRef="c97_From1Jan2018To31Jan2018">the Company&amp;#x2019;s board of directors approved its 2018 Stock Incentive Plan (&amp;#x201c;2018 Plan&amp;#x201d;). The 2018 Plan provides for the grant of non-qualified stock options and incentive stock options to purchase shares of the Company&amp;#x2019;s common stock, the grant of restricted and unrestricted share awards and grant of restricted stock units. The Company initially reserved 1,630,000 shares of its common stock under the 2018 Plan; however, upon completion of the Company&amp;#x2019;s IPO the number of shares reserved for issuance under the 2018 Plan increased to 3,284,480, representing 15% of the Company&amp;#x2019;s outstanding shares of common stock calculated on a fully diluted basis upon the close of the IPO. All of the Company&amp;#x2019;s employees and any subsidiary employees (including officers and directors who are also employees), as well as all of the Company&amp;#x2019;s nonemployee directors and other consultants, advisors and other persons who provide services to the Company will be eligible to receive incentive awards under the 2018 Plan.</us-gaap:DeferredCompensationArrangementsOverallDescription>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">9074000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm contextRef="c0_From1Jan2020To31Dec2020">P2Y146D</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm>
  <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Year Ended&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center&quot;&gt;Year Ended&lt;/td&gt;&lt;td style=&quot;font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt;
2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt;
2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Research and development&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;140,278&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;General and administrative&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,046,871&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;590,041&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,187,149&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;590,041&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c98_From1Jan2020To31Dec2020_ResearchAndDevelopmentExpenseMember" decimals="0">140278</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c99_From1Jan2019To31Dec2019_ResearchAndDevelopmentExpenseMember" xs:nil="true"/>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c100_From1Jan2020To31Dec2020_GeneralAndAdministrativeExpenseMember" decimals="0">2046871</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation unitRef="usd" contextRef="c101_From1Jan2019To31Dec2019_GeneralAndAdministrativeExpenseMember" decimals="0">590041</us-gaap:ShareBasedCompensation>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;text-align: center; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Year Ended&lt;br/&gt; December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Year Ended&lt;br/&gt; December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Weighted average exercise price&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;10.42&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;4.42&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Weighted average grant date fair value&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.25&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.08&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Assumptions&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;87-91&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;88-90&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Expected term (in years)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;6.3-10&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;6.3&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;0.36-1.47&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;1.68-2.31&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;text-align: left; padding-left: 0.125in; text-indent: -0.125in&quot;&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">10.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c5_From1Jan2019To31Dec2019" decimals="2">4.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">9.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue unitRef="usdPershares" contextRef="c5_From1Jan2019To31Dec2019" decimals="2">3.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c93_From1Jan2020To31Dec2020_MinimumMember" decimals="2">0.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c94_From1Jan2020To31Dec2020_MaximumMember" decimals="2">0.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c89_From1Jan2019To31Dec2019_MinimumMember" decimals="2">0.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate unitRef="pure" contextRef="c90_From1Jan2019To31Dec2019_MaximumMember" decimals="2">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c93_From1Jan2020To31Dec2020_MinimumMember">P6Y109D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c94_From1Jan2020To31Dec2020_MaximumMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c5_From1Jan2019To31Dec2019">P6Y109D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c93_From1Jan2020To31Dec2020_MinimumMember" decimals="4">0.0036</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c94_From1Jan2020To31Dec2020_MaximumMember" decimals="4">0.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c89_From1Jan2019To31Dec2019_MinimumMember" decimals="4">0.0168</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate unitRef="pure" contextRef="c90_From1Jan2019To31Dec2019_MaximumMember" decimals="4">0.0231</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Number of Shares&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-Average&lt;br/&gt; Exercise Prices&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Weighted-Average Remaining
    Contractual Term (In&amp;#xa0;Years)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Intrinsic Value&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 52%; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Outstanding at January 1, 2019&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;1,073,082&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2.50&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;9.64&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;1,065,996&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4.42&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Outstanding at December 31, 2019&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2,139,078&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.46&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;9.17&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;4,052,512&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Granted&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;782,045&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;10.42&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Exercised&lt;/font&gt;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(285,003&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;2.74&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Cancelled&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(25,625&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4.86&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;&amp;#x2014;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Outstanding at December 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;2,610,495&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;5.63&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8.60&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;22,789,233&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt; text-align: left&quot;&gt;&lt;font style=&quot;font-size: 10pt&quot;&gt;Exercisable at December 31, 2020&lt;/font&gt;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;755,885&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;3.25&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8.04&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;8,365,946&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber unitRef="shares" contextRef="c10_AsOf31Dec2018" decimals="INF">1073082</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c10_AsOf31Dec2018" decimals="2">2.50</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice>
  <tffp:WeightedaverageRemainingContractualTermOutstandingBeginningBalance1 contextRef="c5_From1Jan2019To31Dec2019">P9Y233D</tffp:WeightedaverageRemainingContractualTermOutstandingBeginningBalance1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c10_AsOf31Dec2018" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod unitRef="shares" contextRef="c5_From1Jan2019To31Dec2019" decimals="INF">1065996</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c5_From1Jan2019To31Dec2019" decimals="2">4.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <tffp:WeightedaverageRemainingContractualTermGranted contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber unitRef="shares" contextRef="c4_AsOf31Dec2019" decimals="INF">2139078</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c4_AsOf31Dec2019" decimals="2">3.46</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice>
  <tffp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="c5_From1Jan2019To31Dec2019">P9Y62D</tffp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">4052512</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">782045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">10.42</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <tffp:WeightedaverageRemainingContractualTermGranted contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">285003</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">2.74</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <tffp:WeightedaverageRemainingContractualTermExercised contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation unitRef="shares" contextRef="c0_From1Jan2020To31Dec2020" decimals="INF">-25625</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">4.86</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <tffp:WeightedaverageRemainingContractualTermCancelled contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <tffp:AggregateIntrinsicValueCancelled unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">2610495</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber>
  <tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">5.63</tffp:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice>
  <tffp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3 contextRef="c0_From1Jan2020To31Dec2020">P8Y219D</tffp:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">22789233</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">755885</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice unitRef="usdPershares" contextRef="c3_AsOf31Dec2020" decimals="2">3.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c0_From1Jan2020To31Dec2020">P8Y14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <tffp:AggregateIntrinsicValueExercisable unitRef="shares" contextRef="c3_AsOf31Dec2020" decimals="INF">8365946</tffp:AggregateIntrinsicValueExercisable>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;NOTE 9 &amp;#x2013; INCOME TAXES&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company had no income tax expense due
to operating losses incurred for the years ended December&amp;#xa0;31, 2020 and 2019. The Company accounts for income taxes in accordance
with ASC 740, which requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded
as an asset to the extent that management assesses that realization is &amp;#x201c;more likely than not.&amp;#x201d; Realization of the future
tax benefits is dependent on the Company&amp;#x2019;s ability to generate sufficient taxable income within the carryforward period.
Because of the Company&amp;#x2019;s recent history of operating losses, management believes that recognition of the deferred tax assets
arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a full
valuation allowance.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company&amp;#x2019;s income tax expense
for the years ended December 31, 2020 and 2019 are summarized below:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Current:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;Federal&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;State&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Foreign&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Total current&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Deferred:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Federal&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(4,502,016&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(2,952,519&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;State&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;Foreign&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(480,666&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Change in valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4,982,682&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,952,519&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Total deferred&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Income tax provision (benefit)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company&amp;#x2019;s deferred tax assets
are as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;6,807,300&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2,789,541&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;Research and development tax credit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,092,345&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;532,711&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;Intangibles&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;136,226&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;105,580&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Stock compensation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;761,741&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;387,098&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.375in; text-indent: -0.125in; text-align: left&quot;&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8,797,612&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,814,930&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Valuation allowances&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(8,797,612&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(3,814,930&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Net deferred tax assets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The effective tax rate of the Company&amp;#x2019;s
provision (benefit) for income taxes differs from the federal statutory rate as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Statutory rate&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;21.00&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;21.00&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;State rate&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Foreign&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(1.81&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Permanent book/tax differences&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(0.26&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(0.12&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Research and development credit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.09&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.99&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Changes in valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(24.02&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(24.87&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;As of December 31, 2020 and 2019, the Company
had gross federal income tax net operating loss (&amp;#x201c;NOL&amp;#x201d;) carryforwards of $30,126,830 and $13,283,530, respectively,
and federal research tax credits of $1,486,704 and $690,525, respectively. Additionally, the Company had gross foreign income tax
net operating loss carryforwards of $1,602,220 as of December 31, 2020. The federal and foreign NOL have an indefinite life while
the federal research tax credits will expire by 2040.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Utilization of U.S. net operating losses
and tax credit carryforwards may be limited by &amp;#x201c;ownership change&amp;#x201d; rules, as defined in Sections&amp;#xa0;382 and 383 of
the Code. Similar rules may apply under state tax laws. The Company has not conducted a study to-date to assess whether a limitation
would apply under Sections&amp;#xa0;382 and 383 of the Code as and when it starts utilizing its net operating losses and tax credits.
The Company will continue to monitor activities in the future. In the event the Company previously experienced an ownership change,
or should experience an ownership change in the future, the amount of net operating losses and research and development credit
carryovers available in any taxable year could be limited and may expire unutilized.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The CARES Act was signed into law on March
27, 2020 as a response to the economic challenges facing U.S. businesses caused by the COVID-19 global pandemic. The CARES Act
allowed net operating loss incurred in 2018-2020 to be carried back five years or carried forward indefinitely, and to be fully
utilized without being subjected to the 80% taxable income limitation. Net operating losses incurred after December 31, 2020 will
be subjected to the 80% taxable income limitation. In assessing the realization of deferred tax assets, management considers whether
it is more likely than not that some portion, or all, of the deferred tax asset will be realized. The ultimate realization of deferred
tax assets is dependent upon the Company attaining future taxable income during periods in which those temporary differences become
deductible.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;Due to the uncertainty surrounding the
realization of the benefits of its deferred assets, including NOL carryforwards, the Company has provided a 100% valuation allowance
on its deferred tax assets at December 31, 2020.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;The Company accounts for uncertain tax
positions in accordance with the provisions of ASC 740, &lt;i&gt;Income Taxes&lt;/i&gt;. When uncertain tax positions exist, the Company recognizes
the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to
whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as
consideration of the available facts and circumstances. As of December 31, 2020, the Company had a reserve for uncertain tax positions
of $394,358, and no interest or penalties have been charged to the Company for the years ended December 31, 2020 and 2019. If incurred,
the Company will classify any interest and penalties as a component of interest expense and operating expense, respectively. If
recognized, $394,358 of the reserve for uncertain tax positions would favorably affect the Company&amp;#x2019;s effective tax rate.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;A reconciliation of the change in the unrecognized
tax positions for the year ended December 31, 2020 is as follows:&lt;/p&gt;&lt;br/&gt;&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Federal and State&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left&quot;&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;157,814&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Additions for tax positions related to current year&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;318,374&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Decreases for tax positions related to prior years&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(81,830&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;394,358&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;&lt;br/&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <tffp:FederalIncomeTaxNetOperatingLoss unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">30126830</tffp:FederalIncomeTaxNetOperatingLoss>
  <tffp:FederalIncomeTaxNetOperatingLoss unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">13283530</tffp:FederalIncomeTaxNetOperatingLoss>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1486704</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">690525</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <tffp:ForeignIncomeTaxNetOperatingLoss unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1602220</tffp:ForeignIncomeTaxNetOperatingLoss>
  <tffp:FederalTaxCreditExpire contextRef="c0_From1Jan2020To31Dec2020">2040</tffp:FederalTaxCreditExpire>
  <tffp:TaxableIncomeForLosses unitRef="pure" contextRef="c102_From3Mar2020To27Mar2020" decimals="2">0.80</tffp:TaxableIncomeForLosses>
  <tffp:TaxableIncomeForLosses unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="2">0.80</tffp:TaxableIncomeForLosses>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="pure" contextRef="c103_From1Jan2020To31Dec2020_EffectiveTaxRateMember" decimals="2">1.00</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <tffp:UncertainTaxPositions unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">394358</tffp:UncertainTaxPositions>
  <tffp:UncertainTaxPositions unitRef="usd" contextRef="c104_AsOf31Dec2020_EffectiveTaxRateMember" decimals="0">394358</tffp:UncertainTaxPositions>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Current:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;Federal&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;State&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Foreign&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Total current&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Deferred:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Federal&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(4,502,016&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;(2,952,519&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;State&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;Foreign&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(480,666&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Change in valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;4,982,682&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;2,952,519&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Total deferred&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Income tax provision (benefit)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:CurrentFederalTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:CurrentFederalTaxExpenseBenefit unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:CurrentStateAndLocalTaxExpenseBenefit unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:CurrentForeignTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:CurrentForeignTaxExpenseBenefit unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:CurrentIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:CurrentIncomeTaxExpenseBenefit unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-4502016</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">-2952519</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">-480666</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
  <us-gaap:DeferredForeignIncomeTaxExpenseBenefit unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" decimals="0">4982682</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
  <us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" decimals="0">2952519</us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions>
  <us-gaap:DeferredOtherTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:DeferredOtherTaxExpenseBenefit unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:IncomeTaxExpenseBenefit unitRef="usd" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Deferred tax assets:&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Net operating loss carryforwards&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;6,807,300&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;2,789,541&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;Research and development tax credit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;1,092,345&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;532,711&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left&quot;&gt;Intangibles&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;136,226&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;105,580&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Stock compensation&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;761,741&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;387,098&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.375in; text-indent: -0.125in; text-align: left&quot;&gt;Total deferred tax assets&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;8,797,612&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3,814,930&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Valuation allowances&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(8,797,612&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(3,814,930&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Net deferred tax assets&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:OperatingLossCarryforwards unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">6807300</us-gaap:OperatingLossCarryforwards>
  <us-gaap:OperatingLossCarryforwards unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">2789541</us-gaap:OperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">1092345</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">532711</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">136226</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">105580</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
  <tffp:DeferredTaxAssetsStockCompensation unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">761741</tffp:DeferredTaxAssetsStockCompensation>
  <tffp:DeferredTaxAssetsStockCompensation unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">387098</tffp:DeferredTaxAssetsStockCompensation>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">8797612</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">3814930</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c3_AsOf31Dec2020" decimals="0">8797612</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance unitRef="usd" contextRef="c4_AsOf31Dec2019" decimals="0">3814930</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c3_AsOf31Dec2020" xs:nil="true"/>
  <us-gaap:DeferredTaxAssetsNet unitRef="usd" contextRef="c4_AsOf31Dec2019" xs:nil="true"/>
  <us-gaap:FederalIncomeTaxNoteTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;December&amp;#xa0;31,&lt;br/&gt; 2019&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left&quot;&gt;Statutory rate&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;21.00&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;21.00&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;State rate&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Foreign&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(1.81&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;0.00&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Permanent book/tax differences&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(0.26&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;(0.12&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Research and development credit&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;5.09&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;3.99&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Changes in valuation allowance&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(24.02&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)%&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(24.87&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Total&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;-&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</us-gaap:FederalIncomeTaxNoteTextBlock>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="4">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="4">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="4">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="4">0.0000</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
  <tffp:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="4">-0.0181</tffp:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars>
  <tffp:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="4">0.0000</tffp:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars>
  <tffp:EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="4">-0.0026</tffp:EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences>
  <tffp:EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="4">-0.0012</tffp:EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="4">0.0509</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="4">0.0399</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" decimals="4">0.2402</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" decimals="4">0.2487</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent unitRef="pure" contextRef="c0_From1Jan2020To31Dec2020" xs:nil="true"/>
  <us-gaap:EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent unitRef="pure" contextRef="c5_From1Jan2019To31Dec2019" xs:nil="true"/>
  <tffp:ScheduleOfUnrecognizedTaxPositionsTableTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;table cellpadding=&quot;0&quot; cellspacing=&quot;0&quot; style=&quot;border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif&quot;&gt;
&lt;tr style=&quot;vertical-align: bottom&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: center&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;font-weight: bold; padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td colspan=&quot;2&quot; style=&quot;font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid&quot;&gt;Federal and State&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; font-weight: bold&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left&quot;&gt;Balance at December 31, 2019&lt;/td&gt;&lt;td style=&quot;width: 1%&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;width: 1%; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;width: 9%; text-align: right&quot;&gt;157,814&lt;/td&gt;&lt;td style=&quot;width: 1%; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left&quot;&gt;Additions for tax positions related to current year&lt;/td&gt;&lt;td&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;text-align: right&quot;&gt;318,374&lt;/td&gt;&lt;td style=&quot;text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; background-color: rgb(204,238,255)&quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt&quot;&gt;Decreases for tax positions related to prior years&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 1.5pt solid; text-align: right&quot;&gt;(81,830&lt;/td&gt;&lt;td style=&quot;padding-bottom: 1.5pt; text-align: left&quot;&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style=&quot;vertical-align: bottom; &quot;&gt;
    &lt;td style=&quot;padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt&quot;&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style=&quot;padding-bottom: 4pt&quot;&gt;&amp;#xa0;&lt;/td&gt;
    &lt;td style=&quot;border-bottom: Black 4pt double; text-align: left&quot;&gt;$&lt;/td&gt;&lt;td style=&quot;border-bottom: Black 4pt double; text-align: right&quot;&gt;394,358&lt;/td&gt;&lt;td style=&quot;padding-bottom: 2pt; text-align: left&quot;&gt;&amp;#xa0;&lt;/td&gt;&lt;/tr&gt;
&lt;/table&gt;</tffp:ScheduleOfUnrecognizedTaxPositionsTableTextBlock>
  <tffp:UncertainTaxPositionsBegnningBalance unitRef="usd" contextRef="c105_AsOf31Dec2019_FederalAndStateMember" decimals="0">157814</tffp:UncertainTaxPositionsBegnningBalance>
  <tffp:AdditionsForTaxPositionsRelatedToCurrentYear unitRef="usd" contextRef="c106_From1Jan2020To31Dec2020_FederalAndStateMember" decimals="0">318374</tffp:AdditionsForTaxPositionsRelatedToCurrentYear>
  <tffp:DecreasesForTaxPositionsRelatedToPriorYears unitRef="usd" contextRef="c106_From1Jan2020To31Dec2020_FederalAndStateMember" decimals="0">-81830</tffp:DecreasesForTaxPositionsRelatedToPriorYears>
  <tffp:UncertainTaxPositionsEndingBalance unitRef="usd" contextRef="c107_AsOf31Dec2020_FederalAndStateMember" decimals="0">394358</tffp:UncertainTaxPositionsEndingBalance>
  <us-gaap:SubsequentEventsTextBlock contextRef="c0_From1Jan2020To31Dec2020">&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify&quot;&gt;&lt;b&gt;&lt;font style=&quot;text-decoration:underline&quot;&gt;NOTE 10 &amp;#x2013; SUBSEQUENT EVENTS&lt;/font&gt;&lt;/b&gt;&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;The Company has performed an evaluation
of events occurring subsequent to December 31, 2020 through the filing date of this Annual Report. Based on its evaluation, nothing
other than the events described below need to be disclosed.&lt;/p&gt;&lt;br/&gt;&lt;p style=&quot;font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify&quot;&gt;Between January 1, 2021 and March 10,
2021, 444,751 shares of common stock were issued in connection with the exercise of warrants and 160,275 shares of common stock
were issued in connection with the exercise of stock options. The Company received total cash proceeds from the exercises of $585,700.&lt;/p&gt;&lt;br/&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c108_AsOf10Mar2021_WarrantMember_SubsequentEventMember" decimals="INF">444751</us-gaap:SharesIssued>
  <us-gaap:SharesIssued unitRef="shares" contextRef="c109_AsOf10Mar2021_OptionMember_SubsequentEventMember" decimals="INF">160275</us-gaap:SharesIssued>
  <us-gaap:ProceedsFromWarrantExercises unitRef="usd" contextRef="c110_From1Jan2021To10Mar2021_SubsequentEventMember" decimals="0">585700</us-gaap:ProceedsFromWarrantExercises>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>tffp-20201231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Mar 09 20:01:28 EST 2021 -->
<xs:schema elementFormDefault="qualified" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" targetNamespace="http://tffp.com/20201231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:tffp="http://tffp.com/20201231" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xlink:type="simple" xlink:href="tffp-20201231_lab.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="tffp-20201231_pre.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="tffp-20201231_def.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef"/>
      <link:linkbaseRef xlink:type="simple" xlink:href="tffp-20201231_cal.xml" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef"/>
      <link:roleType roleURI="http://tffp.com/role/ConsolidatedBalanceSheet" id="tffp_r_ConsolidatedBalanceSheet">
        <link:definition>001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals" id="tffp_r_ConsolidatedBalanceSheet_Parentheticals">
        <link:definition>002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ConsolidatedIncomeStatement" id="tffp_r_ConsolidatedIncomeStatement">
        <link:definition>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ShareholdersEquityType2or3" id="tffp_r_ShareholdersEquityType2or3">
        <link:definition>004 - Statement - Consolidated Statements of Stockholders&#8217; Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ConsolidatedCashFlow" id="tffp_r_ConsolidatedCashFlow">
        <link:definition>005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/OrganizationAndDescriptionOfBusiness" id="tffp_r_OrganizationAndDescriptionOfBusiness">
        <link:definition>006 - Disclosure - Organization And Description Of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/LiquidityandManagementsPlans" id="tffp_r_LiquidityandManagementsPlans">
        <link:definition>007 - Disclosure - Liquidity and Management&#8217;s Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/SummaryofSignificantAccountingPolicies" id="tffp_r_SummaryofSignificantAccountingPolicies">
        <link:definition>008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/CommitmentsAndContingencies" id="tffp_r_CommitmentsAndContingencies">
        <link:definition>009 - Disclosure - Commitments And Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/LicenseandAgreements" id="tffp_r_LicenseandAgreements">
        <link:definition>010 - Disclosure - License and Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/StockholdersEquity" id="tffp_r_StockholdersEquity">
        <link:definition>011 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/Warrants" id="tffp_r_Warrants">
        <link:definition>012 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/StockBasedCompensation" id="tffp_r_StockBasedCompensation">
        <link:definition>013 - Disclosure - Stock Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/IncomeTaxes" id="tffp_r_IncomeTaxes">
        <link:definition>014 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/SubsequentEvents" id="tffp_r_SubsequentEvents">
        <link:definition>015 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/AccountingPoliciesByPolicy" id="tffp_r_AccountingPoliciesByPolicy">
        <link:definition>016 - Disclosure - Accounting Policies, by Policy (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables" id="tffp_r_SummaryofSignificantAccountingPoliciesTables">
        <link:definition>017 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/CommitmentsAndContingenciesTables" id="tffp_r_CommitmentsAndContingenciesTables">
        <link:definition>018 - Disclosure - Commitments And Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/WarrantsTables" id="tffp_r_WarrantsTables">
        <link:definition>019 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/StockBasedCompensationTables" id="tffp_r_StockBasedCompensationTables">
        <link:definition>020 - Disclosure - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/IncomeTaxesTables" id="tffp_r_IncomeTaxesTables">
        <link:definition>021 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/OrganizationAndDescriptionOfBusinessDetails" id="tffp_r_OrganizationAndDescriptionOfBusinessDetails">
        <link:definition>022 - Disclosure - Organization And Description Of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/LiquidityandManagementsPlansDetails" id="tffp_r_LiquidityandManagementsPlansDetails">
        <link:definition>023 - Disclosure - Liquidity and Management&#8217;s Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails" id="tffp_r_SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>024 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleofBasicandDilutedEarningsperCommonShareTable" id="tffp_r_ScheduleofBasicandDilutedEarningsperCommonShareTable">
        <link:definition>025 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Earnings per Common Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/CommitmentsAndContingenciesDetails" id="tffp_r_CommitmentsAndContingenciesDetails">
        <link:definition>026 - Disclosure - Commitments And Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable" id="tffp_r_ScheduleoffutureminimumleasepaymentsTable">
        <link:definition>027 - Disclosure - Commitments And Contingencies (Details) - Schedule of future minimum lease payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/LicenseandAgreementsDetails" id="tffp_r_LicenseandAgreementsDetails">
        <link:definition>028 - Disclosure - License and Agreements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/StockholdersEquityDetails" id="tffp_r_StockholdersEquityDetails">
        <link:definition>029 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/WarrantsDetails" id="tffp_r_WarrantsDetails">
        <link:definition>030 - Disclosure - Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleofwarrantactivityTable" id="tffp_r_ScheduleofwarrantactivityTable">
        <link:definition>031 - Disclosure - Warrants (Details) - Schedule of warrant activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/StockBasedCompensationDetails" id="tffp_r_StockBasedCompensationDetails">
        <link:definition>032 - Disclosure - Stock Based Compensation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable" id="tffp_r_ScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable">
        <link:definition>033 - Disclosure - Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and restricted stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZox5kKltS1j4H1Hm6x5rsVySu3GvyFidfKO4jLCc6vqlIAk2/hDR2bzzoxw5NX+h9OcfjdvrLHYAuwh2Zi7sQ0UOAQ0i8qn20R76xjgd36yBDZMSKJy6UF8YlRJlhDvltYdDBaXR3sWPsW9VT/9h3wyKkqYRK0lALx3+SAcoHi554Ul7Qas6aWvZyHzgVs3yUxQiUxznSb+4W06RUjjJQ1] CSR-->
      <link:roleType roleURI="http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable" id="tffp_r_ScheduleoffairvalueofemployeestockoptionsTable">
        <link:definition>034 - Disclosure - Stock Based Compensation (Details) - Schedule of fair value of employee stock options</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleofstockoptionactivityTable" id="tffp_r_ScheduleofstockoptionactivityTable">
        <link:definition>035 - Disclosure - Stock Based Compensation (Details) - Schedule of stock option activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/IncomeTaxesDetails" id="tffp_r_IncomeTaxesDetails">
        <link:definition>036 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleofincometaxexpenseTable" id="tffp_r_ScheduleofincometaxexpenseTable">
        <link:definition>037 - Disclosure - Income Taxes (Details) - Schedule of income tax expense</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleofdeferredtaxassetsTable" id="tffp_r_ScheduleofdeferredtaxassetsTable">
        <link:definition>038 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleofprovisionfederalstatutoryrateTable" id="tffp_r_ScheduleofprovisionfederalstatutoryrateTable">
        <link:definition>039 - Disclosure - Income Taxes (Details) - Schedule of provision federal statutory rate</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/ScheduleofunrecognizedtaxpositionsTable" id="tffp_r_ScheduleofunrecognizedtaxpositionsTable">
        <link:definition>040 - Disclosure - Income Taxes (Details) - Schedule of unrecognized tax positions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/SubsequentEventsDetails" id="tffp_r_SubsequentEventsDetails">
        <link:definition>041 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://tffp.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
        <link:definition>000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://fasb.org/srt-types/2020-01-31" schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/sic/2020-01-31" schemaLocation="https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd"/>
  <xs:element name="LiquidityAndManagementsPlansAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_LiquidityAndManagementsPlansAbstract"/>
  <xs:element name="ScheduleOfBasicAndDilutedEarningsPerCommonShareAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfBasicAndDilutedEarningsPerCommonShareAbstract"/>
  <xs:element name="ScheduleOfFutureMinimumLeasePaymentsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract"/>
  <xs:element name="LicenseAndAgreementsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_LicenseAndAgreementsDisclosureAbstract"/>
  <xs:element name="WarrantsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_WarrantsAbstract"/>
  <xs:element name="ScheduleOfWarrantActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfWarrantActivityAbstract"/>
  <xs:element name="ScheduleOfStockBasedCompensationExpenseStockOptionsAndRestrictedStockAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndRestrictedStockAbstract"/>
  <xs:element name="ScheduleOfFairValueOfEmployeeStockOptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract"/>
  <xs:element name="ScheduleOfStockOptionActivityAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfStockOptionActivityAbstract"/>
  <xs:element name="ScheduleOfIncomeTaxExpenseAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfIncomeTaxExpenseAbstract"/>
  <xs:element name="ScheduleOfDeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfDeferredTaxAssetsAbstract"/>
  <xs:element name="ScheduleOfProvisionFederalStatutoryRateAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfProvisionFederalStatutoryRateAbstract"/>
  <xs:element name="ScheduleOfUnrecognizedTaxPositionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfUnrecognizedTaxPositionsAbstract"/>
  <xs:element name="ConsolidatedStatementsOfComprehensiveLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ConsolidatedStatementsOfComprehensiveLossAbstract"/>
  <xs:element name="OtherComprehensiveLossAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_OtherComprehensiveLossAbstract"/>
  <xs:element name="AssumptionsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_AssumptionsAbstract"/>
  <xs:element name="DeferredTaxAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_DeferredTaxAssetsAbstract"/>
  <xs:element name="ForeignCurrencyTranslationAdjustments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ForeignCurrencyTranslationAdjustments"/>
  <xs:element name="IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount"/>
  <xs:element name="IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares"/>
  <xs:element name="IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense"/>
  <xs:element name="IssuanceOfCommonStockForStockOptionExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockForStockOptionExercises"/>
  <xs:element name="IssuanceOfCommonStockForStockOptionExercisesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockForStockOptionExercisesShares"/>
  <xs:element name="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises"/>
  <xs:element name="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares"/>
  <xs:element name="ForeignCurrencyTranslationAdjustment" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ForeignCurrencyTranslationAdjustment"/>
  <xs:element name="StockBasedCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_StockBasedCompensation"/>
  <xs:element name="IncreaseDecreaseDeferredResearchGrantRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_IncreaseDecreaseDeferredResearchGrantRevenue"/>
  <xs:element name="IncreaseDecreaseInAccruedResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense"/>
  <xs:element name="ProceedsFromIssuanceOfCommonStockValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ProceedsFromIssuanceOfCommonStockValue"/>
  <xs:element name="ProceedsFromIssuanceOfCommonStockForStockOptionExercises" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
  <xs:element name="EffectOfExchangeRateChangesOnCashAndCashEquivalent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent"/>
  <xs:element name="AccruedDividend" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_AccruedDividend"/>
  <xs:element name="ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock"/>
  <xs:element name="OfferingCostsNettedWithProceedsFromIPO" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_OfferingCostsNettedWithProceedsFromIPO"/>
  <xs:element name="DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock"/>
  <xs:element name="CashlessExerciseOfWarrants" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_CashlessExerciseOfWarrants"/>
  <xs:element name="ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock"/>
  <xs:element name="LiquidityAndManagementsPlansTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_LiquidityAndManagementsPlansTextBlock"/>
  <xs:element name="LicenseAndAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_LicenseAndAgreementsDisclosureTextBlock"/>
  <xs:element name="WarrantsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_WarrantsTextBlock"/>
  <xs:element name="GeographicConcentrationsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_GeographicConcentrationsPolicyTextBlock"/>
  <xs:element name="CommonStockWarrantsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_CommonStockWarrantsPolicyTextBlock"/>
  <xs:element name="BeneficialConversionFeaturePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_BeneficialConversionFeaturePolicyTextBlock"/>
  <xs:element name="ScheduleOfWarrantActivity" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfWarrantActivity"/>
  <xs:element name="ScheduleOfUnrecognizedTaxPositionsTableTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems"/>
  <xs:element name="WarrantsDetailsScheduleofwarrantactivityTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_WarrantsDetailsScheduleofwarrantactivityTable"/>
  <xs:element name="WarrantsDetailsScheduleofwarrantactivityLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems"/>
  <xs:element name="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable"/>
  <xs:element name="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
  <xs:element name="WeightedaverageRemainingContractualTermOutstandingBeginningBalance1" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1"/>
  <xs:element name="WeightedaverageRemainingContractualTermGranted" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_WeightedaverageRemainingContractualTermGranted"/>
  <xs:element name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
  <xs:element name="WeightedaverageRemainingContractualTermExercised" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_WeightedaverageRemainingContractualTermExercised"/>
  <xs:element name="WeightedaverageRemainingContractualTermCancelled" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_WeightedaverageRemainingContractualTermCancelled"/>
  <xs:element name="AggregateIntrinsicValueCancelled" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_AggregateIntrinsicValueCancelled"/>
  <xs:element name="AggregateIntrinsicValueExercisable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tffp_AggregateIntrinsicValueExercisable"/>
  <xs:element name="DeferredTaxAssetsStockCompensation" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_DeferredTaxAssetsStockCompensation"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars"/>
  <xs:element name="EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences"/>
  <xs:element name="IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable"/>
  <xs:element name="IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems"/>
  <xs:element name="UncertainTaxPositionsBegnningBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_UncertainTaxPositionsBegnningBalance"/>
  <xs:element name="AdditionsForTaxPositionsRelatedToCurrentYear" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_AdditionsForTaxPositionsRelatedToCurrentYear"/>
  <xs:element name="DecreasesForTaxPositionsRelatedToPriorYears" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_DecreasesForTaxPositionsRelatedToPriorYears"/>
  <xs:element name="UncertainTaxPositionsEndingBalance" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_UncertainTaxPositionsEndingBalance"/>
  <xs:element name="ExchangeOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tffp_ExchangeOfCommonStock"/>
  <xs:element name="OrganizationAndDescriptionsOfBusinessDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_OrganizationAndDescriptionsOfBusinessDescription"/>
  <xs:element name="ReceivedNetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ReceivedNetProceeds"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_SummaryofSignificantAccountingPoliciesDetailsTable"/>
  <xs:element name="SummaryofSignificantAccountingPoliciesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
  <xs:element name="MaintenanceOfPropertyAndEquipment" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_MaintenanceOfPropertyAndEquipment"/>
  <xs:element name="DeferredResearchGrantRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_DeferredResearchGrantRevenue"/>
  <xs:element name="ConversionPricePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ConversionPricePercentage"/>
  <xs:element name="ExpireDate" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ExpireDate"/>
  <xs:element name="LicenseandAgreementsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_LicenseandAgreementsDetailsTable"/>
  <xs:element name="LicenseandAgreementsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_LicenseandAgreementsDetailsLineItems"/>
  <xs:element name="MilestoneFee" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_MilestoneFee"/>
  <xs:element name="CommonShareOutstandingPricePercentage" type="num:percentItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tffp_CommonShareOutstandingPricePercentage"/>
  <xs:element name="AmountOfCommonShareDuePayable" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_AmountOfCommonShareDuePayable"/>
  <xs:element name="ClosingStockPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tffp_ClosingStockPrice"/>
  <xs:element name="DescriptionOfLicenseAndAgreements" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_DescriptionOfLicenseAndAgreements"/>
  <xs:element name="AgreementTremDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_AgreementTremDescription"/>
  <xs:element name="PremarketingApprovals" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_PremarketingApprovals"/>
  <xs:element name="StockholdersEquityDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_StockholdersEquityDetailsTable"/>
  <xs:element name="StockholdersEquityDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_StockholdersEquityDetailsLineItems"/>
  <xs:element name="StockholdersEquityDescription" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_StockholdersEquityDescription"/>
  <xs:element name="FairValueAssumptionExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tffp_FairValueAssumptionExercisePrice"/>
  <xs:element name="NetProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_NetProceeds"/>
  <xs:element name="IssuanceOfCommonStockForStockOptionExerciseShares" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockForStockOptionExerciseShares"/>
  <xs:element name="StockOptionExercisesTotalProceeds" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_StockOptionExercisesTotalProceeds"/>
  <xs:element name="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise"/>
  <xs:element name="IssuanceOfCommonStockWarrant" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockWarrant"/>
  <xs:element name="WarrantsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_WarrantsDetailsTable"/>
  <xs:element name="WarrantsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_WarrantsDetailsLineItems"/>
  <xs:element name="WarrantToPurchaseSharesOfCommonStock" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tffp_WarrantToPurchaseSharesOfCommonStock"/>
  <xs:element name="FairValueAssumptionsCommonStockValue" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_FairValueAssumptionsCommonStockValue"/>
  <xs:element name="FairValueAssumptionsExpectedTerms" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_FairValueAssumptionsExpectedTerms"/>
  <xs:element name="FairValueAssumptionsExpectedDividendRates" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_FairValueAssumptionsExpectedDividendRates"/>
  <xs:element name="FairValueAssumptionExpectedVolatilityRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_FairValueAssumptionExpectedVolatilityRate"/>
  <xs:element name="FairValueAssumptionRiskFreeInterestRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_FairValueAssumptionRiskFreeInterestRate"/>
  <xs:element name="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare" type="num:perShareItemType" abstract="false" xbrli:periodType="instant" nillable="true" substitutionGroup="xbrli:item" id="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare"/>
  <xs:element name="WarrantOutstandingAggregateIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_WarrantOutstandingAggregateIntrinsicValue"/>
  <xs:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm"/>
  <xs:element name="IncomeTaxesDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_IncomeTaxesDetailsTable"/>
  <xs:element name="IncomeTaxesDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_IncomeTaxesDetailsLineItems"/>
  <xs:element name="FederalIncomeTaxNetOperatingLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_FederalIncomeTaxNetOperatingLoss"/>
  <xs:element name="ForeignIncomeTaxNetOperatingLoss" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item" id="tffp_ForeignIncomeTaxNetOperatingLoss"/>
  <xs:element name="FederalTaxCreditExpire" type="xbrli:gYearItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_FederalTaxCreditExpire"/>
  <xs:element name="TaxableIncomeForLosses" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_TaxableIncomeForLosses"/>
  <xs:element name="UncertainTaxPositions" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item" id="tffp_UncertainTaxPositions"/>
  <xs:element name="SubsequentEventsDetailsTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem" id="tffp_SubsequentEventsDetailsTable"/>
  <xs:element name="SubsequentEventsDetailsLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_SubsequentEventsDetailsLineItems"/>
  <xs:element name="BPDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_BPDirectorsMember"/>
  <xs:element name="ConformClinicalDevelopmentIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_ConformClinicalDevelopmentIncMember"/>
  <xs:element name="CoreRxMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_CoreRxMember"/>
  <xs:element name="EffectiveTaxRateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_EffectiveTaxRateMember"/>
  <xs:element name="FederalAndStateMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_FederalAndStateMember"/>
  <xs:element name="IrisysLlcMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_IrisysLlcMember"/>
  <xs:element name="MasterServicesMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_MasterServicesMember"/>
  <xs:element name="NationalSecuritiesCorporationsWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_NationalSecuritiesCorporationsWarrantsMember"/>
  <xs:element name="NovotechAustraliaPtyLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_NovotechAustraliaPtyLtdMember"/>
  <xs:element name="NucleusNetworkPtyLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_NucleusNetworkPtyLtdMember"/>
  <xs:element name="QPharmPtyLtdMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_QPharmPtyLtdMember"/>
  <xs:element name="TenYearsWarrantMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_TenYearsWarrantMember"/>
  <xs:element name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item" id="tffp_DocumentAndEntityInformationAbstract"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>tffp-20201231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Mar 09 20:01:28 EST 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ConsolidatedBalanceSheet" roleURI="http://tffp.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ConsolidatedIncomeStatement" roleURI="http://tffp.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ConsolidatedCashFlow" roleURI="http://tffp.com/role/ConsolidatedCashFlow"/>
  <calculationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZox5kKltS1j4H1Hm6x5rsVySu3GvyFidfKO4jLCc6vqlIAk2/hDR2bzzoxw5NX+h9OcfjdvrLHYAuwh2Zi7sQ0UOAQ0i8qn20R76xjgd36yBDZMSKJy6UF8YlRJlhDvltYdDBaXR3sWPsW9VT/9h3wyKkqYRK0lALx3+SAcoHi554Ul7Qas6aWvZyHzgVs3yWg5s6TnRTdv09V+lGcrW0B] CSR-->
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestIncomeExpenseNet" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="2" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments" order="3" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_NetIncomeLoss" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="tffp_ForeignCurrencyTranslationAdjustments" xlink:href="tffp-20201231.xsd#tffp_ForeignCurrencyTranslationAdjustments"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="tffp_ForeignCurrencyTranslationAdjustments" order="2" weight="-1"/>
  </calculationLink>
  <calculationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensation" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensation"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tffp_StockBasedCompensation" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense" xlink:href="tffp-20201231.xsd#tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense" order="4" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="5" weight="-1"/>
    <loc xlink:type="locator" xlink:label="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" xlink:href="tffp-20201231.xsd#tffp_IncreaseDecreaseDeferredResearchGrantRevenue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" order="6" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="1" weight="1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="2" weight="1"/>
    <loc xlink:type="locator" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockValue" xlink:href="tffp-20201231.xsd#tffp_ProceedsFromIssuanceOfCommonStockValue"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockValue" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20201231.xsd#tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" order="4" weight="-1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="2" weight="1"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="3" weight="1"/>
    <loc xlink:type="locator" xlink:label="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" xlink:href="tffp-20201231.xsd#tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent"/>
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" order="4" weight="1"/>
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>tffp-20201231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Mar 09 20:01:28 EST 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ConsolidatedBalanceSheet" roleURI="http://tffp.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ConsolidatedIncomeStatement" roleURI="http://tffp.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ShareholdersEquityType2or3" roleURI="http://tffp.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ConsolidatedCashFlow" roleURI="http://tffp.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_OrganizationAndDescriptionOfBusiness" roleURI="http://tffp.com/role/OrganizationAndDescriptionOfBusiness"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_LiquidityandManagementsPlans" roleURI="http://tffp.com/role/LiquidityandManagementsPlans"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_SummaryofSignificantAccountingPolicies" roleURI="http://tffp.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_CommitmentsAndContingencies" roleURI="http://tffp.com/role/CommitmentsAndContingencies"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_LicenseandAgreements" roleURI="http://tffp.com/role/LicenseandAgreements"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_StockholdersEquity" roleURI="http://tffp.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_Warrants" roleURI="http://tffp.com/role/Warrants"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_StockBasedCompensation" roleURI="http://tffp.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_IncomeTaxes" roleURI="http://tffp.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_SubsequentEvents" roleURI="http://tffp.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_AccountingPoliciesByPolicy" roleURI="http://tffp.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_CommitmentsAndContingenciesTables" roleURI="http://tffp.com/role/CommitmentsAndContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_WarrantsTables" roleURI="http://tffp.com/role/WarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_StockBasedCompensationTables" roleURI="http://tffp.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_IncomeTaxesTables" roleURI="http://tffp.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofBasicandDilutedEarningsperCommonShareTable" roleURI="http://tffp.com/role/ScheduleofBasicandDilutedEarningsperCommonShareTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleoffutureminimumleasepaymentsTable" roleURI="http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofwarrantactivityTable" roleURI="http://tffp.com/role/ScheduleofwarrantactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable" roleURI="http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleoffairvalueofemployeestockoptionsTable" roleURI="http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofstockoptionactivityTable" roleURI="http://tffp.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofincometaxexpenseTable" roleURI="http://tffp.com/role/ScheduleofincometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofdeferredtaxassetsTable" roleURI="http://tffp.com/role/ScheduleofdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofprovisionfederalstatutoryrateTable" roleURI="http://tffp.com/role/ScheduleofprovisionfederalstatutoryrateTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofunrecognizedtaxpositionsTable" roleURI="http://tffp.com/role/ScheduleofunrecognizedtaxpositionsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_OrganizationAndDescriptionOfBusinessDetails" roleURI="http://tffp.com/role/OrganizationAndDescriptionOfBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_LiquidityandManagementsPlansDetails" roleURI="http://tffp.com/role/LiquidityandManagementsPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_CommitmentsAndContingenciesDetails" roleURI="http://tffp.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_LicenseandAgreementsDetails" roleURI="http://tffp.com/role/LicenseandAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_StockholdersEquityDetails" roleURI="http://tffp.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_WarrantsDetails" roleURI="http://tffp.com/role/WarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_StockBasedCompensationDetails" roleURI="http://tffp.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_IncomeTaxesDetails" roleURI="http://tffp.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_SubsequentEventsDetails" roleURI="http://tffp.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#DocumentAndEntityInformation" roleURI="http://tffp.com/role/DocumentAndEntityInformation"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member"/>
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all"/>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_AssetsCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_Liabilities" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ForeignCurrencyTranslationAdjustments" xlink:href="tffp-20201231.xsd#tffp_ForeignCurrencyTranslationAdjustments"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="tffp_ForeignCurrencyTranslationAdjustments" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockForStockOptionExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExercises" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercisesShares" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockForStockOptionExercisesShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExercisesShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ForeignCurrencyTranslationAdjustment" xlink:href="tffp-20201231.xsd#tffp_ForeignCurrencyTranslationAdjustment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="tffp_ForeignCurrencyTranslationAdjustment" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStockStock" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="18" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensation" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="tffp_StockBasedCompensation" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" xlink:href="tffp-20201231.xsd#tffp_IncreaseDecreaseDeferredResearchGrantRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense" xlink:href="tffp-20201231.xsd#tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockValue" xlink:href="tffp-20201231.xsd#tffp_ProceedsFromIssuanceOfCommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20201231.xsd#tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" xlink:href="tffp-20201231.xsd#tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AccruedDividend" xlink:href="tffp-20201231.xsd#tffp_AccruedDividend"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tffp_AccruedDividend" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock" xlink:href="tffp-20201231.xsd#tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_OfferingCostsNettedWithProceedsFromIPO" xlink:href="tffp-20201231.xsd#tffp_OfferingCostsNettedWithProceedsFromIPO"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tffp_OfferingCostsNettedWithProceedsFromIPO" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock" xlink:href="tffp-20201231.xsd#tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_CashlessExerciseOfWarrants" xlink:href="tffp-20201231.xsd#tffp_CashlessExerciseOfWarrants"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tffp_CashlessExerciseOfWarrants" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:href="tffp-20201231.xsd#tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/OrganizationAndDescriptionOfBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/LiquidityandManagementsPlans">
    <loc xlink:type="locator" xlink:label="tffp_LiquidityAndManagementsPlansAbstract" xlink:href="tffp-20201231.xsd#tffp_LiquidityAndManagementsPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="tffp_LiquidityAndManagementsPlansTextBlock" xlink:href="tffp-20201231.xsd#tffp_LiquidityAndManagementsPlansTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LiquidityAndManagementsPlansAbstract" xlink:to="tffp_LiquidityAndManagementsPlansTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/CommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/LicenseandAgreements">
    <loc xlink:type="locator" xlink:label="tffp_LicenseAndAgreementsDisclosureAbstract" xlink:href="tffp-20201231.xsd#tffp_LicenseAndAgreementsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="tffp_LicenseAndAgreementsDisclosureTextBlock" xlink:href="tffp-20201231.xsd#tffp_LicenseAndAgreementsDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseAndAgreementsDisclosureAbstract" xlink:to="tffp_LicenseAndAgreementsDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/Warrants">
    <loc xlink:type="locator" xlink:label="tffp_WarrantsAbstract" xlink:href="tffp-20201231.xsd#tffp_WarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="tffp_WarrantsTextBlock" xlink:href="tffp-20201231.xsd#tffp_WarrantsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsAbstract" xlink:to="tffp_WarrantsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyDisclosureTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_GeographicConcentrationsPolicyTextBlock" xlink:href="tffp-20201231.xsd#tffp_GeographicConcentrationsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tffp_GeographicConcentrationsPolicyTextBlock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_CommonStockWarrantsPolicyTextBlock" xlink:href="tffp-20201231.xsd#tffp_CommonStockWarrantsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tffp_CommonStockWarrantsPolicyTextBlock" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_BeneficialConversionFeaturePolicyTextBlock" xlink:href="tffp-20201231.xsd#tffp_BeneficialConversionFeaturePolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tffp_BeneficialConversionFeaturePolicyTextBlock" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/CommitmentsAndContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/WarrantsTables">
    <loc xlink:type="locator" xlink:label="tffp_WarrantsAbstract" xlink:href="tffp-20201231.xsd#tffp_WarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfWarrantActivity" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfWarrantActivity"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsAbstract" xlink:to="tffp_ScheduleOfWarrantActivity" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxNoteTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalIncomeTaxNoteTextBlock" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock" order="3" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofBasicandDilutedEarningsperCommonShareTable">
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems" xlink:href="tffp-20201231.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable" xlink:href="tffp-20201231.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems" xlink:to="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_StockOptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_WarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable">
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofwarrantactivityTable">
    <loc xlink:type="locator" xlink:label="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:href="tffp-20201231.xsd#tffp_WarrantsDetailsScheduleofwarrantactivityLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_WarrantsDetailsScheduleofwarrantactivityTable" xlink:href="tffp-20201231.xsd#tffp_WarrantsDetailsScheduleofwarrantactivityTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="tffp_WarrantsDetailsScheduleofwarrantactivityTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="tffp-20201231.xsd#tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" order="14" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable">
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems" xlink:to="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable">
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:to="srt_RangeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZox5kKltS1j4H1Hm6x5rsVySu3GvyFidfKO4jLCc6vqlIAk2/hDR2bzzoxw5NX+h9OcfjdvrLHYAuwh2Zi7sQ0UOAQ0i8qn20R76xjgd36yBDZMSKJy6UF8YlRJlhDvltYdDBaXR3sWPsW9VT/9h3wyKkqYRK0lALx3+SAcoHi554Ul7Qas6aWvZyHzgVs3yUoVkIJABJ0cc4mXvtM7Gyh] CSR-->
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="6" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfStockOptionActivityAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1" xlink:href="tffp-20201231.xsd#tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_WeightedaverageRemainingContractualTermGranted" xlink:href="tffp-20201231.xsd#tffp_WeightedaverageRemainingContractualTermGranted"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_WeightedaverageRemainingContractualTermGranted" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_WeightedaverageRemainingContractualTermExercised" xlink:href="tffp-20201231.xsd#tffp_WeightedaverageRemainingContractualTermExercised"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_WeightedaverageRemainingContractualTermExercised" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_WeightedaverageRemainingContractualTermCancelled" xlink:href="tffp-20201231.xsd#tffp_WeightedaverageRemainingContractualTermCancelled"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_WeightedaverageRemainingContractualTermCancelled" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AggregateIntrinsicValueCancelled" xlink:href="tffp-20201231.xsd#tffp_AggregateIntrinsicValueCancelled"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_AggregateIntrinsicValueCancelled" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:href="tffp-20201231.xsd#tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AggregateIntrinsicValueExercisable" xlink:href="tffp-20201231.xsd#tffp_AggregateIntrinsicValueExercisable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_AggregateIntrinsicValueExercisable" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofincometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfIncomeTaxExpenseAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfIncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfIncomeTaxExpenseAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfIncomeTaxExpenseAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfIncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfIncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfDeferredTaxAssetsAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="tffp_DeferredTaxAssetsAbstract" xlink:href="tffp-20201231.xsd#tffp_DeferredTaxAssetsAbstract"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="tffp_DeferredTaxAssetsAbstract" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_DeferredTaxAssetsAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_DeferredTaxAssetsStockCompensation" xlink:href="tffp-20201231.xsd#tffp_DeferredTaxAssetsStockCompensation"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_DeferredTaxAssetsAbstract" xlink:to="tffp_DeferredTaxAssetsStockCompensation" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_DeferredTaxAssetsStockCompensation" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofprovisionfederalstatutoryrateTable">
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfProvisionFederalStatutoryRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars" xlink:href="tffp-20201231.xsd#tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:to="tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences" xlink:href="tffp-20201231.xsd#tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:to="tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="0" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofunrecognizedtaxpositionsTable">
    <loc xlink:type="locator" xlink:label="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" xlink:href="tffp-20201231.xsd#tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable" xlink:href="tffp-20201231.xsd#tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" xlink:to="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_FederalAndStateMember" xlink:href="tffp-20201231.xsd#tffp_FederalAndStateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="tffp_FederalAndStateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_UncertainTaxPositionsBegnningBalance" xlink:href="tffp-20201231.xsd#tffp_UncertainTaxPositionsBegnningBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" xlink:to="tffp_UncertainTaxPositionsBegnningBalance" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AdditionsForTaxPositionsRelatedToCurrentYear" xlink:href="tffp-20201231.xsd#tffp_AdditionsForTaxPositionsRelatedToCurrentYear"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" xlink:to="tffp_AdditionsForTaxPositionsRelatedToCurrentYear" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_DecreasesForTaxPositionsRelatedToPriorYears" xlink:href="tffp-20201231.xsd#tffp_DecreasesForTaxPositionsRelatedToPriorYears"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" xlink:to="tffp_DecreasesForTaxPositionsRelatedToPriorYears" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_UncertainTaxPositionsEndingBalance" xlink:href="tffp-20201231.xsd#tffp_UncertainTaxPositionsEndingBalance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" xlink:to="tffp_UncertainTaxPositionsEndingBalance" order="4" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/OrganizationAndDescriptionOfBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="tffp_ExchangeOfCommonStock" xlink:href="tffp-20201231.xsd#tffp_ExchangeOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tffp_ExchangeOfCommonStock" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SharePrice" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_OrganizationAndDescriptionsOfBusinessDescription" xlink:href="tffp-20201231.xsd#tffp_OrganizationAndDescriptionsOfBusinessDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tffp_OrganizationAndDescriptionsOfBusinessDescription" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ReceivedNetProceeds" xlink:href="tffp-20201231.xsd#tffp_ReceivedNetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="tffp_ReceivedNetProceeds" order="5" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/LiquidityandManagementsPlansDetails">
    <loc xlink:type="locator" xlink:label="tffp_LiquidityAndManagementsPlansAbstract" xlink:href="tffp-20201231.xsd#tffp_LiquidityAndManagementsPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreconfirmationCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreconfirmationCashAndCashEquivalents"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LiquidityAndManagementsPlansAbstract" xlink:to="us-gaap_PreconfirmationCashAndCashEquivalents" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SurplusNotes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SurplusNotes"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LiquidityAndManagementsPlansAbstract" xlink:to="us-gaap_SurplusNotes" order="1" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="tffp-20201231.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tffp_SummaryofSignificantAccountingPoliciesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_MaintenanceOfPropertyAndEquipment" xlink:href="tffp-20201231.xsd#tffp_MaintenanceOfPropertyAndEquipment"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tffp_MaintenanceOfPropertyAndEquipment" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_Cash" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_DeferredResearchGrantRevenue" xlink:href="tffp-20201231.xsd#tffp_DeferredResearchGrantRevenue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tffp_DeferredResearchGrantRevenue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ConversionPricePercentage" xlink:href="tffp-20201231.xsd#tffp_ConversionPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tffp_ConversionPricePercentage" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="10" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="tffp_ExpireDate" xlink:href="tffp-20201231.xsd#tffp_ExpireDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="tffp_ExpireDate" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseAndRentalExpense" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/LicenseandAgreementsDetails">
    <loc xlink:type="locator" xlink:label="tffp_LicenseandAgreementsDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_LicenseandAgreementsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_LicenseandAgreementsDetailsTable" xlink:href="tffp-20201231.xsd#tffp_LicenseandAgreementsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_LicenseandAgreementsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_LicenseandAgreementsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain_0" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_MasterServicesMember" xlink:href="tffp-20201231.xsd#tffp_MasterServicesMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tffp_MasterServicesMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IrisysLlcMember" xlink:href="tffp-20201231.xsd#tffp_IrisysLlcMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tffp_IrisysLlcMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_CoreRxMember" xlink:href="tffp-20201231.xsd#tffp_CoreRxMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tffp_CoreRxMember" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ConformClinicalDevelopmentIncMember" xlink:href="tffp-20201231.xsd#tffp_ConformClinicalDevelopmentIncMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tffp_ConformClinicalDevelopmentIncMember" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_NovotechAustraliaPtyLtdMember" xlink:href="tffp-20201231.xsd#tffp_NovotechAustraliaPtyLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tffp_NovotechAustraliaPtyLtdMember" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_NucleusNetworkPtyLtdMember" xlink:href="tffp-20201231.xsd#tffp_NucleusNetworkPtyLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tffp_NucleusNetworkPtyLtdMember" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_QPharmPtyLtdMember" xlink:href="tffp-20201231.xsd#tffp_QPharmPtyLtdMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="tffp_QPharmPtyLtdMember" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_MilestoneFee" xlink:href="tffp-20201231.xsd#tffp_MilestoneFee"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_MilestoneFee" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_CommonShareOutstandingPricePercentage" xlink:href="tffp-20201231.xsd#tffp_CommonShareOutstandingPricePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_CommonShareOutstandingPricePercentage" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AmountOfCommonShareDuePayable" xlink:href="tffp-20201231.xsd#tffp_AmountOfCommonShareDuePayable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_AmountOfCommonShareDuePayable" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionReasonsForElection" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOptionReasonsForElection"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_FairValueOptionReasonsForElection" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ClosingStockPrice" xlink:href="tffp-20201231.xsd#tffp_ClosingStockPrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_ClosingStockPrice" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_DescriptionOfLicenseAndAgreements" xlink:href="tffp-20201231.xsd#tffp_DescriptionOfLicenseAndAgreements"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_DescriptionOfLicenseAndAgreements" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_AgreementTremDescription" xlink:href="tffp-20201231.xsd#tffp_AgreementTremDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_AgreementTremDescription" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_PremarketingApprovals" xlink:href="tffp-20201231.xsd#tffp_PremarketingApprovals"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_PremarketingApprovals" order="11" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="tffp_StockholdersEquityDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_StockholdersEquityDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_StockholdersEquityDetailsTable" xlink:href="tffp-20201231.xsd#tffp_StockholdersEquityDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="tffp_StockholdersEquityDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_StockholdersEquityDescription" xlink:href="tffp-20201231.xsd#tffp_StockholdersEquityDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="tffp_StockholdersEquityDescription" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_FairValueAssumptionExercisePrice" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionExercisePrice"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="tffp_FairValueAssumptionExercisePrice" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_NetProceeds" xlink:href="tffp-20201231.xsd#tffp_NetProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="tffp_NetProceeds" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExerciseShares" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockForStockOptionExerciseShares"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExerciseShares" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_StockOptionExercisesTotalProceeds" xlink:href="tffp-20201231.xsd#tffp_StockOptionExercisesTotalProceeds"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="tffp_StockOptionExercisesTotalProceeds" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockWarrant" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockWarrant"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="tffp_IssuanceOfCommonStockWarrant" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DividendsPayableCurrent" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConversionOfStockDescription" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="19" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/WarrantsDetails">
    <loc xlink:type="locator" xlink:label="tffp_WarrantsDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_WarrantsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_WarrantsDetailsTable" xlink:href="tffp-20201231.xsd#tffp_WarrantsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="tffp_WarrantsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_WarrantsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_WarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_WarrantsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesAPreferredStockMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_BPDirectorsMember" xlink:href="tffp-20201231.xsd#tffp_BPDirectorsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="tffp_BPDirectorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_NationalSecuritiesCorporationsWarrantsMember" xlink:href="tffp-20201231.xsd#tffp_NationalSecuritiesCorporationsWarrantsMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tffp_NationalSecuritiesCorporationsWarrantsMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_TenYearsWarrantMember" xlink:href="tffp-20201231.xsd#tffp_TenYearsWarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="tffp_TenYearsWarrantMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" xbrldt:closed="true"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="tffp_BPDirectorsMember" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_WarrantToPurchaseSharesOfCommonStock" xlink:href="tffp-20201231.xsd#tffp_WarrantToPurchaseSharesOfCommonStock"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="tffp_WarrantToPurchaseSharesOfCommonStock" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_FairValueAssumptionsCommonStockValue" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionsCommonStockValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="tffp_FairValueAssumptionsCommonStockValue" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_FairValueAssumptionsExpectedTerms" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionsExpectedTerms"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="tffp_FairValueAssumptionsExpectedTerms" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_FairValueAssumptionsExpectedDividendRates" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionsExpectedDividendRates"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="tffp_FairValueAssumptionsExpectedDividendRates" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_FairValueAssumptionExpectedVolatilityRate" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionExpectedVolatilityRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="tffp_FairValueAssumptionExpectedVolatilityRate" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_FairValueAssumptionRiskFreeInterestRate" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionRiskFreeInterestRate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="tffp_FairValueAssumptionRiskFreeInterestRate" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_WarrantOutstandingAggregateIntrinsicValue" xlink:href="tffp-20201231.xsd#tffp_WarrantOutstandingAggregateIntrinsicValue"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="tffp_WarrantOutstandingAggregateIntrinsicValue" order="12" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementsOverallDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementsOverallDescription"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DeferredCompensationArrangementsOverallDescription" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="tffp_IncomeTaxesDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_IncomeTaxesDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_IncomeTaxesDetailsTable" xlink:href="tffp-20201231.xsd#tffp_IncomeTaxesDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_IncomeTaxesDetailsLineItems" xlink:to="tffp_IncomeTaxesDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_EffectiveTaxRateMember" xlink:href="tffp-20201231.xsd#tffp_EffectiveTaxRateMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="tffp_EffectiveTaxRateMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_FederalIncomeTaxNetOperatingLoss" xlink:href="tffp-20201231.xsd#tffp_FederalIncomeTaxNetOperatingLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_IncomeTaxesDetailsLineItems" xlink:to="tffp_FederalIncomeTaxNetOperatingLoss" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_ForeignIncomeTaxNetOperatingLoss" xlink:href="tffp-20201231.xsd#tffp_ForeignIncomeTaxNetOperatingLoss"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_IncomeTaxesDetailsLineItems" xlink:to="tffp_ForeignIncomeTaxNetOperatingLoss" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_FederalTaxCreditExpire" xlink:href="tffp-20201231.xsd#tffp_FederalTaxCreditExpire"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_IncomeTaxesDetailsLineItems" xlink:to="tffp_FederalTaxCreditExpire" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_TaxableIncomeForLosses" xlink:href="tffp-20201231.xsd#tffp_TaxableIncomeForLosses"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_IncomeTaxesDetailsLineItems" xlink:to="tffp_TaxableIncomeForLosses" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="tffp_UncertainTaxPositions" xlink:href="tffp-20201231.xsd#tffp_UncertainTaxPositions"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_IncomeTaxesDetailsLineItems" xlink:to="tffp_UncertainTaxPositions" order="7" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="tffp_SubsequentEventsDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_SubsequentEventsDetailsLineItems"/>
    <loc xlink:type="locator" xlink:label="tffp_SubsequentEventsDetailsTable" xlink:href="tffp-20201231.xsd#tffp_SubsequentEventsDetailsTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="tffp_SubsequentEventsDetailsLineItems" xlink:to="tffp_SubsequentEventsDetailsTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="tffp_SubsequentEventsDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_OptionMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="tffp_SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="2" xbrldt:closed="true"/>
  </definitionLink>
  <definitionLink xlink:type="extended" xlink:role="http://tffp.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" order="0" xbrldt:contextElement="segment" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="1" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="2" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="3" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="4" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="5" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="6" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="7" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="8" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="9" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="10" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="11" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="12" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="13" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="14" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="15" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="16" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="17" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="18" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="19" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="20" xbrldt:closed="true"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="21" xbrldt:closed="true"/>
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>tffp-20201231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Mar 09 20:01:28 EST 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/>
  <labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl0" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl1" xml:lang="en-US">Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl0" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss applicable to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl" xml:lang="en-US">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders&apos; Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl0" xml:lang="en-US">Balance (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents at beginning of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0" xml:lang="en-US">Cash and cash equivalents at end of year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl1"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LiquidityAndManagementsPlansAbstract" xlink:href="tffp-20201231.xsd#tffp_LiquidityAndManagementsPlansAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LiquidityAndManagementsPlansAbstract_lbl" xml:lang="en-US">Liquidity And Managements Plans [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LiquidityAndManagementsPlansAbstract" xlink:to="tffp_LiquidityAndManagementsPlansAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfBasicAndDilutedEarningsPerCommonShareAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfBasicAndDilutedEarningsPerCommonShareAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfBasicAndDilutedEarningsPerCommonShareAbstract_lbl" xml:lang="en-US">Schedule of Basic and Diluted Earnings per Common Share [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfBasicAndDilutedEarningsPerCommonShareAbstract" xlink:to="tffp_ScheduleOfBasicAndDilutedEarningsPerCommonShareAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract_lbl" xml:lang="en-US">Schedule of future minimum lease payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract" xlink:to="tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LicenseAndAgreementsDisclosureAbstract" xlink:href="tffp-20201231.xsd#tffp_LicenseAndAgreementsDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LicenseAndAgreementsDisclosureAbstract_lbl" xml:lang="en-US">License And Agreements Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LicenseAndAgreementsDisclosureAbstract" xlink:to="tffp_LicenseAndAgreementsDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US">Stockholders&apos; Equity Note [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WarrantsAbstract" xlink:href="tffp-20201231.xsd#tffp_WarrantsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WarrantsAbstract_lbl" xml:lang="en-US">Warrants [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WarrantsAbstract" xlink:to="tffp_WarrantsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfWarrantActivityAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfWarrantActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfWarrantActivityAbstract_lbl" xml:lang="en-US">Schedule of warrant activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfWarrantActivityAbstract" xlink:to="tffp_ScheduleOfWarrantActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Outstanding, beginning (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0" xml:lang="en-US">Number of Shares, Outstanding, ending (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice_lbl" xml:lang="en-US">Range of Exercise Prices, Outstanding, beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice_lbl0" xml:lang="en-US">Range of Exercise Prices, Outstanding, ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, Outstanding, beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-Average Exercise Prices, Outstanding, ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndRestrictedStockAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndRestrictedStockAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndRestrictedStockAbstract_lbl" xml:lang="en-US">Schedule of stock-based compensation expense stock options and restricted stock [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndRestrictedStockAbstract" xlink:to="tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndRestrictedStockAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract_lbl" xml:lang="en-US">Schedule of fair value of employee stock options [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract" xlink:to="tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfStockOptionActivityAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfStockOptionActivityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfStockOptionActivityAbstract_lbl" xml:lang="en-US">Schedule of stock option activity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfStockOptionActivityAbstract" xlink:to="tffp_ScheduleOfStockOptionActivityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl" xml:lang="en-US">Number of Shares, Outstanding, beginning balance shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl0" xml:lang="en-US">Number of Shares, Outstanding, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl0"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, Outstanding, beginning balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Weighted-Average Exercise Prices, Outstanding, Outstanding ending balance (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding beginning balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding ending balance (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfIncomeTaxExpenseAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfIncomeTaxExpenseAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfIncomeTaxExpenseAbstract_lbl" xml:lang="en-US">Schedule of income tax expense [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfIncomeTaxExpenseAbstract" xlink:to="tffp_ScheduleOfIncomeTaxExpenseAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfDeferredTaxAssetsAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfDeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfDeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Schedule of deferred tax assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfDeferredTaxAssetsAbstract" xlink:to="tffp_ScheduleOfDeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfProvisionFederalStatutoryRateAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfProvisionFederalStatutoryRateAbstract_lbl" xml:lang="en-US">Schedule of provision federal statutory rate [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:to="tffp_ScheduleOfProvisionFederalStatutoryRateAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfUnrecognizedTaxPositionsAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfUnrecognizedTaxPositionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfUnrecognizedTaxPositionsAbstract_lbl" xml:lang="en-US">Schedule of unrecognized tax positions [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfUnrecognizedTaxPositionsAbstract" xlink:to="tffp_ScheduleOfUnrecognizedTaxPositionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_UncertainTaxPositionsBegnningBalance" xlink:href="tffp-20201231.xsd#tffp_UncertainTaxPositionsBegnningBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="tffp_UncertainTaxPositionsBegnningBalance_lbl" xml:lang="en-US">Balance at December 31, 2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_UncertainTaxPositionsBegnningBalance" xlink:to="tffp_UncertainTaxPositionsBegnningBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_UncertainTaxPositionsEndingBalance" xlink:href="tffp-20201231.xsd#tffp_UncertainTaxPositionsEndingBalance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="tffp_UncertainTaxPositionsEndingBalance_lbl" xml:lang="en-US">Balance at December 31, 2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_UncertainTaxPositionsEndingBalance" xlink:to="tffp_UncertainTaxPositionsEndingBalance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid assets and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US">Deferred research grant revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl" xml:lang="en-US">Accrued research and development expense (see Note 5)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (see Note 4)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock; $0.001 par value, 45,000,000 shares authorized; 22,534,874 and 18,450,992 shares issued and outstanding as of December 31, 2020 and 2019, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl0" xml:lang="en-US">Common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherIncomeAbstract_lbl" xml:lang="en-US">Other income:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl" xml:lang="en-US">Interest income</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss applicable to common stock per share, basic and diluted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average common shares outstanding, basic and diluted (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ConsolidatedStatementsOfComprehensiveLossAbstract" xlink:href="tffp-20201231.xsd#tffp_ConsolidatedStatementsOfComprehensiveLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ConsolidatedStatementsOfComprehensiveLossAbstract_lbl" xml:lang="en-US">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConsolidatedStatementsOfComprehensiveLossAbstract" xlink:to="tffp_ConsolidatedStatementsOfComprehensiveLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_OtherComprehensiveLossAbstract" xlink:href="tffp-20201231.xsd#tffp_OtherComprehensiveLossAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_OtherComprehensiveLossAbstract_lbl" xml:lang="en-US">Other comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_OtherComprehensiveLossAbstract" xlink:to="tffp_OtherComprehensiveLossAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount_lbl" xml:lang="en-US">Issuance of common stock in connection with IPO, including underwriter&#8217;s over- allotment, net of offering costs and underwriter&#8217;s discount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares_lbl" xml:lang="en-US">Issuance of common stock in connection with IPO, including underwriter&#8217;s over- allotment, net of offering costs and underwriter&#8217;s discount (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl0" xml:lang="en-US">Stock based compensation expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Series A Preferred Stock (including accrued dividends) to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl" xml:lang="en-US">Conversion of Series A Preferred Stock (including accrued dividends) to common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Sale of common stock, net of offering costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Sale of common stock, net of offering costs (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl" xml:lang="en-US">Issuance of common stock for accrued research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Issuance of common stock for accrued research and development expense (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense" xlink:to="tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockForStockOptionExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercises_lbl" xml:lang="en-US">Issuance of common stock for stock option exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockForStockOptionExercises" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercisesShares" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockForStockOptionExercisesShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercisesShares_lbl" xml:lang="en-US">Issuance of common stock for stock option exercises (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockForStockOptionExercisesShares" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExercisesShares_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises_lbl" xml:lang="en-US">Issuance of common stock in connection with cashless warrant exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares_lbl" xml:lang="en-US">Issuance of common stock in connection with cashless warrant exercises (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ForeignCurrencyTranslationAdjustment" xlink:href="tffp-20201231.xsd#tffp_ForeignCurrencyTranslationAdjustment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ForeignCurrencyTranslationAdjustment_lbl" xml:lang="en-US">Foreign currency translation adjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignCurrencyTranslationAdjustment" xlink:to="tffp_ForeignCurrencyTranslationAdjustment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustment to reconcile net loss to net cash used in operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensation" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_StockBasedCompensation_lbl" xml:lang="en-US">Stock based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensation" xlink:to="tffp_StockBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense" xlink:href="tffp-20201231.xsd#tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Accrued research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense" xlink:to="tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from issuance of common stock in connection with IPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US">Net proceeds from issuance of preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockValue" xlink:href="tffp-20201231.xsd#tffp_ProceedsFromIssuanceOfCommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockValue_lbl" xml:lang="en-US">Net proceeds from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ProceedsFromIssuanceOfCommonStockValue" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" xlink:href="tffp-20201231.xsd#tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent_lbl" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" xlink:to="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AccruedDividend" xlink:href="tffp-20201231.xsd#tffp_AccruedDividend"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_AccruedDividend_lbl" xml:lang="en-US">Accrued dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AccruedDividend" xlink:to="tffp_AccruedDividend_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock" xlink:href="tffp-20201231.xsd#tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock_lbl" xml:lang="en-US">Conversion of Series A Preferred Stock (including accrued dividends) to common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock" xlink:to="tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_OfferingCostsNettedWithProceedsFromIPO" xlink:href="tffp-20201231.xsd#tffp_OfferingCostsNettedWithProceedsFromIPO"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_OfferingCostsNettedWithProceedsFromIPO_lbl" xml:lang="en-US">Offering costs netted with proceeds from IPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_OfferingCostsNettedWithProceedsFromIPO" xlink:to="tffp_OfferingCostsNettedWithProceedsFromIPO_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock" xlink:href="tffp-20201231.xsd#tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock_lbl" xml:lang="en-US">Deemed dividend for beneficial conversion feature of Series A Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock" xlink:to="tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_CashlessExerciseOfWarrants" xlink:href="tffp-20201231.xsd#tffp_CashlessExerciseOfWarrants"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_CashlessExerciseOfWarrants_lbl" xml:lang="en-US">Cashless exercise of warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CashlessExerciseOfWarrants" xlink:to="tffp_CashlessExerciseOfWarrants_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:href="tffp-20201231.xsd#tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock_lbl" xml:lang="en-US">Issuance of common stock for accrued research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:to="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl" xml:lang="en-US">Preferred stock dividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl" xml:lang="en-US">Deemed dividend for beneficial conversion feature of Series A Preferred Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ForeignCurrencyTranslationAdjustments" xlink:href="tffp-20201231.xsd#tffp_ForeignCurrencyTranslationAdjustments"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tffp_ForeignCurrencyTranslationAdjustments_lbl" xml:lang="en-US">Foreign currency translation adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignCurrencyTranslationAdjustments" xlink:to="tffp_ForeignCurrencyTranslationAdjustments_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DividendsPreferredStockStock_lbl" xml:lang="en-US">Dividends on preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Prepaid assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" xlink:href="tffp-20201231.xsd#tffp_IncreaseDecreaseDeferredResearchGrantRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tffp_IncreaseDecreaseDeferredResearchGrantRevenue_lbl" xml:lang="en-US">Deferred research grant revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" xlink:to="tffp_IncreaseDecreaseDeferredResearchGrantRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20201231.xsd#tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_lbl" xml:lang="en-US">Proceeds from issuance of common stock for stock option exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">ORGANIZATION AND DESCRIPTION OF BUSINESS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LiquidityAndManagementsPlansTextBlock" xlink:href="tffp-20201231.xsd#tffp_LiquidityAndManagementsPlansTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_LiquidityAndManagementsPlansTextBlock_lbl" xml:lang="en-US">LIQUIDITY AND MANAGEMENT&#8217;S PLANS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LiquidityAndManagementsPlansTextBlock" xlink:to="tffp_LiquidityAndManagementsPlansTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Basic and Diluted Earnings per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potential common stock equivalents outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of future minimum lease payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LicenseAndAgreementsDisclosureTextBlock" xlink:href="tffp-20201231.xsd#tffp_LicenseAndAgreementsDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_LicenseAndAgreementsDisclosureTextBlock_lbl" xml:lang="en-US">LICENSE AND AGREEMENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LicenseAndAgreementsDisclosureTextBlock" xlink:to="tffp_LicenseAndAgreementsDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">STOCKHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WarrantsTextBlock" xlink:href="tffp-20201231.xsd#tffp_WarrantsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_WarrantsTextBlock_lbl" xml:lang="en-US">WARRANTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WarrantsTextBlock" xlink:to="tffp_WarrantsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfWarrantActivity" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfWarrantActivity"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ScheduleOfWarrantActivity_lbl" xml:lang="en-US">Schedule of warrant activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfWarrantActivity" xlink:to="tffp_ScheduleOfWarrantActivity_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted-Average Remaining Life, Outstanding, beginning</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross_lbl" xml:lang="en-US">Number of Shares, Issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice_lbl" xml:lang="en-US">Range of Exercise Prices, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross_lbl" xml:lang="en-US">Number of Shares, Cancelled (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled_lbl" xml:lang="en-US">Range of Exercise Prices, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="tffp-20201231.xsd#tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted-Average Remaining Life, Outstanding, ending</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised_lbl" xml:lang="en-US">Number of Shares, Exercised (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised_lbl" xml:lang="en-US">Range of Exercise Prices, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">STOCK BASED COMPENSATION</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock-based compensation expense stock options and restricted stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of fair value of employee stock options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant date fair value (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AssumptionsAbstract" xlink:href="tffp-20201231.xsd#tffp_AssumptionsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_AssumptionsAbstract_lbl" xml:lang="en-US">Assumptions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AssumptionsAbstract" xlink:to="tffp_AssumptionsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of stock option activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1" xlink:href="tffp-20201231.xsd#tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Outstanding beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1" xlink:to="tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xml:lang="en-US">Number of Shares, Outstanding, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, Outstanding, Granted (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WeightedaverageRemainingContractualTermGranted" xlink:href="tffp-20201231.xsd#tffp_WeightedaverageRemainingContractualTermGranted"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_WeightedaverageRemainingContractualTermGranted_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedaverageRemainingContractualTermGranted" xlink:to="tffp_WeightedaverageRemainingContractualTermGranted_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Granted (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0" xml:lang="en-US">Aggregate Intrinsic Value, Exercised (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl0"/>
    <loc xlink:type="locator" xlink:label="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:href="tffp-20201231.xsd#tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Outstanding ending balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, Outstanding, Exercised (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WeightedaverageRemainingContractualTermExercised" xlink:href="tffp-20201231.xsd#tffp_WeightedaverageRemainingContractualTermExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_WeightedaverageRemainingContractualTermExercised_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedaverageRemainingContractualTermExercised" xlink:to="tffp_WeightedaverageRemainingContractualTermExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xml:lang="en-US">Number of Shares, Outstanding, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, outstanding, Cancelled (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WeightedaverageRemainingContractualTermCancelled" xlink:href="tffp-20201231.xsd#tffp_WeightedaverageRemainingContractualTermCancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_WeightedaverageRemainingContractualTermCancelled_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual term, Cancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedaverageRemainingContractualTermCancelled" xlink:to="tffp_WeightedaverageRemainingContractualTermCancelled_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AggregateIntrinsicValueCancelled" xlink:href="tffp-20201231.xsd#tffp_AggregateIntrinsicValueCancelled"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_AggregateIntrinsicValueCancelled_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Cancelled (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AggregateIntrinsicValueCancelled" xlink:to="tffp_AggregateIntrinsicValueCancelled_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of Shares, Outstanding, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted-Average Exercise Prices, Outstanding, Exercisable (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AggregateIntrinsicValueExercisable" xlink:href="tffp-20201231.xsd#tffp_AggregateIntrinsicValueExercisable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_AggregateIntrinsicValueExercisable_lbl" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AggregateIntrinsicValueExercisable" xlink:to="tffp_AggregateIntrinsicValueExercisable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">INCOME TAXES</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US">Schedule of income tax expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Current:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Total current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xml:lang="en-US">Deferred:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl" xml:lang="en-US">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit_lbl" xml:lang="en-US">Total deferred</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax provision (benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_DeferredTaxAssetsAbstract" xlink:href="tffp-20201231.xsd#tffp_DeferredTaxAssetsAbstract"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_DeferredTaxAssetsAbstract_lbl" xml:lang="en-US">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DeferredTaxAssetsAbstract" xlink:to="tffp_DeferredTaxAssetsAbstract_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xml:lang="en-US">Research and development tax credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xml:lang="en-US">Intangibles</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_DeferredTaxAssetsStockCompensation" xlink:href="tffp-20201231.xsd#tffp_DeferredTaxAssetsStockCompensation"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_DeferredTaxAssetsStockCompensation_lbl" xml:lang="en-US">Stock compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DeferredTaxAssetsStockCompensation" xlink:to="tffp_DeferredTaxAssetsStockCompensation_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Total deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxNoteTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FederalIncomeTaxNoteTextBlock_lbl" xml:lang="en-US">Schedule of provision federal statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxNoteTextBlock" xlink:to="us-gaap_FederalIncomeTaxNoteTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars" xlink:href="tffp-20201231.xsd#tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars_lbl" xml:lang="en-US">Foreign</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars" xlink:to="tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences" xlink:href="tffp-20201231.xsd#tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences_lbl" xml:lang="en-US">Permanent book/tax differences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences" xlink:to="tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl" xml:lang="en-US">Research and development credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl" xml:lang="en-US">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock_lbl" xml:lang="en-US">Schedule of unrecognized tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock" xlink:to="tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AdditionsForTaxPositionsRelatedToCurrentYear" xlink:href="tffp-20201231.xsd#tffp_AdditionsForTaxPositionsRelatedToCurrentYear"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_AdditionsForTaxPositionsRelatedToCurrentYear_lbl" xml:lang="en-US">Additions for tax positions related to current year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AdditionsForTaxPositionsRelatedToCurrentYear" xlink:to="tffp_AdditionsForTaxPositionsRelatedToCurrentYear_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_DecreasesForTaxPositionsRelatedToPriorYears" xlink:href="tffp-20201231.xsd#tffp_DecreasesForTaxPositionsRelatedToPriorYears"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_DecreasesForTaxPositionsRelatedToPriorYears_lbl" xml:lang="en-US">Decreases for tax positions related to prior years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DecreasesForTaxPositionsRelatedToPriorYears" xlink:to="tffp_DecreasesForTaxPositionsRelatedToPriorYears_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">SUBSEQUENT EVENTS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Number of Shares, Outstanding, Exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Changes in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Valuation allowance on deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WarrantMember_lbl0" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_FederalAndStateMember" xlink:href="tffp-20201231.xsd#tffp_FederalAndStateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_FederalAndStateMember_lbl" xml:lang="en-US">Federal and State [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FederalAndStateMember" xlink:to="tffp_FederalAndStateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Product and Service [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ExchangeOfCommonStock" xlink:href="tffp-20201231.xsd#tffp_ExchangeOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ExchangeOfCommonStock_lbl" xml:lang="en-US">Exchange of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ExchangeOfCommonStock" xlink:to="tffp_ExchangeOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0" xml:lang="en-US">Purchase of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Stock issued, value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_OrganizationAndDescriptionsOfBusinessDescription" xlink:href="tffp-20201231.xsd#tffp_OrganizationAndDescriptionsOfBusinessDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_OrganizationAndDescriptionsOfBusinessDescription_lbl" xml:lang="en-US">Organization and description of business, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_OrganizationAndDescriptionsOfBusinessDescription" xlink:to="tffp_OrganizationAndDescriptionsOfBusinessDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ReceivedNetProceeds" xlink:href="tffp-20201231.xsd#tffp_ReceivedNetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ReceivedNetProceeds_lbl" xml:lang="en-US">Received net proceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ReceivedNetProceeds" xlink:to="tffp_ReceivedNetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreconfirmationCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreconfirmationCashAndCashEquivalents"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreconfirmationCashAndCashEquivalents_lbl" xml:lang="en-US">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreconfirmationCashAndCashEquivalents" xlink:to="us-gaap_PreconfirmationCashAndCashEquivalents_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SurplusNotes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SurplusNotes"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SurplusNotes_lbl" xml:lang="en-US">Working capital surplus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SurplusNotes" xlink:to="us-gaap_SurplusNotes_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_MaintenanceOfPropertyAndEquipment" xlink:href="tffp-20201231.xsd#tffp_MaintenanceOfPropertyAndEquipment"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_MaintenanceOfPropertyAndEquipment_lbl" xml:lang="en-US">Maintenance of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MaintenanceOfPropertyAndEquipment" xlink:to="tffp_MaintenanceOfPropertyAndEquipment_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful lives</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_DeferredResearchGrantRevenue" xlink:href="tffp-20201231.xsd#tffp_DeferredResearchGrantRevenue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_DeferredResearchGrantRevenue_lbl" xml:lang="en-US">Deferred research grant revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DeferredResearchGrantRevenue" xlink:to="tffp_DeferredResearchGrantRevenue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Basic weighted average shares outstanding (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Aggregate exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0" xml:lang="en-US">Warrant to purchase share of common stock, per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl" xml:lang="en-US">Conversion share price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ConversionPricePercentage" xlink:href="tffp-20201231.xsd#tffp_ConversionPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ConversionPricePercentage_lbl" xml:lang="en-US">Conversion price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConversionPricePercentage" xlink:to="tffp_ConversionPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">IPO price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl0" xml:lang="en-US">Sale of stock, price per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl" xml:lang="en-US">Beneficial conversion amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ExpireDate" xlink:href="tffp-20201231.xsd#tffp_ExpireDate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ExpireDate_lbl" xml:lang="en-US">Rent expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ExpireDate" xlink:to="tffp_ExpireDate_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseCost_lbl" xml:lang="en-US">Short-term lease expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl" xml:lang="en-US">Assignment fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_MilestoneFee" xlink:href="tffp-20201231.xsd#tffp_MilestoneFee"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_MilestoneFee_lbl" xml:lang="en-US">Milestone fee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MilestoneFee" xlink:to="tffp_MilestoneFee_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_CommonShareOutstandingPricePercentage" xlink:href="tffp-20201231.xsd#tffp_CommonShareOutstandingPricePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_CommonShareOutstandingPricePercentage_lbl" xml:lang="en-US">Common shares outstanding price percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CommonShareOutstandingPricePercentage" xlink:to="tffp_CommonShareOutstandingPricePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AmountOfCommonShareDuePayable" xlink:href="tffp-20201231.xsd#tffp_AmountOfCommonShareDuePayable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_AmountOfCommonShareDuePayable_lbl" xml:lang="en-US">Amount of common shares due payable (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AmountOfCommonShareDuePayable" xlink:to="tffp_AmountOfCommonShareDuePayable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionReasonsForElection" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOptionReasonsForElection"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOptionReasonsForElection_lbl" xml:lang="en-US">Fair value of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionReasonsForElection" xlink:to="us-gaap_FairValueOptionReasonsForElection_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ClosingStockPrice" xlink:href="tffp-20201231.xsd#tffp_ClosingStockPrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ClosingStockPrice_lbl" xml:lang="en-US">Closing stock price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ClosingStockPrice" xlink:to="tffp_ClosingStockPrice_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_DescriptionOfLicenseAndAgreements" xlink:href="tffp-20201231.xsd#tffp_DescriptionOfLicenseAndAgreements"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_DescriptionOfLicenseAndAgreements_lbl" xml:lang="en-US">Description of license and agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DescriptionOfLicenseAndAgreements" xlink:to="tffp_DescriptionOfLicenseAndAgreements_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_AgreementTremDescription" xlink:href="tffp-20201231.xsd#tffp_AgreementTremDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_AgreementTremDescription_lbl" xml:lang="en-US">Agreement term, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AgreementTremDescription" xlink:to="tffp_AgreementTremDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and development expense (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xml:lang="en-US">Research and development expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_PremarketingApprovals" xlink:href="tffp-20201231.xsd#tffp_PremarketingApprovals"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_PremarketingApprovals_lbl" xml:lang="en-US">Pre-marketing approvals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_PremarketingApprovals" xlink:to="tffp_PremarketingApprovals_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockholdersEquityDescription" xlink:href="tffp-20201231.xsd#tffp_StockholdersEquityDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_StockholdersEquityDescription_lbl" xml:lang="en-US">Stockholders equity deficit, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockholdersEquityDescription" xlink:to="tffp_StockholdersEquityDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xml:lang="en-US">Convertible preferred stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_FairValueAssumptionExercisePrice" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionExercisePrice"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_FairValueAssumptionExercisePrice_lbl" xml:lang="en-US">Exercise price (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FairValueAssumptionExercisePrice" xlink:to="tffp_FairValueAssumptionExercisePrice_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl" xml:lang="en-US">Gross proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_NetProceeds" xlink:href="tffp-20201231.xsd#tffp_NetProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_NetProceeds_lbl" xml:lang="en-US">Net proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_NetProceeds" xlink:to="tffp_NetProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExerciseShares" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockForStockOptionExerciseShares"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExerciseShares_lbl" xml:lang="en-US">Issuance of common stock for stock option exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockForStockOptionExerciseShares" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExerciseShares_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockOptionExercisesTotalProceeds" xlink:href="tffp-20201231.xsd#tffp_StockOptionExercisesTotalProceeds"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_StockOptionExercisesTotalProceeds_lbl" xml:lang="en-US">Stock option exercises total proceeds (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockOptionExercisesTotalProceeds" xlink:to="tffp_StockOptionExercisesTotalProceeds_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise_lbl" xml:lang="en-US">Issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockWarrant" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockWarrant"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockWarrant_lbl" xml:lang="en-US">Issuance of common stock warrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockWarrant" xlink:to="tffp_IssuanceOfCommonStockWarrant_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl0" xml:lang="en-US">Preferred stock, shares issued (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl" xml:lang="en-US">Dividend rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DividendsPayableCurrent_lbl" xml:lang="en-US">Series A preferred stock dividend payable (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrent" xlink:to="us-gaap_DividendsPayableCurrent_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConversionOfStockDescription_lbl" xml:lang="en-US">Series A preferred stock conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl" xml:lang="en-US">Convertible preferred stock terms of conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xml:lang="en-US">Purchase of company&apos;s amount equal to common stock, percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WarrantToPurchaseSharesOfCommonStock" xlink:href="tffp-20201231.xsd#tffp_WarrantToPurchaseSharesOfCommonStock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_WarrantToPurchaseSharesOfCommonStock_lbl" xml:lang="en-US">Warrant to purchase shares of common stock (in Shares)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WarrantToPurchaseSharesOfCommonStock" xlink:to="tffp_WarrantToPurchaseSharesOfCommonStock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_FairValueAssumptionsCommonStockValue" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionsCommonStockValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_FairValueAssumptionsCommonStockValue_lbl" xml:lang="en-US">Common stock value, per share (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FairValueAssumptionsCommonStockValue" xlink:to="tffp_FairValueAssumptionsCommonStockValue_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_FairValueAssumptionsExpectedTerms" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionsExpectedTerms"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_FairValueAssumptionsExpectedTerms_lbl" xml:lang="en-US">Contractual life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FairValueAssumptionsExpectedTerms" xlink:to="tffp_FairValueAssumptionsExpectedTerms_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_FairValueAssumptionsExpectedDividendRates" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionsExpectedDividendRates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_FairValueAssumptionsExpectedDividendRates_lbl" xml:lang="en-US">Dividend yield</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FairValueAssumptionsExpectedDividendRates" xlink:to="tffp_FairValueAssumptionsExpectedDividendRates_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_FairValueAssumptionExpectedVolatilityRate" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionExpectedVolatilityRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_FairValueAssumptionExpectedVolatilityRate_lbl" xml:lang="en-US">Volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FairValueAssumptionExpectedVolatilityRate" xlink:to="tffp_FairValueAssumptionExpectedVolatilityRate_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_FairValueAssumptionRiskFreeInterestRate" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionRiskFreeInterestRate"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_FairValueAssumptionRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FairValueAssumptionRiskFreeInterestRate" xlink:to="tffp_FairValueAssumptionRiskFreeInterestRate_lbl"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZox5kKltS1j4H1Hm6x5rsVySu3GvyFidfKO4jLCc6vqlIAk2/hDR2bzzoxw5NX+h9OcfjdvrLHYAuwh2Zi7sQ0UOAQ0i8qn20R76xjgd36yBDZMSKJy6UF8YlRJlhDvltYdDBaXR3sWPsW9VT/9h3wyKkqYRK0lALx3+SAcoHi554Ul7Qas6aWvZyHzgVs3yVCB4hbr6I8hV2x+3q52unvf4h4dUvIKT4=] CSR-->
    <loc xlink:type="locator" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare_lbl" xml:lang="en-US">Warrant price per unit (in Dollars per share)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WarrantOutstandingAggregateIntrinsicValue" xlink:href="tffp-20201231.xsd#tffp_WarrantOutstandingAggregateIntrinsicValue"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_WarrantOutstandingAggregateIntrinsicValue_lbl" xml:lang="en-US">Aggregate intrinsic value (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WarrantOutstandingAggregateIntrinsicValue" xlink:to="tffp_WarrantOutstandingAggregateIntrinsicValue_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementsOverallDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementsOverallDescription"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredCompensationArrangementsOverallDescription_lbl" xml:lang="en-US">Stock based compensation, description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementsOverallDescription" xlink:to="us-gaap_DeferredCompensationArrangementsOverallDescription_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xml:lang="en-US">Unrecognized compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm_lbl" xml:lang="en-US">Weighted-average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_FederalIncomeTaxNetOperatingLoss" xlink:href="tffp-20201231.xsd#tffp_FederalIncomeTaxNetOperatingLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_FederalIncomeTaxNetOperatingLoss_lbl" xml:lang="en-US">Federal income tax net operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FederalIncomeTaxNetOperatingLoss" xlink:to="tffp_FederalIncomeTaxNetOperatingLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Federal research tax credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ForeignIncomeTaxNetOperatingLoss" xlink:href="tffp-20201231.xsd#tffp_ForeignIncomeTaxNetOperatingLoss"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ForeignIncomeTaxNetOperatingLoss_lbl" xml:lang="en-US">Foreign income tax net operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignIncomeTaxNetOperatingLoss" xlink:to="tffp_ForeignIncomeTaxNetOperatingLoss_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_FederalTaxCreditExpire" xlink:href="tffp-20201231.xsd#tffp_FederalTaxCreditExpire"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_FederalTaxCreditExpire_lbl" xml:lang="en-US">Federal tax credit expire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FederalTaxCreditExpire" xlink:to="tffp_FederalTaxCreditExpire_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_TaxableIncomeForLosses" xlink:href="tffp-20201231.xsd#tffp_TaxableIncomeForLosses"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_TaxableIncomeForLosses_lbl" xml:lang="en-US">Taxable income for losses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_TaxableIncomeForLosses" xlink:to="tffp_TaxableIncomeForLosses_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_UncertainTaxPositions" xlink:href="tffp-20201231.xsd#tffp_UncertainTaxPositions"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_UncertainTaxPositions_lbl" xml:lang="en-US">Uncertain tax positions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_UncertainTaxPositions" xlink:to="tffp_UncertainTaxPositions_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharesIssued_lbl" xml:lang="en-US">Common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Cash proceeds from the exercises (in Dollars)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xml:lang="en-US">Principles of Consolidation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock_lbl" xml:lang="en-US">Foreign Currency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:to="us-gaap_ForeignCurrencyDisclosureTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_GeographicConcentrationsPolicyTextBlock" xlink:href="tffp-20201231.xsd#tffp_GeographicConcentrationsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_GeographicConcentrationsPolicyTextBlock_lbl" xml:lang="en-US">Geographic Concentrations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_GeographicConcentrationsPolicyTextBlock" xlink:to="tffp_GeographicConcentrationsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl" xml:lang="en-US">Deferred Offering Costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:to="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xml:lang="en-US">Fair Value of Financial Instruments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xml:lang="en-US">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Basic and Diluted Earnings per Common Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_CommonStockWarrantsPolicyTextBlock" xlink:href="tffp-20201231.xsd#tffp_CommonStockWarrantsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_CommonStockWarrantsPolicyTextBlock_lbl" xml:lang="en-US">Common Stock Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CommonStockWarrantsPolicyTextBlock" xlink:to="tffp_CommonStockWarrantsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_BeneficialConversionFeaturePolicyTextBlock" xlink:href="tffp-20201231.xsd#tffp_BeneficialConversionFeaturePolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_BeneficialConversionFeaturePolicyTextBlock_lbl" xml:lang="en-US">Beneficial Conversion Feature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_BeneficialConversionFeaturePolicyTextBlock" xlink:to="tffp_BeneficialConversionFeaturePolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl" xml:lang="en-US">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Standards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US">Computer Equipment and Software [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_MasterServicesMember" xlink:href="tffp-20201231.xsd#tffp_MasterServicesMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_MasterServicesMember_lbl" xml:lang="en-US">Master Services [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MasterServicesMember" xlink:to="tffp_MasterServicesMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IrisysLlcMember" xlink:href="tffp-20201231.xsd#tffp_IrisysLlcMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_IrisysLlcMember_lbl" xml:lang="en-US">Irisys, LLC [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IrisysLlcMember" xlink:to="tffp_IrisysLlcMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_CoreRxMember" xlink:href="tffp-20201231.xsd#tffp_CoreRxMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_CoreRxMember_lbl" xml:lang="en-US">CoreRx [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CoreRxMember" xlink:to="tffp_CoreRxMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_ConformClinicalDevelopmentIncMember" xlink:href="tffp-20201231.xsd#tffp_ConformClinicalDevelopmentIncMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_ConformClinicalDevelopmentIncMember_lbl" xml:lang="en-US">Conform Clinical Development, Inc. [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConformClinicalDevelopmentIncMember" xlink:to="tffp_ConformClinicalDevelopmentIncMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_NovotechAustraliaPtyLtdMember" xlink:href="tffp-20201231.xsd#tffp_NovotechAustraliaPtyLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_NovotechAustraliaPtyLtdMember_lbl" xml:lang="en-US">Novotech (Australia) Pty Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_NovotechAustraliaPtyLtdMember" xlink:to="tffp_NovotechAustraliaPtyLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_NucleusNetworkPtyLtdMember" xlink:href="tffp-20201231.xsd#tffp_NucleusNetworkPtyLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_NucleusNetworkPtyLtdMember_lbl" xml:lang="en-US">Nucleus Network Pty Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_NucleusNetworkPtyLtdMember" xlink:to="tffp_NucleusNetworkPtyLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_QPharmPtyLtdMember" xlink:href="tffp-20201231.xsd#tffp_QPharmPtyLtdMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_QPharmPtyLtdMember_lbl" xml:lang="en-US">Q-Pharm Pty Ltd [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_QPharmPtyLtdMember" xlink:to="tffp_QPharmPtyLtdMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrivatePlacementMember_lbl" xml:lang="en-US">2019 Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_NationalSecuritiesCorporationsWarrantsMember" xlink:href="tffp-20201231.xsd#tffp_NationalSecuritiesCorporationsWarrantsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_NationalSecuritiesCorporationsWarrantsMember_lbl" xml:lang="en-US">National Securities Corporation Warrants [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_NationalSecuritiesCorporationsWarrantsMember" xlink:to="tffp_NationalSecuritiesCorporationsWarrantsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_TenYearsWarrantMember" xlink:href="tffp-20201231.xsd#tffp_TenYearsWarrantMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_TenYearsWarrantMember_lbl" xml:lang="en-US">Ten Year Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_TenYearsWarrantMember" xlink:to="tffp_TenYearsWarrantMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_BPDirectorsMember" xlink:href="tffp-20201231.xsd#tffp_BPDirectorsMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_BPDirectorsMember_lbl" xml:lang="en-US">BP Directors [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_BPDirectorsMember" xlink:to="tffp_BPDirectorsMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_EffectiveTaxRateMember" xlink:href="tffp-20201231.xsd#tffp_EffectiveTaxRateMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="tffp_EffectiveTaxRateMember_lbl" xml:lang="en-US">Effective Tax [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_EffectiveTaxRateMember" xlink:to="tffp_EffectiveTaxRateMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OptionMember_lbl" xml:lang="en-US">Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US">Equity Component [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US">Sale of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable" xlink:href="tffp-20201231.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Earnings per Common Share [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable" xlink:to="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems" xlink:href="tffp-20201231.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Earnings per Common Share [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems" xlink:to="tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US">Statistical Measurement [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WarrantsDetailsScheduleofwarrantactivityTable" xlink:href="tffp-20201231.xsd#tffp_WarrantsDetailsScheduleofwarrantactivityTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WarrantsDetailsScheduleofwarrantactivityTable_lbl" xml:lang="en-US">Warrants (Details) - Schedule of warrant activity [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityTable" xlink:to="tffp_WarrantsDetailsScheduleofwarrantactivityTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:href="tffp-20201231.xsd#tffp_WarrantsDetailsScheduleofwarrantactivityLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems_lbl" xml:lang="en-US">Warrants (Details) - Schedule of warrant activity [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="tffp_WarrantsDetailsScheduleofwarrantactivityLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US">Income Statement Location [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable_lbl" xml:lang="en-US">Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and restricted stock [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable" xlink:to="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems_lbl" xml:lang="en-US">Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and restricted stock [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems" xlink:to="tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable_lbl" xml:lang="en-US">Stock Based Compensation (Details) - Schedule of fair value of employee stock options [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:to="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems_lbl" xml:lang="en-US">Stock Based Compensation (Details) - Schedule of fair value of employee stock options [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US">Income Tax Authority [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable" xlink:href="tffp-20201231.xsd#tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of unrecognized tax positions [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable" xlink:to="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" xlink:href="tffp-20201231.xsd#tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) - Schedule of unrecognized tax positions [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" xlink:to="tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="tffp-20201231.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsTable_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="tffp_SummaryofSignificantAccountingPoliciesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl" xml:lang="en-US">Summary of Significant Accounting Policies (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductsAndServicesDomain_lbl" xml:lang="en-US">Product and Service [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LicenseandAgreementsDetailsTable" xlink:href="tffp-20201231.xsd#tffp_LicenseandAgreementsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LicenseandAgreementsDetailsTable_lbl" xml:lang="en-US">License and Agreements (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LicenseandAgreementsDetailsTable" xlink:to="tffp_LicenseandAgreementsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_LicenseandAgreementsDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_LicenseandAgreementsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LicenseandAgreementsDetailsLineItems_lbl" xml:lang="en-US">License and Agreements (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LicenseandAgreementsDetailsLineItems" xlink:to="tffp_LicenseandAgreementsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockDomain_lbl" xml:lang="en-US">Class of Stock [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockholdersEquityDetailsTable" xlink:href="tffp-20201231.xsd#tffp_StockholdersEquityDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockholdersEquityDetailsTable_lbl" xml:lang="en-US">Stockholders&apos; Equity (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockholdersEquityDetailsTable" xlink:to="tffp_StockholdersEquityDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_StockholdersEquityDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_StockholdersEquityDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockholdersEquityDetailsLineItems_lbl" xml:lang="en-US">Stockholders&apos; Equity (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockholdersEquityDetailsLineItems" xlink:to="tffp_StockholdersEquityDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WarrantsDetailsTable" xlink:href="tffp-20201231.xsd#tffp_WarrantsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WarrantsDetailsTable_lbl" xml:lang="en-US">Warrants (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WarrantsDetailsTable" xlink:to="tffp_WarrantsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_WarrantsDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_WarrantsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WarrantsDetailsLineItems_lbl" xml:lang="en-US">Warrants (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WarrantsDetailsLineItems" xlink:to="tffp_WarrantsDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IncomeTaxesDetailsTable" xlink:href="tffp-20201231.xsd#tffp_IncomeTaxesDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IncomeTaxesDetailsTable_lbl" xml:lang="en-US">Income Taxes (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IncomeTaxesDetailsTable" xlink:to="tffp_IncomeTaxesDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_IncomeTaxesDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_IncomeTaxesDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IncomeTaxesDetailsLineItems_lbl" xml:lang="en-US">Income Taxes (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IncomeTaxesDetailsLineItems" xlink:to="tffp_IncomeTaxesDetailsLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xml:lang="en-US">Subsequent Event Type [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US">Financial Instruments [Domain]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_SubsequentEventsDetailsTable" xlink:href="tffp-20201231.xsd#tffp_SubsequentEventsDetailsTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_SubsequentEventsDetailsTable_lbl" xml:lang="en-US">Subsequent Events (Details) [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SubsequentEventsDetailsTable" xlink:to="tffp_SubsequentEventsDetailsTable_lbl"/>
    <loc xlink:type="locator" xlink:label="tffp_SubsequentEventsDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_SubsequentEventsDetailsLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_SubsequentEventsDetailsLineItems_lbl" xml:lang="en-US">Subsequent Events (Details) [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SubsequentEventsDetailsLineItems" xlink:to="tffp_SubsequentEventsDetailsLineItems_lbl"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_AccruedDividend_lbl0" xml:lang="en-US">Amount of accrued dividend.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AccruedDividend" xlink:to="tffp_AccruedDividend_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_AdditionsForTaxPositionsRelatedToCurrentYear_lbl0" xml:lang="en-US">Additions for tax positions related to current year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AdditionsForTaxPositionsRelatedToCurrentYear" xlink:to="tffp_AdditionsForTaxPositionsRelatedToCurrentYear_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_AggregateIntrinsicValueCancelled_lbl0" xml:lang="en-US">Aggregate intrinsic value, Cancelled.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AggregateIntrinsicValueCancelled" xlink:to="tffp_AggregateIntrinsicValueCancelled_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ClosingStockPrice_lbl0" xml:lang="en-US">Closing stock price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ClosingStockPrice" xlink:to="tffp_ClosingStockPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock_lbl0" xml:lang="en-US">Conversion of Series A Preferred Stock (including accrued dividends) to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock" xlink:to="tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock_lbl0" xml:lang="en-US">Amount related to Conversion of Series A Preferred Stock (including accrued dividends) to common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:to="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_DecreasesForTaxPositionsRelatedToPriorYears_lbl0" xml:lang="en-US">Additions for tax positions related to prior years.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DecreasesForTaxPositionsRelatedToPriorYears" xlink:to="tffp_DecreasesForTaxPositionsRelatedToPriorYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_DescriptionOfLicenseAndAgreements_lbl0" xml:lang="en-US">Description of license and agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DescriptionOfLicenseAndAgreements" xlink:to="tffp_DescriptionOfLicenseAndAgreements_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ExchangeOfCommonStock_lbl0" xml:lang="en-US">Exchange of common stock.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ExchangeOfCommonStock" xlink:to="tffp_ExchangeOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_FairValueAssumptionsExpectedTerms_lbl0" xml:lang="en-US">Period the instrument, asset or liability is expected to be outstanding, in &apos;PnYnMnDTnHnMnS&apos; format, for example, &apos;P1Y5M13D&apos; represents the reported fact of one year, five months, and thirteen days.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FairValueAssumptionsExpectedTerms" xlink:to="tffp_FairValueAssumptionsExpectedTerms_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_FederalIncomeTaxNetOperatingLoss_lbl0" xml:lang="en-US">Federal income tax net operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FederalIncomeTaxNetOperatingLoss" xlink:to="tffp_FederalIncomeTaxNetOperatingLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_FederalTaxCreditExpire_lbl0" xml:lang="en-US">Federal tax credit expire.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FederalTaxCreditExpire" xlink:to="tffp_FederalTaxCreditExpire_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ForeignCurrencyTranslationAdjustment_lbl0" xml:lang="en-US">Foreign currency translation adjustment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignCurrencyTranslationAdjustment" xlink:to="tffp_ForeignCurrencyTranslationAdjustment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ForeignCurrencyTranslationAdjustments_lbl0" xml:lang="en-US">Foreign currency translation adjustments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignCurrencyTranslationAdjustments" xlink:to="tffp_ForeignCurrencyTranslationAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ForeignIncomeTaxNetOperatingLoss_lbl0" xml:lang="en-US">Foreign income tax net operating loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignIncomeTaxNetOperatingLoss" xlink:to="tffp_ForeignIncomeTaxNetOperatingLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Issuance of common stock for accrued research and development expense, Shares.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense" xlink:to="tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_IssuanceOfCommonStockWarrant_lbl0" xml:lang="en-US">Issuance of common stock warrant.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockWarrant" xlink:to="tffp_IssuanceOfCommonStockWarrant_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_LicenseAndAgreementsDisclosureTextBlock_lbl0" xml:lang="en-US">License and Agreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LicenseAndAgreementsDisclosureTextBlock" xlink:to="tffp_LicenseAndAgreementsDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_MaintenanceOfPropertyAndEquipment_lbl0" xml:lang="en-US">Maintenance of property and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MaintenanceOfPropertyAndEquipment" xlink:to="tffp_MaintenanceOfPropertyAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_MilestoneFee_lbl0" xml:lang="en-US">Milestone fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MilestoneFee" xlink:to="tffp_MilestoneFee_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockValue_lbl0" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ProceedsFromIssuanceOfCommonStockValue" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm_lbl0" xml:lang="en-US">weighted-average period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl1" xml:lang="en-US">Number of options outstanding, including both vested and non-vested options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Weighted-average exercise prices, outstanding, beginning balance (in Dollars per share).</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Number of weighted-average exercise per share prices issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross_lbl0" xml:lang="en-US">Number of warrant shares issued.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl0" xml:lang="en-US">Weighted-average remaining contractual term, outstanding ending balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_StockBasedCompensation_lbl0" xml:lang="en-US">Stock based compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensation" xlink:to="tffp_StockBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_StockholdersEquityDescription_lbl0" xml:lang="en-US">Description of stockholders equity deficit.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockholdersEquityDescription" xlink:to="tffp_StockholdersEquityDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_UncertainTaxPositions_lbl0" xml:lang="en-US">Uncertain Tax Positions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_UncertainTaxPositions" xlink:to="tffp_UncertainTaxPositions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_WarrantOutstandingAggregateIntrinsicValue_lbl0" xml:lang="en-US">Amount of warrant outstanding aggregate intrinsic value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WarrantOutstandingAggregateIntrinsicValue" xlink:to="tffp_WarrantOutstandingAggregateIntrinsicValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_WeightedaverageRemainingContractualTermCancelled_lbl0" xml:lang="en-US">Weighted-average remaining contractual term, Cancelled.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedaverageRemainingContractualTermCancelled" xlink:to="tffp_WeightedaverageRemainingContractualTermCancelled_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_WeightedaverageRemainingContractualTermExercised_lbl0" xml:lang="en-US">Weighted-average remaining contractual term, Exercised.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedaverageRemainingContractualTermExercised" xlink:to="tffp_WeightedaverageRemainingContractualTermExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_WeightedaverageRemainingContractualTermGranted_lbl0" xml:lang="en-US">Weighted-average remaining contractual term, Granted.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedaverageRemainingContractualTermGranted" xlink:to="tffp_WeightedaverageRemainingContractualTermGranted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1_lbl0" xml:lang="en-US">Weighted-average remaining contractual term, outstanding beginning balance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1" xlink:to="tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_FairValueAssumptionsCommonStockValue_lbl0" xml:lang="en-US">FairValueAssumptionsCommonStockValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FairValueAssumptionsCommonStockValue" xlink:to="tffp_FairValueAssumptionsCommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExerciseShares_lbl0" xml:lang="en-US">IssuanceOfCommonStockForStockOptionExerciseShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockForStockOptionExerciseShares" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExerciseShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl2" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_FederalTaxCreditExpire_lbl1" xml:lang="en-US">FederalTaxCreditExpire</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FederalTaxCreditExpire" xlink:to="tffp_FederalTaxCreditExpire_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares_lbl0" xml:lang="en-US">IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AggregateIntrinsicValueExercisable_lbl0" xml:lang="en-US">AggregateIntrinsicValueExercisable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AggregateIntrinsicValueExercisable" xlink:to="tffp_AggregateIntrinsicValueExercisable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare_lbl0" xml:lang="en-US">IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_TaxableIncomeForLosses_lbl0" xml:lang="en-US">TaxableIncomeForLosses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_TaxableIncomeForLosses" xlink:to="tffp_TaxableIncomeForLosses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_FairValueAssumptionExpectedVolatilityRate_lbl0" xml:lang="en-US">FairValueAssumptionExpectedVolatilityRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FairValueAssumptionExpectedVolatilityRate" xlink:to="tffp_FairValueAssumptionExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock_lbl1" xml:lang="en-US">ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:to="tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ExchangeOfCommonStock_lbl1" xml:lang="en-US">ExchangeOfCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ExchangeOfCommonStock" xlink:to="tffp_ExchangeOfCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_NucleusNetworkPtyLtdMember_lbl0" xml:lang="en-US">NucleusNetworkPtyLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_NucleusNetworkPtyLtdMember" xlink:to="tffp_NucleusNetworkPtyLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ForeignIncomeTaxNetOperatingLoss_lbl1" xml:lang="en-US">ForeignIncomeTaxNetOperatingLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignIncomeTaxNetOperatingLoss" xlink:to="tffp_ForeignIncomeTaxNetOperatingLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl2" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">IncreaseDecreaseInAccruedResearchAndDevelopmentExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense" xlink:to="tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LiquidityAndManagementsPlansTextBlock_lbl0" xml:lang="en-US">LiquidityAndManagementsPlansTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LiquidityAndManagementsPlansTextBlock" xlink:to="tffp_LiquidityAndManagementsPlansTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ForeignCurrencyTranslationAdjustment_lbl1" xml:lang="en-US">ForeignCurrencyTranslationAdjustment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignCurrencyTranslationAdjustment" xlink:to="tffp_ForeignCurrencyTranslationAdjustment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl1" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:to="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_MilestoneFee_lbl1" xml:lang="en-US">MilestoneFee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MilestoneFee" xlink:to="tffp_MilestoneFee_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockOptionExercisesTotalProceeds_lbl0" xml:lang="en-US">StockOptionExercisesTotalProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockOptionExercisesTotalProceeds" xlink:to="tffp_StockOptionExercisesTotalProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_DeferredTaxAssetsStockCompensation_lbl0" xml:lang="en-US">DeferredTaxAssetsStockCompensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DeferredTaxAssetsStockCompensation" xlink:to="tffp_DeferredTaxAssetsStockCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AggregateIntrinsicValueCancelled_lbl1" xml:lang="en-US">AggregateIntrinsicValueCancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AggregateIntrinsicValueCancelled" xlink:to="tffp_AggregateIntrinsicValueCancelled_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ConsolidatedStatementsOfComprehensiveLossAbstract_lbl0" xml:lang="en-US">ConsolidatedStatementsOfComprehensiveLossAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConsolidatedStatementsOfComprehensiveLossAbstract" xlink:to="tffp_ConsolidatedStatementsOfComprehensiveLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_DescriptionOfLicenseAndAgreements_lbl1" xml:lang="en-US">DescriptionOfLicenseAndAgreements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DescriptionOfLicenseAndAgreements" xlink:to="tffp_DescriptionOfLicenseAndAgreements_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AmountOfCommonShareDuePayable_lbl0" xml:lang="en-US">AmountOfCommonShareDuePayable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AmountOfCommonShareDuePayable" xlink:to="tffp_AmountOfCommonShareDuePayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockWarrant_lbl1" xml:lang="en-US">IssuanceOfCommonStockWarrant</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockWarrant" xlink:to="tffp_IssuanceOfCommonStockWarrant_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_UncertainTaxPositionsEndingBalance_lbl0" xml:lang="en-US">UncertainTaxPositionsEndingBalance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_UncertainTaxPositionsEndingBalance" xlink:to="tffp_UncertainTaxPositionsEndingBalance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent_lbl0" xml:lang="en-US">EffectOfExchangeRateChangesOnCashAndCashEquivalent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent" xlink:to="tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ConformClinicalDevelopmentIncMember_lbl0" xml:lang="en-US">ConformClinicalDevelopmentIncMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConformClinicalDevelopmentIncMember" xlink:to="tffp_ConformClinicalDevelopmentIncMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfWarrantActivity_lbl0" xml:lang="en-US">ScheduleOfWarrantActivity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfWarrantActivity" xlink:to="tffp_ScheduleOfWarrantActivity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_UncertainTaxPositionsBegnningBalance_lbl0" xml:lang="en-US">UncertainTaxPositionsBegnningBalance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_UncertainTaxPositionsBegnningBalance" xlink:to="tffp_UncertainTaxPositionsBegnningBalance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_QPharmPtyLtdMember_lbl0" xml:lang="en-US">QPharmPtyLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_QPharmPtyLtdMember" xlink:to="tffp_QPharmPtyLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AgreementTremDescription_lbl0" xml:lang="en-US">AgreementTremDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AgreementTremDescription" xlink:to="tffp_AgreementTremDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares_lbl0" xml:lang="en-US">IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1_lbl1" xml:lang="en-US">WeightedaverageRemainingContractualTermOutstandingBeginningBalance1</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1" xlink:to="tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockBasedCompensation_lbl1" xml:lang="en-US">StockBasedCompensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockBasedCompensation" xlink:to="tffp_StockBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IrisysLlcMember_lbl0" xml:lang="en-US">IrisysLlcMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IrisysLlcMember" xlink:to="tffp_IrisysLlcMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AccruedDividend_lbl1" xml:lang="en-US">AccruedDividend</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AccruedDividend" xlink:to="tffp_AccruedDividend_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_DeferredResearchGrantRevenue_lbl0" xml:lang="en-US">DeferredResearchGrantRevenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DeferredResearchGrantRevenue" xlink:to="tffp_DeferredResearchGrantRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_UncertainTaxPositions_lbl1" xml:lang="en-US">UncertainTaxPositions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_UncertainTaxPositions" xlink:to="tffp_UncertainTaxPositions_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount_lbl0" xml:lang="en-US">IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_CommonStockWarrantsPolicyTextBlock_lbl0" xml:lang="en-US">CommonStockWarrantsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CommonStockWarrantsPolicyTextBlock" xlink:to="tffp_CommonStockWarrantsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock_lbl1" xml:lang="en-US">ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock" xlink:to="tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock_lbl0" xml:lang="en-US">DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock" xlink:to="tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_MaintenanceOfPropertyAndEquipment_lbl1" xml:lang="en-US">MaintenanceOfPropertyAndEquipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MaintenanceOfPropertyAndEquipment" xlink:to="tffp_MaintenanceOfPropertyAndEquipment_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_CashlessExerciseOfWarrants_lbl0" xml:lang="en-US">CashlessExerciseOfWarrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CashlessExerciseOfWarrants" xlink:to="tffp_CashlessExerciseOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock_lbl0" xml:lang="en-US">ScheduleOfUnrecognizedTaxPositionsTableTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock" xlink:to="tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl0" xml:lang="en-US">SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:to="tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_FairValueAssumptionsExpectedTerms_lbl1" xml:lang="en-US">FairValueAssumptionsExpectedTerms</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FairValueAssumptionsExpectedTerms" xlink:to="tffp_FairValueAssumptionsExpectedTerms_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_BPDirectorsMember_lbl0" xml:lang="en-US">BPDirectorsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_BPDirectorsMember" xlink:to="tffp_BPDirectorsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercises_lbl0" xml:lang="en-US">IssuanceOfCommonStockForStockOptionExercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockForStockOptionExercises" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_OrganizationAndDescriptionsOfBusinessDescription_lbl0" xml:lang="en-US">OrganizationAndDescriptionsOfBusinessDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_OrganizationAndDescriptionsOfBusinessDescription" xlink:to="tffp_OrganizationAndDescriptionsOfBusinessDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_CommonShareOutstandingPricePercentage_lbl0" xml:lang="en-US">CommonShareOutstandingPricePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CommonShareOutstandingPricePercentage" xlink:to="tffp_CommonShareOutstandingPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_FairValueAssumptionRiskFreeInterestRate_lbl0" xml:lang="en-US">FairValueAssumptionRiskFreeInterestRate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FairValueAssumptionRiskFreeInterestRate" xlink:to="tffp_FairValueAssumptionRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WarrantOutstandingAggregateIntrinsicValue_lbl1" xml:lang="en-US">WarrantOutstandingAggregateIntrinsicValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WarrantOutstandingAggregateIntrinsicValue" xlink:to="tffp_WarrantOutstandingAggregateIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IncreaseDecreaseDeferredResearchGrantRevenue_lbl0" xml:lang="en-US">IncreaseDecreaseDeferredResearchGrantRevenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IncreaseDecreaseDeferredResearchGrantRevenue" xlink:to="tffp_IncreaseDecreaseDeferredResearchGrantRevenue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_BeneficialConversionFeaturePolicyTextBlock_lbl0" xml:lang="en-US">BeneficialConversionFeaturePolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_BeneficialConversionFeaturePolicyTextBlock" xlink:to="tffp_BeneficialConversionFeaturePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ConversionPricePercentage_lbl0" xml:lang="en-US">ConversionPricePercentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ConversionPricePercentage" xlink:to="tffp_ConversionPricePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice_lbl1" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_NationalSecuritiesCorporationsWarrantsMember_lbl0" xml:lang="en-US">NationalSecuritiesCorporationsWarrantsMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_NationalSecuritiesCorporationsWarrantsMember" xlink:to="tffp_NationalSecuritiesCorporationsWarrantsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WarrantsTextBlock_lbl0" xml:lang="en-US">WarrantsTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WarrantsTextBlock" xlink:to="tffp_WarrantsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WarrantToPurchaseSharesOfCommonStock_lbl0" xml:lang="en-US">WarrantToPurchaseSharesOfCommonStock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WarrantToPurchaseSharesOfCommonStock" xlink:to="tffp_WarrantToPurchaseSharesOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise_lbl0" xml:lang="en-US">IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WeightedaverageRemainingContractualTermGranted_lbl1" xml:lang="en-US">WeightedaverageRemainingContractualTermGranted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedaverageRemainingContractualTermGranted" xlink:to="tffp_WeightedaverageRemainingContractualTermGranted_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_NovotechAustraliaPtyLtdMember_lbl0" xml:lang="en-US">NovotechAustraliaPtyLtdMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_NovotechAustraliaPtyLtdMember" xlink:to="tffp_NovotechAustraliaPtyLtdMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_EffectiveTaxRateMember_lbl0" xml:lang="en-US">EffectiveTaxRateMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_EffectiveTaxRateMember" xlink:to="tffp_EffectiveTaxRateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_CoreRxMember_lbl0" xml:lang="en-US">CoreRxMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_CoreRxMember" xlink:to="tffp_CoreRxMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockValue_lbl1" xml:lang="en-US">ProceedsFromIssuanceOfCommonStockValue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ProceedsFromIssuanceOfCommonStockValue" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_OfferingCostsNettedWithProceedsFromIPO_lbl0" xml:lang="en-US">OfferingCostsNettedWithProceedsFromIPO</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_OfferingCostsNettedWithProceedsFromIPO" xlink:to="tffp_OfferingCostsNettedWithProceedsFromIPO_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockForStockOptionExercisesShares_lbl0" xml:lang="en-US">IssuanceOfCommonStockForStockOptionExercisesShares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockForStockOptionExercisesShares" xlink:to="tffp_IssuanceOfCommonStockForStockOptionExercisesShares_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_lbl0" xml:lang="en-US">ProceedsFromIssuanceOfCommonStockForStockOptionExercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:to="tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ReceivedNetProceeds_lbl0" xml:lang="en-US">ReceivedNetProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ReceivedNetProceeds" xlink:to="tffp_ReceivedNetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_OtherComprehensiveLossAbstract_lbl0" xml:lang="en-US">OtherComprehensiveLossAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_OtherComprehensiveLossAbstract" xlink:to="tffp_OtherComprehensiveLossAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ClosingStockPrice_lbl1" xml:lang="en-US">ClosingStockPrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ClosingStockPrice" xlink:to="tffp_ClosingStockPrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences_lbl0" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences" xlink:to="tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense" xlink:to="tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_DecreasesForTaxPositionsRelatedToPriorYears_lbl1" xml:lang="en-US">DecreasesForTaxPositionsRelatedToPriorYears</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DecreasesForTaxPositionsRelatedToPriorYears" xlink:to="tffp_DecreasesForTaxPositionsRelatedToPriorYears_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_NetProceeds_lbl0" xml:lang="en-US">NetProceeds</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_NetProceeds" xlink:to="tffp_NetProceeds_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_FairValueAssumptionsExpectedDividendRates_lbl0" xml:lang="en-US">FairValueAssumptionsExpectedDividendRates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FairValueAssumptionsExpectedDividendRates" xlink:to="tffp_FairValueAssumptionsExpectedDividendRates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AdditionsForTaxPositionsRelatedToCurrentYear_lbl1" xml:lang="en-US">AdditionsForTaxPositionsRelatedToCurrentYear</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AdditionsForTaxPositionsRelatedToCurrentYear" xlink:to="tffp_AdditionsForTaxPositionsRelatedToCurrentYear_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_FederalAndStateMember_lbl0" xml:lang="en-US">FederalAndStateMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FederalAndStateMember" xlink:to="tffp_FederalAndStateMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WeightedaverageRemainingContractualTermCancelled_lbl1" xml:lang="en-US">WeightedaverageRemainingContractualTermCancelled</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedaverageRemainingContractualTermCancelled" xlink:to="tffp_WeightedaverageRemainingContractualTermCancelled_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_FairValueAssumptionExercisePrice_lbl0" xml:lang="en-US">FairValueAssumptionExercisePrice</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FairValueAssumptionExercisePrice" xlink:to="tffp_FairValueAssumptionExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ForeignCurrencyTranslationAdjustments_lbl1" xml:lang="en-US">ForeignCurrencyTranslationAdjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ForeignCurrencyTranslationAdjustments" xlink:to="tffp_ForeignCurrencyTranslationAdjustments_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_FederalIncomeTaxNetOperatingLoss_lbl1" xml:lang="en-US">FederalIncomeTaxNetOperatingLoss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_FederalIncomeTaxNetOperatingLoss" xlink:to="tffp_FederalIncomeTaxNetOperatingLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises_lbl0" xml:lang="en-US">IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" xlink:to="tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_AssumptionsAbstract_lbl0" xml:lang="en-US">AssumptionsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_AssumptionsAbstract" xlink:to="tffp_AssumptionsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_WeightedaverageRemainingContractualTermExercised_lbl1" xml:lang="en-US">WeightedaverageRemainingContractualTermExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_WeightedaverageRemainingContractualTermExercised" xlink:to="tffp_WeightedaverageRemainingContractualTermExercised_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_MasterServicesMember_lbl0" xml:lang="en-US">MasterServicesMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_MasterServicesMember" xlink:to="tffp_MasterServicesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_TenYearsWarrantMember_lbl0" xml:lang="en-US">TenYearsWarrantMember</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_TenYearsWarrantMember" xlink:to="tffp_TenYearsWarrantMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised_lbl0" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised" xlink:to="tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_StockholdersEquityDescription_lbl1" xml:lang="en-US">StockholdersEquityDescription</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_StockholdersEquityDescription" xlink:to="tffp_StockholdersEquityDescription_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_LicenseAndAgreementsDisclosureTextBlock_lbl1" xml:lang="en-US">LicenseAndAgreementsDisclosureTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_LicenseAndAgreementsDisclosureTextBlock" xlink:to="tffp_LicenseAndAgreementsDisclosureTextBlock_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_PremarketingApprovals_lbl0" xml:lang="en-US">PremarketingApprovals</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_PremarketingApprovals" xlink:to="tffp_PremarketingApprovals_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_GeographicConcentrationsPolicyTextBlock_lbl0" xml:lang="en-US">GeographicConcentrationsPolicyTextBlock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_GeographicConcentrationsPolicyTextBlock" xlink:to="tffp_GeographicConcentrationsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_DeferredTaxAssetsAbstract_lbl0" xml:lang="en-US">DeferredTaxAssetsAbstract</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_DeferredTaxAssetsAbstract" xlink:to="tffp_DeferredTaxAssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_ExpireDate_lbl0" xml:lang="en-US">ExpireDate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_ExpireDate" xlink:to="tffp_ExpireDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars_lbl0" xml:lang="en-US">EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars" xlink:to="tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl0" xml:lang="en-US">Research and Development in Process</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl0" xml:lang="en-US">Liabilities, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl0" xml:lang="en-US">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl0" xml:lang="en-US">Furniture and Fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl0" xml:lang="en-US">Nonoperating Income (Expense)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl0" xml:lang="en-US">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SurplusNotes_lbl0" xml:lang="en-US">Surplus Notes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SurplusNotes" xlink:to="us-gaap_SurplusNotes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl0" xml:lang="en-US">Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl0" xml:lang="en-US">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0" xml:lang="en-US">AOCI Attributable to Parent [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl0" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl0" xml:lang="en-US">Deferred Policy Acquisition Costs, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:to="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0" xml:lang="en-US">Revenue [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl0" xml:lang="en-US">Common Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl0" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl0" xml:lang="en-US">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl0" xml:lang="en-US">Entity Incorporation, State or Country Code</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseCost_lbl0" xml:lang="en-US">Operating Lease, Cost</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl0" xml:lang="en-US">Assets, Current [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl0" xml:lang="en-US">Entity Shell Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl0" xml:lang="en-US">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl2" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock_lbl0" xml:lang="en-US">Foreign Currency Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:to="us-gaap_ForeignCurrencyDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredCompensationArrangementsOverallDescription_lbl0" xml:lang="en-US">Deferred Compensation Arrangements, Overall, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementsOverallDescription" xlink:to="us-gaap_DeferredCompensationArrangementsOverallDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FederalIncomeTaxNoteTextBlock_lbl0" xml:lang="en-US">Federal Income Tax Note [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FederalIncomeTaxNoteTextBlock" xlink:to="us-gaap_FederalIncomeTaxNoteTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl0" xml:lang="en-US">Other Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl0" xml:lang="en-US">Liabilities, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl0" xml:lang="en-US">Stock Issued During Period, Value, Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl0" xml:lang="en-US">Assets, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl0" xml:lang="en-US">Liabilities and Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl0" xml:lang="en-US">General and Administrative Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrivatePlacementMember_lbl0" xml:lang="en-US">Private Placement [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl0" xml:lang="en-US">Convertible Preferred Stock, Terms of Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl0" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl0" xml:lang="en-US">Other Accrued Liabilities, Noncurrent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPayableCurrent_lbl0" xml:lang="en-US">Dividends Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPayableCurrent" xlink:to="us-gaap_DividendsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl0" xml:lang="en-US">Additional Paid in Capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl0" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl1" xml:lang="en-US">Common Stock, Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0" xml:lang="en-US">Proceeds from Issuance of Private Placement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DividendsPreferredStockStock_lbl0" xml:lang="en-US">Dividends, Preferred Stock, Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DividendsPreferredStockStock" xlink:to="us-gaap_DividendsPreferredStockStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl0" xml:lang="en-US">Cash</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl0" xml:lang="en-US">Operating Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl0" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0" xml:lang="en-US">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl0" xml:lang="en-US">Equity Option [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl0" xml:lang="en-US">Other Preferred Stock Dividends and Adjustments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl0" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement, Activity [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl1" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Conversion Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl0" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl0" xml:lang="en-US">Entity File Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl0" xml:lang="en-US">Entity Small Business</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl0" xml:lang="en-US">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl0" xml:lang="en-US">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Period Increase (Decrease), Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl0" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl1" xml:lang="en-US">Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets_lbl0" xml:lang="en-US">Prepaid Expense and Other Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreconfirmationCashAndCashEquivalents_lbl0" xml:lang="en-US">Preconfirmation, Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreconfirmationCashAndCashEquivalents" xlink:to="us-gaap_PreconfirmationCashAndCashEquivalents_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl0" xml:lang="en-US">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0" xml:lang="en-US">Stock Issued During Period, Value, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl0" xml:lang="en-US">Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl0" xml:lang="en-US">Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl0" xml:lang="en-US">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl0" xml:lang="en-US">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0" xml:lang="en-US">Research and Development Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl0" xml:lang="en-US">Assets [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeriesAPreferredStockMember_lbl0" xml:lang="en-US">Series A Preferred Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesAPreferredStockMember" xlink:to="us-gaap_SeriesAPreferredStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl0" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl0" xml:lang="en-US">Common Stock, Value, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0" xml:lang="en-US">Proceeds from Issuance of Warrants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl0" xml:lang="en-US">Operating Loss Carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl0" xml:lang="en-US">Subsequent Events [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl0" xml:lang="en-US">Deferred Tax Assets, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0" xml:lang="en-US">Increase (Decrease) in Accounts Payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense_lbl1" xml:lang="en-US">Other Research and Development Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl2"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl0" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Other Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFeeAmount_lbl0" xml:lang="en-US">Debt Instrument, Fee Amount</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFeeAmount" xlink:to="us-gaap_DebtInstrumentFeeAmount_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl0" xml:lang="en-US">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl1" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl0" xml:lang="en-US">Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl0" xml:lang="en-US">Stockholders&apos; Equity Attributable to Parent [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl0" xml:lang="en-US">Proceeds from Warrant Exercises</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl0" xml:lang="en-US">IPO [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0" xml:lang="en-US">Stockholders&apos; Equity Note Disclosure [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl0" xml:lang="en-US">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl0" xml:lang="en-US">Retained Earnings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl1" xml:lang="en-US">Preferred Stock, Shares Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl0" xml:lang="en-US">Entity Emerging Growth Company</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl0" xml:lang="en-US">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl0" xml:lang="en-US">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl0" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl0" xml:lang="en-US">Entity Interactive Data Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl0" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl0" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockDividendRatePercentage_lbl0" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockDividendRatePercentage" xlink:to="us-gaap_PreferredStockDividendRatePercentage_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl0" xml:lang="en-US">Debt Instrument, Convertible, Beneficial Conversion Feature</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl0" xml:lang="en-US">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0" xml:lang="en-US">Deferred Tax Assets, in Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl0" xml:lang="en-US">Accounts Payable, Current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl0" xml:lang="en-US">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl0" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0" xml:lang="en-US">Compensation Related Costs, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl0" xml:lang="en-US">Operating Expenses [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl0" xml:lang="en-US">Tax Adjustments, Settlements, and Unusual Provisions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl0" xml:lang="en-US">Computer Equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0" xml:lang="en-US">General and Administrative Expense [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl0" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherIncomeAbstract_lbl0" xml:lang="en-US">Component of Operating Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_OtherIncomeAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl0" xml:lang="en-US">Entity Ex Transition Period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl1" xml:lang="en-US">Sale of Stock, Price Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl0" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNet_lbl0" xml:lang="en-US">Interest Income (Expense), Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_InterestIncomeExpenseNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConversionOfStockDescription_lbl0" xml:lang="en-US">Conversion of Stock, Description</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockDescription" xlink:to="us-gaap_ConversionOfStockDescription_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl0" xml:lang="en-US">Operating Leases, Rent Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl0" xml:lang="en-US">Property, Plant and Equipment, Net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0" xml:lang="en-US">Effective Income Tax Rate Reconciliation,Other Reconciling Items, Percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOptionReasonsForElection_lbl0" xml:lang="en-US">Fair Value, Option, Reasons for Election</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOptionReasonsForElection" xlink:to="us-gaap_FairValueOptionReasonsForElection_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax_lbl0" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl0" xml:lang="en-US">Operating Income (Loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionMember_lbl0" xml:lang="en-US">Options Held [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionMember" xlink:to="us-gaap_OptionMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl0" xml:lang="en-US">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl1" xml:lang="en-US">Warrant [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl1"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl0" xml:lang="en-US">Earnings Per Share, Basic and Diluted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl0"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssued_lbl0" xml:lang="en-US">Shares, Issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssued" xlink:to="us-gaap_SharesIssued_lbl0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <loc xlink:type="locator" xlink:label="srt_StatementScenarioAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementScenarioAxis"/>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>tffp-20201231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- Generated by CompSci Transform (tm) - http://www.compsciresources.com -->
<!-- Created: Tue Mar 09 20:01:28 EST 2021 -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ConsolidatedBalanceSheet" roleURI="http://tffp.com/role/ConsolidatedBalanceSheet"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ConsolidatedBalanceSheet_Parentheticals" roleURI="http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ConsolidatedIncomeStatement" roleURI="http://tffp.com/role/ConsolidatedIncomeStatement"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ShareholdersEquityType2or3" roleURI="http://tffp.com/role/ShareholdersEquityType2or3"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ConsolidatedCashFlow" roleURI="http://tffp.com/role/ConsolidatedCashFlow"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_OrganizationAndDescriptionOfBusiness" roleURI="http://tffp.com/role/OrganizationAndDescriptionOfBusiness"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_LiquidityandManagementsPlans" roleURI="http://tffp.com/role/LiquidityandManagementsPlans"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_SummaryofSignificantAccountingPolicies" roleURI="http://tffp.com/role/SummaryofSignificantAccountingPolicies"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_CommitmentsAndContingencies" roleURI="http://tffp.com/role/CommitmentsAndContingencies"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_LicenseandAgreements" roleURI="http://tffp.com/role/LicenseandAgreements"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_StockholdersEquity" roleURI="http://tffp.com/role/StockholdersEquity"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_Warrants" roleURI="http://tffp.com/role/Warrants"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_StockBasedCompensation" roleURI="http://tffp.com/role/StockBasedCompensation"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_IncomeTaxes" roleURI="http://tffp.com/role/IncomeTaxes"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_SubsequentEvents" roleURI="http://tffp.com/role/SubsequentEvents"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_AccountingPoliciesByPolicy" roleURI="http://tffp.com/role/AccountingPoliciesByPolicy"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_SummaryofSignificantAccountingPoliciesTables" roleURI="http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_CommitmentsAndContingenciesTables" roleURI="http://tffp.com/role/CommitmentsAndContingenciesTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_WarrantsTables" roleURI="http://tffp.com/role/WarrantsTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_StockBasedCompensationTables" roleURI="http://tffp.com/role/StockBasedCompensationTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_IncomeTaxesTables" roleURI="http://tffp.com/role/IncomeTaxesTables"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofBasicandDilutedEarningsperCommonShareTable" roleURI="http://tffp.com/role/ScheduleofBasicandDilutedEarningsperCommonShareTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleoffutureminimumleasepaymentsTable" roleURI="http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofwarrantactivityTable" roleURI="http://tffp.com/role/ScheduleofwarrantactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable" roleURI="http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleoffairvalueofemployeestockoptionsTable" roleURI="http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofstockoptionactivityTable" roleURI="http://tffp.com/role/ScheduleofstockoptionactivityTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofincometaxexpenseTable" roleURI="http://tffp.com/role/ScheduleofincometaxexpenseTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofdeferredtaxassetsTable" roleURI="http://tffp.com/role/ScheduleofdeferredtaxassetsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofprovisionfederalstatutoryrateTable" roleURI="http://tffp.com/role/ScheduleofprovisionfederalstatutoryrateTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_ScheduleofunrecognizedtaxpositionsTable" roleURI="http://tffp.com/role/ScheduleofunrecognizedtaxpositionsTable"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_OrganizationAndDescriptionOfBusinessDetails" roleURI="http://tffp.com/role/OrganizationAndDescriptionOfBusinessDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_LiquidityandManagementsPlansDetails" roleURI="http://tffp.com/role/LiquidityandManagementsPlansDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_SummaryofSignificantAccountingPoliciesDetails" roleURI="http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_CommitmentsAndContingenciesDetails" roleURI="http://tffp.com/role/CommitmentsAndContingenciesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_LicenseandAgreementsDetails" roleURI="http://tffp.com/role/LicenseandAgreementsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_StockholdersEquityDetails" roleURI="http://tffp.com/role/StockholdersEquityDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_WarrantsDetails" roleURI="http://tffp.com/role/WarrantsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_StockBasedCompensationDetails" roleURI="http://tffp.com/role/StockBasedCompensationDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_IncomeTaxesDetails" roleURI="http://tffp.com/role/IncomeTaxesDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#tffp_r_SubsequentEventsDetails" roleURI="http://tffp.com/role/SubsequentEventsDetails"/>
  <roleRef xlink:type="simple" xlink:href="tffp-20201231.xsd#DocumentAndEntityInformation" roleURI="http://tffp.com/role/DocumentAndEntityInformation"/>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedBalanceSheet">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="us-gaap_AssetsCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Assets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherLiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesNoncurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesNoncurrent" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Liabilities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherAccruedLiabilitiesNoncurrent" xlink:to="us-gaap_Liabilities" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedIncomeStatement">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_OperatingExpenses" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherIncomeAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherIncomeAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherIncomeAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_InterestIncomeExpenseNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestIncomeExpenseNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherIncomeAbstract" xlink:to="us-gaap_InterestIncomeExpenseNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InterestIncomeExpenseNet" xlink:to="us-gaap_NonoperatingIncomeExpense" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_ProfitLoss" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_PreferredStockDividendsIncomeStatementImpact" order="4.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherPreferredStockDividendsAndAdjustments" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherPreferredStockDividendsAndAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherPreferredStockDividendsAndAdjustments" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyTranslationAdjustments" xlink:href="tffp-20201231.xsd#tffp_ForeignCurrencyTranslationAdjustments"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="ForeignCurrencyTranslationAdjustments" order="10.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossTax" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossTax" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ShareholdersEquityType2or3">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementTable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementLineItems" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="4.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockForStockOptionExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockForStockOptionExercises" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockForStockOptionExercisesShares" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockForStockOptionExercisesShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockForStockOptionExercisesShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignCurrencyTranslationAdjustment" xlink:href="tffp-20201231.xsd#tffp_ForeignCurrencyTranslationAdjustment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="ForeignCurrencyTranslationAdjustment" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPreferredStockStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPreferredStockStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DividendsPreferredStockStock" order="14.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProfitLoss" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_0" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesOutstanding_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_0" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ConsolidatedCashFlow">
    <loc xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProfitLoss" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensation" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="StockBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseDeferredResearchGrantRevenue" xlink:href="tffp-20201231.xsd#tffp_IncreaseDecreaseDeferredResearchGrantRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseDeferredResearchGrantRevenue" order="2.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="IncreaseDecreaseInAccruedResearchAndDevelopmentExpense" xlink:href="tffp-20201231.xsd#tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="IncreaseDecreaseInAccruedResearchAndDevelopmentExpense" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfCommonStockValue" xlink:href="tffp-20201231.xsd#tffp_ProceedsFromIssuanceOfCommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStockValue" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ProceedsFromIssuanceOfCommonStockForStockOptionExercises" xlink:href="tffp-20201231.xsd#tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="ProceedsFromIssuanceOfCommonStockForStockOptionExercises" order="3.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="EffectOfExchangeRateChangesOnCashAndCashEquivalent" xlink:href="tffp-20201231.xsd#tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="EffectOfExchangeRateChangesOnCashAndCashEquivalent" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_0" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AccruedDividend" xlink:href="tffp-20201231.xsd#tffp_AccruedDividend"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="AccruedDividend" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock" xlink:href="tffp-20201231.xsd#tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OfferingCostsNettedWithProceedsFromIPO" xlink:href="tffp-20201231.xsd#tffp_OfferingCostsNettedWithProceedsFromIPO"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="OfferingCostsNettedWithProceedsFromIPO" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock" xlink:href="tffp-20201231.xsd#tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CashlessExerciseOfWarrants" xlink:href="tffp-20201231.xsd#tffp_CashlessExerciseOfWarrants"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="CashlessExerciseOfWarrants" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" xlink:href="tffp-20201231.xsd#tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/OrganizationAndDescriptionOfBusiness">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/LiquidityandManagementsPlans">
    <loc xlink:type="locator" xlink:label="LiquidityAndManagementsPlansAbstract" xlink:href="tffp-20201231.xsd#tffp_LiquidityAndManagementsPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="LiquidityAndManagementsPlansTextBlock" xlink:href="tffp-20201231.xsd#tffp_LiquidityAndManagementsPlansTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndManagementsPlansAbstract" xlink:to="LiquidityAndManagementsPlansTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/SummaryofSignificantAccountingPolicies">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/CommitmentsAndContingencies">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/LicenseandAgreements">
    <loc xlink:type="locator" xlink:label="LicenseAndAgreementsDisclosureAbstract" xlink:href="tffp-20201231.xsd#tffp_LicenseAndAgreementsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LicenseAndAgreementsDisclosureTextBlock" xlink:href="tffp-20201231.xsd#tffp_LicenseAndAgreementsDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAndAgreementsDisclosureAbstract" xlink:to="LicenseAndAgreementsDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/StockholdersEquity">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/Warrants">
    <loc xlink:type="locator" xlink:label="WarrantsAbstract" xlink:href="tffp-20201231.xsd#tffp_WarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsTextBlock" xlink:href="tffp-20201231.xsd#tffp_WarrantsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="WarrantsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/StockBasedCompensation">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/IncomeTaxes">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/SubsequentEvents">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/AccountingPoliciesByPolicy">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ForeignCurrencyDisclosureTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="GeographicConcentrationsPolicyTextBlock" xlink:href="tffp-20201231.xsd#tffp_GeographicConcentrationsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="GeographicConcentrationsPolicyTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonStockWarrantsPolicyTextBlock" xlink:href="tffp-20201231.xsd#tffp_CommonStockWarrantsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="CommonStockWarrantsPolicyTextBlock" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BeneficialConversionFeaturePolicyTextBlock" xlink:href="tffp-20201231.xsd#tffp_BeneficialConversionFeaturePolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="BeneficialConversionFeaturePolicyTextBlock" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CompensationRelatedCostsPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CompensationRelatedCostsPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CompensationRelatedCostsPolicyTextBlock" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/CommitmentsAndContingenciesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/WarrantsTables">
    <loc xlink:type="locator" xlink:label="WarrantsAbstract" xlink:href="tffp-20201231.xsd#tffp_WarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivity" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfWarrantActivity"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="ScheduleOfWarrantActivity" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/StockBasedCompensationTables">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/IncomeTaxesTables">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FederalIncomeTaxNoteTextBlock" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FederalIncomeTaxNoteTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_FederalIncomeTaxNoteTextBlock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ScheduleOfUnrecognizedTaxPositionsTableTextBlock" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="ScheduleOfUnrecognizedTaxPositionsTableTextBlock" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofBasicandDilutedEarningsperCommonShareTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfBasicAndDilutedEarningsPerCommonShareAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfBasicAndDilutedEarningsPerCommonShareAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable" xlink:href="tffp-20201231.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems" xlink:href="tffp-20201231.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfBasicAndDilutedEarningsPerCommonShareAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockOptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockOptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_StockOptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_WarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFutureMinimumLeasePaymentsAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFutureMinimumLeasePaymentsAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofwarrantactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfWarrantActivityAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfWarrantActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsScheduleofwarrantactivityTable" xlink:href="tffp-20201231.xsd#tffp_WarrantsDetailsScheduleofwarrantactivityTable"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:href="tffp-20201231.xsd#tffp_WarrantsDetailsScheduleofwarrantactivityLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfWarrantActivityAbstract" xlink:to="WarrantsDetailsScheduleofwarrantactivityTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityTable" xlink:to="WarrantsDetailsScheduleofwarrantactivityLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice_0" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice_0" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" xlink:href="tffp-20201231.xsd#tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsScheduleofwarrantactivityLineItems" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockBasedCompensationExpenseStockOptionsAndRestrictedStockAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfStockBasedCompensationExpenseStockOptionsAndRestrictedStockAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockBasedCompensationExpenseStockOptionsAndRestrictedStockAbstract" xlink:to="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable" xlink:to="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems" xlink:to="us-gaap_ShareBasedCompensation" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfFairValueOfEmployeeStockOptionsAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfFairValueOfEmployeeStockOptionsAbstract"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable"/>
    <loc xlink:type="locator" xlink:label="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:href="tffp-20201231.xsd#tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfFairValueOfEmployeeStockOptionsAbstract" xlink:to="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:to="srt_RangeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsTable" xlink:to="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<!-- [WMV5][XcpuxYn59dz7vgYynUDuwG7r97K2jUTysl7vcz0lJt/tSeJz73kx1cLt0ZFF2SK/vxBCY0vdSrZox5kKltS1j4H1Hm6x5rsVySu3GvyFidfKO4jLCc6vqlIAk2/hDR2bzzoxw5NX+h9OcfjdvrLHYAuwh2Zi7sQ0UOAQ0i8qn20R76xjgd36yBDZMSKJy6UF8YlRJlhDvltYdDBaXR3sWPsW9VT/9h3wyKkqYRK0lALx3+SAcoHi554Ul7Qas6aWvZyHzgVs3yWdX8pBQqs/1LEbTyYy2xOw] CSR-->
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofstockoptionactivityTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfStockOptionActivityAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfStockOptionActivityAbstract"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedaverageRemainingContractualTermOutstandingBeginningBalance1" xlink:href="tffp-20201231.xsd#tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="WeightedaverageRemainingContractualTermOutstandingBeginningBalance1" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedaverageRemainingContractualTermGranted" xlink:href="tffp-20201231.xsd#tffp_WeightedaverageRemainingContractualTermGranted"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="WeightedaverageRemainingContractualTermGranted" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="8.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedaverageRemainingContractualTermExercised" xlink:href="tffp-20201231.xsd#tffp_WeightedaverageRemainingContractualTermExercised"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="WeightedaverageRemainingContractualTermExercised" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_0" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WeightedaverageRemainingContractualTermCancelled" xlink:href="tffp-20201231.xsd#tffp_WeightedaverageRemainingContractualTermCancelled"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="WeightedaverageRemainingContractualTermCancelled" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIntrinsicValueCancelled" xlink:href="tffp-20201231.xsd#tffp_AggregateIntrinsicValueCancelled"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="AggregateIntrinsicValueCancelled" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_0" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber_0" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_0" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice_0" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" xlink:href="tffp-20201231.xsd#tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_0" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="21.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="22.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AggregateIntrinsicValueExercisable" xlink:href="tffp-20201231.xsd#tffp_AggregateIntrinsicValueExercisable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfStockOptionActivityAbstract" xlink:to="AggregateIntrinsicValueExercisable" order="23.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofincometaxexpenseTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfIncomeTaxExpenseAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfIncomeTaxExpenseAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxExpenseAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxExpenseAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredOtherTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredOtherTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxExpenseAbstract" xlink:to="us-gaap_DeferredOtherTaxExpenseBenefit" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfIncomeTaxExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofdeferredtaxassetsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfDeferredTaxAssetsAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfDeferredTaxAssetsAbstract"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsAbstract" xlink:href="tffp-20201231.xsd#tffp_DeferredTaxAssetsAbstract"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsAbstract" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLossCarryforwards"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_OperatingLossCarryforwards" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredTaxAssetsStockCompensation" xlink:href="tffp-20201231.xsd#tffp_DeferredTaxAssetsStockCompensation"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsAbstract" xlink:to="DeferredTaxAssetsStockCompensation" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DeferredTaxAssetsStockCompensation" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfDeferredTaxAssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofprovisionfederalstatutoryrateTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfProvisionFederalStatutoryRateAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars" xlink:href="tffp-20201231.xsd#tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences" xlink:href="tffp-20201231.xsd#tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:to="EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfProvisionFederalStatutoryRateAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/ScheduleofunrecognizedtaxpositionsTable">
    <loc xlink:type="locator" xlink:label="ScheduleOfUnrecognizedTaxPositionsAbstract" xlink:href="tffp-20201231.xsd#tffp_ScheduleOfUnrecognizedTaxPositionsAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable" xlink:href="tffp-20201231.xsd#tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" xlink:href="tffp-20201231.xsd#tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ScheduleOfUnrecognizedTaxPositionsAbstract" xlink:to="IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="FederalAndStateMember" xlink:href="tffp-20201231.xsd#tffp_FederalAndStateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="FederalAndStateMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsTable" xlink:to="IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="UncertainTaxPositionsBegnningBalance" xlink:href="tffp-20201231.xsd#tffp_UncertainTaxPositionsBegnningBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" xlink:to="UncertainTaxPositionsBegnningBalance" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <loc xlink:type="locator" xlink:label="AdditionsForTaxPositionsRelatedToCurrentYear" xlink:href="tffp-20201231.xsd#tffp_AdditionsForTaxPositionsRelatedToCurrentYear"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" xlink:to="AdditionsForTaxPositionsRelatedToCurrentYear" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DecreasesForTaxPositionsRelatedToPriorYears" xlink:href="tffp-20201231.xsd#tffp_DecreasesForTaxPositionsRelatedToPriorYears"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" xlink:to="DecreasesForTaxPositionsRelatedToPriorYears" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UncertainTaxPositionsEndingBalance" xlink:href="tffp-20201231.xsd#tffp_UncertainTaxPositionsEndingBalance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems" xlink:to="UncertainTaxPositionsEndingBalance" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/OrganizationAndDescriptionOfBusinessDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="ExchangeOfCommonStock" xlink:href="tffp-20201231.xsd#tffp_ExchangeOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ExchangeOfCommonStock" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharePrice" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SharePrice" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="OrganizationAndDescriptionsOfBusinessDescription" xlink:href="tffp-20201231.xsd#tffp_OrganizationAndDescriptionsOfBusinessDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="OrganizationAndDescriptionsOfBusinessDescription" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ReceivedNetProceeds" xlink:href="tffp-20201231.xsd#tffp_ReceivedNetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="ReceivedNetProceeds" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/LiquidityandManagementsPlansDetails">
    <loc xlink:type="locator" xlink:label="LiquidityAndManagementsPlansAbstract" xlink:href="tffp-20201231.xsd#tffp_LiquidityAndManagementsPlansAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreconfirmationCashAndCashEquivalents" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreconfirmationCashAndCashEquivalents"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndManagementsPlansAbstract" xlink:to="us-gaap_PreconfirmationCashAndCashEquivalents" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SurplusNotes" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SurplusNotes"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LiquidityAndManagementsPlansAbstract" xlink:to="us-gaap_SurplusNotes" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:href="tffp-20201231.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="SummaryofSignificantAccountingPoliciesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ComputerEquipmentMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ComputerEquipmentMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_RangeAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="srt_RangeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_RangeMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0.0"/>
    <loc xlink:type="locator" xlink:label="srt_MinimumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="srt_MaximumMember" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsTable" xlink:to="SummaryofSignificantAccountingPoliciesDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="MaintenanceOfPropertyAndEquipment" xlink:href="tffp-20201231.xsd#tffp_MaintenanceOfPropertyAndEquipment"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="MaintenanceOfPropertyAndEquipment" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_Cash" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Cash"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_Cash" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DeferredResearchGrantRevenue" xlink:href="tffp-20201231.xsd#tffp_DeferredResearchGrantRevenue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="DeferredResearchGrantRevenue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleConversionPrice1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleConversionPrice1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleConversionPrice1" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConversionPricePercentage" xlink:href="tffp-20201231.xsd#tffp_ConversionPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="ConversionPricePercentage" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SummaryofSignificantAccountingPoliciesDetailsLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/CommitmentsAndContingenciesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="ExpireDate" xlink:href="tffp-20201231.xsd#tffp_ExpireDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="ExpireDate" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseAndRentalExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseAndRentalExpense" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OperatingLeaseCost" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseCost"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/LicenseandAgreementsDetails">
    <loc xlink:type="locator" xlink:label="LicenseAndAgreementsDisclosureAbstract" xlink:href="tffp-20201231.xsd#tffp_LicenseAndAgreementsDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="LicenseandAgreementsDetailsTable" xlink:href="tffp-20201231.xsd#tffp_LicenseandAgreementsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="LicenseandAgreementsDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_LicenseandAgreementsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseAndAgreementsDisclosureAbstract" xlink:to="LicenseandAgreementsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="srt_ProductOrServiceAxis" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsTable" xlink:to="srt_ProductOrServiceAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="srt_ProductsAndServicesDomain" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="MasterServicesMember" xlink:href="tffp-20201231.xsd#tffp_MasterServicesMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="MasterServicesMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IrisysLlcMember" xlink:href="tffp-20201231.xsd#tffp_IrisysLlcMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="IrisysLlcMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CoreRxMember" xlink:href="tffp-20201231.xsd#tffp_CoreRxMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="CoreRxMember" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ConformClinicalDevelopmentIncMember" xlink:href="tffp-20201231.xsd#tffp_ConformClinicalDevelopmentIncMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="ConformClinicalDevelopmentIncMember" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NovotechAustraliaPtyLtdMember" xlink:href="tffp-20201231.xsd#tffp_NovotechAustraliaPtyLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="NovotechAustraliaPtyLtdMember" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NucleusNetworkPtyLtdMember" xlink:href="tffp-20201231.xsd#tffp_NucleusNetworkPtyLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="NucleusNetworkPtyLtdMember" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="QPharmPtyLtdMember" xlink:href="tffp-20201231.xsd#tffp_QPharmPtyLtdMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="QPharmPtyLtdMember" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsTable" xlink:to="LicenseandAgreementsDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DebtInstrumentFeeAmount" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtInstrumentFeeAmount"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_DebtInstrumentFeeAmount" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="MilestoneFee" xlink:href="tffp-20201231.xsd#tffp_MilestoneFee"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="MilestoneFee" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="CommonShareOutstandingPricePercentage" xlink:href="tffp-20201231.xsd#tffp_CommonShareOutstandingPricePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="CommonShareOutstandingPricePercentage" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AmountOfCommonShareDuePayable" xlink:href="tffp-20201231.xsd#tffp_AmountOfCommonShareDuePayable"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="AmountOfCommonShareDuePayable" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FairValueOptionReasonsForElection" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueOptionReasonsForElection"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_FairValueOptionReasonsForElection" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ClosingStockPrice" xlink:href="tffp-20201231.xsd#tffp_ClosingStockPrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="ClosingStockPrice" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="DescriptionOfLicenseAndAgreements" xlink:href="tffp-20201231.xsd#tffp_DescriptionOfLicenseAndAgreements"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="DescriptionOfLicenseAndAgreements" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="AgreementTremDescription" xlink:href="tffp-20201231.xsd#tffp_AgreementTremDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="AgreementTremDescription" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="PremarketingApprovals" xlink:href="tffp-20201231.xsd#tffp_PremarketingApprovals"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="LicenseandAgreementsDetailsLineItems" xlink:to="PremarketingApprovals" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/StockholdersEquityDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsTable" xlink:href="tffp-20201231.xsd#tffp_StockholdersEquityDetailsTable"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_StockholdersEquityDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="StockholdersEquityDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PrivatePlacementMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrivatePlacementMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsTable" xlink:to="StockholdersEquityDetailsLineItems" order="3.0"/>
    <loc xlink:type="locator" xlink:label="StockholdersEquityDescription" xlink:href="tffp-20201231.xsd#tffp_StockholdersEquityDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="StockholdersEquityDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAssumptionExercisePrice" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionExercisePrice"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="FairValueAssumptionExercisePrice" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPrivatePlacement"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPrivatePlacement" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="NetProceeds" xlink:href="tffp-20201231.xsd#tffp_NetProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="NetProceeds" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockForStockOptionExerciseShares" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockForStockOptionExerciseShares"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="IssuanceOfCommonStockForStockOptionExerciseShares" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="StockOptionExercisesTotalProceeds" xlink:href="tffp-20201231.xsd#tffp_StockOptionExercisesTotalProceeds"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="StockOptionExercisesTotalProceeds" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockWarrant" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockWarrant"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="IssuanceOfCommonStockWarrant" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockDividendRatePercentage" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_PreferredStockDividendRatePercentage" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DividendsPayableCurrent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DividendsPayableCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_DividendsPayableCurrent" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConversionOfStockDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConversionOfStockDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConversionOfStockDescription" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ConvertiblePreferredStockTermsOfConversion" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConvertiblePreferredStockTermsOfConversion"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityDetailsLineItems" xlink:to="us-gaap_ConvertiblePreferredStockTermsOfConversion" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/WarrantsDetails">
    <loc xlink:type="locator" xlink:label="WarrantsAbstract" xlink:href="tffp-20201231.xsd#tffp_WarrantsAbstract"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsTable" xlink:href="tffp-20201231.xsd#tffp_WarrantsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="WarrantsDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_WarrantsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsAbstract" xlink:to="WarrantsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementClassOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfStockDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfStockDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SeriesAPreferredStockMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SeriesAPreferredStockMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_SeriesAPreferredStockMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BPDirectorsMember" xlink:href="tffp-20201231.xsd#tffp_BPDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="BPDirectorsMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="NationalSecuritiesCorporationsWarrantsMember" xlink:href="tffp-20201231.xsd#tffp_NationalSecuritiesCorporationsWarrantsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="NationalSecuritiesCorporationsWarrantsMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TenYearsWarrantMember" xlink:href="tffp-20201231.xsd#tffp_TenYearsWarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="TenYearsWarrantMember" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IPOMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IPOMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_IPOMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="BPDirectorsMember_0" xlink:href="tffp-20201231.xsd#tffp_BPDirectorsMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="BPDirectorsMember_0" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsTable" xlink:to="WarrantsDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantToPurchaseSharesOfCommonStock" xlink:href="tffp-20201231.xsd#tffp_WarrantToPurchaseSharesOfCommonStock"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="WarrantToPurchaseSharesOfCommonStock" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAssumptionsCommonStockValue" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionsCommonStockValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="FairValueAssumptionsCommonStockValue" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAssumptionsExpectedTerms" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionsExpectedTerms"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="FairValueAssumptionsExpectedTerms" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAssumptionsExpectedDividendRates" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionsExpectedDividendRates"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="FairValueAssumptionsExpectedDividendRates" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAssumptionExpectedVolatilityRate" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionExpectedVolatilityRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="FairValueAssumptionExpectedVolatilityRate" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FairValueAssumptionRiskFreeInterestRate" xlink:href="tffp-20201231.xsd#tffp_FairValueAssumptionRiskFreeInterestRate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="FairValueAssumptionRiskFreeInterestRate" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="us-gaap_OtherResearchAndDevelopmentExpense" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare" xlink:href="tffp-20201231.xsd#tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="WarrantOutstandingAggregateIntrinsicValue" xlink:href="tffp-20201231.xsd#tffp_WarrantOutstandingAggregateIntrinsicValue"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="WarrantsDetailsLineItems" xlink:to="WarrantOutstandingAggregateIntrinsicValue" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/StockBasedCompensationDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementsOverallDescription" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredCompensationArrangementsOverallDescription"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DeferredCompensationArrangementsOverallDescription" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" xlink:href="tffp-20201231.xsd#tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/IncomeTaxesDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsTable" xlink:href="tffp-20201231.xsd#tffp_IncomeTaxesDetailsTable"/>
    <loc xlink:type="locator" xlink:label="IncomeTaxesDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_IncomeTaxesDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="IncomeTaxesDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="EffectiveTaxRateMember" xlink:href="tffp-20201231.xsd#tffp_EffectiveTaxRateMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="EffectiveTaxRateMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsTable" xlink:to="IncomeTaxesDetailsLineItems" order="2.0"/>
    <loc xlink:type="locator" xlink:label="FederalIncomeTaxNetOperatingLoss" xlink:href="tffp-20201231.xsd#tffp_FederalIncomeTaxNetOperatingLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="FederalIncomeTaxNetOperatingLoss" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="ForeignIncomeTaxNetOperatingLoss" xlink:href="tffp-20201231.xsd#tffp_ForeignIncomeTaxNetOperatingLoss"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="ForeignIncomeTaxNetOperatingLoss" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="FederalTaxCreditExpire" xlink:href="tffp-20201231.xsd#tffp_FederalTaxCreditExpire"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="FederalTaxCreditExpire" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="TaxableIncomeForLosses" xlink:href="tffp-20201231.xsd#tffp_TaxableIncomeForLosses"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="TaxableIncomeForLosses" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="UncertainTaxPositions" xlink:href="tffp-20201231.xsd#tffp_UncertainTaxPositions"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxesDetailsLineItems" xlink:to="UncertainTaxPositions" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/SubsequentEventsDetails">
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsTable" xlink:href="tffp-20201231.xsd#tffp_SubsequentEventsDetailsTable"/>
    <loc xlink:type="locator" xlink:label="SubsequentEventsDetailsLineItems" xlink:href="tffp-20201231.xsd#tffp_SubsequentEventsDetailsLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="SubsequentEventsDetailsTable" order="1.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_WarrantMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WarrantMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_FinancialInstrumentAxis" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <loc xlink:type="locator" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_OptionMember" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OptionMember"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_OptionMember" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsTable" xlink:to="SubsequentEventsDetailsLineItems" order="4.0"/>
    <loc xlink:type="locator" xlink:label="us-gaap_SharesIssued" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharesIssued"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_SharesIssued" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromWarrantExercises"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="SubsequentEventsDetailsLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
  <presentationLink xlink:type="extended" xlink:role="http://tffp.com/role/DocumentAndEntityInformation">
    <loc xlink:type="locator" xlink:label="DocumentAndEntityInformationAbstract" xlink:href="tffp-20201231.xsd#tffp_DocumentAndEntityInformationAbstract"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationTable"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentInformationLineItems"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentInformationTable" order="1.0"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" order="1.0"/>
    <loc xlink:type="locator" xlink:label="dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" order="0.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" order="1.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" order="2.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" order="3.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" order="4.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" order="5.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" order="6.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" order="7.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" order="8.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" order="9.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" order="11.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" order="12.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" order="13.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" order="14.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" order="15.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" order="16.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityExTransitionPeriod"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityExTransitionPeriod" order="17.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" order="18.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" order="19.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <loc xlink:type="locator" xlink:label="dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent"/>
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" order="20.0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837129388248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Mar. 05, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TFF Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,139,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 83,662,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001733413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837131001176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,300,805<span></span>
</td>
<td class="nump">$ 28,094,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid assets and other current assets</a></td>
<td class="nump">2,258,229<span></span>
</td>
<td class="nump">1,092,462<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">37,559,034<span></span>
</td>
<td class="nump">29,187,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">1,102,808<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">38,661,842<span></span>
</td>
<td class="nump">29,187,398<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,297,725<span></span>
</td>
<td class="nump">410,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Deferred research grant revenue</a></td>
<td class="nump">24,315<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">1,322,040<span></span>
</td>
<td class="nump">410,638<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesNoncurrent', window );">Accrued research and development expense (see Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,132,013<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,322,040<span></span>
</td>
<td class="nump">1,542,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (see Note 4)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock; $0.001 par value, 45,000,000 shares authorized; 22,534,874 and 18,450,992 shares issued and outstanding as of December 31, 2020 and 2019, respectively</a></td>
<td class="nump">22,535<span></span>
</td>
<td class="nump">18,451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">71,648,453<span></span>
</td>
<td class="nump">43,338,710<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(51,538)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(34,279,648)<span></span>
</td>
<td class="num">(15,712,414)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">37,339,802<span></span>
</td>
<td class="nump">27,644,747<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 38,661,842<span></span>
</td>
<td class="nump">$ 29,187,398<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated adjustment, net of tax, that results from the process of translating subsidiary financial statements and foreign equity investments into the reporting currency from the functional currency of the reporting entity, net of reclassification of realized foreign currency translation gains or losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=116690757&amp;loc=SL116692626-108610<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837226617384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in Dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">45,000,000<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">22,534,874<span></span>
</td>
<td class="nump">18,450,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">22,534,874<span></span>
</td>
<td class="nump">18,450,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837131068120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 10,681,565<span></span>
</td>
<td class="nump">$ 8,822,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">8,012,085<span></span>
</td>
<td class="nump">3,165,331<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">18,693,650<span></span>
</td>
<td class="nump">11,987,557<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(18,693,650)<span></span>
</td>
<td class="num">(11,987,557)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNet', window );">Interest income</a></td>
<td class="nump">126,416<span></span>
</td>
<td class="nump">117,329<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">126,416<span></span>
</td>
<td class="nump">117,329<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(18,567,234)<span></span>
</td>
<td class="num">(11,870,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Preferred stock dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(875,359)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPreferredStockDividendsAndAdjustments', window );">Deemed dividend for beneficial conversion feature of Series A Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(23,929,751)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common stock</a></td>
<td class="num">$ (18,567,234)<span></span>
</td>
<td class="num">$ (36,675,338)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss applicable to common stock per share, basic and diluted (in Dollars per share)</a></td>
<td class="num">$ (0.91)<span></span>
</td>
<td class="num">$ (5.31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding, basic and diluted (in Shares)</a></td>
<td class="nump">20,425,162<span></span>
</td>
<td class="nump">6,904,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,567,234)<span></span>
</td>
<td class="num">$ (11,870,228)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ForeignCurrencyTranslationAdjustments', window );">Foreign currency translation adjustments</a></td>
<td class="num">(51,538)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Comprehensive loss</a></td>
<td class="num">$ (18,618,772)<span></span>
</td>
<td class="num">$ (11,870,228)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ForeignCurrencyTranslationAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign currency translation adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ForeignCurrencyTranslationAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of operating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e640-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPreferredStockDividendsAndAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of preferred stock dividends and adjustments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1377-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 7<br> -Subparagraph (SAB Topic 5.Q)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187283-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPreferredStockDividendsAndAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837129429176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders&#8217; Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 596,724<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">$ (3,842,186)<span></span>
</td>
<td class="num">$ (3,241,462)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2018</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount', window );">Issuance of common stock in connection with IPO, including underwriter&#8217;s over- allotment, net of offering costs and underwriter&#8217;s discount</a></td>
<td class="nump">$ 4,879<span></span>
</td>
<td class="nump">21,748,969<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">21,753,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares', window );">Issuance of common stock in connection with IPO, including underwriter&#8217;s over- allotment, net of offering costs and underwriter&#8217;s discount (in Shares)</a></td>
<td class="nump">4,879,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">590,041<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">590,041<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockStock', window );">Dividends on preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(875,359)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(875,359)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of Series A Preferred Stock (including accrued dividends) to common stock</a></td>
<td class="nump">$ 9,572<span></span>
</td>
<td class="nump">21,278,335<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">21,287,907<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of Series A Preferred Stock (including accrued dividends) to common stock (in Shares)</a></td>
<td class="nump">9,571,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(11,870,228)<span></span>
</td>
<td class="num">(11,870,228)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 18,451<span></span>
</td>
<td class="nump">43,338,710<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(15,712,414)<span></span>
</td>
<td class="nump">27,644,747<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2019</a></td>
<td class="nump">18,450,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Sale of common stock, net of offering costs</a></td>
<td class="nump">$ 3,048<span></span>
</td>
<td class="nump">24,277,235<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">24,280,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Sale of common stock, net of offering costs (in Shares)</a></td>
<td class="nump">3,048,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Issuance of common stock for accrued research and development expense</a></td>
<td class="nump">$ 221<span></span>
</td>
<td class="nump">1,131,792<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">1,132,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense', window );">Issuance of common stock for accrued research and development expense (in Shares)</a></td>
<td class="nump">220,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockForStockOptionExercises', window );">Issuance of common stock for stock option exercises</a></td>
<td class="nump">$ 285<span></span>
</td>
<td class="nump">714,097<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">714,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockForStockOptionExercisesShares', window );">Issuance of common stock for stock option exercises (in Shares)</a></td>
<td class="nump">285,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises', window );">Issuance of common stock in connection with cashless warrant exercises</a></td>
<td class="nump">$ 530<span></span>
</td>
<td class="num">(530)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares', window );">Issuance of common stock in connection with cashless warrant exercises (in Shares)</a></td>
<td class="nump">529,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,187,149<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">2,187,149<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ForeignCurrencyTranslationAdjustment', window );">Foreign currency translation adjustment</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(51,538)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(51,538)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(18,567,234)<span></span>
</td>
<td class="num">(18,567,234)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 22,535<span></span>
</td>
<td class="nump">$ 71,648,453<span></span>
</td>
<td class="num">$ (51,538)<span></span>
</td>
<td class="num">$ (34,279,648)<span></span>
</td>
<td class="nump">$ 37,339,802<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in Shares) at Dec. 31, 2020</a></td>
<td class="nump">22,534,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ForeignCurrencyTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign currency translation adjustment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ForeignCurrencyTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock for accrued research and development expense, Shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockForAccruedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockForStockOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockForStockOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockForStockOptionExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockForStockOptionExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockInConnectionWithIpoIncludingUnderwritersOverAllotmentNetOfOfferingCostsAndUnderwritersDiscountShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837131196040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (18,567,234)<span></span>
</td>
<td class="num">$ (11,870,228)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustment to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">2,187,149<span></span>
</td>
<td class="nump">590,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaid assets</a></td>
<td class="num">(1,122,495)<span></span>
</td>
<td class="num">(1,080,397)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">862,676<span></span>
</td>
<td class="nump">12,449<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IncreaseDecreaseDeferredResearchGrantRevenue', window );">Deferred research grant revenue</a></td>
<td class="nump">24,315<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense', window );">Accrued research and development expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,132,013<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(16,615,589)<span></span>
</td>
<td class="num">(11,216,122)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(1,102,808)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1,102,808)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock in connection with IPO</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,851,160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Net proceeds from issuance of preferred stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,198,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ProceedsFromIssuanceOfCommonStockValue', window );">Net proceeds from issuance of common stock</a></td>
<td class="nump">24,280,283<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises', window );">Proceeds from issuance of common stock for stock option exercises</a></td>
<td class="nump">714,382<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">24,994,665<span></span>
</td>
<td class="nump">29,049,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(70,399)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">7,205,869<span></span>
</td>
<td class="nump">17,833,265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">28,094,936<span></span>
</td>
<td class="nump">10,261,671<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">35,300,805<span></span>
</td>
<td class="nump">28,094,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AccruedDividend', window );">Accrued dividend</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">875,359<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock', window );">Conversion of Series A Preferred Stock (including accrued dividends) to common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">21,287,907<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_OfferingCostsNettedWithProceedsFromIPO', window );">Offering costs netted with proceeds from IPO</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">97,312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock', window );">Deemed dividend for beneficial conversion feature of Series A Preferred Stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">23,929,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_CashlessExerciseOfWarrants', window );">Cashless exercise of warrants</a></td>
<td class="nump">530<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock', window );">Issuance of common stock for accrued research and development expense</a></td>
<td class="nump">$ 1,132,013<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AccruedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accrued dividend.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AccruedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_CashlessExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_CashlessExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Series A Preferred Stock (including accrued dividends) to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ConversionOfSeriesAPreferredStockincludingAccruedDividendsToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount related to Conversion of Series A Preferred Stock (including accrued dividends) to common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ConversionOfSeriesPreferredStockIncludingAccruedDividendsToCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_DeemedDividendForBeneficialConversionFeatureOfSeriesAPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_EffectOfExchangeRateChangesOnCashAndCashEquivalent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IncreaseDecreaseDeferredResearchGrantRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IncreaseDecreaseDeferredResearchGrantRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IncreaseDecreaseInAccruedResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_OfferingCostsNettedWithProceedsFromIPO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_OfferingCostsNettedWithProceedsFromIPO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ProceedsFromIssuanceOfCommonStockForStockOptionExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ProceedsFromIssuanceOfCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ProceedsFromIssuanceOfCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_StockBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_StockBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837139501160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization And Description Of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">ORGANIZATION AND DESCRIPTION OF BUSINESS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><font style="text-decoration:underline">NOTE 1 &#x2013; ORGANIZATION AND DESCRIPTION OF BUSINESS</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">TFF Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;)
was incorporated in the State of Delaware on January 24, 2018 by Lung Therapeutics, Inc. (&#x201c;LTI&#x201d;), at which time the
Company and LTI entered into a Contribution and Subscription Agreement (&#x201c;Contribution Agreement&#x201d;) pursuant to which
LTI agreed to transfer to the Company certain of LTI&#x2019;s non-core intellectual property rights and other assets, including
LTI&#x2019;s rights under a patent license agreement with the University of Texas at Austin (see Note 5), in exchange for 4,000,000
shares of the Company&#x2019;s common stock. The transactions under the Contribution Agreement closed in March 2018. LTI&#x2019;s
basis in such assets were minimal. LTI is an early-stage biotechnology company focused on the development of certain technologies
in the pulmonary field. The Company&#x2019;s initial focus is on the development of inhaled dry powder drugs to enhance the treatment
of pulmonary diseases and conditions. In December 2019, the Company established a wholly-owned Australian subsidiary, TFF Pharmaceuticals
Australia Pty Ltd (&#x201c;TFF Australia&#x201d;), in order to conduct clinical research. TFF Pharmaceuticals, Inc., along with TFF
Australia, are collectively referred to as the &#x201c;Company&#x201d;. The Company is in the development stage and is devoting substantially
all of its efforts toward technology research and development.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>October 2019 Initial Public Offering</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In October 2019, the Company completed
an initial public offering (&#x201c;IPO&#x201d;), selling 4,400,000 shares of common stock at an offering price of $5.00 per share.
The Company received gross proceeds of approximately $22,000,000. In addition, the Company granted the underwriter a 45-day option
to purchase an additional 660,000 shares of common stock at the initial public offering price, less underwriting discounts and
commissions. The option was exercised in November 2019 and the underwriter purchased an additional 479,300 shares of common stock
and the Company received additional gross proceeds of approximately $2,397,000.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>August 2020 Private Placement</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 13, 2020, the Company conducted
a private placement of 3,048,654 shares of its common stock, at a purchase price per share of $8.50, for aggregate gross proceeds
to the Company of approximately $25,914,000, before deducting selling commissions and other offering expenses payable by the Company.
After deducting the placement agent and other offering expenses, the Company received net proceeds of approximately $24,280,000.
See Note 6 for additional details of the private placement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>COVID-19</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On March 11, 2020, the World Health Organization
declared a novel strain of coronavirus disease (&#x201c;COVID-19&#x201d;) a global pandemic. At this time, the United States and
certain other countries are the subject of lock-downs and self-isolation procedures, which have significantly limited business
operations and restricted internal and external meetings.&#xa0;The Company had expected to commence Phase I clinical trials of
its thin film freezing, or TFF, formulation of Tacrolimus in Australia in the first quarter of 2020, and on March 13, 2020 the
Company received the approval of the Alfred Hospital Human Research Ethics Committee to commence Phase I trials, however, later
in March 2020, the Company&#x2019;s contract research organization in Australia informed the Company that because of the spread
of the COVID-19 virus in Australia, there would be a delay in initiating the trial. During the second quarter of 2020, the Company
was able to begin dosing in the Phase I Tacrolimus trial in Melbourne, Victoria, Australia. However, due to the resurgence of COVID-19
in the Melbourne area, in July 2020 the Phase I trials were delayed. With the flaring of COVID-19 in the Melbourne area and in
order to remain dynamic, the Company opened a second clinical trial site in Brisbane, Queensland, Australia. and dosing in the
Phase 1 clinical trial resumed in Australia during the third quarter 2020. We expect that dosing in this trial will be completed
early in the second quarter of 2021. Any financial impact from the COVID-19 global pandemic cannot be reasonably estimated at this
time, but may materially affect our business and financial condition. The extent to which COVID-19 impacts our results will depend
on future developments, which are highly uncertain and cannot be predicted, including new information which may emerge concerning
the severity of COVID-19 and the actions to contain COVID-19 or treat its impact, among others.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837139466872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity and Management&#8217;s Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LiquidityAndManagementsPlansAbstract', window );"><strong>Liquidity And Managements Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LiquidityAndManagementsPlansTextBlock', window );">LIQUIDITY AND MANAGEMENT&#8217;S PLANS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><font style="text-decoration:underline">NOTE 2 &#x2013; LIQUIDITY AND MANAGEMENT&#x2019;S PLANS</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2020, the Company had
cash and cash equivalents of approximately $35,301,000 and a working capital surplus of approximately $36,237,000. The Company
has not generated revenues since inception and has incurred recurring operating losses. The Company expects to continue incurring
losses for the foreseeable future and may need to raise additional capital to pursue its product development.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company expects to further increase
its research and development activities, which will increase the amount of cash utilized subsequent to December 31, 2020. Specifically,
the Company expects increased spending on research and development activities and higher payroll expenses as it increases its professional
and scientific staff and continues to prepare for anticipated manufacturing activities. If we encounter unforeseen delays or expenses,
we have the ability to curtail our presently planned level of operations. The Company currently believes its existing cash and
cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements for at least the next 12
months from the date of issuance of these consolidated financial statements.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_LiquidityAndManagementsPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_LiquidityAndManagementsPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_LiquidityAndManagementsPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_LiquidityAndManagementsPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837135034792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><font style="text-decoration:underline">NOTE 3 &#x2013; SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Basis of Presentation</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company&#x2019;s consolidated financial
statements are presented in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;)
and the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and reflect the financial position,
results of operations and cash flows for all periods presented.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Principles of Consolidation</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The consolidated financial statements include
the accounts of TFF Pharmaceuticals, Inc. and its wholly-owned subsidiary, TFF Australia. All material intercompany accounts and
transactions have been eliminated in consolidation.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Foreign Currency</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The currency of TFF Australia, the Company&#x2019;s
international subsidiary, is in Australian dollars. Foreign currency denominated assets and liabilities are translated into U.S.
dollars using the exchange rates in effect at each balance sheet date. Results of operations and cash flows are translated using
the average exchange rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities
is included as a separate component of stockholders&#x2019; equity in accumulated other comprehensive income (loss).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Geographic Concentrations</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company conducts business in the U.S.
and Australia. As of December 31, 2020, the Company maintained 100% of its net property and equipment in the U.S. There was no
property and equipment as of December 31, 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Deferred Offering Costs</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company complies with the requirements
of Accounting Standards Codification (&#x201c;ASC&#x201d;) 340, <i>Other Assets and Deferred Costs</i>. Deferred offering costs of
consisted primarily of legal, accounting and filing fees that were related to the Company&#x2019;s IPO and were charged to capital
upon completion of the IPO in October 2019. There are no deferred offering costs as of December&#xa0;31, 2020 and 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company maintains its operating accounts
in financial institutions in the U.S. and in Australia. The balances are insured up to specified limits. The Company&#x2019;s cash
is maintained in checking accounts and money market funds with maturities of less than three months when purchased, which are readily
convertible to known amounts of cash, and which in the opinion of management are subject to insignificant risk of loss in value.
As of December 31, 2020 and 2019, the Company had cash in Australia of AUD$214,240 (US$165,092) and $0, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Property and Equipment</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Property and equipment are stated at cost
less accumulated depreciation and amortization. The Company calculates depreciation using the straight-line method over the estimated
useful lives of the assets, which range from&#xa0;two&#xa0;to&#xa0;five&#xa0;years for furniture, fixtures, lab and computer equipment
and software. Assets held within construction in progress are not depreciated. Construction in progress is related to the construction
or development of property and equipment that have not yet been placed in service for its intended use. As of December 31, 2020,
all of the Company&#x2019;s property and equipment consist of lab equipment that are considered construction in progress. Expenditures
for repairs and maintenance of assets are charged to expense as incurred.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Authoritative guidance requires disclosure
of the fair value of financial instruments. The Company&#x2019;s financial instruments consist of cash and cash equivalents and
accounts payable, the carrying amounts of which approximate their estimated fair values primarily due to the short-term nature
of the instruments or based on information obtained from market sources and management estimates. The Company measures the fair
value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality
and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value which
is not equivalent to cost will be classified and disclosed in one of the following three categories:</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Level 1 &#x2014; Quoted prices (unadjusted)
in active markets for identical assets and liabilities.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Level 2 &#x2014; Inputs other than Level
1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted
quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market
data for substantially the full term of the assets or liabilities.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Level 3 &#x2014; Unobservable inputs that
are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Income Taxes</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In accordance with authoritative guidance,
deferred tax assets and liabilities are recorded for temporary differences between the financial reporting and tax bases of assets
and liabilities using the current enacted tax rate expected to be in effect when the differences are expected to reverse. A valuation
allowance is recorded on deferred tax assets unless realization is considered more likely than not.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company evaluates its tax positions
taken or expected to be taken in the course of preparing the Company&#x2019;s tax returns to determine whether the tax positions
are &#x201c;more-likely-than-not&#x201d; of being sustained by the applicable tax authority. Tax positions not deemed to meet the
&#x201c;more-likely-than-not&#x201d; threshold are not recorded as a tax benefit or expense in the current year. The Company recognizes
interest and penalties, if any, related to uncertain tax positions in interest expense. No interest and penalties related to uncertain
tax positions were accrued at either December&#xa0;31, 2020 or 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company follows authoritative guidance
which requires the evaluation of existing tax positions. The Company files in the federal and various state jurisdictions. Management
has analyzed all open tax years, as defined by the statute of limitations, for all major jurisdictions. Open tax years are those
that are open for examination by taxing authorities. The Company was incorporated during 2018 which is the only open year at this
time.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Revenue Recognition</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company entered into a feasibility
and material transfer agreement (&#x201c;Feasibility Agreement&#x201d;) with a third party that provided the Company funds in return
for certain research and development activities. Revenue from the Feasibility Agreement will be recognized in the period during
which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Feasibility
Agreement have been met.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Feasibility Agreement is on a best-effort
basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable.
The costs associated with the agreement are expensed as incurred and will be reflected as a component of research and development
expense in the accompanying consolidated statements of operations.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Funds received from the Feasibility Agreement
will be recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Feasibility
Agreement are part of the Company&#x2019;s development programs. In those instances where the Company first receives consideration
in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company
provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt
of consideration, the Company records a grant receivable. As of December 31, 2020 and 2019, the Company had deferred grant revenue
of $24,315 and $0, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Research and Development Expenses</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In accordance with authoritative guidance,
the Company charges research and development costs to operations as incurred. Research and development expenses consist of personnel
costs for the design, development, testing and enhancement of the Company&#x2019;s technology, and certain other allocated costs,
such as depreciation and other facilities related expenditures.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Basic and Diluted Earnings per Common Share</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share
is computed by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding
for the period, determined using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods
presented, all potentially dilutive securities are anti-dilutive. Basic weighted average shares outstanding for the years ended
December 31, 2020 and 2019 include 400,000 shares underlying a warrant to purchase common shares. As the shares underlying this
warrant can be issued for little consideration (an aggregate exercise price of $0.01 per share), these shares are deemed to be
issued for purposes of basic earnings per share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For the years ended December 31, 2020 and
2019, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of
diluted net loss per common share because inclusion thereof would be anti-dilutive:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Stock Options</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2,610,495</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2,139,078</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">417,355</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,076,463</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,027,850</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,215,541</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Common Stock Warrants</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company classifies as equity any warrants
that (i) require physical settlement or net-share settlement or (ii)&#xa0;provide the Company with a choice of net-cash settlement
or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities
any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs
and if that event is outside the Company&#x2019;s control), (ii) gives the counterparty a choice of net-cash settlement or settlement
in shares (physical settlement or net-share settlement) or (iii) that contain reset provisions that do not qualify for the scope
exception. The Company assesses classification of its common stock warrants and other freestanding derivatives at each reporting
date to determine whether a change in classification between assets and liabilities is required. The Company&#x2019;s freestanding
derivatives consist of warrants to purchase common stock that were issued in connection with services provided to the Company.
The Company evaluated these warrants to assess their proper classification and determined that the common stock warrants meet the
criteria for equity classification in the consolidated balance sheet. Such warrants are measured at fair value, which the Company
determines using the Black-Scholes-Merton option-pricing model.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Beneficial Conversion Feature</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On the date of the IPO, the outstanding
Series A Convertible Preferred Stock (&#x201c;Series A Preferred Stock&#x201d;), and related accrued and unpaid dividends, automatically
converted into shares of the Company&#x2019;s common stock. The conversion share calculation was based on the $2.50 initial issuance
price for the Series A Preferred Stock plus any accrued but unpaid dividends and converted to common stock using a stated divisor
conversion price equal to 50% of the IPO price to the public, which was $5.00 per share. In accordance with relevant accounting
literature, since the stated terms of the conversion option did not permit the Company to compute the additional number of shares
that it would need to issue upon conversion of the Series A Preferred Stock when the contingent event occurred, the Company recorded
the beneficial conversion amount of approximately $23,930,000 as a deemed dividend at the date of the IPO.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Stock-Based Compensation</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company computes stock-based compensation
in accordance with authoritative guidance. The Company uses the Black-Scholes-Merton option-pricing model to determine the fair
value of its stock options. The Black-Scholes-Merton option-pricing model includes various assumptions, including the fair market
value of the common stock of the Company, expected life of stock options, the expected volatility and the expected risk-free interest
rate, among others. These assumptions reflect the Company&#x2019;s best estimates, but they involve inherent uncertainties based
on market conditions generally outside the control of the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As a result, if other assumptions had been
used, stock-based compensation cost, as determined in accordance with authoritative guidance, could have been materially impacted.
Furthermore, if the Company uses different assumptions on future grants, stock-based compensation cost could be materially affected
in future periods.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Use of Estimates</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The preparation of consolidated financial
statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and
the reported amounts of expenses during the reporting period. Significant estimates include the fair value of stock-based compensation
and warrants, valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Recent Accounting Standards</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In February 2016, the Financial Accounting
Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, <i>Leases (Topic 842)</i>.
This ASU will require lessees to recognize a right-of-use asset and lease liability on the consolidated balance sheet for leases
with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern
of expense recognition in the income statement. ASU No. 2016-02 supersedes the lease accounting requirements of ASC Topic 840,
<i>Leases.</i> The Company adopted this standard on January 1, 2020, using the modified retrospective approach, which did not cause
adjustments to prior comparative periods. The new standard provides a number of optional practical expedients in transition. The
Company has elected the following &#x201c;package of practical expedients&#x201d; when assessing the transition impact as the lessee
as of January 1, 2020: (1) not to reassess whether any expired or existing contracts, contain leases; (2) not to reassess the lease
classification for any expired or existing leases; and (3) not to reassess initial direct costs for any existing leases. Leases
with an initial term of 12 months or less are considered short-term leases and are not recorded on the balance sheet as the Company
recognizes lease expense for these leases on a straight-line basis over the lease term. The Company reviewed all contracts that
may contain leases and has determined that there was no impact related to the adoption of ASU 2016-02 as the only contract that
contains a lease on the adoption date is for office space in Doylestown, Pennsylvania, which is considered a short-term lease.
See Note 4 for more information regarding the leased office space.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In July 2017, the FASB issued ASU 2017-11,
<i>Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815):
I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily
Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with
a Scope Exception</i>, (ASU 2017-11). Part I of this update addresses the complexity of accounting for certain financial instruments
with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result
in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost
and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features
that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses
the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content
in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements
about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling
interests. The amendments in Part II of this update do not have an accounting effect. This guidance is effective for public business
entities for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and effective
for all other entities for fiscal years beginning after December 15, 2019 and interim periods within fiscal years beginning after
December 15, 2020. The adoption of this standard did not have a material effect on the Company&#x2019;s consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In June 2018, the FASB issued ASU No. 2018-07,
<i>Compensation &#x2014; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</i>. The guidance
in this ASU expands the scope of ASC Topic 718 to include all share-based payment arrangements related to the acquisition of goods
and services from both nonemployees and employees. This guidance is effective for public business entities for fiscal years beginning
after December 15, 2018, including interim periods within those fiscal years, and effective for all other entities for fiscal years
beginning after December 15, 2019 and interim periods within fiscal years beginning after December 15, 2020. The adoption of this
standard did not have a material effect on the Company&#x2019;s consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In August 2018, the FASB issued ASU 2018-13,
&#x201c;<i>Fair Value Measurement</i> (Topic 820), - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value
Measurement,&#x201d; which makes a number of changes meant to add, modify or remove certain disclosure requirements associated with
the movement amongst or hierarchy associated with Level 1, Level 2 and Level&#xa0;3 fair value measurements. This guidance is effective
for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The adoption of this standard
did not have a material effect on the Company&#x2019;s consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In December 2019, the FASB issued ASU 2019-12,&#xa0;<i>Income
Taxes (Topic 740), Simplifying the Accounting for Income Taxes,&#xa0;</i>which clarifies and simplifies certain aspects of the
accounting for income taxes.&#xa0;The standard is effective&#xa0;for years beginning after December&#xa0;15, 2020, and interim
periods within annual periods beginning after December&#xa0;15, 2020. The adoption of this standard on January 1, 2021 is not expected
to have a material impact on the Company&#x2019;s consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In January 2020,
the FASB issued ASU 2020-01, <i>Investments &#x2013; Equity Securities, Investments &#x2013; Equity Method and Joint Ventures, and
Derivatives and Hedging &#x2013; Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815</i>, intended to clarify
the interactions between ASC 321, ASC 323 and ASC 815. The new standard addresses accounting for the transition into and out of
the equity method and measurement of certain purchased options and forward contracts to acquire investments. The standard is effective
for annual and interim periods beginning after December 15, 2020, with early adoption permitted. Adoption of the standard requires
changes to be made prospectively. The adoption of this standard on January 1, 2021 is not expected to have a material impact on
the Company&#x2019;s consolidated financial statements.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837134945704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><font style="text-decoration:underline">NOTE 4 &#x2013; COMMITMENTS AND CONTINGENCIES</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Operating Leases</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In October 2018, the Company entered into
a lease agreement for office space in Doylestown, Pennsylvania. The lease commenced on October 15, 2018, the Company exercised
a one-year lease renewal in October 2019, and another one-year lease renewal in October 2020 that will expire on October 31, 2021.
The lease has an additional one-year option for renewal, and the base rent is $36,000 per year. The Company has determined that
the lease agreement is considered a short-term lease under ASC 842 and has not recorded a right-of-use asset or liability. The
Company rents another office space on a month-to-month basis with no long-term commitment, which is considered a short-term lease
as well. Short-term lease expense for the years ended December 31, 2020 and 2019 was approximately $59,000 and $28,000, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Approximate future minimum lease payments
required under the operating lease, as amended, are as follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year ending December 31,</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">2021</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,000</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Legal</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company may be involved, from time
to time, in legal proceedings and claims arising in the ordinary course of its business. Such matters are subject to many uncertainties
and outcomes and are not predictable with assurance. While management believes that such matters are currently insignificant, matters
arising in the ordinary course of business for which the Company is or could become involved in litigation may have a material
adverse effect on its business and financial condition. To the Company&#x2019;s knowledge, neither the Company nor any of its properties
are subject to any pending legal proceedings.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837139467432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseAndAgreementsDisclosureAbstract', window );"><strong>License And Agreements Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseAndAgreementsDisclosureTextBlock', window );">LICENSE AND AGREEMENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><font style="text-decoration:underline">NOTE 5 &#x2013; LICENSE AND AGREEMENTS</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In July 2015, the University of Texas at
Austin (&#x201c;UT&#x201d;) granted to the Company&#x2019;s former parent, LTI, an exclusive worldwide, royalty bearing license to
the patent rights for the TFF platform in all fields of use, other than vaccines for which LTI received a non-exclusive worldwide,
royalty bearing license to the patent rights for the TFF platform. In March 2018, LTI completed an assignment to the Company all
of its interest to the TFF platform, including the patent license agreement with UT, at which time the Company paid UT an assignment
fee of $100,000 in accordance with the patent license agreement. In November 2018, the Company and UT entered into an amendment
to the patent license agreement pursuant to which, among other things, the Company&#x2019;s exclusive patent rights to the TFF platform
were expanded to all fields of use. The patent license agreement requires the Company to pay royalties and milestone payments and
conform to a variety of covenants and agreements, and in the event of the Company&#x2019;s breach of agreement, UT may elect to
terminate the agreement. During the year ended December 31, 2019, the Company achieved one milestone by gaining IND approval on
first indication of a licensed product on November 24, 2019. The milestone fee associated with this achievement to be paid is $50,000
and the Company must issue UT common shares equal to 1% of the Company&#x2019;s outstanding shares of common stock, on a fully diluted
basis, as of 30 days after IND approval, which was December 24, 2019. The total amount of common shares due and payable on December
31, 2019 to UT were 220,666 common shares, which have a fair value of approximately $1,132,000 based on the closing stock price
of $5.13 on December 24, 2019. As of December 31, 2019, the Company had not paid the $50,000 or issued the shares and has included
the $50,000 in accounts payable and the share amount due as a research and development expense payable. The Company paid the $50,000
and issued the shares in January 2020. As of the date of these consolidated financial statements, the Company is in compliance
with the patent license agreement as all required amounts have been paid in accordance with the agreement.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In May 2018, the Company entered into a
master services agreement and associated individual study contracts with ITR Canada, Inc. (&#x201c;ITR&#x201d;) to provide initial
contract pre-clinical research and development services for the Company&#x2019;s drug product candidates. The fees payable for pre-clinical
research and development services under these study contracts totaled $1,790,000, with no minimum fee requirement. In January 2019,
the Company cancelled all of the individual study contracts with ITR and entered into a contract with 11036114 Canada Inc. (initially
dba VJO Non-Clinical Development and now dba Strategy Point Innovations (&#x201c;SPI&#x201d;)) to complete additional pre-clinical
research and development services in order to take advantage of eligible Canadian Tax Credits. The services related to the contract
with SPI were sub-contracted to ITR under substantially the same terms as the initial contract with ITR, with fees payable for
services under statements of work that are currently open totaling $4,582,000, as amended. During the years ended December 31,
2020 and 2019, the Company recorded research and development costs of approximately $1,177,000 and $2,746,000, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In April 2019, the Company entered into
a master services agreement with Irisys, LLC to provide contract manufacturing services for one of the Company&#x2019;s drug product
candidates, Voriconazole. The fees payable for open contract manufacturing services under this agreement total approximately $3,220,000,
as amended, with additional pass-through costs. During the years ended December 31, 2020 and 2019, the Company recorded research
and development costs of approximately $1,837,000 and $867,000, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In June 2019, the Company entered into
a master services agreement with CoreRx to provide contract manufacturing services for one of the Company&#x2019;s drug product
candidates, Tacrolimus. The fees payable for open contract manufacturing services under this agreement total approximately $1,103,000,
as amended, with additional pass-through costs. During the years ended December 31, 2020 and 2019, the Company recorded research
and development costs of approximately $839,000 and $290,000, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In August 2019, the Company entered into
a master services agreement and associated individual study contracts with Conform Clinical Development, Inc. and its affiliates,
Les Entreprises Envie Inc. (dba Envie Ventures) and Desire Ventures LLC, which sub-contracted with Inflamax Research Limited (dba
Cliantha Research) to perform a Phase I study of one of the Company&#x2019;s drug candidates, Voriconazole. The fees payable for
the open services under this contract total approximately $1,484,000, as amended. During the years ended December 31, 2020 and
2019, the Company recorded research and development costs of approximately $1,824,000 and $977,000, respectively.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In January 2020, TFF Australia entered
into a master consultancy agreement with Novotech (Australia) Pty Ltd. (formally known as Clinical Network Services Pty Ltd.) to
provide initial contract clinical research and development services for the Company&#x2019;s drug product candidates. The fees payable
for clinical research and development services under these open study contracts totaled AUD$1,942,981 (US$1,355,580), as amended.
During the year ended December 31, 2020, the Company recorded research and development costs of approximately AUD$590,000 (US$407,000).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In May 2020, TFF Australia entered into
an amended clinical trial research agreement with Nucleus Network Pty Ltd. to provide a Phase I study of one of the Company&#x2019;s
drug candidates, Tacrolimus. The fees payable for services under this contract totaled AUD$1,392,805 (US$953,388), as amended.
During the year ended December 31, 2020, the Company recorded research and development costs of approximately AUD$489,000 (US$337,000).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In August 2020, TFF Australia entered into
a clinical trial research agreement with Q-Pharm Pty Ltd. to provide a Phase I study of one of the Company&#x2019;s drug candidates,
Tacrolimus. The fees payable for services under this contract totaled AUD$704,600 (US$505,488). During the year ended December
31, 2020, the Company recorded research and development costs of approximately AUD$557,000 (US$384,000).</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 12, 2020, the Company entered
into a licensing and collaboration agreement with UNION therapeutics A/S in which UNION acquired an option to obtain a worldwide
exclusive license for the TFF technology in combination with niclosamide. Pursuant to the terms of the license agreement, UNION
can exercise its option to obtain the license within 45 days after the complete data has been received by UNION from investigator-initiated
trials. Upon exercise of the option, UNION shall be responsible to pay all expenses incurred in the development of any licensed
product. The Company will be eligible to receive milestone payments upon the achievement of certain milestones in the development
the licensed products, based on completion of clinical trials, pre-marketing approvals and/or the receipt of at least $25,000,000
of grant funding. The Company will receive a single-digit tiered royalty on net sales. The Company will also be entitled to receive
sales-related milestone payments based on the commercial success of the licensed products.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_LicenseAndAgreementsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_LicenseAndAgreementsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_LicenseAndAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and Agreements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_LicenseAndAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837139430440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">STOCKHOLDERS' EQUITY</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><font style="text-decoration:underline">NOTE 6 &#x2013; STOCKHOLDERS&#x2019;
EQUITY</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Common Stock</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="text-decoration:underline">IPO</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In October 2019, the Company completed
an IPO, selling 4,400,000 shares of common stock at an offering price of $5.00 per share. The Company received gross proceeds of
approximately $22,000,000. In addition, the Company granted the underwriter a 45-day option to purchase an additional 660,000 shares
of common stock at the initial public offering price. The option was exercised and the underwriter purchased an additional 479,300
shares of common stock and the Company received additional gross proceeds of approximately $2,397,000. The Company received net
proceeds from the IPO and the underwriter&#x2019;s purchase of additional shares of approximately $21,754,000, after deducting underwriting
discounts and commissions and offering-related expenses. Warrants for 317,155 shares of the Company&#x2019;s common stock were issued
to the IPO underwriter at an exercise price of $6.25 per share as part of the underwriter&#x2019;s compensation for the IPO. The
estimated fair value of the warrants of approximately $977,000 was considered an offering cost and netted against additional paid-in
capital.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In conjunction with the IPO, the Company&#x2019;s
outstanding shares of Series A Preferred Stock automatically converted into 9,571,692 shares of its common stock (see below). Also
in conjunction with the issuance of shares in the IPO, the Company granted options to officers and directors to purchase 627,984
shares of common stock at an exercise price of $5.00.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="text-decoration:underline">UT Agreement</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In November 2019, the Company achieved
a milestone in connection with the UT agreement (see Note 5). As a result of the milestone, the Company owed UT 220,666 shares
of common stock, which had a fair value of approximately $1,132,000, which was accrued in accrued research and development expense
as of December 31, 2019. In January 2020, the Company issued the 220,666 shares of common stock to UT.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="text-decoration:underline">August 2020 Private Placement</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On August 10, 2020, the Company entered
into a Securities Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;) and a Registration Rights Agreement (the &#x201c;Registration
Rights Agreement&#x201d;) with certain institutional and other accredited investors pursuant to which the Company issued and sold
to the investors 3,048,654 shares of the Company&#x2019;s common stock at a price of $8.50 per share for gross proceeds of approximately
$25.91 million, before deducting placement agent and other offering expenses. After deducting the placement agent and other offering
expenses, the Company received net proceeds of approximately $24.28 million. The Purchase Agreement included customary representations,
warranties, and covenants by the investors and the Company, and an indemnity from the Company in favor of the investors. Jefferies
LLC acted as placement agent for the private placement and the private placement closed on August 13, 2020. Pursuant to the terms
of the Registration Rights Agreement, the Company filed a resale registration statement on Form S-1 with the SEC that was declared
effective on September 15, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="text-decoration:underline">Stock Option Exercises</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During November and December 2020, 285,003
shares of common stock were issued in connection with the exercise of stock options for total proceeds of $714,382.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="text-decoration:underline">Cashless Warrant Exercises</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">During August through December 2020, 529,559
shares of common stock were issued in connection with the cashless exercise of 659,108 common stock warrants.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Series A Convertible Preferred Stock</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Prior to our initial public offering in
October 2019, the Company&#x2019;s amended and restated certificate of incorporation authorized the Company to issue up to 10,000,000
shares of preferred stock, all of which was designated as Series A preferred stock and there were 8,930,000&#xa0;shares of Series
A preferred stock issued and outstanding immediately prior to the Company&#x2019;s initial public offering. Pursuant to the Company&#x2019;s
amended and restated certificate of incorporation, all outstanding shares of Series A preferred stock automatically converted to
common stock at the close of our initial public offering and thereafter the Company was no longer authorized to issue any preferred
stock.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Series A Preferred Stock ranked senior
to common stock with respect to dividends rights and liquidation preferences and had full voting rights. The Series A Preferred
Stock accrued a dividend at a rate of 6% per annum, and $875,359 of dividends accrued during the year ended December 31, 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Pursuant to the Company&#x2019;s amended
and restated certificate of incorporation, holders of the Series&#xa0;A Preferred Stock had the following methods of conversion:
(i) automatic conversion into common stock upon the consummation of an IPO at a conversion price of 50% of the IPO price, (ii)
automatic conversion into common stock upon the consummation of a subsequent private placement of securities at a conversion price
of 50% of the purchase price of the securities being sold by the Company approved by the holders of the Series&#xa0;A preferred
stock, and (iii) at any time after the issuance date and until ten calendar days prior to the consummation of an IPO, each holder
shall be entitled to convert into common stock at a conversion price of $2.50 per share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Series A Preferred Stock automatically
converted into 9,571,692 common shares upon completion of the IPO in October 2019, based on the number of shares of Series A Preferred
Stock outstanding as of the date of the IPO. The conversion share calculation was based on the $2.50 initial issue price for the
Series A Preferred Stock plus $1,603,709 of accrued and unpaid dividends and automatically converted into shares of the Company&#x2019;s
common stock using a stated divisor conversion price equal to 50% of the IPO price to the public which was $5.00 per share.&#xa0;In
accordance with relevant accounting literature, since the terms of the conversion option did not permit the Company to compute
the additional number of shares that it would need to issue upon conversion of the Series A Preferred when the contingent event
occurred, the Company recorded the beneficial conversion amount of approximately $23,930,000 as a deemed dividend at the date of
the IPO.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><font style="text-decoration:underline">2019 Private Placement</font></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In May 2019, the Company entered into a
securities purchase agreement with various accredited investors to raise gross proceeds of $8.2 million in a private placement
(the &#x201c;2019 Private Placement&#x201d;), issuing 3,268,000 shares of its Series A Preferred Stock. The shares of the Series
A Preferred Stock were sold for $2.50 per share. The Company received net proceeds of approximately $7.2 million from the 2019
Private Placement, after paying placement agent fees and offering expenses.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837139439432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantsTextBlock', window );">WARRANTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><font style="text-decoration:underline">NOTE 7 &#x2013; WARRANTS</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On March 13, 2018 and March 22, 2018, the
Company issued to National Securities Corporation warrants to purchase shares of the Company&#x2019;s common stock in an amount
equal to 10% of the shares of common stock issuable upon conversion of 5,662,000 shares of the Company&#x2019;s Series&#xa0;A Preferred
Stock. In connection with the conversion of the Series A Preferred Stock as a result of the IPO, the Company issued additional
warrants to purchase 53,679 shares of common stock. The additional warrants were considered offering costs and netted with the
proceeds from the IPO.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On May 16, 2019 and May 23, 2019, the Company
issued to National Securities Corporation 326,800 warrants to purchase shares of the Company&#x2019;s common stock. The fair value
of the warrants on the grant date was estimated using the Black-Scholes-Merton option pricing model with a common stock value of
$1.67 per share, a contractual life of 5 years, a dividend yield of 0%, a volatility of 89.6% and an assumed risk-free interest
rate of 2.11%. The fair value of the warrants was determined to be approximately $347,000 and was included in general and administrative
expenses in the statement of operations. On September 13, 2019, these warrants were cancelled by the individual warrant holders
and the Company determined that the related expense should be reversed. The reversal of the expense was recorded during the three
months ended September 30, 2019, when the warrants were cancelled.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On October 29, 2019, the Company issued
a ten-year warrant to purchase 43,794 shares of common stock at $5.00 per share to BP Directors, LP (&#x201c;BP&#x201d;). The warrant
represented consideration for board service from Dr. Aaron Fletcher. The fair value of the warrant on the grant date was estimated
using the Black-Scholes-Merton option pricing model with a common stock value of $5.01 per share, a contractual life of 6.0 years,
a dividend yield of 0%, a volatility of 88.48% and an assumed risk-free interest rate of 1.70%. The warrant is subject to a 25%
cliff vesting at one year from the date of grant and the balance vesting quarterly over the following two years. The fair value
of the warrant was determined to be $161,419 and is being amortized in general and administrative expenses in the consolidated
statements of operations over the vesting term.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On November 26, 2019, the Company issued
to National Securities Corporation and its representatives underwriter warrants to purchase 317,155 shares of the Company&#x2019;s
common stock in connection with the IPO. The exercise price of the warrants is $6.25 per share, each has a contractual life of
5 years and they were not exercisable for one year from the date of grant.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On November 29, 2019, the Company issued
a ten-year warrant to purchase 3,623 shares of common stock at $5.00 per share to BP. The warrant represented consideration for
board service from Dr. Aaron Fletcher. The fair value of the warrant on the grant date was estimated using the Black-Scholes-Merton
option pricing model with a common stock value of $5.26 per share, a contractual life of 6.0 years, a dividend yield of 0%, a volatility
of 90.16% and an assumed risk-free interest rate of 1.68%. The warrant is subject to a 25% cliff vesting at one year from the date
of grant and the balance vesting quarterly over the following two years. The fair value of the warrant was determined to be $14,300
and is being amortized in general and administrative expenses in the consolidated statements of operations over the vesting term.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In determining the fair value for warrants,
the expected life of the Company&#x2019;s warrants was determined using the contractual life. The methodology in determining all
other inputs to calculate the fair value utilizing the Black-Scholes-Merton option pricing model is the same as the stock option
methodology described in Note 8 for stock options.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A summary of warrant activity for the years
ended December 31, 2020 and 2019 is as follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Range of Exercise Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average Exercise Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average Remaining Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font-size: 10pt">Outstanding at January 1, 2019</font></td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,058,212</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><font style="font-size: 10pt">0.01 &#x2013; $2.50</font></td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.56</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">4.6</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font-size: 10pt">Issued</font></td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">745,051</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">1.67 &#x2013; 6.25</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.26</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#x2014;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font-size: 10pt">Cancelled</font></td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(326,800</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font-size: 10pt">Outstanding at December 31, 2019</font></td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,476,463</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">0.01 &#x2013; 6.25</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.71</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.1</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font-size: 10pt">Exercised</font></td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(659,108</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2.50 &#x2013; 6.25</font></td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.75</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font-size: 10pt">Outstanding at December 31, 2020</font></td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">817,355</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-size: 10pt">0.01 &#x2013; $6.25</font></td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.68</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3.7</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The warrants outstanding at December 31,
2020 had an aggregate intrinsic value of approximately $9,511,000.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837132894984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK BASED COMPENSATION</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><font style="text-decoration:underline">NOTE 8 &#x2013; STOCK BASED COMPENSATION</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In January 2018, the Company&#x2019;s board
of directors approved its 2018 Stock Incentive Plan (&#x201c;2018 Plan&#x201d;). The 2018 Plan provides for the grant of non-qualified
stock options and incentive stock options to purchase shares of the Company&#x2019;s common stock, the grant of restricted and unrestricted
share awards and grant of restricted stock units. The Company initially reserved 1,630,000 shares of its common stock under the
2018 Plan; however, upon completion of the Company&#x2019;s IPO the number of shares reserved for issuance under the 2018 Plan increased
to 3,284,480, representing 15% of the Company&#x2019;s outstanding shares of common stock calculated on a fully diluted basis upon
the close of the IPO. All of the Company&#x2019;s employees and any subsidiary employees (including officers and directors who are
also employees), as well as all of the Company&#x2019;s nonemployee directors and other consultants, advisors and other persons
who provide services to the Company will be eligible to receive incentive awards under the 2018 Plan.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following table summarizes the stock-based
compensation expense recorded in the Company&#x2019;s results of operations during the years ended December 31, 2020 and 2019 for
stock options and warrants:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/>
2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/>
2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Research and development</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">140,278</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#x2014;</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,046,871</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">590,041</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,187,149</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">590,041</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2020, there was approximately
$9,074,000 of total unrecognized compensation expense related to non-vested share-based compensation arrangements that are expected
to vest. This cost is expected to be recognized over a weighted-average period of 2.4 years.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company records compensation expense
for employee awards with graded vesting using the straight-line method. The Company records compensation expense for nonemployee
awards with graded vesting using the accelerated expense attribution method. The Company recognizes compensation expense over the
requisite service period applicable to each individual award, which generally equals the vesting term. The Company estimates the
fair value of each option award using the Black-Scholes-Merton option pricing model. Forfeitures are recognized when realized.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company estimated the fair value of
employee and non-employee stock options using the Black-Scholes option pricing model. The fair value of employee stock options
is being amortized on a straight-line basis over the requisite service periods of the respective awards. The fair value of stock
options issued was estimated using the following assumptions:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted average exercise price</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10.42</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.42</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted average grant date fair value</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.25</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.08</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Assumptions</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Expected volatility</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">87-91</font></td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">88-90</font></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Expected term (in years)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">6.3-10</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.3</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Risk-free interest rate</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">0.36-1.47</font></td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">1.68-2.31</font></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Expected dividend yield</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The risk-free interest rate was obtained
from U.S. Treasury rates for the applicable periods. The Company&#x2019;s expected volatility was based upon the historical volatility
for industry peers and used an average of those volatilities. The expected life of the Company&#x2019;s options was determined using
the simplified method as a result of limited historical data regarding the Company&#x2019;s activity for employee awards and the
contractual term for nonemployee awards. The dividend yield considers that the Company has not historically paid dividends, and
does not expect to pay dividends in the foreseeable future.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For grants prior to the IPO, the fair value
of the common stock was determined by the board of directors based on a variety of factors, including valuations prepared by third
parties, the Company&#x2019;s financial position, the status of development efforts within the Company, the current climate in the
marketplace and the prospects of a liquidity event, among others. For grants after the IPO, the Company uses the closing stock
price on the date of grant as the fair value of the common stock.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The following table summarizes stock option
activity during the years ended December 31, 2020 and 2019:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average<br/> Exercise Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average Remaining
    Contractual Term (In&#xa0;Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%; text-align: left"><font style="font-size: 10pt">Outstanding at January 1, 2019</font></td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,073,082</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.50</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">9.64</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#x2014;</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"><font style="font-size: 10pt">Granted</font></td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,065,996</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.42</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><font style="font-size: 10pt">Outstanding at December 31, 2019</font></td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,139,078</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.46</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.17</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,052,512</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><font style="font-size: 10pt">Granted</font></td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">782,045</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">10.42</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#x2014;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#x2014;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><font style="font-size: 10pt">Exercised</font></td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(285,003</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.74</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#x2014;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#x2014;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"><font style="font-size: 10pt">Cancelled</font></td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.86</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt; text-align: left"><font style="font-size: 10pt">Outstanding at December 31, 2020</font></td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,610,495</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.63</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">8.60</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">22,789,233</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt; text-align: left"><font style="font-size: 10pt">Exercisable at December 31, 2020</font></td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">755,885</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.25</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">8.04</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,365,946</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837139451688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><font style="text-decoration:underline">NOTE 9 &#x2013; INCOME TAXES</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company had no income tax expense due
to operating losses incurred for the years ended December&#xa0;31, 2020 and 2019. The Company accounts for income taxes in accordance
with ASC 740, which requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded
as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future
tax benefits is dependent on the Company&#x2019;s ability to generate sufficient taxable income within the carryforward period.
Because of the Company&#x2019;s recent history of operating losses, management believes that recognition of the deferred tax assets
arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a full
valuation allowance.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company&#x2019;s income tax expense
for the years ended December 31, 2020 and 2019 are summarized below:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Current:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Federal</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">State</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total current</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deferred:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">Federal</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,502,016</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,952,519</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">State</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Foreign</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(480,666</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,982,682</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,952,519</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total deferred</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Income tax provision (benefit)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company&#x2019;s deferred tax assets
are as follows:</p><br/><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deferred tax assets:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">Net operating loss carryforwards</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,807,300</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,789,541</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Research and development tax credit</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,092,345</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">532,711</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Intangibles</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">136,226</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">105,580</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Stock compensation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">761,741</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">387,098</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">Total deferred tax assets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8,797,612</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,814,930</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Valuation allowances</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,797,612</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,814,930</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Net deferred tax assets</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The effective tax rate of the Company&#x2019;s
provision (benefit) for income taxes differs from the federal statutory rate as follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Statutory rate</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">State rate</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Foreign</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(1.81</td><td style="text-align: left">)%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Permanent book/tax differences</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(0.26</td><td style="text-align: left">)%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(0.12</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Research and development credit</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.09</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.99</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Changes in valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24.02</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24.87</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As of December 31, 2020 and 2019, the Company
had gross federal income tax net operating loss (&#x201c;NOL&#x201d;) carryforwards of $30,126,830 and $13,283,530, respectively,
and federal research tax credits of $1,486,704 and $690,525, respectively. Additionally, the Company had gross foreign income tax
net operating loss carryforwards of $1,602,220 as of December 31, 2020. The federal and foreign NOL have an indefinite life while
the federal research tax credits will expire by 2040.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Utilization of U.S. net operating losses
and tax credit carryforwards may be limited by &#x201c;ownership change&#x201d; rules, as defined in Sections&#xa0;382 and 383 of
the Code. Similar rules may apply under state tax laws. The Company has not conducted a study to-date to assess whether a limitation
would apply under Sections&#xa0;382 and 383 of the Code as and when it starts utilizing its net operating losses and tax credits.
The Company will continue to monitor activities in the future. In the event the Company previously experienced an ownership change,
or should experience an ownership change in the future, the amount of net operating losses and research and development credit
carryovers available in any taxable year could be limited and may expire unutilized.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The CARES Act was signed into law on March
27, 2020 as a response to the economic challenges facing U.S. businesses caused by the COVID-19 global pandemic. The CARES Act
allowed net operating loss incurred in 2018-2020 to be carried back five years or carried forward indefinitely, and to be fully
utilized without being subjected to the 80% taxable income limitation. Net operating losses incurred after December 31, 2020 will
be subjected to the 80% taxable income limitation. In assessing the realization of deferred tax assets, management considers whether
it is more likely than not that some portion, or all, of the deferred tax asset will be realized. The ultimate realization of deferred
tax assets is dependent upon the Company attaining future taxable income during periods in which those temporary differences become
deductible.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Due to the uncertainty surrounding the
realization of the benefits of its deferred assets, including NOL carryforwards, the Company has provided a 100% valuation allowance
on its deferred tax assets at December 31, 2020.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company accounts for uncertain tax
positions in accordance with the provisions of ASC 740, <i>Income Taxes</i>. When uncertain tax positions exist, the Company recognizes
the tax benefit of tax positions to the extent that the benefit will more likely than not be realized. The determination as to
whether the tax benefit will more likely than not be realized is based upon the technical merits of the tax position as well as
consideration of the available facts and circumstances. As of December 31, 2020, the Company had a reserve for uncertain tax positions
of $394,358, and no interest or penalties have been charged to the Company for the years ended December 31, 2020 and 2019. If incurred,
the Company will classify any interest and penalties as a component of interest expense and operating expense, respectively. If
recognized, $394,358 of the reserve for uncertain tax positions would favorably affect the Company&#x2019;s effective tax rate.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A reconciliation of the change in the unrecognized
tax positions for the year ended December 31, 2020 is as follows:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Federal and State</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">Balance at December 31, 2019</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">157,814</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Additions for tax positions related to current year</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">318,374</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Decreases for tax positions related to prior years</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(81,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Balance at December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">394,358</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837132894984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><font style="text-decoration:underline">NOTE 10 &#x2013; SUBSEQUENT EVENTS</font></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company has performed an evaluation
of events occurring subsequent to December 31, 2020 through the filing date of this Annual Report. Based on its evaluation, nothing
other than the events described below need to be disclosed.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Between January 1, 2021 and March 10,
2021, 444,751 shares of common stock were issued in connection with the exercise of warrants and 160,275 shares of common stock
were issued in connection with the exercise of stock options. The Company received total cash proceeds from the exercises of $585,700.</p><br/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837129942840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounting Policies, by Policy (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Basis of Presentation</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company&#x2019;s consolidated financial
statements are presented in accordance with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;)
and the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;) and reflect the financial position,
results of operations and cash flows for all periods presented.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Principles of Consolidation</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The consolidated financial statements include
the accounts of TFF Pharmaceuticals, Inc. and its wholly-owned subsidiary, TFF Australia. All material intercompany accounts and
transactions have been eliminated in consolidation.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDisclosureTextBlock', window );">Foreign Currency</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Foreign Currency</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The currency of TFF Australia, the Company&#x2019;s
international subsidiary, is in Australian dollars. Foreign currency denominated assets and liabilities are translated into U.S.
dollars using the exchange rates in effect at each balance sheet date. Results of operations and cash flows are translated using
the average exchange rates throughout the period. The effect of exchange rate fluctuations on translation of assets and liabilities
is included as a separate component of stockholders&#x2019; equity in accumulated other comprehensive income (loss).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_GeographicConcentrationsPolicyTextBlock', window );">Geographic Concentrations</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Geographic Concentrations</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company conducts business in the U.S.
and Australia. As of December 31, 2020, the Company maintained 100% of its net property and equipment in the U.S. There was no
property and equipment as of December 31, 2019.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy', window );">Deferred Offering Costs</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Deferred Offering Costs</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company complies with the requirements
of Accounting Standards Codification (&#x201c;ASC&#x201d;) 340, <i>Other Assets and Deferred Costs</i>. Deferred offering costs of
consisted primarily of legal, accounting and filing fees that were related to the Company&#x2019;s IPO and were charged to capital
upon completion of the IPO in October 2019. There are no deferred offering costs as of December&#xa0;31, 2020 and 2019.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company maintains its operating accounts
in financial institutions in the U.S. and in Australia. The balances are insured up to specified limits. The Company&#x2019;s cash
is maintained in checking accounts and money market funds with maturities of less than three months when purchased, which are readily
convertible to known amounts of cash, and which in the opinion of management are subject to insignificant risk of loss in value.
As of December 31, 2020 and 2019, the Company had cash in Australia of AUD$214,240 (US$165,092) and $0, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Property and Equipment</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Property and equipment are stated at cost
less accumulated depreciation and amortization. The Company calculates depreciation using the straight-line method over the estimated
useful lives of the assets, which range from&#xa0;two&#xa0;to&#xa0;five&#xa0;years for furniture, fixtures, lab and computer equipment
and software. Assets held within construction in progress are not depreciated. Construction in progress is related to the construction
or development of property and equipment that have not yet been placed in service for its intended use. As of December 31, 2020,
all of the Company&#x2019;s property and equipment consist of lab equipment that are considered construction in progress. Expenditures
for repairs and maintenance of assets are charged to expense as incurred.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Fair Value of Financial Instruments</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Authoritative guidance requires disclosure
of the fair value of financial instruments. The Company&#x2019;s financial instruments consist of cash and cash equivalents and
accounts payable, the carrying amounts of which approximate their estimated fair values primarily due to the short-term nature
of the instruments or based on information obtained from market sources and management estimates. The Company measures the fair
value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality
and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value which
is not equivalent to cost will be classified and disclosed in one of the following three categories:</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Level 1 &#x2014; Quoted prices (unadjusted)
in active markets for identical assets and liabilities.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Level 2 &#x2014; Inputs other than Level
1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted
quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market
data for substantially the full term of the assets or liabilities.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Level 3 &#x2014; Unobservable inputs that
are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Income Taxes</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In accordance with authoritative guidance,
deferred tax assets and liabilities are recorded for temporary differences between the financial reporting and tax bases of assets
and liabilities using the current enacted tax rate expected to be in effect when the differences are expected to reverse. A valuation
allowance is recorded on deferred tax assets unless realization is considered more likely than not.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company evaluates its tax positions
taken or expected to be taken in the course of preparing the Company&#x2019;s tax returns to determine whether the tax positions
are &#x201c;more-likely-than-not&#x201d; of being sustained by the applicable tax authority. Tax positions not deemed to meet the
&#x201c;more-likely-than-not&#x201d; threshold are not recorded as a tax benefit or expense in the current year. The Company recognizes
interest and penalties, if any, related to uncertain tax positions in interest expense. No interest and penalties related to uncertain
tax positions were accrued at either December&#xa0;31, 2020 or 2019.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company follows authoritative guidance
which requires the evaluation of existing tax positions. The Company files in the federal and various state jurisdictions. Management
has analyzed all open tax years, as defined by the statute of limitations, for all major jurisdictions. Open tax years are those
that are open for examination by taxing authorities. The Company was incorporated during 2018 which is the only open year at this
time.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Revenue Recognition</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company entered into a feasibility
and material transfer agreement (&#x201c;Feasibility Agreement&#x201d;) with a third party that provided the Company funds in return
for certain research and development activities. Revenue from the Feasibility Agreement will be recognized in the period during
which the related qualifying services are rendered and costs are incurred, provided that the applicable conditions under the Feasibility
Agreement have been met.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Feasibility Agreement is on a best-effort
basis and does not require scientific achievement as a performance obligation. All fees received under the agreement are non-refundable.
The costs associated with the agreement are expensed as incurred and will be reflected as a component of research and development
expense in the accompanying consolidated statements of operations.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Funds received from the Feasibility Agreement
will be recorded as revenue as the Company is the principal participant in the arrangement because the activities under the Feasibility
Agreement are part of the Company&#x2019;s development programs. In those instances where the Company first receives consideration
in advance of providing underlying services, the Company classifies such consideration as deferred revenue until (or as) the Company
provides the underlying services. In those instances where the Company first provides the underlying services prior to its receipt
of consideration, the Company records a grant receivable. As of December 31, 2020 and 2019, the Company had deferred grant revenue
of $24,315 and $0, respectively.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Research and Development Expenses</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In accordance with authoritative guidance,
the Company charges research and development costs to operations as incurred. Research and development expenses consist of personnel
costs for the design, development, testing and enhancement of the Company&#x2019;s technology, and certain other allocated costs,
such as depreciation and other facilities related expenditures.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Basic and Diluted Earnings per Common Share</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Basic and Diluted Earnings per Common Share</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Basic net loss per common share is calculated
by dividing the net loss by the weighted-average number of common shares outstanding for the period. Diluted net loss per share
is computed by dividing the net loss by the weighted-average number of common shares and dilutive share equivalents outstanding
for the period, determined using the treasury-stock and if-converted methods. Since the Company has had net losses for all periods
presented, all potentially dilutive securities are anti-dilutive. Basic weighted average shares outstanding for the years ended
December 31, 2020 and 2019 include 400,000 shares underlying a warrant to purchase common shares. As the shares underlying this
warrant can be issued for little consideration (an aggregate exercise price of $0.01 per share), these shares are deemed to be
issued for purposes of basic earnings per share.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">For the years ended December 31, 2020 and
2019, the Company had the following potential common stock equivalents outstanding which were not included in the calculation of
diluted net loss per common share because inclusion thereof would be anti-dilutive:</p><br/><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Stock Options</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2,610,495</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2,139,078</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">417,355</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,076,463</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,027,850</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,215,541</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_CommonStockWarrantsPolicyTextBlock', window );">Common Stock Warrants</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Common Stock Warrants</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company classifies as equity any warrants
that (i) require physical settlement or net-share settlement or (ii)&#xa0;provide the Company with a choice of net-cash settlement
or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities
any contracts that (i) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs
and if that event is outside the Company&#x2019;s control), (ii) gives the counterparty a choice of net-cash settlement or settlement
in shares (physical settlement or net-share settlement) or (iii) that contain reset provisions that do not qualify for the scope
exception. The Company assesses classification of its common stock warrants and other freestanding derivatives at each reporting
date to determine whether a change in classification between assets and liabilities is required. The Company&#x2019;s freestanding
derivatives consist of warrants to purchase common stock that were issued in connection with services provided to the Company.
The Company evaluated these warrants to assess their proper classification and determined that the common stock warrants meet the
criteria for equity classification in the consolidated balance sheet. Such warrants are measured at fair value, which the Company
determines using the Black-Scholes-Merton option-pricing model.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_BeneficialConversionFeaturePolicyTextBlock', window );">Beneficial Conversion Feature</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Beneficial Conversion Feature</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">On the date of the IPO, the outstanding
Series A Convertible Preferred Stock (&#x201c;Series A Preferred Stock&#x201d;), and related accrued and unpaid dividends, automatically
converted into shares of the Company&#x2019;s common stock. The conversion share calculation was based on the $2.50 initial issuance
price for the Series A Preferred Stock plus any accrued but unpaid dividends and converted to common stock using a stated divisor
conversion price equal to 50% of the IPO price to the public, which was $5.00 per share. In accordance with relevant accounting
literature, since the stated terms of the conversion option did not permit the Company to compute the additional number of shares
that it would need to issue upon conversion of the Series A Preferred Stock when the contingent event occurred, the Company recorded
the beneficial conversion amount of approximately $23,930,000 as a deemed dividend at the date of the IPO.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsPolicyTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Stock-Based Compensation</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company computes stock-based compensation
in accordance with authoritative guidance. The Company uses the Black-Scholes-Merton option-pricing model to determine the fair
value of its stock options. The Black-Scholes-Merton option-pricing model includes various assumptions, including the fair market
value of the common stock of the Company, expected life of stock options, the expected volatility and the expected risk-free interest
rate, among others. These assumptions reflect the Company&#x2019;s best estimates, but they involve inherent uncertainties based
on market conditions generally outside the control of the Company.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">As a result, if other assumptions had been
used, stock-based compensation cost, as determined in accordance with authoritative guidance, could have been materially impacted.
Furthermore, if the Company uses different assumptions on future grants, stock-based compensation cost could be materially affected
in future periods.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Use of Estimates</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The preparation of consolidated financial
statements in conformity with GAAP requires the Company&#x2019;s management to make estimates and assumptions that affect the reported
amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and
the reported amounts of expenses during the reporting period. Significant estimates include the fair value of stock-based compensation
and warrants, valuation allowance against deferred tax assets and related disclosures. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><b><i>Recent Accounting Standards</i></b></p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In February 2016, the Financial Accounting
Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2016-02, <i>Leases (Topic 842)</i>.
This ASU will require lessees to recognize a right-of-use asset and lease liability on the consolidated balance sheet for leases
with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern
of expense recognition in the income statement. ASU No. 2016-02 supersedes the lease accounting requirements of ASC Topic 840,
<i>Leases.</i> The Company adopted this standard on January 1, 2020, using the modified retrospective approach, which did not cause
adjustments to prior comparative periods. The new standard provides a number of optional practical expedients in transition. The
Company has elected the following &#x201c;package of practical expedients&#x201d; when assessing the transition impact as the lessee
as of January 1, 2020: (1) not to reassess whether any expired or existing contracts, contain leases; (2) not to reassess the lease
classification for any expired or existing leases; and (3) not to reassess initial direct costs for any existing leases. Leases
with an initial term of 12 months or less are considered short-term leases and are not recorded on the balance sheet as the Company
recognizes lease expense for these leases on a straight-line basis over the lease term. The Company reviewed all contracts that
may contain leases and has determined that there was no impact related to the adoption of ASU 2016-02 as the only contract that
contains a lease on the adoption date is for office space in Doylestown, Pennsylvania, which is considered a short-term lease.
See Note 4 for more information regarding the leased office space.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In July 2017, the FASB issued ASU 2017-11,
<i>Earnings Per Share (Topic 260), Distinguishing Liabilities from Equity (Topic 480) and Derivatives and Hedging (Topic 815):
I. Accounting for Certain Financial Instruments with Down Round Features; II. Replacement of the Indefinite Deferral for Mandatorily
Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with
a Scope Exception</i>, (ASU 2017-11). Part I of this update addresses the complexity of accounting for certain financial instruments
with down round features. Down round features are features of certain equity-linked instruments (or embedded features) that result
in the strike price being reduced on the basis of the pricing of future equity offerings. Current accounting guidance creates cost
and complexity for entities that issue financial instruments (such as warrants and convertible instruments) with down round features
that require fair value measurement of the entire instrument or conversion option. Part II of this update addresses
the difficulty of navigating Topic 480, Distinguishing Liabilities from Equity, because of the existence of extensive pending content
in the FASB Accounting Standards Codification. This pending content is the result of the indefinite deferral of accounting requirements
about mandatorily redeemable financial instruments of certain nonpublic entities and certain mandatorily redeemable noncontrolling
interests. The amendments in Part II of this update do not have an accounting effect. This guidance is effective for public business
entities for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years, and effective
for all other entities for fiscal years beginning after December 15, 2019 and interim periods within fiscal years beginning after
December 15, 2020. The adoption of this standard did not have a material effect on the Company&#x2019;s consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In June 2018, the FASB issued ASU No. 2018-07,
<i>Compensation &#x2014; Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</i>. The guidance
in this ASU expands the scope of ASC Topic 718 to include all share-based payment arrangements related to the acquisition of goods
and services from both nonemployees and employees. This guidance is effective for public business entities for fiscal years beginning
after December 15, 2018, including interim periods within those fiscal years, and effective for all other entities for fiscal years
beginning after December 15, 2019 and interim periods within fiscal years beginning after December 15, 2020. The adoption of this
standard did not have a material effect on the Company&#x2019;s consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In August 2018, the FASB issued ASU 2018-13,
&#x201c;<i>Fair Value Measurement</i> (Topic 820), - Disclosure Framework - Changes to the Disclosure Requirements for Fair Value
Measurement,&#x201d; which makes a number of changes meant to add, modify or remove certain disclosure requirements associated with
the movement amongst or hierarchy associated with Level 1, Level 2 and Level&#xa0;3 fair value measurements. This guidance is effective
for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. The adoption of this standard
did not have a material effect on the Company&#x2019;s consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In December 2019, the FASB issued ASU 2019-12,&#xa0;<i>Income
Taxes (Topic 740), Simplifying the Accounting for Income Taxes,&#xa0;</i>which clarifies and simplifies certain aspects of the
accounting for income taxes.&#xa0;The standard is effective&#xa0;for years beginning after December&#xa0;15, 2020, and interim
periods within annual periods beginning after December&#xa0;15, 2020. The adoption of this standard on January 1, 2021 is not expected
to have a material impact on the Company&#x2019;s consolidated financial statements.</p><br/><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">In January 2020,
the FASB issued ASU 2020-01, <i>Investments &#x2013; Equity Securities, Investments &#x2013; Equity Method and Joint Ventures, and
Derivatives and Hedging &#x2013; Clarifying the Interactions Between Topic 321, Topic 323, and Topic 815</i>, intended to clarify
the interactions between ASC 321, ASC 323 and ASC 815. The new standard addresses accounting for the transition into and out of
the equity method and measurement of certain purchased options and forward contracts to acquire investments. The standard is effective
for annual and interim periods beginning after December 15, 2020, with early adoption permitted. Adoption of the standard requires
changes to be made prospectively. The adoption of this standard on January 1, 2021 is not expected to have a material impact on
the Company&#x2019;s consolidated financial statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_BeneficialConversionFeaturePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_BeneficialConversionFeaturePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_CommonStockWarrantsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_CommonStockWarrantsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_GeographicConcentrationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_GeographicConcentrationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for deferred policy acquisition costs, including the nature, type, and amount of capitalized costs incurred to write or acquire insurance contracts, and the basis for and methodologies applied in capitalizing and amortizing such costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35755530&amp;loc=d3e11264-158415<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizationOfDeferredPolicyAcquisitionCostsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for salaries, bonuses, incentive awards, postretirement and postemployment benefits granted to employees, including equity-based arrangements; discloses methodologies for measurement, and the bases for recognizing related assets and liabilities and recognizing and reporting compensation expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30885-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI http://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e32280-109318<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837147519848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earnings per Common Share</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Stock Options</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2,610,495</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">2,139,078</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Warrants</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">417,355</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,076,463</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,027,850</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3,215,541</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837145927368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of future minimum lease payments</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: left">Year ending December 31,</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Amount</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">2021</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">30,000</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837147519848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantsAbstract', window );"><strong>Warrants [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ScheduleOfWarrantActivity', window );">Schedule of warrant activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Range of Exercise Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average Exercise Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average Remaining Life</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 52%; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font-size: 10pt">Outstanding at January 1, 2019</font></td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,058,212</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right"><font style="font-size: 10pt">0.01 &#x2013; $2.50</font></td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1.56</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">4.6</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font-size: 10pt">Issued</font></td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">745,051</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">1.67 &#x2013; 6.25</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.26</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#x2014;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font-size: 10pt">Cancelled</font></td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(326,800</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.50</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font-size: 10pt">Outstanding at December 31, 2019</font></td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,476,463</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">0.01 &#x2013; 6.25</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.71</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">4.1</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font-size: 10pt">Exercised</font></td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(659,108</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><font style="font-size: 10pt">2.50 &#x2013; 6.25</font></td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2.75</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-bottom: 2pt; text-align: left; padding-left: 0.125in; text-indent: -0.125in"><font style="font-size: 10pt">Outstanding at December 31, 2020</font></td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">817,355</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right"><font style="font-size: 10pt">0.01 &#x2013; $6.25</font></td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2.68</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">3.7</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ScheduleOfWarrantActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ScheduleOfWarrantActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_WarrantsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_WarrantsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837134924552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of stock-based compensation expense stock options and restricted stock</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#xa0;</td><td style="font-weight: bold">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">Year Ended</td><td style="font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/>
2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/>
2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Research and development</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">140,278</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#x2014;</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,046,871</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">590,041</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">2,187,149</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">590,041</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of employee stock options</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="text-align: center; padding-left: 0.125in; text-indent: -0.125in">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Year Ended<br/> December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 76%; text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted average exercise price</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">10.42</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">4.42</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Weighted average grant date fair value</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">9.25</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.08</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Assumptions</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Expected volatility</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">87-91</font></td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">88-90</font></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Expected term (in years)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">6.3-10</font></td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">6.3</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Risk-free interest rate</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">0.36-1.47</font></td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right"><font style="font-size: 10pt">1.68-2.31</font></td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 0.125in; text-indent: -0.125in">Expected dividend yield</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Number of Shares</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average<br/> Exercise Prices</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Weighted-Average Remaining
    Contractual Term (In&#xa0;Years)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Intrinsic Value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 52%; text-align: left"><font style="font-size: 10pt">Outstanding at January 1, 2019</font></td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">1,073,082</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2.50</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">9.64</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">&#x2014;</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"><font style="font-size: 10pt">Granted</font></td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,065,996</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.42</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><font style="font-size: 10pt">Outstanding at December 31, 2019</font></td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2,139,078</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">3.46</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">9.17</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">4,052,512</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><font style="font-size: 10pt">Granted</font></td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">782,045</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">10.42</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#x2014;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#x2014;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left"><font style="font-size: 10pt">Exercised</font></td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(285,003</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">2.74</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#x2014;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#x2014;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 1.5pt; text-align: left"><font style="font-size: 10pt">Cancelled</font></td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(25,625</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4.86</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">&#x2014;</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt; text-align: left"><font style="font-size: 10pt">Outstanding at December 31, 2020</font></td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">2,610,495</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">5.63</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">8.60</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">22,789,233</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; padding-bottom: 4pt; text-align: left"><font style="font-size: 10pt">Exercisable at December 31, 2020</font></td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">755,885</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">3.25</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">8.04</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">8,365,946</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837131518744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2020</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of income tax expense</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Current:</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td>
    <td colspan="2" style="text-align: center">&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Federal</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">State</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Foreign</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total current</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deferred:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">Federal</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(4,502,016</td><td style="width: 1%; text-align: left">)</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">(2,952,519</td><td style="width: 1%; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">State</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Foreign</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(480,666</td><td style="text-align: left">)</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">-</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Change in valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,982,682</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,952,519</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Total deferred</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Income tax provision (benefit)</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of deferred tax assets</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Deferred tax assets:</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; width: 76%; text-align: left">Net operating loss carryforwards</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">6,807,300</td><td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">2,789,541</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Research and development tax credit</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">1,092,345</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">532,711</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left">Intangibles</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">136,226</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">105,580</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Stock compensation</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">761,741</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">387,098</td><td style="padding-bottom: 1.5pt; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left">Total deferred tax assets</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">8,797,612</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3,814,930</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Valuation allowances</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(8,797,612</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(3,814,930</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.375in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Net deferred tax assets</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FederalIncomeTaxNoteTextBlock', window );">Schedule of provision federal statutory rate</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">December&#xa0;31,<br/> 2019</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 76%; text-align: left">Statutory rate</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">&#xa0;</td><td style="width: 9%; text-align: right">21.00</td><td style="width: 1%; text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">State rate</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Foreign</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(1.81</td><td style="text-align: left">)%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">0.00</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Permanent book/tax differences</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(0.26</td><td style="text-align: left">)%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">(0.12</td><td style="text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Research and development credit</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">5.09</td><td style="text-align: left">%</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">3.99</td><td style="text-align: left">%</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Changes in valuation allowance</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24.02</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(24.87</td><td style="padding-bottom: 1.5pt; text-align: left">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">&#xa0;</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.25in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Total</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">&#xa0;</td><td style="border-bottom: Black 4pt double; text-align: right">-</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock', window );">Schedule of unrecognized tax positions</a></td>
<td class="text"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr style="vertical-align: bottom">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: center">&#xa0;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#xa0;</td>
    <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Federal and State</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; width: 88%; text-align: left">Balance at December 31, 2019</td><td style="width: 1%">&#xa0;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">157,814</td><td style="width: 1%; text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left">Additions for tax positions related to current year</td><td>&#xa0;</td>
    <td style="text-align: left">&#xa0;</td><td style="text-align: right">318,374</td><td style="text-align: left">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 1.5pt">Decreases for tax positions related to prior years</td><td style="padding-bottom: 1.5pt">&#xa0;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#xa0;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(81,830</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
<tr style="vertical-align: bottom; ">
    <td style="padding-left: 0.125in; text-indent: -0.125in; text-align: left; padding-bottom: 4pt">Balance at December 31, 2020</td><td style="padding-bottom: 4pt">&#xa0;</td>
    <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">394,358</td><td style="padding-bottom: 2pt; text-align: left">&#xa0;</td></tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ScheduleOfUnrecognizedTaxPositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalIncomeTaxNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the federal tax basis of investment holdings.  This item captures the aggregate cost of securities, aggregate gross unrealized appreciation for all securities in which there is an excess of value over tax cost, aggregate gross unrealized depreciation for all securities in which there is an excess of tax cost over value, net unrealized appreciation (depreciation), and an explanation of the differences between tax and book.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401367&amp;loc=d3e600178-122990<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalIncomeTaxNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837130989800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization And Description Of Business (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 13, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Jan. 24, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ExchangeOfCommonStock', window );">Exchange of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued</a></td>
<td class="nump">3,048,654<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock issued, value</a></td>
<td class="nump">$ 25,914,000<span></span>
</td>
<td class="nump">$ 22,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_OrganizationAndDescriptionsOfBusinessDescription', window );">Organization and description of business, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the underwriter a 45-day option to purchase an additional 660,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The option was exercised in November 2019 and the underwriter purchased an additional 479,300 shares of common stock and the Company received additional gross proceeds of approximately $2,397,000.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ReceivedNetProceeds', window );">Received net proceeds</a></td>
<td class="nump">$ 24,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ExchangeOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ExchangeOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_OrganizationAndDescriptionsOfBusinessDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_OrganizationAndDescriptionsOfBusinessDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ReceivedNetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ReceivedNetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837130952760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Liquidity and Management&#8217;s Plans (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LiquidityAndManagementsPlansAbstract', window );"><strong>Liquidity And Managements Plans [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreconfirmationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 35,301,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SurplusNotes', window );">Working capital surplus</a></td>
<td class="nump">$ 36,237,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_LiquidityAndManagementsPlansAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_LiquidityAndManagementsPlansAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreconfirmationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents at the balance sheet date before fresh-start adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120604989&amp;loc=SL2890621-112765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreconfirmationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SurplusNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial instruments issued by insurance entities (surplus notes) that are includable in surplus for statutory accounting purposes as prescribed or permitted by state laws and regulations that are liabilities of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 470<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6486086&amp;loc=d3e24387-158525<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SurplusNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837129828840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>AUD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_MaintenanceOfPropertyAndEquipment', window );">Maintenance of property and equipment</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 165,092<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 214,240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_DeferredResearchGrantRevenue', window );">Deferred research grant revenue | $</a></td>
<td class="nump">$ 24,315<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic weighted average shares outstanding (in Shares) | shares</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Aggregate exercise price (in Dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleConversionPrice1', window );">Conversion share price (in Dollars per share)</a></td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ConversionPricePercentage', window );">Conversion price percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">IPO price (in Dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature', window );">Beneficial conversion amount | $</a></td>
<td class="nump">$ 23,930,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment and Software [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment and Software [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ConversionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ConversionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_DeferredResearchGrantRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_DeferredResearchGrantRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_MaintenanceOfPropertyAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maintenance of property and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_MaintenanceOfPropertyAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_SummaryofSignificantAccountingPoliciesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of a favorable spread to a debt holder between the amount of debt being converted and the value of the securities received upon conversion. This is an embedded conversion feature of convertible debt issued that is in-the-money at the commitment date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleBeneficialConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleConversionPrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120520924&amp;loc=SL6031898-161870<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleConversionPrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837130972552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Earnings per Common Share - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Earnings per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common stock equivalents outstanding</a></td>
<td class="nump">3,027,850<span></span>
</td>
<td class="nump">3,215,541<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_StockOptionMember', window );">Stock option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Earnings per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common stock equivalents outstanding</a></td>
<td class="nump">2,610,495<span></span>
</td>
<td class="nump">2,139,078<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems', window );"><strong>Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Earnings per Common Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential common stock equivalents outstanding</a></td>
<td class="nump">417,355<span></span>
</td>
<td class="nump">1,076,463<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_SummaryofSignificantAccountingPoliciesDetailsScheduleofBasicandDilutedEarningsperCommonShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837131235272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments And Contingencies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ExpireDate', window );">Rent expenses</a></td>
<td class="text">The lease commenced on October 15, 2018, the Company exercised a one-year lease renewal in October 2019, and another one-year lease renewal in October 2020 that will expire on October 31, 2021.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expenses</a></td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Short-term lease expense</a></td>
<td class="nump">$ 59,000<span></span>
</td>
<td class="nump">$ 28,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ExpireDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ExpireDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121568110&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837134910872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments And Contingencies (Details) - Schedule of future minimum lease payments<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract', window );"><strong>Schedule of future minimum lease payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2021</a></td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ScheduleOfFutureMinimumLeasePaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121573735&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121580752&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837055868952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License and Agreements (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2020 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>AUD ($)</div>
</th>
<th class="th">
<div>Dec. 24, 2019 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Assignment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 953,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_MilestoneFee', window );">Milestone fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_CommonShareOutstandingPricePercentage', window );">Common shares outstanding price percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AmountOfCommonShareDuePayable', window );">Amount of common shares due payable (in Shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOptionReasonsForElection', window );">Fair value of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">$1,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ClosingStockPrice', window );">Closing stock price (in Dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_DescriptionOfLicenseAndAgreements', window );">Description of license and agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">As of December 31, 2019, the Company had not paid the $50,000 or issued the shares and has included the $50,000 in accounts payable and the share amount due as a research and development expense payable. The Company paid the $50,000 and issued the shares in January 2020.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,824,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">977,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_PremarketingApprovals', window );">Pre-marketing approvals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tffp_MasterServicesMember', window );">Master Services [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Assignment fee</a></td>
<td class="nump">$ 4,582,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,790,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AgreementTremDescription', window );">Agreement term, description</a></td>
<td class="text">In January 2019, the Company cancelled all of the individual study contracts with ITR and entered into a contract with 11036114 Canada Inc. (initially dba VJO Non-Clinical Development and now dba Strategy Point Innovations (&#x201c;SPI&#x201d;)) to complete additional pre-clinical research and development services in order to take advantage of eligible Canadian Tax Credits.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,177,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,746,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tffp_IrisysLlcMember', window );">Irisys, LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Assignment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,837,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">867,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tffp_CoreRxMember', window );">CoreRx [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Assignment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,103,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">839,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tffp_ConformClinicalDevelopmentIncMember', window );">Conform Clinical Development, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Assignment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,484,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tffp_NovotechAustraliaPtyLtdMember', window );">Novotech (Australia) Pty Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Assignment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,355,580<span></span>
</td>
<td class="nump">$ 1,942,981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">407,000<span></span>
</td>
<td class="nump">$ 590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tffp_NucleusNetworkPtyLtdMember', window );">Nucleus Network Pty Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Assignment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,392,805<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">337,000<span></span>
</td>
<td class="nump">489,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=tffp_QPharmPtyLtdMember', window );">Q-Pharm Pty Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_LicenseandAgreementsDetailsLineItems', window );"><strong>License and Agreements (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFeeAmount', window );">Assignment fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 505,488<span></span>
</td>
<td class="nump">$ 704,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 384,000<span></span>
</td>
<td class="nump">$ 557,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AgreementTremDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AgreementTremDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AmountOfCommonShareDuePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AmountOfCommonShareDuePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ClosingStockPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Closing stock price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ClosingStockPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_CommonShareOutstandingPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_CommonShareOutstandingPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_DescriptionOfLicenseAndAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of license and agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_DescriptionOfLicenseAndAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_LicenseandAgreementsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_LicenseandAgreementsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_MilestoneFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_MilestoneFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_PremarketingApprovals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_PremarketingApprovals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the fee that accompanies borrowing money under the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOptionReasonsForElection">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents a narrative discussing management's reasons for electing a fair value option for each eligible item or group of similar eligible items as of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOptionReasonsForElection</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tffp_MasterServicesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tffp_MasterServicesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tffp_IrisysLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tffp_IrisysLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tffp_CoreRxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tffp_CoreRxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tffp_ConformClinicalDevelopmentIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tffp_ConformClinicalDevelopmentIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tffp_NovotechAustraliaPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tffp_NovotechAustraliaPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tffp_NucleusNetworkPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tffp_NucleusNetworkPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=tffp_QPharmPtyLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=tffp_QPharmPtyLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837128178824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 13, 2020</div></th>
<th class="th"><div>Aug. 10, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of common stock</a></td>
<td class="nump">3,048,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,534,874<span></span>
</td>
<td class="nump">18,450,992<span></span>
</td>
<td class="nump">220,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockForStockOptionExerciseShares', window );">Issuance of common stock for stock option exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">285,003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockOptionExercisesTotalProceeds', window );">Stock option exercises total proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 714,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 714,382<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise', window );">Issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">529,559<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockWarrant', window );">Issuance of common stock warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">659,108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,930,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Series A preferred stock dividend payable (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 875,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockDescription', window );">Series A preferred stock conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Pursuant to the Company&#x2019;s amended and restated certificate of incorporation, holders of the Series A Preferred Stock had the following methods of conversion: (i) automatic conversion into common stock upon the consummation of an IPO at a conversion price of 50% of the IPO price, (ii) automatic conversion into common stock upon the consummation of a subsequent private placement of securities at a conversion price of 50% of the purchase price of the securities being sold by the Company approved by the holders of the Series A preferred stock, and (iii) at any time after the issuance date and until ten calendar days prior to the consummation of an IPO, each holder shall be entitled to convert into common stock at a conversion price of $2.50 per share.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockTermsOfConversion', window );">Convertible preferred stock terms of conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Series A Preferred Stock automatically converted into 9,571,692 common shares upon completion of the IPO in October 2019, based on the number of shares of Series A Preferred Stock outstanding as of the date of the IPO. The conversion share calculation was based on the $2.50 initial issue price for the Series A Preferred Stock plus $1,603,709 of accrued and unpaid dividends and automatically converted into shares of the Company&#x2019;s common stock using a stated divisor conversion price equal to 50% of the IPO price to the public which was $5.00 per share. In accordance with relevant accounting literature, since the terms of the conversion option did not permit the Company to compute the additional number of shares that it would need to issue upon conversion of the Series A Preferred when the contingent event occurred, the Company recorded the beneficial conversion amount of approximately $23,930,000 as a deemed dividend at the date of the IPO.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockholdersEquityDescription', window );">Stockholders equity deficit, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company completed an IPO, selling 4,400,000 shares of common stock at an offering price of $5.00 per share. The Company received gross proceeds of approximately $22,000,000. In addition, the Company granted the underwriter a 45-day option to purchase an additional 660,000 shares of common stock at the initial public offering price. The option was exercised and the underwriter purchased an additional 479,300 shares of common stock and the Company received additional gross proceeds of approximately $2,397,000. The Company received net proceeds from the IPO and the underwriter&#x2019;s purchase of additional shares of approximately $21,754,000, after deducting underwriting discounts and commissions and offering-related expenses. Warrants for 317,155 shares of the Company&#x2019;s common stock were issued to the IPO underwriter at an exercise price of $6.25 per share as part of the underwriter&#x2019;s compensation for the IPO. The estimated fair value of the warrants of approximately $977,000 was considered an offering cost and netted against additional paid-in capital.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Purchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">627,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_FairValueAssumptionExercisePrice', window );">Exercise price (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">2019 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,048,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_NetProceeds', window );">Net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,280,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,571,692<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | 2019 Private Placement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockholdersEquityDetailsLineItems', window );"><strong>Stockholders' Equity (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement', window );">Gross proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_NetProceeds', window );">Net proceeds (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,268,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_FairValueAssumptionExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_FairValueAssumptionExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockForStockOptionExerciseShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockForStockOptionExerciseShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of common stock warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_NetProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_NetProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_StockOptionExercisesTotalProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_StockOptionExercisesTotalProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_StockholdersEquityDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stockholders equity deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_StockholdersEquityDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_StockholdersEquityDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_StockholdersEquityDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockTermsOfConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific terms relevant to convertibility. Includes class of preferred stock and number of shares convertible into, exercise (or conversion) price or rates, dates relevant to conversion timing and events relevant to conversion. Describe also any beneficial conversion features. where convertible preferred stock with a nondetachable conversion feature is in-the-money at commitment date. For contingently convertible preferred stock, discuss the circumstances of the contingency, including the events or changes in circumstance that would cause the contingency to be met and any of the significant features necessary to understand the conversion rights and the timing of those rights. Include also an events or changes in circumstance, if any, that could adjust or change the contingency, conversion price, or number of shares, including significant terms of those changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockTermsOfConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPrivatePlacement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPrivatePlacement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837127618488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="6">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 29, 2019</div></th>
<th class="th"><div>Nov. 26, 2019</div></th>
<th class="th"><div>Aug. 29, 2019</div></th>
<th class="th"><div>May 23, 2019</div></th>
<th class="th"><div>May 16, 2019</div></th>
<th class="th"><div>Mar. 13, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Oct. 31, 2019</div></th>
<th class="th"><div>Mar. 22, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,930,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantToPurchaseSharesOfCommonStock', window );">Warrant to purchase shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase share of common stock, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare', window );">Warrant price per unit (in Dollars per share)</a></td>
<td class="nump">$ 5.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantOutstandingAggregateIntrinsicValue', window );">Aggregate intrinsic value (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,511,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=tffp_NationalSecuritiesCorporationsWarrantsMember', window );">National Securities Corporation Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase of company's amount equal to common stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantToPurchaseSharesOfCommonStock', window );">Warrant to purchase shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">326,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_FairValueAssumptionsCommonStockValue', window );">Common stock value, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.67<span></span>
</td>
<td class="nump">$ 1.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_FairValueAssumptionsExpectedTerms', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_FairValueAssumptionsExpectedDividendRates', window );">Dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_FairValueAssumptionExpectedVolatilityRate', window );">Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.60%<span></span>
</td>
<td class="nump">89.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_FairValueAssumptionRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.11%<span></span>
</td>
<td class="nump">2.11%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense (in Dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347,000<span></span>
</td>
<td class="nump">$ 347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase share of common stock, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=tffp_NationalSecuritiesCorporationsWarrantsMember', window );">National Securities Corporation Warrants [Member] | IPO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantToPurchaseSharesOfCommonStock', window );">Warrant to purchase shares of common stock (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">317,155<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=tffp_TenYearsWarrantMember', window );">Ten Year Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantToPurchaseSharesOfCommonStock', window );">Warrant to purchase shares of common stock (in Shares)</a></td>
<td class="nump">3,623<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,794<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_FairValueAssumptionsCommonStockValue', window );">Common stock value, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_FairValueAssumptionsExpectedTerms', window );">Contractual life</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_FairValueAssumptionsExpectedDividendRates', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_FairValueAssumptionExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">90.16%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.48%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_FairValueAssumptionRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Research and development expense (in Dollars)</a></td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,419<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=tffp_TenYearsWarrantMember', window );">Ten Year Warrant [Member] | BP Directors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase share of common stock, per share (in Dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock [Member] | National Securities Corporation Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,662,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=tffp_BPDirectorsMember', window );">BP Directors [Member] | Ten Year Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantsDetailsLineItems', window );"><strong>Warrants (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant to purchase share of common stock, per share (in Dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_FairValueAssumptionExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_FairValueAssumptionExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_FairValueAssumptionRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_FairValueAssumptionRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_FairValueAssumptionsCommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_FairValueAssumptionsCommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_FairValueAssumptionsExpectedDividendRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_FairValueAssumptionsExpectedDividendRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_FairValueAssumptionsExpectedTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_FairValueAssumptionsExpectedTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IssuanceOfCommonStockInConnectionWithCashlessWarrantExercisesShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_WarrantOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of warrant outstanding aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_WarrantOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_WarrantToPurchaseSharesOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_WarrantToPurchaseSharesOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_WarrantsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_WarrantsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=tffp_NationalSecuritiesCorporationsWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=tffp_NationalSecuritiesCorporationsWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=tffp_TenYearsWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=tffp_TenYearsWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=tffp_BPDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=tffp_BPDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=tffp_BPDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=tffp_BPDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837127594136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details) - Schedule of warrant activity - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantsDetailsScheduleofwarrantactivityLineItems', window );"><strong>Warrants (Details) - Schedule of warrant activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding, beginning (in Shares)</a></td>
<td class="nump">1,476,463<span></span>
</td>
<td class="nump">1,058,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, Outstanding, beginning</a></td>
<td class="nump">$ 2.71<span></span>
</td>
<td class="nump">$ 1.56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Life, Outstanding, beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 219 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross', window );">Number of Shares, Issued (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">745,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.26<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross', window );">Number of Shares, Cancelled (in Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(326,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled', window );">Range of Exercise Prices, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised', window );">Number of Shares, Exercised (in Shares)</a></td>
<td class="num">(659,108)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised', window );">Weighted-Average Exercise Prices, Exercised</a></td>
<td class="nump">$ 2.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares, Outstanding, ending (in Shares)</a></td>
<td class="nump">817,355<span></span>
</td>
<td class="nump">1,476,463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, Outstanding, ending</a></td>
<td class="nump">$ 2.68<span></span>
</td>
<td class="nump">$ 2.71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm', window );">Weighted-Average Remaining Life, Outstanding, ending</a></td>
<td class="text">3 years 255 days<span></span>
</td>
<td class="text">4 years 36 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantsDetailsScheduleofwarrantactivityLineItems', window );"><strong>Warrants (Details) - Schedule of warrant activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice', window );">Range of Exercise Prices, Outstanding, beginning</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice', window );">Range of Exercise Prices, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised', window );">Range of Exercise Prices, Exercised</a></td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice', window );">Range of Exercise Prices, Outstanding, ending</a></td>
<td class="nump">0.01<span></span>
</td>
<td class="nump">0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WarrantsDetailsScheduleofwarrantactivityLineItems', window );"><strong>Warrants (Details) - Schedule of warrant activity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice', window );">Range of Exercise Prices, Outstanding, beginning</a></td>
<td class="nump">6.25<span></span>
</td>
<td class="nump">2.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice', window );">Range of Exercise Prices, Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised', window );">Range of Exercise Prices, Exercised</a></td>
<td class="nump">6.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice', window );">Range of Exercise Prices, Outstanding, ending</a></td>
<td class="nump">$ 6.25<span></span>
</td>
<td class="nump">$ 6.25<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of weighted-average exercise per share prices issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIssuedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantCancelledInPeriodGrossExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrant shares issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantIssuedInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsPriceExercisePricesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceIssuedPriceExercisePricesCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsRangeOfExercisePriceOutstandingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedWeightedAverageExercisePricePricesExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_WarrantsDetailsScheduleofwarrantactivityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_WarrantsDetailsScheduleofwarrantactivityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837131525432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCompensationArrangementsOverallDescription', window );">Stock based compensation, description</a></td>
<td class="text">the Company&#x2019;s board of directors approved its 2018 Stock Incentive Plan (&#x201c;2018 Plan&#x201d;). The 2018 Plan provides for the grant of non-qualified stock options and incentive stock options to purchase shares of the Company&#x2019;s common stock, the grant of restricted and unrestricted share awards and grant of restricted stock units. The Company initially reserved 1,630,000 shares of its common stock under the 2018 Plan; however, upon completion of the Company&#x2019;s IPO the number of shares reserved for issuance under the 2018 Plan increased to 3,284,480, representing 15% of the Company&#x2019;s outstanding shares of common stock calculated on a fully diluted basis upon the close of the IPO. All of the Company&#x2019;s employees and any subsidiary employees (including officers and directors who are also employees), as well as all of the Company&#x2019;s nonemployee directors and other consultants, advisors and other persons who provide services to the Company will be eligible to receive incentive awards under the 2018 Plan.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,074,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm', window );">Weighted-average period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 146 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>weighted-average period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementsOverallDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>General description of deferred compensation arrangements. Deferred compensation represents currently earned compensation that, under the terms of a profit-sharing, rabbi trust, pension, employee contract, or equity-based (including stock or unit option) plan, is not actually paid until a later date and is therefore not taxable until that date. May also include some split-dollar life insurance arrangements. This type of arrangement is usually made to help employees postpone paying taxes on the income and also to retain employees longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementsOverallDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837146431144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and restricted stock - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems', window );"><strong>Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and restricted stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 2,187,149<span></span>
</td>
<td class="nump">$ 590,041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems', window );"><strong>Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and restricted stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expenses</a></td>
<td class="nump">140,278<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems', window );"><strong>Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and restricted stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation expenses</a></td>
<td class="nump">$ 2,046,871<span></span>
</td>
<td class="nump">$ 590,041<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_StockBasedCompensationDetailsScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837128139736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Details) - Schedule of fair value of employee stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems', window );"><strong>Stock Based Compensation (Details) - Schedule of fair value of employee stock options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice', window );">Weighted average exercise price (in Dollars per share)</a></td>
<td class="nump">$ 10.42<span></span>
</td>
<td class="nump">$ 4.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value (in Dollars per share)</a></td>
<td class="nump">$ 9.25<span></span>
</td>
<td class="nump">$ 3.08<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 109 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems', window );"><strong>Stock Based Compensation (Details) - Schedule of fair value of employee stock options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">87.00%<span></span>
</td>
<td class="nump">88.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 109 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.36%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems', window );"><strong>Stock Based Compensation (Details) - Schedule of fair value of employee stock options [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">91.00%<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.47%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_StockBasedCompensationDetailsScheduleoffairvalueofemployeestockoptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the weighted average exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837128153736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Based Compensation (Details) - Schedule of stock option activity - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ScheduleOfStockOptionActivityAbstract', window );"><strong>Schedule of stock option activity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber', window );">Number of Shares, Outstanding, beginning balance shares</a></td>
<td class="nump">2,139,078<span></span>
</td>
<td class="nump">1,073,082<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, Outstanding, beginning balance (in Dollars per share)</a></td>
<td class="nump">$ 3.46<span></span>
</td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1', window );">Weighted-Average Remaining Contractual Term, Outstanding beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 233 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding beginning balance (in Dollars)</a></td>
<td class="nump">$ 4,052,512<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Number of Shares, Outstanding, Granted</a></td>
<td class="nump">782,045<span></span>
</td>
<td class="nump">1,065,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, Outstanding, Granted (in Dollars per share)</a></td>
<td class="nump">$ 10.42<span></span>
</td>
<td class="nump">$ 4.42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WeightedaverageRemainingContractualTermGranted', window );">Weighted-Average Remaining Contractual Term, Granted</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Granted (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares, Outstanding, Exercised</a></td>
<td class="num">(285,003)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, Outstanding, Exercised (in Dollars per share)</a></td>
<td class="nump">$ 2.74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WeightedaverageRemainingContractualTermExercised', window );">Weighted-Average Remaining Contractual Term, Exercised</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate Intrinsic Value, Exercised (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Number of Shares, Outstanding, Cancelled</a></td>
<td class="num">(25,625)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, outstanding, Cancelled (in Dollars per share)</a></td>
<td class="nump">$ 4.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_WeightedaverageRemainingContractualTermCancelled', window );">Weighted-Average Remaining Contractual term, Cancelled</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AggregateIntrinsicValueCancelled', window );">Aggregate Intrinsic Value, Cancelled (in Dollars)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber', window );">Number of Shares, Outstanding, Outstanding ending balance</a></td>
<td class="nump">2,610,495<span></span>
</td>
<td class="nump">2,139,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, Outstanding, Outstanding ending balance (in Dollars per share)</a></td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="nump">$ 3.46<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3', window );">Weighted-Average Remaining Contractual Term, Outstanding ending balance</a></td>
<td class="text">8 years 219 days<span></span>
</td>
<td class="text">9 years 62 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding ending balance (in Dollars)</a></td>
<td class="nump">$ 22,789,233<span></span>
</td>
<td class="nump">$ 4,052,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares, Outstanding, Exercisable</a></td>
<td class="nump">755,885<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Prices, Outstanding, Exercisable (in Dollars per share)</a></td>
<td class="nump">$ 3.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">8 years 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AggregateIntrinsicValueExercisable', window );">Aggregate Intrinsic Value, Exercisable</a></td>
<td class="nump">8,365,946<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AggregateIntrinsicValueCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate intrinsic value, Cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AggregateIntrinsicValueCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AggregateIntrinsicValueExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AggregateIntrinsicValueExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ScheduleOfStockOptionActivityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ScheduleOfStockOptionActivityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise prices, outstanding, beginning balance (in Dollars per share).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average remaining contractual term, outstanding ending balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_WeightedaverageRemainingContractualTermCancelled">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average remaining contractual term, Cancelled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_WeightedaverageRemainingContractualTermCancelled</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_WeightedaverageRemainingContractualTermExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average remaining contractual term, Exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_WeightedaverageRemainingContractualTermExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_WeightedaverageRemainingContractualTermGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average remaining contractual term, Granted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_WeightedaverageRemainingContractualTermGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average remaining contractual term, outstanding beginning balance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_WeightedaverageRemainingContractualTermOutstandingBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837128137432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 27, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_FederalIncomeTaxNetOperatingLoss', window );">Federal income tax net operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,126,830<span></span>
</td>
<td class="nump">$ 13,283,530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Federal research tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,486,704<span></span>
</td>
<td class="nump">$ 690,525<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ForeignIncomeTaxNetOperatingLoss', window );">Foreign income tax net operating loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,602,220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_FederalTaxCreditExpire', window );">Federal tax credit expire</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_TaxableIncomeForLosses', window );">Taxable income for losses</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance on deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.02%<span></span>
</td>
<td class="nump">24.87%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_UncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 394,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=tffp_EffectiveTaxRateMember', window );">Effective Tax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IncomeTaxesDetailsLineItems', window );"><strong>Income Taxes (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance on deferred tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_UncertainTaxPositions', window );">Uncertain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 394,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_FederalIncomeTaxNetOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal income tax net operating loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_FederalIncomeTaxNetOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_FederalTaxCreditExpire">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal tax credit expire.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_FederalTaxCreditExpire</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ForeignIncomeTaxNetOperatingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Foreign income tax net operating loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ForeignIncomeTaxNetOperatingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IncomeTaxesDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IncomeTaxesDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_TaxableIncomeForLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_TaxableIncomeForLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_UncertainTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Uncertain Tax Positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_UncertainTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=tffp_EffectiveTaxRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=tffp_EffectiveTaxRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837129544312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of income tax expense - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(4,502,016)<span></span>
</td>
<td class="num">(2,952,519)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="num">(480,666)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions', window );">Change in valuation allowance</a></td>
<td class="nump">4,982,682<span></span>
</td>
<td class="nump">2,952,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOtherTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOtherTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other deferred income tax expense (benefit) pertaining to income (loss) from continuing operations. For example, but not limited to, acquisition-date income tax benefits or expenses recognized from changes in the acquirer's valuation allowance for its previously existing deferred tax assets resulting from a business combination and adjustments to beginning-of-year balance of a valuation allowance because of a change in circumstance causing a change in judgment about the realizability of the related deferred tax asset in future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOtherTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) to previously recorded tax expense. Includes, but is not limited to, significant settlements of income tax disputes, and unusual tax positions or infrequent actions taken by the entity, including tax assessment reversal, and IRS tax settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121573983&amp;loc=d3e28511-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121573983&amp;loc=d3e28446-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxAdjustmentsSettlementsAndUnusualProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837128060264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of deferred tax assets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_DeferredTaxAssetsAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 6,807,300<span></span>
</td>
<td class="nump">$ 2,789,541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development tax credit</a></td>
<td class="nump">1,092,345<span></span>
</td>
<td class="nump">532,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangibles</a></td>
<td class="nump">136,226<span></span>
</td>
<td class="nump">105,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_DeferredTaxAssetsStockCompensation', window );">Stock compensation</a></td>
<td class="nump">761,741<span></span>
</td>
<td class="nump">387,098<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">8,797,612<span></span>
</td>
<td class="nump">3,814,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowances</a></td>
<td class="num">(8,797,612)<span></span>
</td>
<td class="num">(3,814,930)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_DeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_DeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_DeferredTaxAssetsStockCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_DeferredTaxAssetsStockCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837161483720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of provision federal statutory rate<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_ScheduleOfProvisionFederalStatutoryRateAbstract', window );"><strong>Schedule of provision federal statutory rate [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars', window );">Foreign</a></td>
<td class="num">(1.81%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences', window );">Permanent book/tax differences</a></td>
<td class="num">(0.26%)<span></span>
</td>
<td class="num">(0.12%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Research and development credit</a></td>
<td class="nump">5.09%<span></span>
</td>
<td class="nump">3.99%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="num">(24.02%)<span></span>
</td>
<td class="num">(24.87%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent', window );">Total</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercentForeigninDollars</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_EffectiveIncomeTaxRateReconciliationPermanentBooktaxDifferences</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_ScheduleOfProvisionFederalStatutoryRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_ScheduleOfProvisionFederalStatutoryRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference, between reported income tax expense (benefit) and the expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, that is attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority interest income (expense), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, change in enacted tax rate, prior year income taxes, change in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherReconcilingItemsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837131632584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details) - Schedule of unrecognized tax positions - Federal and State [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems', window );"><strong>Income Taxes (Details) - Schedule of unrecognized tax positions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_UncertainTaxPositionsBegnningBalance', window );">Balance at December 31, 2019</a></td>
<td class="nump">$ 157,814<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_AdditionsForTaxPositionsRelatedToCurrentYear', window );">Additions for tax positions related to current year</a></td>
<td class="nump">318,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_DecreasesForTaxPositionsRelatedToPriorYears', window );">Decreases for tax positions related to prior years</a></td>
<td class="num">(81,830)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_UncertainTaxPositionsEndingBalance', window );">Balance at December 31, 2020</a></td>
<td class="nump">$ 394,358<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_AdditionsForTaxPositionsRelatedToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions for tax positions related to current year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_AdditionsForTaxPositionsRelatedToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_DecreasesForTaxPositionsRelatedToPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additions for tax positions related to prior years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_DecreasesForTaxPositionsRelatedToPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_IncomeTaxesDetailsScheduleofunrecognizedtaxpositionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_UncertainTaxPositionsBegnningBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_UncertainTaxPositionsBegnningBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_UncertainTaxPositionsEndingBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_UncertainTaxPositionsEndingBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=tffp_FederalAndStateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=tffp_FederalAndStateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.4</span><table class="report" border="0" cellspacing="2" id="idm139837140651688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event [Member]<br></strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 10, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Cash proceeds from the exercises (in Dollars) | $</a></td>
<td class="nump">$ 585,700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common stock issued</a></td>
<td class="nump">160,275<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_tffp_SubsequentEventsDetailsLineItems', window );"><strong>Subsequent Events (Details) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Common stock issued</a></td>
<td class="nump">444,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_tffp_SubsequentEventsDetailsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">tffp_SubsequentEventsDetailsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>tffp_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_OptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M-@#W5U*:W<2VJ^'KE/\%4$L#!!0    ( -6 :E+H?/(&D00  .8/   8
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&ULE5?;;N,V$/T50NC#%MB-1,FZ!;:!
M7'I98+<-XF[WF9'&MAI)=$G:SOY]AY(L.19%N'F(=9DY.F=FR.',CUR\RBV
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M*:^YW.(@#D(;X/LUY^ITHS_0C_;+_P!02P,$%     @ U8!J4BO)V,5X!@
MTR$  !@   !X;"]W;W)K<VAE971S+W-H965T-2YX;6S56FVOVC84_BL6FZ96
M*B5VWCLN4B\0K=*V7O6NVV<W,9>L(6:V@=M_/SOD!A([!JIHTKY $GP>'Y_G
M'.<Y"=,#95_YFA !GC=%R>]&:R&V[R83GJ[)!O.W=$M*^<N*L@T6\I0]3?B6
M$9Q51IMB@APGF&QP7HYFT^K: YM-Z4X4>4D>&."[S0:S;_>DH(>[$1R]7/B4
M/ZV%NC"93;?XB3P2\7G[P.39I$')\@TI>4Y+P,CJ;O0>ODN0KPRJ$7_FY,#/
MCH%:RA=*OZJ3#]G=R%$>D8*D0D%@^;4G<U(4"DGZ\4\-.FKF5(;GQR_H2;5X
MN9@OF),Y+?[*,[&^&T4CD)$5WA7B$SW\0NH%50ZFM.#5)SC48YT12'=<T$UM
M+#W8Y.7Q&S_7@3@S@&Z/ :H-4,< A3T&;FW@=@S</@.O-O"Z,_2MP:\-_&O7
M$-0&017[8["J2"^PP+,IHP? U&B)I@XJNBIK&>"\5)GU*)C\-9=V8C:G):=%
MGF%!,O HY)=,&\$!7<DSFGY=TR(CC/_T0X1@^#-8_K/+Q3<P!I\?%^#5CZ^G
M$R&=4%"3M)[P_C@AZIUPLY$958$;K.=VZ_=9EJN,Q 5XP'D&\A+,\387N#!@
M+2Y@I>ENLRNJE7\4:\* ]$V6YUK5S9Z 7RGG!M3E]:@+LLK37!A $CO('U1;
MT402V["+&G91A>/UX-SC I<I 5A(7]*WP(5O ')@9*+MB!142&H_VL\\QW&F
MD_TY._H@/PY"Y+6'+:Q>J<WR'=_BE-R-9+@Y87LRF@%3J/7IQF[D(1@%[0D3
MTT#D02] S<!6 -TF@.Y5 7PE$^UQC:6WKZ\*YA'5[P3S/)XM=[S&'<_JS@?.
M=Y4_LCS38R%Q54BJ#E):EO5V?<C%&GQX^/A&7D^+79:73V!7RCH^L%P05A>S
M+/(]86. BX(*5?5O0"EO91*:KE:$*:.4<KD7X#(SFF<Y3^FN-.7WO:=G4Q3&
MG6SRM"A)8"^*@\[ A34J-^330#B)T7%?IF9DYM=O^/7_A_R>9[^):U]/=LFU
MVY?L01.,P!J,ZA8Q5K(A4\&06HICM7R3"U:DZXF=!]I2_-AQ/-C)QX&F6PZ$
MDUQTNT5 V! 06@E8Y/L\(V4F$ZD$T@.9-$QRP7MNW?=6M!M("+75C"-977YW
M5QAHON5 .,EEOULT1 T-D94&*=%D'5=27JDR6;F$@_?@H2&D*A15I"][ 4Y3
MMI,_9"\$O@:"MC84$WV1MF7'?H@Z6W9DV/E0&+FNWR''NJ8;R!D()S$Z+K<I
M)S2S$S?LQ/\Y.Y<VW%A;BV0*!G&/V('.J1EPK(OY7=X?"K/LO;>;WE#>0P$M
MA@):UD"MRH4P"AV$HH[0O&IH._IGK1C\'K4>&]F 6K7"R/,[-ZIY/:QU;W9=
M-PIA1]DO[+[=$DQ]RC&4Z:GD>#>8^E 4!IX7>CU%"4^-#[RN\[$(=W-<D>:2
MBJL3]Q;7J96 ]E[B$1>:L.N19$;/7(UQU_&B+N%ZYX$\%(9(VZ#MWMY"^$!
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M376X)C@C3 V0OZ\H%2\GZB5Z\S^.V;]02P,$%     @ U8!J4F,<-;QA!@
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M,E 60OPP-Y_SFU%@/.(ES[19@L'/GL]X69J5P(^?]:*CQJ:9>'S]LOH?%CR
M63#%9Z+\I\CU^F:4C%#.EVQ7ZF_B\4]> PK->IDHE?V+'NNQP0AE.Z7%IIX,
M'FR*ZO#+GNI '$W T< $4D\@W0F3@0FTGD MT(-G%M8]TVQZ+<4CDF8TK&8N
M;&SL;$!35&8;'[2$_Q8P3T]GHE*B+'*F>8X>-/S 'FF%Q!+-F%JC/V"?%?J
MOC_<HW>_O;\>:S!JIHZSVL#=P0 9,( )^B(JO5;H4Y7S_'2!,7C;N$Q>7+XC
MWA7O>?814?P[(@$)' [-7CT=IQYW:!-!:M>C0Q$T85K:,"VEV""H,,ET4:T.
M*5KH@JLKCYU)8V=B[4P&[/P%-5T*I5Q;<)@9V9FF</?3#S@)HYC0R?5X?QP;
MUTB<Q $A23/RQ+VP<2_TAN$V_Q>RU20/T@(*/!-55I0<5;7;YJFYSDRX=@JR
MK:@NCE74.!-Y8_6@1?;#EG>.,K&!GJ>8Z1JNV!U6"H\B0B @>))V(M<?%Z9!
M,,'NL,6-I[$_>]:L6G'5"892'&J053DJ"[8HRK.!21ISB3<P<\FWK,AK"ZYP
M)#V8D""$3-*P$P_7P" ):!J[(Y(V+J9>%V^S3.Q,"]JR9[8HN<O)M&<[B4@4
M1QT7^\,PF1QM[(E_.&A;9N#U\)XON9206I(KSF2V1BO)(.\EW_-JYW2X7O$D
MRR84=V/J-VPH_4IM6<9O1EMC6^[Y:(H\:8&/: "?B[K<'4,RR9<#H%)L;5'S
M)U-%;G#>I5_E=0T?]S<,4^C3=&#+2 N/G&V>9SN/$QMQI'D4X3!,N@W".103
M'$'Y#/C?<@R^C&2*:L_5!8T3MRR#_30SW\'N0^.T$F K39STL\T&_G-7V%QP
MQFGB A^0)$BZ8?+:?T..MPR%P\N2P!5%)[CPU>"\'KP!7,MX.+HH0Y9%Q8"!
M7Y\A+6/A^&P8(3$RSO.7;%1J!\:X21F@VPW(<V49&&(,.J"J)?MCH=?H\_RK
M,\1>FY?TD-C%YR'&43!0A"UW8C]Y^H&#7S4M6.Q.D-[U+P'9)]\8IPDA ]R+
M6_+%?O9]_>8Z ?89ETR@3$A"NX7B=>/R0B$M>Q,_>\]?E[KPAEQ?B:W-7O[$
M958H=X<@?7X'"4D3TH'M]^T-L%N")WZ";YH?[.Z^@#<QM'AV-@DGO#XQ@R),
M)U'453"ND6DP26DRD)JDY7#BY_!/RR4T$K-1_"FSLAD!A7.4U1(:]L@"-%QE
M+PQA[5EIWF>=H!Q\'8-^[?*ZWZTW[%G+^H2>W;.BRB0'/K:]]")XM)^2) B3
MJ(>O/Q#'":7D:'-/ ;1B@OC%Q&S(8<0T6O!5454F^6!+GT%U.E'T=07TDQ02
MJBOV'2.!HB,<Q0.O:*05#L0O'+PP.#SW >AK!QK2 -Z4>J73']F#>@J@%0?$
M+PX>=MMM:4]V6(GR0F7P1KZ3MNE5HOI@81V)(4!TJ7P@K7P@?OGP\J:1%Z8-
M5;DS:+]*#9"^&DCBD(8#[X"DU0+$KP5F L(E[6$F!/&!2X@/ND7S1@0<CB#>
M0?F6N_P0QU/<ZKTY$CG'J'XW+HE$7S(03)(X#88:<ZL9B%\S?(7&+ W$3"BH
MB8IK<YAHU=ZIE!C0?O[E+\'8EQ]I3/' VQ=M)0,]]\(/M=/NG-4&"U[Q99$5
M4%!9FPM+SG1=6$,YX8J W_X%$:".<P::DC0.!YH@;04$]0L(TP1+KE0CA S(
M1R;-T8>3@&A?"D#CZS0]O]'+R96V<H+ZY<1GG_)C_^,XI+9[?,;:/<6HL?\J
M83$^.O_?<+FRGT44LN=HAW/UYFGSZ>76?G#H/+_#5[/#!Y1VF</WG"], ELK
M5/(E+!E\C&%;Y>$3R>%&BZW]RK 06HN-O5QSEG-I!L#_ET+HEQMCH/E0-?T/
M4$L#!!0    ( -6 :E*4JYVHCPD  (T6   8    >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&ULC5C;<MLX$GWG5Z"\4ULS5;)NEA-GXKA*OF3CJ8RMC9VD:K?V
M 2(A"1L0T "@9<_7[^D&25&*G=F'. ()]/7TZ09/-\Y_"RNEHG@LC0WO#E8Q
MKG\=#$*^4J4,?;=6%F\6SI<R8NF7@[#V2A9\J#2#\7#X:E!*;0_.3OG9S)^=
MNBH:;=7,BU"5I?1/Y\JXS;N#T4'SX)->KB(]&)R=KN52W:GX>3WS6 U:*84N
ME0W:6>'5XMW!=/3K^83V\X8O6FU"Y[<@3^;.?:/%=?'N8$@&*:/R2!(D_GM0
M%\H8$@0S_JAE'K0JZ6#W=R/]/?L.7^8RJ MGONHBKMX=G!R(0BUD9>(GM_F@
M:G^.25[N3."_8I/V3J QKT)T97T8ZU+;]+]\K./0.7 R?.' N#XP9KN3(K;R
M4D9Y=NK=1GC:#6GT@UWETS!.6TK*7?1XJW$NGMWZI;3Z3\DAFMI"7*J0>[WF
M]>U"G%<!)T(X'41HHS.#O)9\GB2/7Y \&HO?G8VK(*YLH8I= 0.8V=HZ;FP]
M'_]0XJ7*^^)HU!/CX7CX WE'K>]'+._H!7G3/'>5C=HNQ<P9G6L5Q+^G\Q ]
ML/*?'RB8M HFK&#R4G __6-Z<_VOZ?WU[8V8WER*RZN[BT_7,U[?OA?GG^^N
M;Z[N[IX+[H\EW]S>7XF1^/O?3L:CT5OQ_RH2]^_?B]E* LZYJJ+.I0D]<6T1
MUY_C2K&\\?#MA2O7TC[Q:O3VEVPC@] V=W[MO(RJP$+0]KN(E7 +@,;(C?3X
M;<5OTE8H;S&>4*)&)V+^)#Y6B/']2GFY9K6MTEKAQ_OK1EE/R"@V*YVO1$3U
MDYZLMD=(X!-;A;)1>38C.B'%!6#F];Q*98X]=]5\"^+ITBL%&HFMMIW][>O&
M +&N?*@D]D,X&Y*13DG["GH&>-BP4)Y_(PJ-=;GR$2Q(\:C]&;U^&X1U]A"A
M4V0MR =L5$DCUAZ\ZN.3\$0;@<UVD.:%#$%%! @!-U4!<&9=:?7V"B6%K6*-
M!,!2@!<\J9*1[.M&QQ5;]]F"]7S04 7#[M4C<HD(3T$ML/7GH)2X<<CB\2^D
M4JC'?"7M4@GPO9CTAL,A_<L",(/J@(2.QZU1N2M+A!)DE7_K4YY3C"03;V-L
M.OA<Y$5N7$BH^EUZ))Y@T^\&,0/Q:L(@F@?>IQ")#4! G*A+:7B[T!1(H:0W
M3X<AHJF(N89S^<HZXY9/9"BG:N% K=#H$HX+]8#NM&9;X&*3R/8@B"&K(;^N
M#%PE?"^T,D7R=C\>,"EJ))G5D%'/Z]%V)0VL*"!M[384I,)7RT# 4GAG<X8_
M@JEDI$,9#FT-*'10Z$<).[FSA>9P]U%:*,A<E7,(1"C?]'9@JA"8N=%H&04
MM%DY@V"YC<620.&ET9+B/ ^ZT-#3>XXTLG:KF %9'V/15A?M;M]NJYH*PQ>I
M:LC8*J>\(U(0A^X.5Y#Y_LL$!5XP#BS"P,:NK05X QR@$7*G1X2?:%I0WJ=R
M!=Y?I+:=](F$L/U$)1Q1C/$>+QPW#(I/!$D@S>8IPQ].*$"I%JB<2#D$(1:B
M [[&29;5T= 7MWET3;+@; +/K$*6<O1@N$(:D=7NOMVD$K"- C5GR%T#OW62
MX!H)38:N9[?;O&! ,O1RTIND6A?;6N_6-9&&M%MA:P_.H4T_'?=Q"&26#O:S
M;D@]<(B4%&+I70C$>CE8E(7+-5:/J-U(&?MI/&[(A@$LBP3G73>7H!7J/_2,
M667C=60BG!P?%A(4QYR?(>U@<3 9<>)6&&+RZM5?.4FR7XH@.]T3!@/15C^]
M0"WR+,'%F)%('4*J1@I',DM0'U6/RN>ZIKL;][ M4\;%OF>-&\6>'Y/7;WI'
M+_J1-:*^RT-'Q%^GI'?TYG7*R+1:HMQX\!(SKQ^H[\\,:I1+Y-8V&T9':3K;
M1R?7.Z&30LBGU^UI*#[J#2<GO5?'DXX_5$Q=GW@PD-N\)@"VN&,HGO2/H9I:
MEURBNRQ)T:Z;V5[3?L;KX]Z;4>I\8JX6U+DQOL)\+ONZ6CH9[K3N%B?J<4W]
M&&KE$\A6T0S4T=K/I@M*[E8NMY8V(B <^ONRW-[SR;6XQ/THGY/>^"256';7
M]/U7*5Q;6!0*S<^TO?Z[?/7%Q>V7Z\M# /:V:=BC43?M7YTWA?B@I %5=R\8
M6:%R(STW'@OH&T$4GD8FC$A0_Z ].F;=V;8#6ZVP'=&D6!HWIP)%D%2I,4I.
MJ7+!T#0T]IK)A[B"A]2Z+IL)C:/*!>MIZ"?XT F0^G_10\@< \0=%FB+*;_(
M^^)0!V?218F#7%2>,I%FU95\P'F]M'J!IF4CXFUTR0;,ZRM41A.?C"UF<!KJ
M\S1/ PX4?'JN'NM%B4L=LAYVN]1*%HP#/LC-M$1:4 HS+HOK;5>%=,F)S*B6
M$!V+H<648H&YZT\([J$C4ROEBBFKVC>:$F7N<2$J*VZ(VU9?=\>%]BCU/S#E
M1P9GG7K&:XN(F@AVYO<6J"2%P?D@30.TJ5D0,CZXL-81CS]4)2CO4],TKV!_
M'B@*B&H$>I]S/7G<$RNW07_U8&KDWF>=P7*/FCHCK.5KW[9+N^[->"\,%"^U
MR[!Q!7J:JUQBL&Q<2M])LF9J;LHF@;PKDFT""#>N0N7,$1R4H4$_TTTW;UF"
M7>R+R\HW3X(B?OT^'QWK^ ;'1(2HS=428@L72$"=TB: G<RS(I[)E9F[REN4
MU1? U7FRMS6]CXS5P2XJU=R)$,7*+SDWL*?QO!FB6XE4>9)GP]\J5$P#F+U\
MID&? Z(P<7]MKC8+< GYT-$@GM60IC>;M0.H5_2]2A1/5H(\=MF4OG<Q0]5Q
MW2TGU'BD^4"<>QWFDH+RSTJ!E UT[(2%I[QND+/DU6A?(L6J3// %F/%-K\
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M;?#/CEFL%-:-;RS'P)78D68$!8@5TF$W1V>!%]+>IX]W=6-=@$<XY)\WF<<
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M9KS.NFS^P[ SS%K?WU.@1"DN+JO=F/W'Z;NJVH:S!T!RM]ZXTX&^% I'K>[
M>'#B.HBU(8BD_0D=*@,=KIIZ?L4EPC-W-8%(V1_\1K_11;@19=5P.)30V4%*
M7@(.N2H0^?F.3A!C<%=\%]OF?/#D[X>D#"YXCFZ]@A>^VDI-0M7VYTV<_MDI
M$@CMSJNC&7=_A3ZN]%QEMZ,>;ABIS*0KQGQPYL8J$?O42-%(G&ZM(80..24/
M8-S13TC//^RH*568@(!H .\.1R"' :]D@G'RH6N(/SIW3*6RW?%N?ZK<#D0
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MT9CRQY7."MW0 _A]4=>M_T(;A->AW_X'4$L#!!0    ( -6 :E(I2F^U!@4
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M+P+XOW0N;E[$P7:W/?L74$L#!!0    ( -6 :E+J?82A+ L  "\B   9
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M(@P..7--Y8++'$O6[4JF0A"N+WK=;MKM=CWB6:9-SLM,!+'?4NPQN-+WHIC
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M9RA!5K%:R=Q'PA0!7B(J%)#&#S&-M!&37K2O89(*0/)L ?"'1:Z,^2^/.-C
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M^TEK)[+*F[X(9W=,"?0>:+)'OHNA\2=^]R\DV;3R8_0M8-2GYXPB1HG]',B
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M!>7I*RZ"A!;<T,RF(DC[HQ2NA.ZXV=3JAEU^#:#L:P.'X('["#R"!O#IFCQ
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M3L12ZP]*9' >3P:+(<(^L]W&DL$NUBA0A0\R3"C"-+S@>75?AZY;U0T-^+&
MH!80=E=\H.N317X\B.>U!:[0=Z"*BR0K0;-JI,"T4*S ]!+&8D*'055>.&KB
M*O"6"5MOEL^M<+7:$[>>(F12E@MLK7T[X2$ Q8YNI:HCZX4-R&_,N@(8Y<.'
M&YS3$"KZR'5UK2RJ!&R\K]0Y?I-D$GLON<_0D<O0 7K)(Q8W0^QRRVGXY61B
M'09J!9R9.B:E&8,_C9U0"XU3!+[@%$D>7PWWY/QX>P-_ <9(?RE+,HHT@=ZP
MLRIN>F2%<=PVG-2:N]IY[UK0VZJ@:/*^M'CTA0.]XIG1L5(\GP#KCOI*5*,1
MZJLGOGYA%;6;ZB)IPR,-MA$-M)[/AN-P-(\'Y(;J#5077;=KQYI7(3(;)<OU
MIJW[)(:&8++X$[HGM09-(Z:313B,YBUA5:<UV+<N-ZXYX4N(<;N-@9)@C2>R
M5+W3 _15O9.9YS<*8$DKI@0KC>T$D9 YM!\(;>R!1")5(2N(00NUD8K_CQT.
M#*",=08I"_P\C.KYJN&_PIM1U6_HPO#YOB2G3/.UH%5">E^T-M;Y!P&P49B'
MBU%[F'1[@^.]C=+0;!YYGD.-<1Q7U.[M\EB/NX_SN]VJ_K2K*_^<[G"/7-/3
MX1H9=(V>EJ]0X"DD>7>[<:H9=@R:D"238HT,T,!&C0=<Y94,[.&N:O0VZ9 )
M7]$>)B ,6+H/4P6S"[Q00+;A*2G?PO A(/N5HTW4-N/?2IXZP+K#&73B[AVV
MBZL2/+N5MFJZ;7TZ!=7@4#6(U)_GN@%5!6[ZB^T$J!!E[JK3^7PV"4>3!;[=
MZUC+21T#H2N?H>,D#AH=?>4/4%4G</ 3J*INI>K"V!L'=!0N6,D,QAU4-V<0
MW[3B0D06CLNO@Q?\Y1YWC3=NK#J(7EE(-P/AT(CWLC9$V&4(=Q& 3FU(\-W6
M)/JE5AC7V><A><'YR^!/'TUTN=3L6XEU\[BD8^'9=]"="@:'"OH)S6N/3QM"
MELQF,\2A;G7\J(7-%G9AU?.^6+4RRD$.O(&1,#;G8*QG9)^P?AI-T3I<74+K
ME4$7 K4+^@B1 @I3^JP/V:\[3"%A% <OJQP2/&33DN'<P4WFDK]BGHXX](;X
M/#YHJ'_ $@=$%_2.\O71CCDM!JI;R<JB&E&\?9&YI%4GARL@K9>VASYYRU"1
M19.RJ8]=6F5C\_JEZ0<W18 Y29E1?]MWH(7S4$W3CE^=^ZI>->AU5Y&5&N?@
M:30*9Y%E)<]I%@QX%],D*F2X4[<E)^>FPUI3:NL)4K$3'J)!WR,,0 J"62"[
M*]EK1%;%:=\S'-T(WXD 3),JM7BOZD7&MLBB^ *!#_ID>$M&3:F 1T!!/*'N
MRNO#&QI6%[ I.$E(@\?EW+0[($16:5B CQO77$?@L3TX;-_),L.!JUDO*XCN
M#^YEZ=V&>4)#B^P]!8Q0)I )4 TL.9KPP"E5W[9D@D&%0!PU#J,Y>J=KZAOY
M'@MO3J!1 W),#XIA ^.!QSBF4L<-QIT@'^ESQU53=77A($:#!F?N;]C]D&E#
MNZ7 5Z7NOB4 (8IBXWT\F,/X'M=CK+T".J;^H'FAT6U)?9,1VN@AK$9A/)VW
MFE&\1>S+3,<#A]GDF]=V%MMVU]8-3/A.POS9>7[6<(,?HM'8X,C8^CZ]H,]=
M=Q4KQ@ZOSO=7%5V_=%TT?D3,F5K;GTKQQ@40Z'Y/]$_]K['7[D?(_7+W4^Y'
MJM8<1L*,K6!K-)A-SEQ;5W\QLK _22ZE 4JS'S>,0O'"!?!^):6IO^ !_C?J
MJ_\#4$L#!!0    ( -6 :E)%OF+8HP<   06   9    >&PO=V]R:W-H965T
M<R]S:&5E=#$S+GAM;+U8;6_CN!'^KE]!N$EQ!RBR)-NRO7D!G&0/M\5M8L3;
M[H>B'VAI;+.11!])Q>O[]9TA);^=$V=[UP*+K$7.#.?EF8<O5RNIGO4"P+!O
M15[JZ];"F.6'=ENG"RBX#N022IR9255P@Y]JWM9+!3RS2D7>CL,P:1=<E*V;
M*SLV5C=7LC*Y*&&LF*Z*@JOU+>1R==V*6LW DY@O# VT;ZZ6? X3,']?CA5^
MM3=6,E% J84LF8+9=6L4?;CMDKP5^(> E=[YS2B2J93/]/$INVZ%Y!#DD!JR
MP/&_%[B#/"=#Z,:OM<W69DE2W/W=6/_)QHZQ3+F&.YE_%9E97+<&+9;!C%>Y
M>9*KGZ&.IT?V4IEK^Y>MG&P<MEA::2.+6AD]*$3I_N??ZCSL* Q>4XAKA=CZ
M[1:R7MYSPV^NE%PQ1=)HC7[84*TV.B=**LK$*)P5J&=NOG*E>&GT5=N@-1IK
MI[7FK=.,7]&,8O99EF:AV<<R@VS?0!O=V/@2-[[<QF]:O(<T8)W(9W$8AV_8
MZVQBZUA[G1.QL7^.IMHH!,"_WK#:W5CM6JO=UZR.GIY&#U\FQS+VMN;#XY>/
MK,_^^I=!'$67K#'$'DOVF:MTP:(.Q1X-&"^S>BB.W9#/S *\.UDL>;EF0NL*
M,F8D>^ $;IZS":25$D: 9G=2+:6R$VS5Y !EEQ5:1 0SO> *Y>2,C++:J'6K
M?ZE9*HL"-1%ZZ3,3V#CXKY!5:3SXM<*5T%(4GC?:6UO[>N@AG^; JB6.I;)\
M 64;&05[?I+$?AB&)QR9@*)P1FR,G0I*0>9-R'C /EF39=W9*V$6UL#^,C3R
M>Q/,FF!<,XZDHK%Y&]E/XT=_UX\FRSS+A$NR=S2;O8Z?](>O)")@7]#BUL2V
M("M0UF,M,B"_Y P=%.4<QS1.$P1*, 9GFOB\I9(I0*;93,FB\3EP^%FS*+%0
M&=;H6;/8P6FX%Y7W?NQTXL0?8)7^((9<"F9<*/;"\PJ\6F=C%@7I>TY?+..&
MIC0#;02R+KI::4H+B=SF/'V^F*0+F8.^^ S*4*F7UMNE$BG)%3*#W.6,[V/2
MKHX>>V=1D/39$I2+PK>"I64( G@N9F!QRM; E:;I3+Q@F3"O:P$YU8J%YS3^
M(G/,52[,FL8&PR YM^FGGL$\%^B]$OKY8J8 L)<,5EH;3U&,*!\'471^F!YV
MF!Y*1@:HBO3O"C=%1"T1#-]L@O(U.^MT^[:A:&V2%V6:5\C*U+]S*$%A6-:O
M#(T((D/:##WXAIN[!I)WS6S0'FZYMB=PXW= T!9B$UCBW!23%NWB2L,AI'F9
MXB:+:T_7UJ@H;?:J+?@9U@]!KSUR:;?C=L-<<&/G%.06!;6O6#)980FF-$/=
M#IG+H/O"1>K\-?*4#@6I5)2.K%(-ELP":^(5;@L#VL)V0NR$38BK!90']=B+
MTN;F,362U.+AD8ZK><3CS$!Y09#:Y&&WH;H=OS_LOL:GF(RS7H 5WJ"6E&_'
M[%Y@<$823'\9LQ^H ^/P\G9L?T27/[KDU MZ"O#HIK' &&W#/:[9\7S'II*K
MC&E0+R(%1S+W*F CKE#@IQP,'@G5";R>ZF;OS^YFFY?H=#<G05CWL_?N?AX$
MW<$[&IHU#1T%_?!\+^-8?#SP3O^--:*"<1;WSKT4?9JQ%\H)AL@I9V!]VQ)[
M5EMT:6SZ9,ISPMU&%?=CA2X@ T@$OQ69R1P/VC;%*^D"/D' QPGF+$HBOUOO
M)AC$%*ROA51&_':*6-@AL1#69"XRBX -R^A]FMD&T<1'/MD&>\ IVYAQ\D:'
MO6-/L]$88H2Z$:R_FE5( &J%"J".[W>=J.]'O=[;^YYW>'8Z=DJQ>_87RU"@
M4H&V">R_YWU,^ED2Q+U=: /',^'"'EZ.8-RK=ZP&+VO'5:4TS5KV2$:M?@)Q
M!TG_ [2&AZ.X\[VLMM]";Y*6]_\@K1-'$.^_(JTX^1[2>M<AA#I[& ;1>TXA
M.Z25#$Z3%GLG:7G_(](ZK-@KI-7U.V'H_>F<Q;Z7L_"&TGC7(&<G%NK IL]]
MKSFMI+104_ECI^K7CH1;=!YBR&6Q +.0F<SE?$W![3K&\]R3J*EP8EDYSDMY
MGE9TZ#ITNR*4_?;]VS>6PIXN>0%T\7(G36H')^WM^I>!3I68NFH]2'1B8-.U
MJX#@&#7/2)2K!A/VB8?V;E*@52R2/'>XNX>T/MO5+PP6 _;"A/ZA6PZ$^H/W
M4%DY-#QQM/7$R[DMRL>&L<?$V)I]M8\^D%V,$ 4<94X*/ &]E%%J?L'R>(^8
M<H-^U"WU-UY6%%-4W^0B/^P-_#B*V1D+Z933O!V<Q4$OQ,$HZ"6L&R3>)W>K
MZW=[J!(Q>\%IA.TFTB6^L2/QI7>W.:/_T%SR?F36I/W3B!UX=Y!!ZU^WG_C=
MI+/OG5TP#OH1KAIY34YPL:0W]*-PT"QV*-][Y\I8NP%NQQW<C@_S8DV=H;%D
MP#I!?Y?5L%=?M^I9JPON2',^5S"G!D"RQ N#%NF6A YN7D._%T5T]PJ.O2VU
M=U[F"E!S^_Y(U^.J-.Z1;C.Z>>(<N9>]K;A['_W,U1Q=83G,4#7$;+60U>V;
MH_LP<FG?^:;2&%G8GPO@N%>2 ,[/)'93_4$+;!Y^;_X#4$L#!!0    ( -6
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M3KA1'?0(\@ &NUS 8*&YK^6\UDXD#CP+#A<(:B$,#4"X!&Z;@',--#ZE_#V
M%3".:M1\"/X%-KX1L=W?8(]A_R7XBISF0!,??Q1;H3:N*;QA\20*DWF*?\Z*
MY"SXFZB@>N&3*T=7EM0WG'^3,)K,PG0>L^DI:GT2!V^P%J?S,)Z<@D6SRBZ=
M"UX9Z. )J+/E#03_D)@\1/$<O#D-H_G$H0<EF[*03W"5J56%\.3L2#A\?2$7
M"&>? %P$6KU&N'>,[[HAQ9M;2G['S"$BN! 'RA1)L&4L,*3;)B$+GP&-2F@@
M&G6]=:.1R(<<[YCT**VERLF.9#3Q$=\'3Y]%YJ!- 4%75U5-/F^E71,^4[Q)
M1<JFVK0Y1=$A%8;46EDI[%KE?UR@P\I>)0=_2";/,HR>VGF_9<0MVL:B=LR/
M:>%<=T01YT]J#5I\KZ61MD.#UJ7(F4)FO"E_P9'0$A@,X*@I7TGQ$* FL;[R
M20S$%=1^?7VW=EBARWW=:(-2T=$%2RXU>^)%[2#9R?%UZ&7T_'!5<"#&0[96
MA3##ST);:EN>=H,F2G2ERD4Q8ABSET+:FGH%Y5TOD[9K07< 3 EX.ZQ8[L3M
M*1;LT@252@70+>QCQQ%UC^CY^%(..\PV0'$L!!WDI=+6EP0UNOU\](VNC2T[
M%MMNO(%[J.!V:'Y((Z=(T-I'G9Z\"%39N6MG] [T.0A+?^@8AO[>5#-KJUG\
M$#J32$]RDR# C$:3!,\)'J_)_1250X6^RF_8Z2B9XC$>16EPN5,CN&GAY4D!
MRV0A[3-+Y\/3F+UE:3H\C=C;'0WE+;5U#RKOV6PT'L81/8*OTGP;+K6@;@@R
M^(%1=;)H-)X-X]%D#G[Q:)8.D]$X[O-TY8.&Q)ZE*'+0 X+?M@_RO#["F=RM
M%A8W8[AMJ57)?AT](%@T5]481+0KIW8@[I5N$_"]/-_--@?\09(\G+L!D=@!
MH3%L@&'1(W38"4# O1+R-Z(=>&KC!N N1B[3:-[JCDK1J-.)Q\ NC@Y_3=Z1
M7KF@H) /?,:Y:<Y(5(R;^!L@=(-4,QT0UT*6DJ3TS$#*$,4**=\F[DNY[HY/
M#CG4(\A0PBX,7>Z61XCH\N4%ON]5U8O@T\"&=]UTQ_[\A8L(N-B>QH#6#9>[
M!*(9K\J#7 E/Z5WI+C+\>4?5CDY0"T.)<!FQK D6'43Z C)4;90YJAV(PQ?X
M%S2QV1NY7P1D\>Q(W/V/[=W_?#8YM'K"_"?@4^PON=L-V6YP)EG-%(>+P0:X
MW;"5N%+BE3+G\*US*2O</G!'8AL%O .+L.G6W-8.[?ISF%C"']9WW?W9TI_*
M:JV)+BL<O#5.##"\?A-V U07;0+0).T0U,G@2#4 ;DY9 W&5#0FMZ49 DYC9
M<SE?V@:D.W^WT4<%^0Y*]Q1WYW$ ["&Q*4F'>1#I$9";UPWK5<#^[U#>;SA!
ME_Y_>I[^$'SIKHH/_K;6 O?PL@&%5PM?!7WUHY*^[I74HX/@V\KU#$#P+;8D
MJB9CO[FTO.M=#%%"[=<)IQ$&^QAC[CB,4FH@R6@:H2_,)OW9FYSG+M/1;!J>
MGLY<FVFW.[(74EY8#CD8RL<T4J>NYTQFD!//J6F%T30)IW'229JG--1/F[;V
M4M!-T_UR]BY)IYC/Q^P]%)]/7E%>TUV[*!SE-)RAV[V'[NGL3^J.J"7A+(["
MR2GUR^EH-F;I:!:1OY)PGIZ&R7C<JN72Y2"/^70:IJGON% E'47DY30<DU?A
MCD.?P$YZWQE+H5?N:RK-JG5E_2?';K7[8'OIOU/NR/W7WL]<KY 5K!!+'(U&
M\^D ?=1]0?4O5FW<5\N%LE:5[N]:8-;61(#]I5*V?2$!W6?LB_\!4$L#!!0
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M8K(VTL)(\81T-8)EE?"L8DA>S:TL'Q@L-\+0T4IKD3'D,[-@]2RX-DR0^QC
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M&RZVY8(DC:N/Y&CFSE&2]7#NT!IP;<H+6W!#'J<^S\!R2>2Y#1Q/ L<ST!
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MB8UYPE!:!W->":&/BB48'\7\'U!+ P04    " #5@&I2;9^@=#P"  #'!
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M01L"Z+XRQA\W(4'_[\J? 5!+ P04    " #5@&I2H'KR_=,"   C!@  &0
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M/=!7#2IK0/L[*<UE8<_!]CMI]3]02P,$%     @ U8!J4HVM^*03 @  :00
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MHBN+&W?QH,7:W4&?A#8W6M=< 5V M /,^Z40^O7!3E#][S'Z%U!+ P04
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M@]XPV8OU0%T8#X-T<#C606=@<-+ +56*6IEOB'38<0X_8*1A\'+D!^\<:KO
M;EJ],(V3_5 /U(5!VN_UX[U4_9T;K 2U<1>[)FY#FQ.]&^T>#Q?NRMP;G]I'
MA;L97VB:%\DU51LF-.&P1LK@+$55JKGDFXZ1E;LG5]+@K>N:!3Z,0-D"G%]+
MW+>V8Q?HGEJ3OU!+ P04    " #5@&I2@3B=Y;$"  #9!@  &0   'AL+W=O
M<FMS:&5E=',O<VAE970R-RYX;6RE5<ENVS 0_15"Z"$!$FOQ4B>P!7AIT1Z"
M!G'3'HH>:&EL$:%(EQS'SM]W2,F*&R\(T(O$9=XR0W$TV&CS9 L 9-M2*CL,
M"L35;1C:K("2VY9>@:*=A38E1YJ:96A7!GCN0:4,DRCJA247*D@'?NW>I .]
M1BD4W!MFUV7)S<L8I-X,@SC8+3R(98%N(4P'*[Z$&>#CZM[0+&Q8<E&"LD(K
M9F Q#$;Q[:3GXGW #P$;NS=F+I.YUD]N\C4?!I$S!!(R= R<7L\P 2D=$=GX
M4W,&C:0#[H]W[)]][I3+G%N8:/E3Y%@,@W[ <ECPM<0'O?D"=3Y=QY=I:?V3
M;:K8;A*P;&U1ES68')1"56^^K>NP!^A')P!)#4C> .+."4"[!K1]HI4SG]:4
M(T\'1F^8<='$Y@:^-AY-V0CE3G&&AG8%X3"=Z+(42,>"EHU4SB9:H5!+4)D
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MP/=W,93'XD)/4+X*<O(/4$L#!!0    ( -6 :E)]/JHP8@D  %HD   9
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MTV%=)92")PE"?3Z9.]7FM:%[D#X0:H L'-]FC_W8^MS'$Q>85A]E5A3M<6T
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M-* 6X%;\R&&K]]K$6EE(^6@[U^G8HU81<$B,I6#XMX$I<&Z94,?OFM1K]K3
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M9OB, F47X/Q22K/KV V:AUG\%U!+ P04    " #5@&I293AZPXH#   E#@
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MNGF3-!6K:G^M?U 6'PF^N,)W'&C7 ;\OE+)/%3= ^S*<_@=02P,$%     @
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M#U>VI0;E-MCO"RG-?N(.:)OTZ3]02P,$%     @ U8!J4KY_T)8N P  VPP
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M3;RAAQ)(2475(]]\A9VA:\,7<RKM$VWJO0/LH;B2BA<[L%90Y*Q^D^WN( X
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M:&5E=#0Q+GAM;+65VVX:,1"&7V6TZD4B-=D3IT2 %$*C1BI2%)KV(LJ%V1W
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M8LAEVX';B1:UZWISH4T/=</2W%HH;8#97PBA-Q-+T-^#V5]02P,$%     @
MU8!J4E;!'[DX @  @ H   T   !X;"]S='EL97,N>&ULU59=:]LP%/TK0AVC
MA5';R9+1U39LA<)@*X7F86]%L:]M@3X\6<Z<_OKIPW&<M!FA#UOZ8MU[[M6Y
M1U?"4MSH-8.'"D"CCC/1)+C2NOX<!$U6 2?-I:Q!F$@A%2?:N*H,FEH!R1L[
MB;-@$H;S@!,J<!J+EM]RW:!,MD(G>#I R _?\@1'\X\8>;H;F4."'\_?_VJE
MOGZ'_'CVX>PL?+RXWL?/7> "!R^2SHX@O0S#P\0V>(A\?ASYW[@=== W*(T+
M*7;[9 %3FW! *\(2?$,872IJ9Q6$4[;V\,0"F612(6TVR(B)+-(\^7#D/;MW
M/0^G0BI7VU?PWV6?OA?8>%8@96P0.,$>2..:: U*W!K')3OP60CU]F)=&X6E
M(NMH,L/;"6XP1992Y:"&,A'>0&G,H+!R%"TK.VI9!S:HM>3&R"DII2!.PV9&
M;QC:#!A[L ?[9['#W16C70WMGHK!-()ZT]-XQ_*/V3SWF#9\%2^JZ4KJKZU9
MCG"^/2QPKZ"@G?.[8A!PB#TZS$[JFJV_,%H*#G[Q1Q=,8[*9ARJIZ).I9H]*
M9@!0&*U :9J-D=^*U OH].8X=<5AS9,WJ/G?]KD$ 8JPL6AS]D^YRZ]6//WT
MOR2[O\J^X!<U]K?5J8N<O061\],7.;TZ28U!?^N,KK:=BVU D7U )/C./E;8
MMBA:MI1I*GJOHGD.XMG]9N@U69KGX Z_R<^A("W3BR&8X*W] W+:\JLAZ]XV
MHL_:VM_M\J*Y*[A]<Z9_ %!+ P04    " #5@&I2EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( -6 :E*5J6,YO ,
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MOS;<J?_KBZ:_:^=QDQB:0^$;S$43P>D@3WU92]'X?V_8&RZYJH'%X-H$L$
MBT<#9'M3GD"6"&3Y'R%G 2+\P#*]8)=K, EDA4!6CP8Y<[I.(/<1R/U'@SSE
M=I5 'B"0![20EV;)E;B+#7%UGX&MC5C'\N4B@7R)0+ZDA?P@KCO1A*3#/>%'
MKO@RQO*[95._BA+(5PCD*UK(6=>VW&SB'!1+)?S/>,B8=:T[GS$3R-<(Y&OJ
M.=FVPO7S,(RVGZ/.2P54+2#-DOD8R^-CZN&N05F(@WVR--"OFY0.M0RQ9D*"
MN5IIV8"Q3]BYGYEND[)A@LF)#?.-&\/OQ0IS24XLDQ@KKSH+8:JUOB?[8,.
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MUM?77-93P\)'?])6[8=GXT4GY:FONU0?-&^V[\>V[_:.?P)02P,$%     @
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MHP1!(2I'02I'82I'@2I'H2I'P2I'X2I' 2M'(:M (:M (:M (:M (:M (:M
M(:M (:M (:M (:M (:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(:M$(6N"
M0M8$A:S)?Y+U7>O57_]+:->X5F5S]&?=#YOY)U!+ 0(4 Q0    ( -6 :E('
M04UB@0   +$    0              "  0    !D;V-0<F]P<R]A<' N>&UL
M4$L! A0#%     @ U8!J4F7D[@7M    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ U8!J4IE<G",0!@  G"<
M !,              ( !RP$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " #5@&I25,M6@VL$   %$0  &               @($,"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ U8!J4N]2MPWA!   BA$
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M965T-BYX;6Q02P$"% ,4    " #5@&I2E*N=J(\)  "-%@  &
M    @(%_)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
MU8!J4G'H<2%+!   5 D  !@              ("!1#   'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( -6 :E+0MRS2_Q4  !H]   8
M          " @<4T  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " #5@&I2*4IOM08%  #G"@  &0              @('Z2@  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( -6 :E+J?82A+ L  "\B
M   9              " @3=0  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ U8!J4K&T,0>M"@  KQX  !D              ("!FEL
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #5@&I21;YB
MV*,'   $%@  &0              @(%^9@  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( -6 :E)6EV\N30D  -(6   9
M  " @5AN  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
MU8!J4GD3P+<E"0  )!<  !D              ("!W'<  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " #5@&I2LK)B!0,#  !V!@  &0
M            @($X@0  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( -6 :E)U)YN4\18  ,]%   9              " @7*$  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ U8!J4@!&CT)V @
M( 4  !D              ("!FIL  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " #5@&I2;9^@=#P"  #'!   &0              @(%'
MG@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( -6 :E*@
M>O+]TP(  ",&   9              " @;J@  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ U8!J4H4\8[5#!   U D  !D
M     ("!Q*,  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( -6 :E)_>E<:V (  '8)   9              "
M@2*W  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ U8!J
M4H$XG>6Q @  V08  !D              ("!,;H  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " #5@&I25K#5^/(!  #[ P  &0
M        @($9O0  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( -6 :E)U;/L#D@<  !8B   9              " @4*_  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ U8!J4GT^JC!B"0  6B0
M !D              ("!"\<  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " #5@&I2SJ4<!" &  #$'P  &0              @(&DT
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( -6 :E*E4^J*
M3@0  $ 4   9              " @?O6  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ U8!J4O^$>1XZ!   EPH  !D
M ("!@-L  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #5
M@&I2W\JF*]H"  "D"0  &0              @('QWP  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( -6 :E)E.'K#B@,  "4.   9
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M970S.2YX;6Q02P$"% ,4    " #5@&I2\I6:S@0#   <"@  &0
M    @($']@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M -6 :E+F::]<F (  ($&   9              " @4+Y  !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ U8!J4@W#+>"0 @  $P<  !D
M             ("!$?P  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " #5@&I25L$?N3@"  " "@  #0              @ '8_@  >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( -6 :E*7BKL<P    !,"   +
M      "  3L! 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( -6 :E*5J6,YO ,
M %\<   /              "  20" 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " #5@&I2OLLS09D!  !U&0  &@              @ $-!@$ >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #5@&I2(]5N#:@!  "X
M&0  $P              @ '>!P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    ,@ R )4-  "W"0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>111</ContextCount>
  <ElementCount>345</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>31</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>5</UnitCount>
  <MyReports>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ConsolidatedBalanceSheet</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ConsolidatedBalanceSheet_Parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ConsolidatedIncomeStatement</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ShareholdersEquityType2or3</Role>
      <ShortName>Consolidated Statements of Stockholders??? Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ConsolidatedCashFlow</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Organization And Description Of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/OrganizationAndDescriptionOfBusiness</Role>
      <ShortName>Organization And Description Of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Liquidity and Management???s Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/LiquidityandManagementsPlans</Role>
      <ShortName>Liquidity and Management???s Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Commitments And Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments And Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - License and Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/LicenseandAgreements</Role>
      <ShortName>License and Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/StockBasedCompensation</Role>
      <ShortName>Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Accounting Policies, by Policy (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/AccountingPoliciesByPolicy</Role>
      <ShortName>Accounting Policies, by Policy (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://tffp.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tffp.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Commitments And Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments And Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tffp.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tffp.com/role/Warrants</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tffp.com/role/StockBasedCompensation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://tffp.com/role/IncomeTaxes</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Organization And Description Of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/OrganizationAndDescriptionOfBusinessDetails</Role>
      <ShortName>Organization And Description Of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/OrganizationAndDescriptionOfBusiness</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Liquidity and Management???s Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/LiquidityandManagementsPlansDetails</Role>
      <ShortName>Liquidity and Management???s Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/LiquidityandManagementsPlans</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Earnings per Common Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleofBasicandDilutedEarningsperCommonShareTable</Role>
      <ShortName>Summary of Significant Accounting Policies (Details) - Schedule of Basic and Diluted Earnings per Common Share</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/SummaryofSignificantAccountingPoliciesTables</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Commitments And Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments And Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Commitments And Contingencies (Details) - Schedule of future minimum lease payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleoffutureminimumleasepaymentsTable</Role>
      <ShortName>Commitments And Contingencies (Details) - Schedule of future minimum lease payments</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - License and Agreements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/LicenseandAgreementsDetails</Role>
      <ShortName>License and Agreements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/LicenseandAgreements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/StockholdersEquity</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/WarrantsDetails</Role>
      <ShortName>Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/WarrantsTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Warrants (Details) - Schedule of warrant activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleofwarrantactivityTable</Role>
      <ShortName>Warrants (Details) - Schedule of warrant activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/WarrantsTables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Stock Based Compensation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/StockBasedCompensationDetails</Role>
      <ShortName>Stock Based Compensation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/StockBasedCompensationTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and restricted stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleofstockbasedcompensationexpensestockoptionsandrestrictedstockTable</Role>
      <ShortName>Stock Based Compensation (Details) - Schedule of stock-based compensation expense stock options and restricted stock</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/StockBasedCompensationTables</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Stock Based Compensation (Details) - Schedule of fair value of employee stock options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleoffairvalueofemployeestockoptionsTable</Role>
      <ShortName>Stock Based Compensation (Details) - Schedule of fair value of employee stock options</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/StockBasedCompensationTables</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Stock Based Compensation (Details) - Schedule of stock option activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleofstockoptionactivityTable</Role>
      <ShortName>Stock Based Compensation (Details) - Schedule of stock option activity</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/StockBasedCompensationTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/IncomeTaxesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Income Taxes (Details) - Schedule of income tax expense</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleofincometaxexpenseTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of income tax expense</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/IncomeTaxesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Income Taxes (Details) - Schedule of deferred tax assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleofdeferredtaxassetsTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of deferred tax assets</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/IncomeTaxesTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Income Taxes (Details) - Schedule of provision federal statutory rate</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleofprovisionfederalstatutoryrateTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of provision federal statutory rate</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/IncomeTaxesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Income Taxes (Details) - Schedule of unrecognized tax positions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/ScheduleofunrecognizedtaxpositionsTable</Role>
      <ShortName>Income Taxes (Details) - Schedule of unrecognized tax positions</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/IncomeTaxesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="tffp-20201231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tffp.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://tffp.com/role/SubsequentEvents</ParentRole>
      <Position>42</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>tffp-20201231.xml</File>
    <File>tffp-20201231.xsd</File>
    <File>tffp-20201231_cal.xml</File>
    <File>tffp-20201231_def.xml</File>
    <File>tffp-20201231_lab.xml</File>
    <File>tffp-20201231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>63
<FILENAME>0001213900-21-014575-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-21-014575-xbrl.zip
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M+'CQ:JM!^%2+W93VW]KKM\U$B#47_T2K?Q0A]C2@;T#&/0F@U;7E%MS1&_G
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M".2]>%<BP&W\:.H%M^Z(^(U&(!5\,L$($U2V 94GF2X.T[C,+#LHO0!7 5R
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MVAZG8XR)E)L\3M&,@8)%\VJ&=!) S#[T)3 5\EPD*$.5&W<3&A, W8U9,0V
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M;D.W+=$5H-&)K:H(X&-EBW>HAKVL?TAKQ3Y/^;6J<M]R;;*_F^9^9BI7%;'
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MK,E BZX&A.U'$W*5QK*LLX%*<AVJ;6<;.IG,BQ'Y6F7+6@YELZB[\;2LAU*
M<VVO5VJO<?N3SD>3YA&^R!R:RB_FG0F*BN:0$=UB\4;G#6$_B(X"]XX*:0#"
M-,M7E1(UG:VE ,7C6LA*!2#:9),<U5*6.BC*4@^2%$BB+>RN@>>A%\^,(VM
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M#:,8KTR!2.Y#XP_C\]ARD;-[G*(WTBCPN.;(V/LJ/9R^>^VH\.8476,9UCC
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M52G>6+,LNVJ<M48E:&H2/P.]LY/!;]0V%L]6@2I&O2?M6UA$NPXJ*JC"6.:
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MUYD<S/?*^K*KCN;8N!S(9[?9ZGJ!)"$L'(P0UNVOY1Q#,B NWZ8=5UUG.82
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M\P;=: &1%U@VU9=MWS=19K3=LVJ,%LZ3+R*J+]KT--:(VP0DW8$%R>PD^^M
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M1T5X]<PBB>W(;(9 O*,O;-!H&41=EU@$Z[/"$D:&B.]C%XJM"XH02%V2/+I
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MD)C2].*-$Y-<2R6B@.CJ/!F=KJ(#%_L?O_RX=2U*_?\'4$L#!!0    ( -6
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MQY!P=]S#8BN+F,G2<KY/ ^K9M""/4EW:O%H$C=<3X(05B.!9,3Z+ ;1"A):
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M6,.3_?^"75IY\HBP'[0*D#3QZQQPM!;10#;R[ ]0</HZL.)AISJQ1)*2IX>
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M]6H ')5I3RCC4%V>*G<;&[DW7H!9U>1;Y-$U>4M\ $C5B;L[(-/T==3%*;T
MV132*F@U ()<6J-WA.32LGRG<4FP:.)+F[(O<[D,@).<Z)3V@0HBM'OE\9:P
MH(DOG)>J0G9"JYZ2%)6N0#8"\<3#$>&4]H=@9U@#3#\9R:DL;U+1R:\Y-B@R
MJRJ5RFP!DQV\PC"C7[.4Y6'W&F)&5E (:@*'QG#CWYII"\CZK<2U%-S.P_I!
MHLQJI$<_R[1EJ72YL0F:[VD1[TF2!BM"'*0)W0Z%R6"S*QFE:XO->@0^U#C#
M<43^](M*JJ&VR=H\3,F7UQ>PXM7$XRA8NZ'7[!29IU_EN?6U?X?F64BGZX[S
M2 ]A?;H'",*,V%8F*=B\#4-6)K2U,I;V2%*U!25$]9GT5/*F-.-.,^I]OB6X
MK++5%:U>#\M<S=,85W?3G-.^B,F0\Z\/8PY]E-X5<I:@&46*5I6Z;[K".2ZN
MV&)1#%>T7MDHL<!_VLEJH59M(7CED>2R=M9<]+7\3Z47;?NS';U)O^RE6UZ,
ML//)>X)Q4FK-D"L& +\NXTKV2S9@H85)A-SAN5Y,,GOP\+QV%T!"3U7SSE!)
MDJWRSP97P+X<?FEU0K8!M'P;K8C-N@"<&3153ASZO,,HC0H:*M=F#EM45G-,
MOM;:LBV8%,(XHN!?+"I2Q:%N?C:2#CF_]-EQ>^&P3EE:+Z';;L7=9JK,,B6L
M$%N/V&;Y//!N@Y UMAQ2"_18<1KH,]8!37&#75=YBLC 7EB]!VT+ 9L^*"0X
MG>DL$9SBNF<:_7@?X3R/ZC-3H<LXSP@73E-I4$1QT$D4 QO*2[5V CRF4G >
M+]@1@%<= 90G!/<(%SDEU!UCKZ'MTN0R4CH1.T:I%X2))EM$ N@L12NUAM_#
M<&(4=03D+(?.M7QR+L""*UX8=H0^!U6]K5& ![/MK<512F;_2<C.R']^EJ!E
M<<.[S<!,=IL$\X"\V[7'-FHL9/08@.2@\(G!^6-WY$GL9[=HGWQ*G&7:V6=8
MK6I,UMW2?([LU8+T^FAOZ;SS5N3/&^R1O;A/A7W,EE$0V.54P5RX$O/]>>/U
MVOT4A).@@9J"#%4[6P$ ^.=SAQ""@X@67A:F@Z!(!0D5I=P&2]\VO%;K/0D;
M1)S>_Z=L>5H=")N"@@IJ%.>D<'@T";C=#YFAL2,BL/#"C"RZ<[JB!FMTC?P,
ML^C&R2.]X@3-Z6U4-!B6I46I\V[^TVQ%EVV0G#DKC+GJCSNXYVP93U5]&VZ;
MO6"I/:L\M2>D"3SW98.\<F_=(US32!QBZ4'BA 5IJ$9A0--MQ$X:4X-22>0X
M0V?1S4/\$7D89'NASX2SJ6@ <GU&&8A[)&D_U=QYR!<3KWX$:-*+O4R%:MFM
M'0)Z827]48UN/U0EHQ[OT1L1SF?O#MX8@]5J(ZPHL?Y!%2U0$YS^>46O&E>,
MH)#?U\P;^=>N:6L."%0\JA8B,=)5BMN.4*2&R$C@RGZ[NL@'\-2%T8E.96H(
M5&-/U$.H2A$%([$Z"!:H"E5I]Z\KU&*%MJNKS4&='&QS9F$IUIW7MKV#9R2\
M1P#)-@8=I62;KZVR0S**5W5G;U&SG]\U=[CIS@HL$@(OLC1)R1:2.*SO,K!X
MEW4FA^_5T-]) H0,YO)V8T9+,;'I<;$H[T*^Q(&/:MRS?ZMME ?A9(I*-210
M=N^8!Y@.'U"PO$O1?+8F>_ E:KS.R.V:D'4W$>E16CPQQ/)T'V,-;=5RM-F_
MU6;_"E'ID\]I&2.-*&5>>(/PZB68M@[\&N[K\/HK[M#(2SN_NEC+SY(D0_.S
MZ!+A()Z_P7&BF 0&0'>JYA ."&F?V=&X?SG[CCV_.A-/3A\7'GF[V^%TJC"H
M.7_J?IYMK5)GX^LT4AHPJ;3>'=QF'7F1C\+0Q4K'(?W5VB<>%/*.P*-;Z1J?
M)]6+C6(!Y/'FZOS=O>(9HREO=SRH22ML<<6@\U53C9.OS^#I :72DWDDZV;)
M^3"63L;#1&,1P^ C[QGM8%GM,+?#JI28@Z_3Q5<#1][\&GXQ%-E1<&W2(?[U
M*)(6)$H-N@UU:-"@KKIV#<O6Q'W\@3&4=Q@?-$LWH24B[/W\F@A0WG:$?1GG
M[TI>$U==QM@7V_)RD^G3V1ZP!64/]EJPB^?-@/P8.M?@'&H4G0_$"^"2QBD^
M'UXMM]9H*( MY$SW:))UG7HIHW-.?TS1!"I&%Y$#JY14K$8?=BZW+TGC@& U
M=5M"$:X<74S0;26ZPAQ00$N]#-TZ8##EYW+(G%:>VT1-L>P<X%8[N-)G%;(C
MZ,@FL4'*%]NI)[J;8/@&1;2'&*$\F]/2TX3=Z;U&X"BJ$7;99$ ;1D59#IM7
M/UP2J1.P7#K2,L$K CU@A;D7X#6]93A>H-5]&&]0X[5[E)FK 2"A#[*)5J9I
M=EY@A0GK>V$E>D.7ZP(IB>Z65@V+IU+?H?>?.G/DJ1#XJ1#XJ1#XJ1#XJ1#X
MJ1 X+_=C&2)DQX9I"YMCE/]_PL5U!B_D+ED(T+,;AVA'.P7>L$/I,D-JYQW8
ME\=>BDZ)X.DU.J-4>MU7<)1L.0$=UU8&E1L"AE7KBKG:94\T?$8#,;_'(1DF
M#-+-%7F-4:FR!MO.FL2-6']U4%>X'F'0@FD1[S0)YP68HL)P^^5[$4 HVZZ!
M!IE55T'RZ10C=!:EB(:X)V%).YG.9_I/_[Z_O_<_'][^_MW__L\?_GWV^#'Z
M[O7\\P_KY<=-]/XX>WCS W[]PV\O_WI_LTG"'];^Y^?AK^E!>HU^_?S#JT^/
M+_SS]/F_3D]?7O]VL'X\//KX?#V_QO^*'[_[]%N87K_XZ]M?7ORR^O[Q.YS\
MOKG.7KU9;TZ#^>*WBV__.C_ROU__'9[-/KT\N#N^>GG[^7/\^/#=NS_^\^[U
MA;_X:[[&Y[]\G&4/=R__%?R0_//Y^XO9/Y\'__@[>OG\ZH?O'_]:SE]]OSD\
M_M?;Z]]^W7S__O0?'\.K7\.[XW68?IP?'WI_7+U*/EPF'U[_?G/P^N[5P^:W
M3W]_O/KM>3@[?WSUG]<S/_XE^.Z[;]^'/_S32[[W/JS_M?GE\_+WY-7F??S[
MI[-?9X>_/O?];U=_K-.W/[S9W/WOWM'UU?[^%S^_8>>*M&[=^1PO[=)QL [F
M*)I/8HYW,CWV \71J&HWY-)B^.&3?W/)[+;IU5T:=[H>U_KZEW> &O:T%HTT
M<)5:SH6DUQU,U6-G[SI7,U$'95MUC?QV==:BRY;9=%THJ]46[&O4HY[A1?U>
MX 4]3UPB4N/P$"V#B/[DT MIZ>4+);VQ06=B2F%%M-+0F^,#%>+TXB!* G^T
M<6,^L^[O85!4IP%PDX;+W)]:C%&Y=CAT6.WJ3*EV05*);\%H4]+GW,/]H:]%
M]J>S4CH!%Z2GH.)RS_A4K,K7'-+5B2>D=U2)2]ZQS]'1>JE;E>[=Q"F];'WL
M?I$2WQ/:T ^+I[S%G_$5G7D_KN,,5SDHC-^D)@=>=P^+=WCJ<3%%/3&0M=T&
M?=;6OI;*3LZWT7N#*6K;P!C+&_9!.3AZC8>T!YW2%LM0;+;;X*E9O.&J @W8
MF(IKVTO4"HWJ'"TPIS%>H(!>]SG=)4;W';["/;0VS$"M\!1-IEZW8>U!O]25
MIMW65]B&3AN]V7*)T=)+47//I(>6=)#I3$]%H<A[L$VA'^ K]5/D@?F:T*;!
M'7:E$@I#HR[#;#03:+RW.;:9G)SC:A^F4J>$H5O'*C4Z;]82ZU/R80:'M51,
M?A#7Q95Z?/9Y=GM<I2,]7F-"2[13M$O%%<2AK;GM-0;[..[U82:3=Z,LEQ(0
MX?TH@V91!ZPI6>H]%FVK>O1LJJ26-SJ[\1Z+1F6&R=/<84S/3XXRC,FTVAWW
M$$5$J"F=/D&4D8ET<8\PFYY)-^=V#&</;D:Q6LM0KEN_/I*'Z5-8<'2*YK3%
M7HLE0,"Y)(?? MB;&!U@\T4+BBCKKSB+YK2]XJ"X2@B[[#P)@J],T HM+OI,
MW!@3-R@:=.+R2'YI$Y<K6GE_!_O+\O!+[RBV%_965[AF,\=H@0CE^4@<JC[L
MN-]JZ #>2_ *35KZ*$.Q[ \XFQ4INW&:+<Z5+@V025NES+ 7W TOP 'H2O0=
MS&Y@W-7$;K4,L*5ZN9O@8J*+*7^9$UTB;;#66X36;/Y7EJ0L,>0:I6G>L3@A
MVO<^RI+,"R]QO YH+U.0FW#T&'!Z48-E[#5%+^]DU6>Z7Z1W" \ZS3D4I^:=
MRP2HT("LQT4X@R V+DO< RN9>17GW P7M9\7.I5ZCUZ2H'1[U4*?N'VIJ=3N
ML%$- _?\<0Q+YOHQIL:.*_64OEMUP"3X)4Q$M5BEHN5YG"1''L:;18SIF23(
M.B^@YB@Y1@D:%6&!W$S7XNXL(MZ CY*D^_HGR*5:F0>'*X(6FOK"!0IWMQAY
M$\?SAR"DMT*=1:D7+0-B^?.O!D%81-]5%*T?M$*)JNRK^J]G+,^ 7T^CNK"U
MAQDU(LJR &DZTM8#3"SW,'.(47*6F:ZN?N)YD\MKF,6-YM+D*5-A&#_0;/A!
MD.H@.QFG44N68)=ZMJB_0\.X(I3.**)!"CHLA(L)3.WNI.%VH/=EX&F1GT D
MJ9=F1 LVQ E&EOIP5L&MXI3CNJ1!VY$:[DW5QC1VUTX6"T03!5$52:#C7B$_
MCOP@#'+TTUW:C1]#3 X;;(V@D$I+(>ISR@HLMEMVZC#7?=Z#0-R57OR,874$
M51,^$O(E5-L6JC#$XLK51]&2=8B^1-C?IO($T7$<AAY6NPC5.M%)Z@20_$'V
MDRIL$HY67D0+#>+X4^H]'@?D(8R($V)/*T0T1G$6 *<%0O'"G,RIL/4NIIY=
M1GY&/++B4&.X\*!E#J>I0E!P@?7/5&'TZ([6+9U%CO;IMEETG_X'JE9::(%<
M2-)W(76E1$*>'*:5 <U17<420Z82&1PN8I%%F#!*G+'/[-S\/D[8X$FO8$5M
M ]"ZS85'\'SW&A>AW]6/@DFK?Q.*-\IUG^:C@P4@O##LL,U6H*U\R!Y";4^C
M.$K)%#C)L\%^?I:@9>'!6?0N*X9G67H78UKY6KN*'"1[J$D)#.X[\B3VLUNT
M7UW";@G^QBSHS"O:$298>G:;X#%;5(;!KZ %MCZ6L.W/&R_57"+%"BQ&IQ06
M3%X-C]Z?SP>'!QP@M/"R,(5"B$K,^LD5F_Z%&TXV72S@U[S77KC =3_IKD90
M9@JJ)8KSRM9M%"/VGGB=F)A56F9X6=K/0[2L7VNC)&ZE@1PED-EU(=1$9KO8
M+^]M,9_GY$YC7*=^A4*/WE@;%R6('Y&G-DFT!G2U.[<+GYX,[9;:%FD?/D9>
M@K@,7.(@QI2\VLY$9SR'H3N[*&H)T6K>$M\&G.27@O4UFLUAOHQ)IR*O4>3V
M7^"E1]XK#\O02&_BXR"_]&]QF"7D!9-2'L^,3YIGOA]GM 9I>1F'@1\@T'IL
M 343U3]Y]%E ZV)Q%*]6]" V]C^I'5UU/NG.(Y/#L#UZZGYIF'V)L!GY._3
MO@() 2A2=EO9J0:;KC#M9@U4U"D9V*Z4#J_8,$2D)A/;Q_ 2U%DG.!<S:(>P
MRR9$5J;/KB#M>UC\A3BIK\35ITHKD/:@4[!TAN)2.;?61NT*^2A8H_D[E+(Z
M';1;H\8!INLYA\=Z&H+O?&.5"PN'\&;/@[^S@&QW-UXT?^M%7G&MQ"7QN&M>
MK#;*U;"S]K!:^<!* QD>=5_2/4JT"/ J/X7U$IJZ0?]W0HBNO9!2@E@"U @[
M2^/5 :^^$BC*4RU!7G]!S_!]F"7OXA1HW:Z//SELFM)1*X$$/_'/5BL/;^+%
M-<V\7 2^%Z5MN]K#"FD1:(4FQ'4*9D.;W?FA0TO]?-]@6+@]1/?)?C\ MQ=O
M& BP_UF^X9H4WR.<;NB$3LD<IY;S/N\Z?D,>ASK95R$+![[:.;_Y-&@N4@H"
M!JF4Y%*F=.$._57(#G+ +,@ T-!Z)2SK$G6%)4R.@"*:#G,%X+!4S2'0 33!
MZ9]7-&ZK:%G)[VM@D7_M M4<$ B*(0SFCF2L=BBLQN[*UN@I]VT:AQN;UJE1
M#8%JY&OT$*J2_3$2JP/CHBI4)1-A8O!/,QRQ>S2):3H-'MF-FLK*JVWE!=3<
M'89I^"]UPRZ2'%2A+NV0D:4(5RS"0<4CY38N;(@55V[6K?];(H]5MK)K_YN#
M.CGPXJQLI:G:>6W;^L](>(\ DFT,.DK)-E\;)+GN+>$M11%-1F%U8&R*U6>7
M4MQ%/HK+\DD[$1<%24'==4#CS2"&GH[KK/RP-RQ-\0!=+<!==MXG:)&%Y\$"
M),M!A:S#U@;6L%,2K^TNQ8U&9&6)\QM,.+A":Q1E:L%FX0#3MW=B^=@^2"_U
M8>=^R?QZWHM%GKE4NRWZT$L"'V+BZ3'P)4Q!39&K'/,;+7*AER07BP\>O98T
MO<!7E*O&9;C5ETGQ;0)RJ:P9(Y.>\#TQ*%1"<'>V6?.^V_0L2L@8=#TXBB.B
MGZPW1?XGC:PPED"40)VXH_(>>Z!KR+D FG\7M=%*O$.G*.$GIDAI&>8_/67C
M+!-,@03_<F6C?!.ONG>X),A6 9#<$QZMZ>]'^&(L4!/=P&S54N972/B!%VY5
MZ11Y-& YJ-$4\>&NM2.\!17*OXP6B LIH#.6:&E'D)8W^^2W!"U1U$Q3ZA&T
MY@X>)/1U:1 =\IYK+09,.^ ]W@<8';?:IW(K@JJ?.RU@, *G5ART?6FP3A+G
MM-J1,'=%E[VPZ$D&H2?=A-P=3!EC(Y$<5(1R>P$)I7L4)R"SN8.*VS.IWC!U
MR4T:R!PDA]ZG"D,V_K,E1GE";GTY,,B>YP[86EHEV?,* YG4W@@&5D] E0XR
M<!\I';%7IETNB6&[0M&SL$L<T]:4%_@:X37ASV9N4^?8CCM J6IC>5;8+1^(
MP]B"$C5X!:U$.=-3!XX. G!;!6GZDTC_=C#HD@Q 7A27FKTL*0D2SM*F>H%A
M/9^J.!U.4E3RTYE&Q3TZ[WC063:"='+7CL.[7MAJ9G+>D@,'R28Y#WT-F>X^
M,P%QME[3OHH>Q1A=/6J(L?& BS"-G@B;[V<Y':",QRYBO#HB7P2^%]8Z8I]%
M.OJI,LX$=%9)'/:+Y-_%ZSA%_MTLH_NJ,/ NT\UY.M>0OW@$!P%H/;E+!&"]
M-WM.-/-#E-'[H!YB_$E?Y/S'AX^R:(I;\.;RPW!M0?_S\L[#*VT!=SSF)C:B
M)]RNMY4?)]LX)CE%:+:BP7[XDY M*8=9 KJA *G48/)1@Q E:1PA0DC-?ZX_
MX+"&W2#.TGQ7E:Y )BX+Z]Q%CQ]KJ3QFY^PJ(TT+ 47IJ.0?&O0U9?.H:JY&
MF3C.T*6W48XVBD=P=9!NA(1$&$IM$O4KH+P LZ9.%ZP]T!7RDKQ%ZDE(;Y_8
M[:]DJ1!*2G2"BX2")&WG#>83F(Q!9NPVUT+-E+6>FIC9:K^UBL]DDB-=ZP1:
ML#JKLZHD;ODH$])X5;E(4^7TUXMR]!N,5KI-X+@/3VN5X(I F@]G=JR=7S'4
M=0<:8#*" M6IH*8C2(7D.#,4N^F>1:QU70+2?$9&TE'2L"E\4@DJY++I&[Q+
M,LD]_ G1_(C9/;WTVPO55ISN)R<B=-&[EW*67C@"WNB,^AYW<4C826C-5KKI
MT]2,-UA+/N+N7_)AS)J5\<;5:$PF'F+P)F3* M\V'),(P5%S,79;#,NZS4M7
M&)M0+<7XQ)PW$E-2T6:/8Z[@0-I+U<G =0;KH.*L:XZRBG948#7$!-92I$4+
MIL$7!Q2'#;UZ0J+6M<NLX^MM$LP##V]J121@YHQ+;(+FC"\XD.9)-2KOO!7Y
M\P9[4>*Q6!><>5.@.L#,$MDZF?YRZJ2X,@0K+9 3AS&&BA"Z-8]V451L<FB$
M(L*T3SW9+>7-"A@;<)VQ1.1<7F_!=ZX:2(F$!=3"_.SR @Z.[> .KTU07PD:
MEXINY0+4S358$Q_G,O1\!-LMCD/)Y70P@X0G,I \ARX/1R^B+Q[!616UG<A"
M.[)O[XK=;?%65:?;-(EYYY/\_I_W]W&TK=T%V1T9L.&JYX06N+WD;#T;9KOU
M>[IGSBZ^FI?-";)HM*UHE78P(S16S& TNM4H&5+I(.XZ%.@;4[E$%-*#GXY*
MG4TFC8-242:-:;.&XI+/NF6&6?.Z24W.]G%E!M,2Z^MNT&.V.LF:\8B:61DV
M#&47XIT2SJDVE UCFYL+F)V8$N7)33)5B=K- <IK/S2O=-RYRG'\,FZ_I3P-
M1[^&LP*M9B]/8\S^?]%P4G(KJB1K_5&G8;E,12;/P3&+4C2I)3=QZH5:DT(^
MRF1,DJI4E/-T+$RD,[IQCO(TZP]!>D?;88<H28I&G26+YG-*E8##?HN6)IBR
M*$M\!?$).^ 6E,W!*P>8UA03RZ*4OKV"G*VKT0Y0S;+T+L;!9YBMD(3B5.:4
MJ@!+Z.Q5)XLHP^U@!=0FX?>I2*W$BA]HZ(_3<; .YBB:7U%7GE.0"($8A^Z$
ML>-)LD21'XHPJJ4NJ"5%B=Y11A@!JJ7FD)K,BB:560F1[5#$]D"ES W@G3':
M/,KBT)L<7&+IE9@)H@UV3R5O$%XEU!]R<AC9ICZ14Q$3N9;8BF,@T"46Y44+
M/0HK=H9H"4BXG> ^;+2[V1E-O72B\\&A"R9D@JPV+MVO^50<X3*;6*1Z3R41
M3R413R41HRZ)*!G+UWIZGVL<L8[;T(:LDR 43$"FK%MH8#EU.^3@K%HW(:CM
MNYY1$REJ'22.L$#6FDY:,+:-"\TX[%LO=!1+&9YJOP8P<=**+^$-"D\57T\5
M7T\57T H/E5\047 Y'M'5Q5?S'@?7AX'&/GD6YT>^.VGQBM:WFM:=ZGSS"R/
MOK@77B,_PT0(*#F*\7V,V<=E6H*.J+4&=%A5)]Q(;!/7M,1C?65A/-R@Z"/R
M<$E- XON)X<_@M23.>=]83;_3^6CMLI'1_YBQF;5R(>@:0ZW'AF'*COQC[Q<
M+H3!)=LC'FZV/[GT-O2CV8.'YY<9]N^\ZBKL6FY2<>(.XH+ <>LNNTCE0&4(
MN* V\U][-I(.O@HY2):[HA?<W<2EAN1$&RJB<S@I'FC$$&A(8YCRS:1&DWVE
M!(/20&.'04T:=CNA<PG38D,_17.6'6&,07,4AQE O4#8D05((W,1W7IF7W\L
MFJ--<5)PY&*WY))?39T3_ST.B1L2D@W3E>K%W^JC31 5GESD598V4+D*DD^G
M&*&S*$5DZ4K[8-(YEJO2L3Z0= M%7B5IZ/(^=0#HX0-;:I#>(^>EX/8"7P7+
MN[31-*+Z,BF^35Y 0&G&R,B]BIY2!FFLWJ?V+>EH. !03)A4O0;&"JPU2:K4
MBIKN<&NW6LV62XR69 D@RP$.HB3PU?=7ZJ.-'3 -N2C4> [6:?]P-_JU30HW
M7:Z/@X2^3X9SY:U&OD+$@:/$DC1IA=62V2V]<]0'*O3IQ9'Q GA<A)\XT<7D
M8HVP%X; Q3,&7#@)W]K5G^9-D_HX@&6+G*SNPWB#4'%_*7N3UBQ\1XM&$O*V
M+-R<-P&H?T^%\"Y./Z+T"OGQ,J(UL+7N 2"97<,P[NY<R;[>#02U_1O=NSEM
M'XP<[AZ,Y">]VUM=$[;]N+GSHH+;ZFT_(.J)DK>F<V^)WM#%\YC(N=INTJ"8
MD@\Q&F:_!-4=ET153FD&\)3.(O(GNO$>4=)PC_3W1ZV!6@ZE>.,C>-YPQ]8:
M4;V CO<LX,:YNXA.0:S;C17OA2V4TIEEHC"&JBSR<_IC*BV@_&P1.;#D.+4$
M;8DN-M)41$(#J7/@4(1+T!83=)N;K:"S"FBI)V9;!PPF(5L.F=-<;)NHJ=:K
MZ*]()XL%C7"MJ2&@!PL:>8^<1UWF_"J9C6IQXKV[58N6G^J@.=WS5B;W'4HO
MB(WVZ+60Y_'NW:6\,R[9(,Y:.>AX!')1@.0*ED$)0G&6)"@EB]WC$?EWD!YY
M&&\6,6;[P?+H!C(RI,K"V.$T%JU*,IC^%(LQV>1$/:>8;)"Q8Z(H"FD2F*F%
MJZ _>;P/%,^7.(].0]2<UY:F=^G7)WB/U#W/F2,(4R 5TX@XCTY"P+S7EF9O
M&06+2X>@XI"Z!300&/E!&.0!PCL:ECF+6E:/QE%R#R\,XP=ZF@@2%K;,HJND
M"LTUQCHRTBPS[0GZGHR+R9M$A.YEG 0=)P.<^=G]I*,C6)W)R7EEA8[\PQRY
M9K<)^CNCN3?KVFWMAM%$SFAZ(47I(&9Q1<ZP&A>;BP88/,*H*NIM"%WX_JYB
MC4\M;^28]FQ]8_N>RZ?&-T^-;YX:WY@WOJG-\!OR"&3;FRY2@"L5D)7CR0SN
M7OH=<H ];[C$!HG-2YK="#15 A!T\T(N2:"^-B*8'/>RZ0L27#O#TR B&\F
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M0KEJDO3:H[$S&;XGUT;TB)N=;X*G6;1*S9:^O04:>"1BV)FPA)/.D),=M=,
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MU$JW!;"*&8!E(-Y[C5SK&KW "IF.XQ*Y4Y+&U1(V2!U=U9__S (XV Y&IY-
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M,^%G^^S2(N\<RC2,MB9;;(-H/6//:^V>$->L#BBY^D<'E4E(L%)ERDMU^H<
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MS-&_,O8>KX$ 5UO-('D9-ZD-2LZ*ZPO^;EV$;S+5U9PK(VY>K[99\^_3+U@
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M,-.Q"732YT8U+%^*\<Z&UTK)U%'#M;'.8"-6^49>-\E4:1LNXS>W0P^0U/]
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M!A\]6-KN4U$UO*S_)71U AEYS'G8M_08$F9$I5ON5)!8-_,+VKXMCF?VCCI
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M@-94E]*_6@-MTJP74)KQ=5"1HI"OA)[)4I_#64)L,!XRS9I<(-_-W5V&[PA
MITF114D>A=_31)=#HC?@.,;R#ZF:AZ)J(L\JVD/UW,]!;T(=9D.&&9%B8FU:
MRZ##F A.<L>,[)=9%&(91\J!92;7E@Z%/-,&< _H+<',.X'3Y)$HU>2O%QMA
M#Z,H">/=FD#:.X9S\@GS(G!TE)0M]?+,ARQK^O1IO<O@9B+Z CT2>2$_QEW
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MHP UB0ZT?15"@(I'66XIBRR6LV\WM]";V5'&9TE.+%C568F?1I$VH(T7V:]
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MOAJM)P;$M<WC12U]*U7'"3-7"H3Q0XF6T"QB0 B_%:0$.0V=Q\2T!1B,BBH
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M-N3XD<84-%N5862=S?H1'Y5%H=H3M39%S:YUQC/9&3;-?WI*"F,?YF*8YUN
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M3'U/*%$RZ='P6'6YZES1SH0$S#11U&@1"9^99:>E!</"M29?859S1JZ)TLB
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MFG+.,LO>TGOM:[ &0?FE95Y>@ Q!VPV\%""54YA"E8:>7D.U%J<IVU*-]"/
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M4VAX2@YRQ*6EK5\*,9K95,@N!$G9WM=U0B^J/7V12QEL3P'9D';6=AZB8Q"
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MNA[C*KZIT!$DO3TOC<_WI"7;K;,!'6Y1=D3Z.< WL5.>G35$C4Z]1GZVYY4
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MM:$QB-=3&YJG-C1/;6@>T[%,=FG5[H0,K85-DK-+3OF(=G@\!<G_1]S-06%
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M73=:]*UK.U&Q"2+.Q/L[QA%+Y+T!4>0G.;W$E#\$,8X=?X;"-<1TL"9,0TX
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MU%;H1N6G%O-F%$U,: D-C++WII*WJQ8@*"4Y*=X><BE#[/HAIK>>)E^WEQ)
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M^,?E0&,NMUFMZ@6[?HACE%C_CNPU(-XGY80C7 E?<A*B=17'=))(.7WJ-#4
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M !$              ( !     '1F9G M,C R,#$R,S$N>&UL4$L! A0#%
M  @ U8!J4@$L4YQT%   TN0  !$              ( !V+$  '1F9G M,C R
M,#$R,S$N>'-D4$L! A0#%     @ U8!J4D(Z?^5V"   *E   !4
M     ( !>\8  '1F9G M,C R,#$R,S%?8V%L+GAM;%!+ 0(4 Q0    ( -6
M:E(7?L2H#C0  *@? P 5              "  23/  !T9F9P+3(P,C Q,C,Q
M7V1E9BYX;6Q02P$"% ,4    " #5@&I2'9-;%3=[  #Y=@8 %0
M    @ %E P$ =&9F<"TR,#(P,3(S,5]L86(N>&UL4$L! A0#%     @ U8!J
M4I=4HAQY-   E50# !4              ( !SWX! '1F9G M,C R,#$R,S%?
=<')E+GAM;%!+!08     !@ & (H!  ![LP$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
